{"c67e2135484bb0037ab424597be97d9bb207f68c": [["infection has not been established in pregnancy and they are not routinely recommended.", [["infection", "DISEASE", 0, 9], ["infection", "PROBLEM", 0, 9]]], ["In influenza virus infection complicated by pneumonia, antibacterial agents active against Staphylococcus aureus and Streptococcus pneumoniae superinfection should be used.", [["influenza virus infection", "DISEASE", 3, 28], ["pneumonia", "DISEASE", 44, 53], ["Staphylococcus aureus", "DISEASE", 91, 112], ["Streptococcus pneumoniae superinfection", "DISEASE", 117, 156], ["influenza virus", "ORGANISM", 3, 18], ["Staphylococcus aureus", "ORGANISM", 91, 112], ["Streptococcus pneumoniae", "ORGANISM", 117, 141], ["influenza virus", "SPECIES", 3, 18], ["Staphylococcus aureus", "SPECIES", 91, 112], ["Streptococcus pneumoniae", "SPECIES", 117, 141], ["influenza virus", "SPECIES", 3, 18], ["Staphylococcus aureus", "SPECIES", 91, 112], ["Streptococcus pneumoniae", "SPECIES", 117, 141], ["influenza virus infection", "PROBLEM", 3, 28], ["pneumonia", "PROBLEM", 44, 53], ["antibacterial agents", "TREATMENT", 55, 75], ["Staphylococcus aureus", "PROBLEM", 91, 112], ["Streptococcus pneumoniae superinfection", "PROBLEM", 117, 156], ["influenza virus infection", "OBSERVATION", 3, 28], ["pneumonia", "OBSERVATION", 44, 53], ["antibacterial", "OBSERVATION_MODIFIER", 55, 68], ["Streptococcus pneumoniae", "OBSERVATION", 117, 141]]]], "PMC7091643": [["Surveillance and Big Data are EverywhereLike it or not, we are under constant, state-sanctioned surveillance (Hanley 2017), which is officially \u201cjustified\u201d on the grounds of national security, crime prevention, road safety or public service improvement.", [["Surveillance", "TEST", 0, 12]]], ["Masses of \u201canonymous\u201d data about population movements, financial transactions and leisure activities are mined, from surveillance cameras, travel cards, smartphones and tablets, wearable devices, internet searches, online orders, credit card use and social media.", [["Masses", "PROBLEM", 0, 6], ["tablets", "TREATMENT", 169, 176], ["wearable devices", "TREATMENT", 178, 194]]], ["Surveillance has a long history, but modern technology has revolutionised the accessibility, scope and speed of data collection and analysis.Surveillance and Big Data are Everywhere\u201cBig Data\u201d refers to the rapidly escalating volume, complexity, variety and speed of data acquisition.", [["data collection", "TEST", 112, 127], ["analysis", "TEST", 132, 140], ["Surveillance", "TEST", 141, 153], ["data acquisition", "TEST", 266, 282]]], ["Even the most sensitive personal data that banks, government agencies, healthcare providers or insurance companies assure us are secure can be accidentally \u201clost\u201d, deliberately leaked, sold or hacked, with loss of privacy, identity or funds (Tanner 2017).Surveillance and Big Data are EverywhereBig Data is used very effectively in marketing and some types of scientific research, such as meteorology, but relatively little, so far, in healthcare, partly because of privacy concerns and partly because data are often not digital (Bansal et al. 2016).", [["Surveillance", "TEST", 255, 267]]], ["However, health service administrative data, patient medical records and laboratory reports are rapidly being digitised.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52]]], ["In the microbiology laboratory, for example, infectious disease research and diagnostics have been transformed by nucleic acid\u2013based pathogen identification and genome sequencing, which are faster, more informative and more amenable to digitisation than traditional culture-based \u201ccottage industry\u201d methods (Gilbert 2002).Surveillance and Big Data are EverywhereIn this paper, we discuss the benefits, risks and ethical implications, for individuals and the community, of the intersecting roles of healthcare digitisation, pathogen genomics and Big Data analytics.", [["genome sequencing", "TEST", 161, 178], ["traditional culture", "TEST", 254, 273], ["Surveillance", "TEST", 322, 334], ["infectious", "OBSERVATION", 45, 55]]], ["Less attention has been paid to the application of Big Data to pathogen genomics than to its application to human genomics but, despite some major differences, there are parallels between them with respect to potential benefits and ethical, legal and social implications (Mattick 2018; Mittelstadt and Floridi 2016; Middleton 2018).", [["human", "ORGANISM", 108, 113], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113]]], ["We argue that an ethical framework is needed, to guide the use of new technologies in communicable disease surveillance and control.Electronic Health Records\u2014Benefits and RisksHospitals, general practitioners, diagnostic services, pharmacies, health insurance companies and government healthcare agencies already store personal health data electronically.", [["new technologies", "TREATMENT", 66, 82], ["communicable disease surveillance", "TEST", 86, 119]]], ["Most people have several separate records, created by different agencies for different purposes.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11]]], ["It would provide immediate access to actionable information in an emergency and could be updated by, and shared among, authorised healthcare providers, as required; it would alert prescribers to drug allergies and interactions, prevent unnecessary investigations and, by the use of personalised decision support systems, provide enhanced diagnostic, therapeutic and prognostic information.Electronic Health Records\u2014Benefits and RisksDespite potential benefits, relatively few countries have successfully implemented universal EHRs.", [["allergies", "DISEASE", 200, 209], ["drug allergies", "PROBLEM", 195, 209], ["unnecessary investigations", "TEST", 236, 262]]], ["Denmark\u2019s system, which is one of the most advanced in the world (Rothstein 2008), has reportedly failed to realise its potential to improve healthcare service delivery, in part because of failure to develop common technical standards for health information exchange (Kierkegaard 2013).", [["healthcare service delivery", "TREATMENT", 141, 168]]], ["Wherever such systems have been proposed, there are unresolved controversies about privacy, effects on doctor/patient relationships and trust, whether individuals can opt out, who controls or can have access to data and when consent is required, how to protect data from unauthorised use or accidental loss (Fairweather and Rogerson 2001), and use of \u201cde-identified\u201d data for ethically approved research.", [["accidental loss", "DISEASE", 291, 306], ["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117]]], ["Many of these issues were widely canvassed in recent debates about Australia\u2019s (limited) My Health Record system (Bragge and Bain 2018; Gillespie 2018).Electronic Health Records\u2014Benefits and RisksA universal EHR system could have major benefits for healthcare research and delivery.", [["healthcare research", "TREATMENT", 249, 268], ["delivery", "TREATMENT", 273, 281]]], ["For example, \u201cde-identified\u201d aggregate data can be used to monitor the use, outcomes and quality of health services and inform improvements or generate new knowledge about disease epidemiology, such as spatiotemporal distribution or socioeconomic, environmental or \u201clifestyle\u201d risk factors.", [["disease epidemiology", "PROBLEM", 172, 192]]], ["This information would support the development and evaluation of new treatments, preventive strategies or decision support systems and help to address social determinants of disease (Hunter 2018; Marmot 2001).", [["evaluation", "TEST", 51, 61], ["new treatments", "TREATMENT", 65, 79], ["preventive strategies", "TREATMENT", 81, 102]]], ["Potential benefits would be attenuated if a substantial proportion of the population were excluded or refused to participate, because of concerns about privacy and data security, or if individual consent were required for access to de-identified data.Electronic Health Records\u2014Benefits and RisksData safety and security cannot be absolutely guaranteed, even with the best technical standards.", [["de-identified data", "TEST", 232, 250], ["substantial", "OBSERVATION_MODIFIER", 44, 55]]], ["Nevertheless, universal EHRs could provide substantial benefits for patient safety and health resource allocation.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75]]], ["In the following sections, we argue that linking EHRs to person-specific pathogen genomic data (and/or that of relevant nonhuman animal or environmental pathogens) would enhance the timeliness, precision and effectiveness of public health responses to infectious diseases emergencies.Communicable Disease Surveillance and Outbreak Investigations\u201cSurveillance serves as the eyes of public health\u201d (Fairchild et al. 2007) or \u201cthe finger on the pulse of the health of a community\u201d (Lee et al. 2012).", [["sections", "ANATOMY", 17, 25], ["eyes", "ANATOMY", 373, 377], ["infectious diseases", "DISEASE", 252, 271], ["Communicable Disease", "DISEASE", 284, 304], ["nonhuman", "ORGANISM", 120, 128], ["eyes", "ORGAN", 373, 377], ["finger", "ORGANISM_SUBDIVISION", 428, 434], ["person", "SPECIES", 57, 63], ["infectious diseases emergencies", "PROBLEM", 252, 283], ["Outbreak Investigations", "TEST", 322, 345], ["finger", "ANATOMY", 428, 434]]], ["The WHO defines surveillance as the \u201c\u2026systematic ongoing collection, collation and analysis of data for public health purposes and the timely dissemination of public health information for assessment and public health response as necessary\u201d(WHO, n.d).", [["surveillance", "TEST", 16, 28], ["the \u201c\u2026systematic ongoing collection", "PROBLEM", 32, 67], ["analysis of data", "TEST", 83, 99], ["public health purposes", "TEST", 104, 126], ["assessment", "TEST", 189, 199]]], ["Communicable disease surveillance dates back to, at least, the nineteenth century.", [["Communicable disease surveillance", "PROBLEM", 0, 33], ["disease", "OBSERVATION", 13, 20]]], ["Its purpose is to identify and provide appropriate care of people affected by diseases of public health importance and their immediate contacts; prevent the spread of disease; and detect, investigate and control outbreaks.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["disease", "PROBLEM", 167, 174]]], ["Recent infectious disease outbreaks and pandemics have demonstrated its continuing importance (Box 1).Communicable Disease Surveillance and Outbreak InvestigationsBox 1 Detecting exotic or emerging infections of high consequenceCommunicable Disease Surveillance and Outbreak InvestigationsThese outbreaks illustrate not only the serious risks for the source countries, of inadequate surveillance and delayed outbreak detection, but also the benefits of prompt public health intervention once outbreaks have been recognised.", [["infectious disease outbreaks", "DISEASE", 7, 35], ["Communicable Disease", "DISEASE", 102, 122], ["infections", "DISEASE", 198, 208], ["Communicable Disease", "DISEASE", 228, 248], ["Recent infectious disease outbreaks", "PROBLEM", 0, 35], ["Communicable Disease", "PROBLEM", 228, 248], ["Outbreak Investigations", "TEST", 266, 289], ["inadequate surveillance", "TEST", 372, 395], ["prompt public health intervention", "TREATMENT", 453, 486], ["infectious", "OBSERVATION", 7, 17], ["infections", "OBSERVATION", 198, 208], ["high consequence", "OBSERVATION_MODIFIER", 212, 228]]], ["The SARS (2003) and H1N1 influenza (2009) pandemics highlighted the importance of effective communicable disease surveillance, for national and international health security.", [["SARS", "DISEASE", 4, 8], ["influenza", "DISEASE", 25, 34], ["The SARS", "PROBLEM", 0, 8], ["H1N1 influenza", "PROBLEM", 20, 34], ["effective communicable disease surveillance", "PROBLEM", 82, 125]]], ["The WHO International Health Regulations (IHR) (WHO 2008) provide a legal framework for disease detection and response.", [["disease detection", "PROBLEM", 88, 105]]], ["In most high-income countries, communicable disease surveillance has been in operation for decades and credited with rapid detection of novel disease incursions, such as Hendra virus in Brisbane, 1994 (Selvey et al. 1995), and West Nile virus in New York, 1999 (Sejvar 2003), and national monitoring of pandemic influenza 2009 (NSW Public Health Network 2009) as well as outbreak control.", [["communicable disease", "DISEASE", 31, 51], ["Hendra virus", "DISEASE", 170, 182], ["influenza", "DISEASE", 312, 321], ["Hendra virus", "ORGANISM", 170, 182], ["West Nile virus", "ORGANISM", 227, 242], ["Hendra virus", "SPECIES", 170, 182], ["West Nile virus", "SPECIES", 227, 242], ["communicable disease surveillance", "PROBLEM", 31, 64], ["novel disease incursions", "PROBLEM", 136, 160], ["pandemic influenza", "PROBLEM", 303, 321]]], ["Methods used range from reports of unusual or suspicious index cases by astute (medical or veterinary) clinicians to mandatory notification of diseases of public health importance, syndromic surveillance and digital epidemiology.Notification of Communicable Diseases of Public Health ImportanceNotification of communicable diseases, to central public health authorities, allows coordinated public health action.", [["communicable diseases", "DISEASE", 310, 331], ["syndromic surveillance", "TEST", 181, 203], ["communicable diseases", "PROBLEM", 310, 331]]], ["Detection and investigation of outbreaks require prompt, accurate laboratory diagnosis and follow-up of affected individuals.", [["affected individuals", "PROBLEM", 104, 124]]], ["This means that personal information\u2014names, ages, addresses and relevant medical data\u2014is reported to public health authorities, often without the person\u2019s knowledge or consent.", [["person", "SPECIES", 146, 152]]], ["Patients and their contacts are questioned to determine the likely sources and the extent of the outbreak.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the outbreak", "PROBLEM", 93, 105], ["outbreak", "OBSERVATION", 97, 105]]], ["Patients are treated, if necessary, and may be isolated, while they remain infectious, to prevent further spread; contacts, or occasionally whole communities, may be quarantined (Koch 2016b), especially if preventive measures, such as vaccination or antibiotic prophylaxis, are unavailable.Notification of Communicable Diseases of Public Health ImportanceThese interventions are intrusive and have been a source of controversy, since the late nineteenth century, when physicians objected to tuberculosis surveillance, which they claimed would encroach on the sanctity of the patient-doctor relationship (Shrady 1897).", [["tuberculosis", "DISEASE", 491, 503], ["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 575, 582], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 575, 582], ["infectious", "PROBLEM", 75, 85], ["preventive measures", "TREATMENT", 206, 225], ["vaccination", "TREATMENT", 235, 246], ["antibiotic prophylaxis", "TREATMENT", 250, 272], ["intrusive", "PROBLEM", 379, 388], ["tuberculosis surveillance", "TEST", 491, 516], ["infectious", "OBSERVATION", 75, 85], ["tuberculosis", "OBSERVATION", 491, 503]]], ["However, throughout most of last century, there has been widespread public acceptance of name-based communicable disease surveillance of selected (prevalent, serious and/or preventable) infectious diseases, based on a generally well-founded assumption of privacy\u2014i.e. that information will be conveyed only to those who need to know.", [["communicable disease", "DISEASE", 100, 120], ["infectious diseases", "DISEASE", 186, 205], ["infectious diseases", "PROBLEM", 186, 205], ["widespread", "OBSERVATION_MODIFIER", 57, 67], ["infectious", "OBSERVATION", 186, 196]]], ["The benefits include development of evidence-based infection prevention, disease control and health service planning strategies and the ability to monitor disease epidemiology (Fairchild et al. 2017) and inform development of vaccines and antimicrobials.Notification of Communicable Diseases of Public Health ImportanceCollection and storage of personal data for communicable disease control are usually protected by public health and privacy legislation.", [["infection", "DISEASE", 51, 60], ["communicable disease", "DISEASE", 363, 383], ["based infection prevention", "PROBLEM", 45, 71], ["disease control", "TREATMENT", 73, 88], ["vaccines", "TREATMENT", 226, 234], ["antimicrobials", "TREATMENT", 239, 253], ["communicable disease control", "PROBLEM", 363, 391], ["infection", "OBSERVATION", 51, 60]]], ["Until recently, it has been relatively inefficient.", [["relatively", "OBSERVATION_MODIFIER", 28, 38], ["inefficient", "OBSERVATION_MODIFIER", 39, 50]]], ["Conventional paper-based disease notification, by mail or fax, and \u201cshoe-leather\u201d outbreak investigations are slow.", [["disease", "OBSERVATION", 25, 32]]], ["Culture-based laboratory diagnosis and referral of isolates to a reference laboratory for strain typing takes days or weeks.", [["Culture", "TEST", 0, 7], ["strain typing", "TEST", 90, 103]]], ["Recently, faster, more accurate pathogen identification and strain typing methods, including whole-genome sequencing (WGS) (K\u00f6ser et al. 2012a), and automated laboratory reporting have improved the timeliness of outbreak detection and provided more accurate microbiological information for public health action.Implications and Risks of WGS for Surveillance and Outbreak Investigations ::: Outbreak Management Using Pathogen Whole-Genome SequencingSurveillance and outbreak investigation has always required the use of personal data.", [["strain typing methods", "TEST", 60, 81], ["outbreak detection", "TEST", 212, 230], ["WGS", "TEST", 337, 340], ["Surveillance", "TEST", 345, 357], ["Outbreak Investigations", "TEST", 362, 385], ["Outbreak Management", "TREATMENT", 390, 409], ["outbreak investigation", "TEST", 465, 487]]], ["Unlike public health surveillance, nosocomial outbreak investigations are not protected by legislation and there is no clarity about privacy protection or the need for informed consent when the use of WGS is extended into new domains.", [["nosocomial outbreak investigations", "TEST", 35, 69], ["privacy protection", "TREATMENT", 133, 151], ["no", "UNCERTAINTY", 116, 118]]], ["In the following case study (Box 2), we outline some ethical issues raised by WGS of stored isolates for retrospective investigation of a hospital outbreak and suggest that, while the benefits would have been greater if WGS had been available at the time, the ethical dilemmas would have been even more challenging.Implications and Risks of WGS for Surveillance and Outbreak Investigations ::: Outbreak Management Using Pathogen Whole-Genome SequencingBox 2 A high stakes neonatal intensive care unit outbreak investigation3 (Pinto et al. 2013)Implications and Risks of WGS for Surveillance and Outbreak Investigations ::: Outbreak Management Using Pathogen Whole-Genome SequencingWGS of stored outbreak isolates, for retrospective outbreak investigation, is likely to provide some answers to epidemiological questions, but before it is done, several important ethical questions should be considered:Should informed consent for WGS be obtained from individuals from whom isolates were obtained (or their carers), despite logistical difficulties and emotional risks?", [["some ethical issues", "PROBLEM", 48, 67], ["retrospective investigation", "TEST", 105, 132], ["WGS", "TEST", 220, 223], ["WGS", "TEST", 341, 344], ["Surveillance", "TEST", 349, 361], ["Outbreak Investigations", "TEST", 366, 389], ["Outbreak Management", "TREATMENT", 394, 413], ["Surveillance", "TEST", 578, 590], ["Outbreak Management", "TREATMENT", 623, 642], ["retrospective outbreak investigation", "TEST", 718, 754], ["WGS", "TEST", 928, 931], ["logistical difficulties", "PROBLEM", 1021, 1044], ["emotional risks", "PROBLEM", 1049, 1064]]], ["Individual consent was given, at least implicitly, for collection of specimens for diagnosis or screening and whatever laboratory procedures were in routine use at the time, but WGS is a new procedure, and its results will have potentially significant implications, for affected individuals.If WGS identifies an individual as a likely source or vector of nosocomial transmission, how would this reflect on her infection control practices or affect her future employment?", [["specimens", "ANATOMY", 69, 78], ["infection", "DISEASE", 410, 419], ["collection of specimens", "TEST", 55, 78], ["diagnosis", "TEST", 83, 92], ["screening", "TEST", 96, 105], ["laboratory procedures", "TEST", 119, 140], ["a new procedure", "TREATMENT", 185, 200], ["affected individuals", "PROBLEM", 270, 290], ["WGS", "TEST", 294, 297], ["nosocomial transmission", "TREATMENT", 355, 378], ["her infection control practices", "TREATMENT", 406, 437]]], ["What would be the psychological effects of discovering that she had transmitted a pathogen to vulnerable patients in her care (even if no blame were attributed to her by others)?", [["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113]]], ["Transient contamination of other staff members\u2019 hands was likely but unverifiable.Who owns microbial isolates and the information they contain\u2014the people from whose clinical samples they were isolated or the laboratory, which isolated and characterised them?Implications and Risks of WGS for Surveillance and Outbreak Investigations ::: Outbreak Management Using Pathogen Whole-Genome SequencingQuestions like these are even more relevant now that the use of WGS is increasing, not only for research or retrospective outbreak investigation but, potentially, for routine pathogen identification, AMR testing and prospective hospital infection control (O'Sullivan et al. 2012).Use of Pathogen WGS and Metagenomics for Routine Diagnosis and Strain Typing ::: Outbreak Management Using Pathogen Whole-Genome SequencingIt is predicted that WGS will replace conventional culture-based pathogen identification and AMR testing, in public hospital and private diagnostic laboratories, within a few years (Kwong et al. 2015).", [["infection", "DISEASE", 632, 641], ["people", "ORGANISM", 147, 153], ["people", "SPECIES", 147, 153], ["WGS", "TEST", 284, 287], ["Surveillance", "TEST", 292, 304], ["Outbreak Investigations", "TEST", 309, 332], ["Outbreak Management", "TREATMENT", 337, 356], ["routine pathogen identification", "TEST", 562, 593], ["AMR testing", "TEST", 595, 606], ["prospective hospital infection control", "TREATMENT", 611, 649], ["Pathogen WGS", "TREATMENT", 682, 694], ["Strain Typing", "TEST", 738, 751], ["Outbreak Management", "TREATMENT", 756, 775], ["conventional culture", "TEST", 852, 872], ["pathogen identification", "TEST", 879, 902], ["AMR testing", "TEST", 907, 918], ["contamination", "OBSERVATION", 10, 23]]], ["Pathogen identification and sequencing, directly from clinical specimens, without the need for culture or prior knowledge of the target pathogen (clinical metagenomics4), is likely to be possible in the future.", [["specimens", "ANATOMY", 63, 72], ["Pathogen identification", "TEST", 0, 23], ["clinical specimens", "TEST", 54, 72], ["culture", "TEST", 95, 102], ["the target pathogen", "PROBLEM", 125, 144], ["likely to be possible", "UNCERTAINTY", 174, 195]]], ["When it is, sequence-based pathogen identification and AMR testing results will be available within hours.", [["based pathogen identification", "TEST", 21, 50], ["AMR testing", "TEST", 55, 66]]], ["This will allow appropriate antimicrobial therapy for a bacterial or fungal infection, to be started much sooner than is currently possible or avoided altogether, if a viral infection is identified.", [["fungal infection", "DISEASE", 69, 85], ["viral infection", "DISEASE", 168, 183], ["appropriate antimicrobial therapy", "TREATMENT", 16, 49], ["a bacterial or fungal infection", "PROBLEM", 54, 85], ["a viral infection", "PROBLEM", 166, 183], ["fungal", "OBSERVATION_MODIFIER", 69, 75], ["infection", "OBSERVATION", 76, 85], ["viral", "OBSERVATION_MODIFIER", 168, 173], ["infection", "OBSERVATION", 174, 183]]], ["Either way, outcomes will be better, with fewer drug side effects, improved antimicrobial stewardship, less AMR and less frequent pathogen transmission.", [["AMR", "DISEASE", 108, 111], ["fewer drug side effects", "PROBLEM", 42, 65], ["less frequent pathogen transmission", "PROBLEM", 116, 151], ["less AMR", "OBSERVATION_MODIFIER", 103, 111], ["less", "OBSERVATION_MODIFIER", 116, 120], ["frequent", "OBSERVATION_MODIFIER", 121, 129], ["pathogen", "OBSERVATION", 130, 138]]], ["There are still major barriers to routine culture-based WGS or culture-independent metagenomics, but decreasing costs, faster sequencing, the potential to identify virulence or AMR markers and polymicrobial infections and/or to predict outbreaks with a single assay, make them attractive options for clinical microbiology (Forbes et al. 2017; Gardy and Loman 2018).Integrating Genomic, Clinical and Epidemiological Data ::: Outbreak Management Using Pathogen Whole-Genome SequencingHuman genomic data and Big Data analytics are already being combined for personalised diagnosis and treatment (\u201cprecision medicine\u201d) of some diseases (Brittain et al. 2017).", [["infections", "DISEASE", 207, 217], ["routine culture", "TEST", 34, 49], ["based WGS", "TEST", 50, 59], ["culture", "TEST", 63, 70], ["independent metagenomics", "PROBLEM", 71, 95], ["decreasing costs", "PROBLEM", 101, 117], ["virulence", "PROBLEM", 164, 173], ["AMR markers", "PROBLEM", 177, 188], ["polymicrobial infections", "PROBLEM", 193, 217], ["Outbreak Management", "TREATMENT", 424, 443], ["treatment (\u201cprecision medicine", "TREATMENT", 582, 612], ["some diseases", "PROBLEM", 618, 631], ["polymicrobial", "OBSERVATION_MODIFIER", 193, 206], ["infections", "OBSERVATION", 207, 217]]], ["The use of pathogen WGS or metagenomic data will expedite the introduction of precision medicine in infectious diseases.", [["infectious diseases", "DISEASE", 100, 119], ["pathogen WGS", "TREATMENT", 11, 23], ["metagenomic data", "TEST", 27, 43], ["precision medicine", "TREATMENT", 78, 96], ["infectious", "OBSERVATION", 100, 110]]], ["Application of Big Data analytics to (i) demographic, clinical and lifestyle risk factors (from EHR); (ii) genetic and immunological predictors of risk and response to therapy (from personal genomic data); and (iii) pathogen virulence and AMR profiles (from WGS data) would allow individually tailored antimicrobial therapy (drug, dose, route of administration, duration) and improved outcomes.Integrating Genomic, Clinical and Epidemiological Data ::: Outbreak Management Using Pathogen Whole-Genome SequencingInfectious diseases differ from most others in that the speed of diagnosis and time to initiation of appropriate therapy (within hours, for life-threatening sepsis) is the major determinant of the outcome, not only for the affected individual but also for her immediate contacts and the wider community.", [["Infectious diseases", "DISEASE", 511, 530], ["sepsis", "DISEASE", 668, 674], ["therapy", "TREATMENT", 168, 175], ["personal genomic data", "TEST", 182, 203], ["(iii) pathogen virulence", "PROBLEM", 210, 234], ["AMR profiles", "TEST", 239, 251], ["WGS data", "TEST", 258, 266], ["tailored antimicrobial therapy", "TREATMENT", 293, 323], ["Outbreak Management", "TREATMENT", 453, 472], ["appropriate therapy", "TREATMENT", 612, 631], ["life-threatening sepsis", "PROBLEM", 651, 674], ["sepsis", "OBSERVATION", 668, 674]]], ["Rapid identification is obviously essential to ensure prompt, appropriate care and isolation of a patient with a potentially fatal meningococcal or an imported pan-resistant Gram-negative bacterial infection; extremely drug-resistant tuberculosis; or an exotic, high impact viral infection, e.g. Ebola or pandemic influenza.", [["bacterial infection", "DISEASE", 188, 207], ["tuberculosis", "DISEASE", 234, 246], ["viral infection", "DISEASE", 274, 289], ["Ebola", "DISEASE", 296, 301], ["influenza", "DISEASE", 314, 323], ["patient", "ORGANISM", 98, 105], ["Gram", "GENE_OR_GENE_PRODUCT", 174, 178], ["Ebola", "ORGANISM", 296, 301], ["patient", "SPECIES", 98, 105], ["Rapid identification", "TEST", 0, 20], ["isolation", "TREATMENT", 83, 92], ["a potentially fatal meningococcal", "PROBLEM", 111, 144], ["an imported pan-resistant Gram-negative bacterial infection", "PROBLEM", 148, 207], ["extremely drug-resistant tuberculosis", "PROBLEM", 209, 246], ["an exotic", "PROBLEM", 251, 260], ["high impact viral infection", "PROBLEM", 262, 289], ["Ebola", "PROBLEM", 296, 301], ["pandemic influenza", "PROBLEM", 305, 323], ["fatal", "OBSERVATION_MODIFIER", 125, 130], ["meningococcal", "OBSERVATION", 131, 144], ["negative bacterial", "OBSERVATION_MODIFIER", 179, 197], ["infection", "OBSERVATION", 198, 207], ["resistant", "OBSERVATION_MODIFIER", 224, 233], ["tuberculosis", "OBSERVATION", 234, 246], ["exotic", "OBSERVATION_MODIFIER", 254, 260], ["high impact", "OBSERVATION_MODIFIER", 262, 273], ["viral infection", "OBSERVATION", 274, 289]]], ["It is also important to allow timely application of appropriate hospital infection control and public health interventions, such as vaccination, antimicrobial prophylaxis and/or quarantine of contacts, to prevent or limit a dangerous outbreak.Integrating Genomic, Clinical and Epidemiological Data ::: Outbreak Management Using Pathogen Whole-Genome SequencingMany benefits for individual patients and their (known) contacts could be achieved by the use of individual EHRs, alone, but personalised treatment regimens and outcome monitoring also depend on the use of algorithms derived from analysis of aggregate data from large numbers of EHRs.", [["infection", "DISEASE", 73, 82], ["patients", "ORGANISM", 389, 397], ["patients", "SPECIES", 389, 397], ["appropriate hospital infection control", "TREATMENT", 52, 90], ["public health interventions", "TREATMENT", 95, 122], ["vaccination", "TREATMENT", 132, 143], ["antimicrobial prophylaxis", "TREATMENT", 145, 170], ["a dangerous outbreak", "PROBLEM", 222, 242], ["Outbreak Management", "TREATMENT", 302, 321], ["personalised treatment regimens", "TREATMENT", 485, 516], ["outcome monitoring", "TEST", 521, 539]]], ["Big Data analytics can not only develop but also validate and improve diagnostic, treatment and decision support algorithms and, potentially, identify previously unrecognised prognostic information such as clinical or genetic markers of susceptibility to infection, an excessive immunological response or of being a \u201csuperspreader\u201d.", [["infection", "DISEASE", 255, 264], ["treatment", "TREATMENT", 82, 91], ["susceptibility to infection", "PROBLEM", 237, 264], ["an excessive immunological response", "PROBLEM", 266, 301], ["infection", "OBSERVATION", 255, 264]]], ["Thus, the community benefits of an EHR system, for disease prevention and research, would depend on widespread\u2014ideally universal\u2014community participation (not unlike vaccination).Integrating Genomic, Clinical and Epidemiological Data ::: Outbreak Management Using Pathogen Whole-Genome SequencingMoreover, to realise the additional benefits of using pathogen WGS data for communicable disease surveillance will require access to and analysis of aggregate WGS data in national or international laboratory networks, linked to clinical and epidemiological databases.", [["communicable disease", "DISEASE", 371, 391], ["an EHR system", "TEST", 32, 45], ["disease prevention", "TREATMENT", 51, 69], ["Outbreak Management", "TREATMENT", 237, 256], ["pathogen WGS data", "TEST", 349, 366], ["communicable disease surveillance", "PROBLEM", 371, 404], ["aggregate WGS data", "TEST", 444, 462]]], ["EHRs of individuals, whose isolates are identified as part of an outbreak, would be scanned for common risk factors, contacts or exposure to environmental sources, of which the individuals, themselves, may be unaware, to expedite outbreak investigation.", [["individuals", "ORGANISM", 8, 19], ["common risk factors", "PROBLEM", 96, 115]]], ["Automatic access to, at least, selected personal EHR data, without the need for individual consent, will be essential, since the effectiveness of public health interventions depends on speed.", [["public health interventions", "TREATMENT", 146, 173]]], ["The trade-off has implications for the effectiveness of surveillance systems because, as \u201cutility increases privacy decreases\u201d (Lubarsky 2017).", [["surveillance systems", "TEST", 56, 76]]], ["The challenge is to ensure an appropriate balance between individual risk and community benefit.Syndromic Surveillance, Digital Epidemiology and Big DataThe use of pathogen WGS or metagenomics for surveillance, as outlined above, is highly specific, but also selective and insensitive.", [["pathogen WGS", "TEST", 164, 176], ["surveillance", "TEST", 197, 209]]], ["Infected (and infectious) people, who are asymptomatic or have mild symptoms, who do not seek or have access to medical care or for whom laboratory tests are not ordered, may unwittingly spread infection to others.", [["infection", "DISEASE", 194, 203], ["people", "ORGANISM", 26, 32], ["people", "SPECIES", 26, 32], ["asymptomatic", "PROBLEM", 42, 54], ["mild symptoms", "PROBLEM", 63, 76], ["laboratory tests", "TEST", 137, 153], ["infectious", "OBSERVATION_MODIFIER", 14, 24], ["mild", "OBSERVATION_MODIFIER", 63, 67], ["infection", "OBSERVATION", 194, 203]]], ["Syndromic surveillance can \u201ccapture\u201d undiagnosed infections and is commonly used to complement other methods.", [["infections", "DISEASE", 49, 59], ["Syndromic surveillance", "TEST", 0, 22], ["undiagnosed infections", "PROBLEM", 37, 59], ["infections", "OBSERVATION", 49, 59]]], ["Automated monitoring of coded, de-identified data, analysed in almost real-time, allows health authorities to rapidly identify the onset, trace the spread and identify trends, over time, of outbreaks, e.g. of diarrhoeal or respiratory diseases; it can provide early warning of seasonal, or even pandemic, influenza, or track adverse reactions to antimicrobial drugs or vaccines (Salath\u00e9 2016).", [["respiratory", "ANATOMY", 223, 234], ["diarrhoeal or respiratory diseases", "DISEASE", 209, 243], ["influenza", "DISEASE", 305, 314], ["Automated monitoring", "TEST", 0, 20], ["de-identified data", "TEST", 31, 49], ["trace the spread", "PROBLEM", 138, 154], ["diarrhoeal", "PROBLEM", 209, 219], ["respiratory diseases", "PROBLEM", 223, 243], ["pandemic", "PROBLEM", 295, 303], ["influenza", "PROBLEM", 305, 314], ["track adverse reactions", "PROBLEM", 319, 342], ["antimicrobial drugs", "TREATMENT", 346, 365], ["vaccines", "TREATMENT", 369, 377], ["respiratory", "ANATOMY", 223, 234], ["diseases", "OBSERVATION", 235, 243]]], ["Although syndromic surveillance contains high levels of background \u201cnoise\u201d, its strengths are timeliness and pattern recognition.Syndromic Surveillance, Digital Epidemiology and Big DataDigital epidemiology refers to the study of disease patterns using digital data (Gardy and Loman 2018; Salath\u00e9 et al. 2012).", [["syndromic surveillance", "TEST", 9, 31], ["the study", "TEST", 217, 226], ["digital data", "TEST", 253, 265], ["high levels", "OBSERVATION_MODIFIER", 41, 52]]], ["For communicable disease epidemiology, data may include conventional syndromic surveillance, as outlined above, as well as, for example, participatory surveillance systems, to which volunteers report symptoms online (Guerrisi et al. 2016); calls to hospital or nurse help lines; ambulance dispatch requests; health insurance claims; and laboratory, pharmacy or EHR records.", [["volunteers", "ORGANISM", 182, 192], ["communicable disease epidemiology", "PROBLEM", 4, 37], ["conventional syndromic surveillance", "TEST", 56, 91], ["participatory surveillance systems", "TEST", 137, 171], ["symptoms", "PROBLEM", 200, 208]]], ["They can also include any of the myriad data collected for unrelated purposes that may (or may not) reflect disease activity, such as school and work absenteeism rates, over-the-counter drug sales, social media posts (Salath\u00e9 et al. 2012; Charles-Smith et al. 2015; Tang et al. 2018) and internet searches (Ginsberg et al. 2009).", [["the myriad data", "TEST", 29, 44], ["disease activity", "PROBLEM", 108, 124]]], ["Data from animal and environmental health sources can help to identify emerging infectious disease risks.Syndromic Surveillance, Digital Epidemiology and Big DataApplying Big Data analytics to diverse and underutilised data, often from otherwise hidden populations, could enhance outbreak detection and our understanding of infectious disease epidemiology on a global scale, rather than the local or national focus of conventional surveillance.", [["infectious disease", "DISEASE", 80, 98], ["emerging infectious disease risks", "PROBLEM", 71, 104], ["conventional surveillance", "TEST", 418, 443]]], ["The greater scope, diversity and geographic range of data sources would increase the potential for acquisition of new knowledge, modelling of disease outbreaks, trends and related human behaviour and, ultimately, for improved global control, reduced morbidity and mortality from communicable diseases and greater health security.", [["communicable diseases", "DISEASE", 279, 300], ["human", "ORGANISM", 180, 185], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 180, 185], ["disease outbreaks", "PROBLEM", 142, 159], ["reduced morbidity", "PROBLEM", 242, 259], ["communicable diseases", "PROBLEM", 279, 300], ["greater", "OBSERVATION_MODIFIER", 4, 11]]], ["But there are also potential, largely unknown and poorly defined, risks.Syndromic Surveillance, Digital Epidemiology and Big DataOne risk is the use of flawed methods for disease prediction or modelling.", [["disease prediction", "PROBLEM", 171, 189], ["poorly defined", "OBSERVATION_MODIFIER", 50, 64]]], ["The accuracy and reliability of different types of data, and the methods used to analyse them, are highly variable, e.g. references to \u201cflu\u201d, on Facebook, \u201cflu-like illness\u201d in an experienced GP\u2019s case notes or \u201cinfluenza A virus identified\u201d in a laboratory report could apply to the same, or to very different, conditions.", [["flu-like illness", "DISEASE", 156, 172], ["influenza A virus", "PROBLEM", 212, 229]]], ["The limitations of novel surveillance systems were illustrated by the demise of Google Flu Trends, which was based on Google searches related to \u201cflu\u201d or symptoms or behaviours interpreted as likely to be due to flu.", [["flu", "DISEASE", 146, 149], ["flu", "DISEASE", 212, 215], ["novel surveillance systems", "TEST", 19, 45], ["Google searches", "TEST", 118, 133], ["\u201cflu\u201d", "PROBLEM", 145, 150], ["symptoms", "PROBLEM", 154, 162], ["flu", "PROBLEM", 212, 215], ["flu", "OBSERVATION", 212, 215]]], ["It was predicted, but ultimately failed, to identify the onset of seasonal influenza 2 weeks in advance of conventional surveillance (Ginsberg et al. 2009; Lazer et al. 2014).", [["influenza", "DISEASE", 75, 84], ["seasonal influenza", "PROBLEM", 66, 84]]], ["Its failure was attributed to the lack of transparency of methods, over-fitting of data and failure to account for changing search behaviours (Lazer and Kennedy 2015).Syndromic Surveillance, Digital Epidemiology and Big DataAnother risk is that many data sources do not capture basic demographics (age, sex, ethnicity) and infants, the elderly and economically disadvantaged groups\u2014who are most at risk from communicable diseases\u2014are likely to be under-represented (Bansal et al. 2016).", [["infants", "ORGANISM", 323, 330], ["infants", "SPECIES", 323, 330], ["Its failure", "PROBLEM", 0, 11], ["transparency of methods", "PROBLEM", 42, 65], ["failure", "PROBLEM", 92, 99], ["communicable diseases\u2014are", "PROBLEM", 408, 433], ["failure", "OBSERVATION", 4, 11], ["failure", "OBSERVATION", 92, 99]]], ["Methods developed to minimise bias and validate results in conventional epidemiological research, such as sampling protocols and case definitions, cannot easily be applied (Lee et al. 2016).Syndromic Surveillance, Digital Epidemiology and Big DataThe harmful effects, of inaccurate or exaggerated outbreak predictions or modelling, include economic impacts on trade, tourism and health services, social consequences of unnecessary public fear and loss of trust in public health authorities.", [["Methods", "TREATMENT", 0, 7], ["sampling protocols", "TEST", 106, 124], ["inaccurate or exaggerated outbreak predictions", "PROBLEM", 271, 317]]], ["Peer review and ethical oversight of methods and validation of results by comparison with conventional data would help to prevent them\u2014albeit at increased cost of program development and maintenance.Syndromic Surveillance, Digital Epidemiology and Big DataPerhaps, the greatest risk, however, is public fear, ignorance and mistrust.", [["them\u2014albeit", "DISEASE", 130, 141]]], ["Ill-informed media scrutiny and political risk aversion could prevent or delay the incorporation of de-identified personal health data into Big Data\u2013based public health surveillance, despite the benefits.", [["political risk aversion", "TREATMENT", 32, 55]]], ["Even the best available de-identification methods, and optimal levels of data security around legitimate use of identified personal data for outbreak investigations, may not placate these fears.", [["outbreak investigations", "TEST", 141, 164]]], ["On the other hand, if important data were, theoretically, available but omitted, public health authorities would attract public, media and political censure if they failed to prevent or limit an infectious disease emergency because they failed to utilise or respond to intelligence, whatever the source, which could have predicted it.Syndromic Surveillance, Digital Epidemiology and Big DataThere is an urgent need for open and informed discussion about the ethical implications, quality and safety of Big Data\u2013based use of varied types of data, including personal and pathogen genomic data, in communicable disease control.", [["an infectious disease emergency", "PROBLEM", 192, 223], ["communicable disease control", "TREATMENT", 595, 623], ["infectious", "OBSERVATION", 195, 205]]], ["Questions for discussion\u2014assuming the most reliable methods of data capture and analysis are in use\u2014might include, but not be limited to:What is the personal significance of a pathogen isolated from an individual, considering the highly specific and sensitive personal information that its WGS can reveal?", [["a pathogen", "PROBLEM", 174, 184]]], ["Should it be subject to a similar degree of privacy protection as that of her personal (human) genome?Given the public benefits (accuracy, reliability, sensitivity, specificity, timeliness) of using as many and varied types of data as possible, in communicable disease surveillance, outbreak investigation and research, should the use of de-identified personal data from EHRs (which may include personal and/or pathogen genomic data) be permitted, and in what circumstances?", [["human", "ORGANISM", 88, 93], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["privacy protection", "TREATMENT", 44, 62], ["sensitivity", "TEST", 152, 163], ["outbreak investigation", "TEST", 283, 305]]], ["Should individual consent be required and if so in what circumstances?What level of probability and reliability, based on Big Data analytics, should be required before issuing a public alert about an impending infectious disease emergency\u2014e.g. due to a previously unknown emerging or highly virulent, transmissible or drug-resistant pathogen\u2014considering the need to balance the risks of delay against those of a false alarm?", [["Big Data analytics", "TEST", 122, 140], ["a false alarm", "TEST", 410, 423], ["false alarm", "OBSERVATION", 412, 423]]], ["(Would a 30% risk of a dangerous infectious disease emergency be morally equivalent to a 30% risk of a category 4 tropical cyclone, for example?)What would be an ethical response to information, based on reliable Big Data analytics that some populations are at increased risk of infection and/or of becoming a risk to others?", [["infection", "DISEASE", 279, 288], ["a dangerous infectious disease", "PROBLEM", 21, 51], ["some populations", "PROBLEM", 237, 253], ["infection", "PROBLEM", 279, 288], ["infection", "OBSERVATION", 279, 288]]], ["Considering the risk of stigmatisation, discrimination, loss of autonomy (e.g. mandatory testing) and/or restriction of liberty (e.g. quarantine), who should be told (the affected group; health professionals; the general public)?Syndromic Surveillance, Digital Epidemiology and Big DataAnswers to these and other questions would inform development of an ethical framework, for future communicable disease control, which, we argue, is needed because recent technological innovations have raised new ethical issues.", [["loss of autonomy", "DISEASE", 56, 72], ["stigmatisation", "PROBLEM", 24, 38], ["loss of autonomy", "PROBLEM", 56, 72], ["e.g. mandatory testing", "TEST", 74, 96], ["future communicable disease control", "TREATMENT", 377, 412], ["new ethical issues", "PROBLEM", 494, 512], ["stigmatisation", "OBSERVATION", 24, 38]]]], "PMC7191387": [], "91404a3f87386157fe0c22fc40386f25df491d76": [["IntroductionThe transmembrane envelope glycoproteins of many viruses use simple a-helical bundle motifs to facilitate fusion between the virus and host membranes during infection.", [["transmembrane", "ANATOMY", 16, 29], ["membranes", "ANATOMY", 152, 161], ["infection", "DISEASE", 169, 178], ["host membranes", "CELLULAR_COMPONENT", 147, 161], ["transmembrane envelope glycoproteins", "PROTEIN", 16, 52], ["a-helical bundle motifs", "PROTEIN", 80, 103], ["The transmembrane envelope glycoproteins", "TREATMENT", 12, 52], ["many viruses", "PROBLEM", 56, 68], ["simple a-helical bundle motifs", "TREATMENT", 73, 103], ["fusion", "TREATMENT", 118, 124], ["the virus", "PROBLEM", 133, 142], ["infection", "PROBLEM", 169, 178], ["fusion", "OBSERVATION", 118, 124], ["host membranes", "OBSERVATION", 147, 161], ["infection", "OBSERVATION", 169, 178]]], ["[1] [2] [3] (Historically, envelope glycopro-teins have been categorized according to structural features with a-helical bundle proteins comprising the so-called ''class I'' family.", [["[1] [2] [3]", "SIMPLE_CHEMICAL", 0, 11], ["a-helical bundle proteins", "PROTEIN", 111, 136], ["class I'' family", "PROTEIN", 164, 180]]], ["2 ) In the general model for membrane fusion, folding of a six-helix bundle by the glycoprotein ectodomain provides the driving force for bringing the two bilayers together.", [["membrane", "ANATOMY", 29, 37], ["membrane", "CELLULAR_COMPONENT", 29, 37], ["six-helix bundle", "PROTEIN", 59, 75], ["glycoprotein ectodomain", "PROTEIN", 83, 106], ["membrane fusion", "TREATMENT", 29, 44], ["a six-helix bundle", "TREATMENT", 57, 75], ["the glycoprotein ectodomain", "TREATMENT", 79, 106], ["membrane fusion", "OBSERVATION", 29, 44]]], ["[1] [2] [3] The prototypic six-helix bundle formed by the N-and Cheptad repeat (NHR and CHR) regions from the human immunodeficiency virus type 1 (HIV-1) transmembrane envelope glycoprotein gp41 has been particularly instructive for understanding this mechanism (Fig. 1 ).", [["human immunodeficiency virus type 1", "ORGANISM", 110, 145], ["HIV-1", "ORGANISM", 147, 152], ["prototypic six-helix bundle", "PROTEIN", 16, 43], ["N", "PROTEIN", 58, 59], ["Cheptad repeat", "PROTEIN", 64, 78], ["NHR", "PROTEIN", 80, 83], ["CHR", "PROTEIN", 88, 91], ["human immunodeficiency virus type 1 (HIV-1) transmembrane envelope glycoprotein gp41", "PROTEIN", 110, 194], ["human", "SPECIES", 110, 115], ["immunodeficiency virus type 1", "SPECIES", 116, 145], ["HIV-1", "SPECIES", 147, 152], ["human immunodeficiency virus type 1", "SPECIES", 110, 145], ["HIV-1", "SPECIES", 147, 152], ["The prototypic six-helix bundle", "TREATMENT", 12, 43], ["the N", "TEST", 54, 59], ["Cheptad repeat (NHR and CHR) regions", "PROBLEM", 64, 100], ["the human immunodeficiency virus type", "TEST", 106, 143], ["HIV", "TEST", 147, 150], ["transmembrane envelope glycoprotein gp41", "TREATMENT", 154, 194]]], ["[4] [5] [6] The primary sequence of gp41 contains a hydrophobic N-terminal fusion peptide (FP), the ectodomain containing the NHR and CHR, and a transmembrane domain that anchors the glycoprotein to the virus.", [["transmembrane", "ANATOMY", 145, 158], ["N", "CHEMICAL", 64, 65], ["gp41", "GENE_OR_GENE_PRODUCT", 36, 40], ["NHR", "GENE_OR_GENE_PRODUCT", 126, 129], ["CHR", "GENE_OR_GENE_PRODUCT", 134, 137], ["gp41", "PROTEIN", 36, 40], ["hydrophobic N-terminal fusion peptide", "PROTEIN", 52, 89], ["FP", "PROTEIN", 91, 93], ["ectodomain", "PROTEIN", 100, 110], ["NHR", "PROTEIN", 126, 129], ["CHR", "PROTEIN", 134, 137], ["transmembrane domain", "PROTEIN", 145, 165], ["glycoprotein", "PROTEIN", 183, 195], ["a hydrophobic N-terminal fusion peptide", "TREATMENT", 50, 89], ["the ectodomain containing the NHR and CHR", "PROBLEM", 96, 137], ["a transmembrane domain", "PROBLEM", 143, 165]]], ["Following receptor binding by the surface glycoprotein (gp120), the FP of gp41 embeds in the membrane of the host cell giving rise to a transient trimeric intermediate known as the ''extended'' or ''prehairpin'' intermediate that spans both the virus and cell membranes and in which the NHR and CHR segments are exposed [ Fig. 1(A) ].", [["surface", "ANATOMY", 34, 41], ["membrane", "ANATOMY", 93, 101], ["cell", "ANATOMY", 114, 118], ["cell membranes", "ANATOMY", 255, 269], ["gp120", "GENE_OR_GENE_PRODUCT", 56, 61], ["gp41", "GENE_OR_GENE_PRODUCT", 74, 78], ["membrane", "CELLULAR_COMPONENT", 93, 101], ["host cell", "CELL", 109, 118], ["prehairpin'' intermediate", "CELLULAR_COMPONENT", 199, 224], ["cell membranes", "CELLULAR_COMPONENT", 255, 269], ["NHR", "GENE_OR_GENE_PRODUCT", 287, 290], ["surface glycoprotein", "PROTEIN", 34, 54], ["gp120", "PROTEIN", 56, 61], ["FP", "PROTEIN", 68, 70], ["gp41", "PROTEIN", 74, 78], ["NHR", "PROTEIN", 287, 290], ["CHR segments", "PROTEIN", 295, 307], ["host cell", "OBSERVATION", 109, 118], ["virus", "OBSERVATION", 245, 250], ["cell membranes", "OBSERVATION", 255, 269], ["CHR segments", "ANATOMY", 295, 307]]], ["Next, folding of the NHR and CHR into the six-helix bundle forces the two anchored membranes into proximity, which promotes mixing and, ultimately, formation of a fusion pore.", [["membranes", "ANATOMY", 83, 92], ["pore", "ANATOMY", 170, 174], ["NHR", "GENE_OR_GENE_PRODUCT", 21, 24], ["membranes", "CELLULAR_COMPONENT", 83, 92], ["NHR", "PROTEIN", 21, 24], ["CHR", "PROTEIN", 29, 32], ["six-helix bundle", "PROTEIN", 42, 58], ["a fusion pore", "TREATMENT", 161, 174], ["six-helix bundle", "ANATOMY", 42, 58], ["two", "OBSERVATION_MODIFIER", 70, 73], ["anchored membranes", "OBSERVATION", 74, 92], ["mixing", "OBSERVATION_MODIFIER", 124, 130], ["fusion pore", "OBSERVATION", 163, 174]]], ["This process likely proceeds via a hemifusion intermediate, in which the outer leaflets are fused but the inner leaflets are not, and it is thought that the transition from this hemifusion intermediate to the fusion pore represents the rate-limiting step during entry.", [["outer leaflets", "ANATOMY", 73, 87], ["inner leaflets", "ANATOMY", 106, 120], ["fusion pore", "ANATOMY", 209, 220], ["outer leaflets", "CELLULAR_COMPONENT", 73, 87], ["inner leaflets", "CELLULAR_COMPONENT", 106, 120], ["a hemifusion intermediate", "TREATMENT", 33, 58], ["the transition", "PROBLEM", 153, 167], ["this hemifusion", "TREATMENT", 173, 188], ["the fusion pore", "TREATMENT", 205, 220], ["outer leaflets", "ANATOMY", 73, 87], ["fused", "OBSERVATION", 92, 97], ["inner leaflets", "ANATOMY", 106, 120], ["fusion", "OBSERVATION", 209, 215]]], ["1 Transmembrane glycoproteins from other viruses such as Ebola virus (EboV) (GP2) and influenza A virus Figure 1 .", [["Ebola virus", "DISEASE", 57, 68], ["influenza A", "DISEASE", 86, 97], ["Ebola virus", "ORGANISM", 57, 68], ["EboV", "ORGANISM", 70, 74], ["GP2", "GENE_OR_GENE_PRODUCT", 77, 80], ["influenza A virus", "ORGANISM", 86, 103], ["Transmembrane glycoproteins", "PROTEIN", 2, 29], ["GP2", "PROTEIN", 77, 80], ["Ebola virus", "SPECIES", 57, 68], ["influenza A virus", "SPECIES", 86, 103], ["Ebola virus", "SPECIES", 57, 68], ["EboV", "SPECIES", 70, 74], ["influenza A virus Figure 1", "SPECIES", 86, 112], ["Transmembrane glycoproteins", "PROBLEM", 2, 29], ["other viruses", "PROBLEM", 35, 48], ["Ebola virus", "PROBLEM", 57, 68], ["influenza A virus Figure", "PROBLEM", 86, 110]]], ["A: General mechanism of viral membrane fusion catalyzed by a-helical bundle containing ectodomains.", [["membrane", "ANATOMY", 30, 38], ["membrane", "CELLULAR_COMPONENT", 30, 38], ["a-helical bundle containing ectodomains", "PROTEIN", 59, 98], ["viral membrane fusion", "TREATMENT", 24, 45], ["viral membrane fusion", "OBSERVATION", 24, 45], ["bundle", "ANATOMY_MODIFIER", 69, 75], ["ectodomains", "OBSERVATION", 87, 98]]], ["In both HIV-1 and EboV, the prefusion assembly consists of a dimer of trimers containing a surface subunit (SU, gp120 for HIV-1 and GP1 for EboV) and the transmembrane subunit that contains the NHR and CHR regions (TM, gp41 for HIV-1 and GP2 for EboV).", [["HIV-1", "ORGANISM", 8, 13], ["EboV", "GENE_OR_GENE_PRODUCT", 18, 22], ["SU", "GENE_OR_GENE_PRODUCT", 108, 110], ["HIV-1", "GENE_OR_GENE_PRODUCT", 122, 127], ["GP1", "GENE_OR_GENE_PRODUCT", 132, 135], ["EboV", "GENE_OR_GENE_PRODUCT", 140, 144], ["transmembrane", "CELLULAR_COMPONENT", 154, 167], ["NHR", "GENE_OR_GENE_PRODUCT", 194, 197], ["HIV-1", "GENE_OR_GENE_PRODUCT", 228, 233], ["GP2", "GENE_OR_GENE_PRODUCT", 238, 241], ["EboV", "GENE_OR_GENE_PRODUCT", 246, 250], ["EboV", "DNA", 18, 22], ["trimers", "PROTEIN", 70, 77], ["surface subunit", "PROTEIN", 91, 106], ["SU", "PROTEIN", 108, 110], ["gp120", "PROTEIN", 112, 117], ["GP1", "PROTEIN", 132, 135], ["EboV", "PROTEIN", 140, 144], ["transmembrane subunit", "PROTEIN", 154, 175], ["NHR", "PROTEIN", 194, 197], ["CHR regions", "PROTEIN", 202, 213], ["TM", "PROTEIN", 215, 217], ["gp41", "PROTEIN", 219, 223], ["GP2", "PROTEIN", 238, 241], ["EboV", "PROTEIN", 246, 250], ["HIV-1", "SPECIES", 8, 13], ["HIV-1", "SPECIES", 8, 13], ["HIV-1", "SPECIES", 122, 127], ["HIV-1", "SPECIES", 228, 233], ["EboV", "PROBLEM", 18, 22], ["a surface subunit", "TREATMENT", 89, 106], ["HIV", "TEST", 122, 125], ["EboV", "PROBLEM", 140, 144], ["the transmembrane subunit", "TEST", 150, 175], ["TM", "TEST", 215, 217], ["HIV", "TEST", 228, 231], ["EboV", "PROBLEM", 246, 250]]], ["In both cases a ''trigger'' leads to insertion of the N-terminal fusion peptide (FP) into the cell membrane resulting in the extended or prehairpin intermediate in which the NHR (cyan) and CHR (blue) are exposed to the environment.", [["cell membrane", "ANATOMY", 94, 107], ["N", "CHEMICAL", 54, 55], ["cell membrane", "CELLULAR_COMPONENT", 94, 107], ["NHR", "GENE_OR_GENE_PRODUCT", 174, 177], ["CHR (blue)", "GENE_OR_GENE_PRODUCT", 189, 199], ["N-terminal fusion peptide", "PROTEIN", 54, 79], ["prehairpin intermediate", "PROTEIN", 137, 160], ["NHR", "PROTEIN", 174, 177], ["CHR", "PROTEIN", 189, 192], ["the N-terminal fusion peptide", "TREATMENT", 50, 79], ["the cell membrane", "TREATMENT", 90, 107], ["CHR (blue", "TREATMENT", 189, 198], ["cell membrane", "OBSERVATION", 94, 107]]], ["Folding of the six-helix bundle juxtaposes the two membranes and ultimately leads to their coalescence.", [["membranes", "ANATOMY", 51, 60], ["membranes", "CELLULAR_COMPONENT", 51, 60], ["six-helix bundle", "PROTEIN", 15, 31], ["their coalescence", "PROBLEM", 85, 102], ["two membranes", "OBSERVATION", 47, 60], ["coalescence", "OBSERVATION_MODIFIER", 91, 102]]], ["Agents that bind the extended/ prehairpin intermediate and prevent six-helix bundle formation have been shown to act as potent antiviral agents in HIV-1 (fusion inhibitors).", [["six-helix bundle", "ANATOMY", 67, 83], ["HIV-1", "ORGANISM", 147, 152], ["HIV-1", "SPECIES", 147, 152], ["HIV-1", "SPECIES", 147, 152], ["Agents", "TREATMENT", 0, 6], ["the extended/ prehairpin intermediate", "TREATMENT", 17, 54], ["six-helix bundle formation", "PROBLEM", 67, 93], ["potent antiviral agents", "TREATMENT", 120, 143], ["HIV-1 (fusion inhibitors", "TREATMENT", 147, 171]]], ["B: Postfusion conformations of HIV-1 gp41 (PDB ID 1AIK) and EboV GP2 ectodomains solved by the Wiley (PDB ID 1EBO) and Kim groups (PDB ID 2EBO).", [["HIV-1 gp41", "GENE_OR_GENE_PRODUCT", 31, 41], ["PDB ID 1AIK", "GENE_OR_GENE_PRODUCT", 43, 54], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 60, 68], ["HIV-1 gp41", "PROTEIN", 31, 41], ["PDB ID 1AIK", "PROTEIN", 43, 54], ["EboV GP2 ectodomains", "PROTEIN", 60, 80], ["HIV-1", "SPECIES", 31, 36], ["HIV-1", "SPECIES", 31, 36], ["HIV", "PROBLEM", 31, 34], ["EboV GP2 ectodomains", "TREATMENT", 60, 80]]], ["The NHR and CHR elements are colored as in panel A; the Wiley GP2 construct contained an N-terminal trimeric GCN4 segment which is shown in green.", [["N", "CHEMICAL", 89, 90], ["Wiley GP2", "GENE_OR_GENE_PRODUCT", 56, 65], ["NHR and CHR elements", "DNA", 4, 24], ["Wiley GP2 construct", "DNA", 56, 75], ["N-terminal trimeric GCN4 segment", "DNA", 89, 121], ["the Wiley GP2 construct", "TEST", 52, 75], ["an N-terminal trimeric GCN4 segment", "TREATMENT", 86, 121], ["terminal", "ANATOMY_MODIFIER", 91, 99], ["trimeric GCN4", "ANATOMY", 100, 113], ["segment", "ANATOMY_MODIFIER", 114, 121]]], ["The six-helix bundle of EboV GP2 is boxed on the structure reported by Kim and coworkers.Introduction(HA2) have similar architectural features and by analogy are thought to promote membrane fusion via similar mechanisms.", [["membrane", "ANATOMY", 181, 189], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 24, 32], ["membrane", "CELLULAR_COMPONENT", 181, 189], ["six-helix bundle", "PROTEIN", 4, 20], ["EboV GP2", "PROTEIN", 24, 32], ["HA2", "PROTEIN", 102, 105], ["membrane fusion", "TREATMENT", 181, 196], ["bundle", "OBSERVATION_MODIFIER", 14, 20], ["EboV GP2", "OBSERVATION", 24, 32], ["membrane fusion", "OBSERVATION", 181, 196]]], ["[1] [2] [3] [7] [8] [9] For EboV, experimental evidence suggests that GP2 also forms an extended intermediate that ultimately collapses into the six-helix bundle and that degradation of the surface subunit (GP1) by host endosomal proteases cathepsins L and B (CatL and CatB) is an obligatory step in the pathway toward this intermediate.", [["endosomal", "ANATOMY", 220, 229], ["[1] [2] [3] [7] [8] [9] For EboV", "SIMPLE_CHEMICAL", 0, 32], ["GP2", "GENE_OR_GENE_PRODUCT", 70, 73], ["GP1", "GENE_OR_GENE_PRODUCT", 207, 210], ["cathepsins L", "GENE_OR_GENE_PRODUCT", 240, 252], ["B", "GENE_OR_GENE_PRODUCT", 257, 258], ["CatL", "GENE_OR_GENE_PRODUCT", 260, 264], ["CatB", "GENE_OR_GENE_PRODUCT", 269, 273], ["GP2", "PROTEIN", 70, 73], ["six-helix bundle", "PROTEIN", 145, 161], ["surface subunit", "PROTEIN", 190, 205], ["GP1", "PROTEIN", 207, 210], ["host endosomal proteases", "PROTEIN", 215, 239], ["cathepsins L", "PROTEIN", 240, 252], ["B", "PROTEIN", 257, 258], ["CatL", "PROTEIN", 260, 264], ["CatB", "PROTEIN", 269, 273], ["EboV", "PROBLEM", 28, 32], ["host endosomal proteases cathepsins L and B (CatL and CatB", "TREATMENT", 215, 273]]], ["[7] [8] [9] [10] [11] [12] However, the precise molecular events that lead to triggering of the envelope spike to form the extended intermediate are still under investigation.IntroductionCrystal structures of the EboV GP2 ectodomain in the putative postfusion conformation were reported independently by the Kim and Wiley groups 8,9 [ Fig. 1(B) ].", [["[7] [8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 0, 26], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 213, 221], ["EboV GP2 ectodomain", "PROTEIN", 213, 232], ["the envelope spike", "PROBLEM", 92, 110], ["the EboV GP2 ectodomain", "TEST", 209, 232], ["EboV GP2 ectodomain", "OBSERVATION", 213, 232]]], ["The structure described by Kim and coworkers 9 was of a protease stable 74-residue fragment encompassing residues 557-630 (Zaire ebolavirus numbering, ''Ebo-74'').", [["protease stable 74-residue fragment", "PROTEIN", 56, 91], ["a protease", "TREATMENT", 54, 64]]], ["The structure reported by Wiley and coworkers 8 contained residues 552-650 of the ectodomain linked to a N-terminal trimeric GCN4 coiled-coil domain to promote solubility and stability (pIIGp2(552-650)).", [["N", "CHEMICAL", 105, 106], ["ectodomain", "PROTEIN", 82, 92], ["N-terminal trimeric GCN4 coiled-coil domain", "PROTEIN", 105, 148], ["the ectodomain", "TREATMENT", 78, 92], ["a N-terminal trimeric GCN4 coiled-coil domain", "TREATMENT", 103, 148], ["solubility", "OBSERVATION_MODIFIER", 160, 170], ["stability", "OBSERVATION_MODIFIER", 175, 184]]], ["The GP2 ectodomain regions in these two structures were in good agreement and revealed several unique features of the ahelical bundle.", [["GP2", "GENE_OR_GENE_PRODUCT", 4, 7], ["GP2 ectodomain regions", "PROTEIN", 4, 26], ["ahelical bundle", "PROTEIN", 118, 133], ["The GP2 ectodomain regions", "PROBLEM", 0, 26], ["GP2 ectodomain", "OBSERVATION", 4, 18], ["ahelical bundle", "ANATOMY", 118, 133]]], ["The EboV GP2 six-helix bundle is much shorter than that of HIV-1 gp41, consisting of segments containing just three a-helical turns each in the NHR and CHR regions compared to seven turns for these regions in gp41.", [["EboV GP2", "GENE_OR_GENE_PRODUCT", 4, 12], ["HIV-1 gp41", "GENE_OR_GENE_PRODUCT", 59, 69], ["gp41", "GENE_OR_GENE_PRODUCT", 209, 213], ["EboV GP2 six-helix bundle", "PROTEIN", 4, 29], ["HIV-1 gp41", "PROTEIN", 59, 69], ["NHR and CHR regions", "DNA", 144, 163], ["gp41", "PROTEIN", 209, 213], ["HIV-1", "SPECIES", 59, 64], ["HIV-1", "SPECIES", 59, 64], ["HIV", "TEST", 59, 62], ["these regions in gp41", "PROBLEM", 192, 213], ["much shorter", "OBSERVATION_MODIFIER", 33, 45], ["segments", "ANATOMY_MODIFIER", 85, 93]]], ["The region linking the NHR and CHR in GP2 contains a short helixturn-helix motif that is stabilized by an intramolecular disulfide bond.", [["disulfide", "CHEMICAL", 121, 130], ["NHR", "GENE_OR_GENE_PRODUCT", 23, 26], ["GP2", "GENE_OR_GENE_PRODUCT", 38, 41], ["NHR", "PROTEIN", 23, 26], ["CHR", "PROTEIN", 31, 34], ["GP2", "PROTEIN", 38, 41], ["short helixturn-helix motif", "PROTEIN", 53, 80], ["a short helixturn-helix motif", "TREATMENT", 51, 80], ["NHR", "OBSERVATION_MODIFIER", 23, 26], ["CHR", "OBSERVATION_MODIFIER", 31, 34], ["short", "OBSERVATION_MODIFIER", 53, 58], ["intramolecular disulfide bond", "OBSERVATION", 106, 135]]], ["Interestingly, this motif is structurally similar to that found in the moloney murine leukemia virus (MoMLV) glycoprotein postfusion core despite the fact that these viruses are not phylogenetically related.", [["moloney murine leukemia virus", "ORGANISM", 71, 100], ["MoMLV", "GENE_OR_GENE_PRODUCT", 102, 107], ["murine", "SPECIES", 79, 85], ["moloney murine leukemia virus", "SPECIES", 71, 100], ["MoMLV", "SPECIES", 102, 107], ["the moloney murine leukemia virus (MoMLV) glycoprotein postfusion core", "PROBLEM", 67, 137], ["these viruses", "PROBLEM", 160, 173], ["moloney murine leukemia virus", "OBSERVATION", 71, 100], ["viruses", "OBSERVATION", 166, 173]]], ["8, 9, 13 Sequence homology suggests that analogous regions in the envelope glycoproteins of avian sarcoma/leukosis virus (ASLV) and human T-cell leukemia virus type I (HTLV-1) adopt similar structures, and mutational studies suggest that a histidine residue in this region plays a role in pH-dependent ASLV viral entry.", [["sarcoma/leukosis", "DISEASE", 98, 114], ["histidine", "CHEMICAL", 240, 249], ["histidine", "CHEMICAL", 240, 249], ["avian sarcoma/leukosis virus", "ORGANISM", 92, 120], ["ASLV", "GENE_OR_GENE_PRODUCT", 122, 126], ["human T-cell leukemia virus type I", "ORGANISM", 132, 166], ["HTLV-1", "ORGANISM", 168, 174], ["ASLV", "GENE_OR_GENE_PRODUCT", 302, 306], ["envelope glycoproteins", "PROTEIN", 66, 88], ["avian sarcoma/leukosis virus", "SPECIES", 92, 120], ["human", "SPECIES", 132, 137], ["T-cell leukemia virus", "SPECIES", 138, 159], ["HTLV-1", "SPECIES", 168, 174], ["avian sarcoma/leukosis virus", "SPECIES", 92, 120], ["ASLV", "SPECIES", 122, 126], ["human T-cell leukemia virus type I", "SPECIES", 132, 166], ["HTLV-1", "SPECIES", 168, 174], ["Sequence homology", "TEST", 9, 26], ["analogous regions", "PROBLEM", 41, 58], ["avian sarcoma", "PROBLEM", 92, 105], ["leukosis virus", "PROBLEM", 106, 120], ["ASLV", "TEST", 122, 126], ["human T-cell leukemia virus type I (HTLV", "PROBLEM", 132, 172], ["mutational studies", "TEST", 206, 224], ["a histidine residue", "PROBLEM", 238, 257], ["avian sarcoma", "OBSERVATION", 92, 105], ["leukosis virus", "OBSERVATION", 106, 120], ["cell leukemia virus", "OBSERVATION", 140, 159], ["viral entry", "OBSERVATION", 307, 318]]], ["14 In EboV GP2, the helix-turn-helix motif appears to contribute to overall stability as the native disulfide bond pairing is required for high thermostability.", [["disulfide", "CHEMICAL", 100, 109], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 6, 14], ["EboV GP2", "PROTEIN", 6, 14], ["helix-turn-helix motif", "PROTEIN", 20, 42], ["helix motif", "PROBLEM", 31, 42], ["the native disulfide bond pairing", "TREATMENT", 89, 122], ["high thermostability", "PROBLEM", 139, 159], ["stability", "OBSERVATION", 76, 85]]], ["9 Another feature of EboV GP2 is the presence of a ''stutter'' in the heptad repeat pattern in the NHR core, noted by both the Kim and Wiley groups.", [["EboV GP2", "GENE_OR_GENE_PRODUCT", 21, 29], ["EboV GP2", "PROTEIN", 21, 29], ["a ''stutter''", "PROBLEM", 49, 62], ["the heptad repeat pattern", "TEST", 66, 91], ["EboV GP2", "OBSERVATION", 21, 29]]], ["Typical a-helical bundle proteins contain a characteristic abcdefg repeat where a and d positions are occupied by hydrophobic residues (the 3-4 repeat).", [["a-helical bundle proteins", "PROTEIN", 8, 33], ["abcdefg repeat", "PROTEIN", 59, 73], ["Typical a-helical bundle proteins", "PROBLEM", 0, 33], ["a and d positions", "TREATMENT", 80, 97], ["hydrophobic residues", "PROBLEM", 114, 134], ["bundle proteins", "OBSERVATION", 18, 33], ["hydrophobic residues", "OBSERVATION", 114, 134]]], ["15 In the NHR region of GP2, there is a stutter in this hydrophobic repeat at position T565 that results in a 3-4-4-3 repeat pattern; a similar stutter exists at the N-terminal end of the low-pH induced influenza A virus HA2 coiled-coil.", [["N", "CHEMICAL", 166, 167], ["GP2", "GENE_OR_GENE_PRODUCT", 24, 27], ["influenza A virus", "ORGANISM", 203, 220], ["NHR region", "PROTEIN", 10, 20], ["GP2", "PROTEIN", 24, 27], ["N-terminal end", "PROTEIN", 166, 180], ["influenza A virus", "SPECIES", 203, 220], ["influenza A virus", "SPECIES", 203, 220], ["a stutter", "PROBLEM", 38, 47], ["a similar stutter", "PROBLEM", 134, 151], ["the low-pH induced influenza A virus HA2 coiled-coil", "TREATMENT", 184, 236], ["GP2", "ANATOMY_MODIFIER", 24, 27], ["stutter", "OBSERVATION", 40, 47], ["similar", "OBSERVATION_MODIFIER", 136, 143], ["stutter", "OBSERVATION", 144, 151], ["terminal", "OBSERVATION_MODIFIER", 168, 176], ["low", "OBSERVATION_MODIFIER", 188, 191], ["influenza", "OBSERVATION", 203, 212]]], ["16 Finally, the central NHR coiledcoil contains an anion binding pocket that also appears to contribute to folding stability.", [["central NHR coiledcoil", "PROTEIN", 16, 38], ["anion binding pocket", "PROTEIN", 51, 71], ["an anion binding pocket", "PROBLEM", 48, 71], ["central", "ANATOMY_MODIFIER", 16, 23], ["NHR", "OBSERVATION_MODIFIER", 24, 27], ["coiledcoil", "OBSERVATION", 28, 38], ["anion binding pocket", "OBSERVATION", 51, 71], ["appears to contribute to", "UNCERTAINTY", 82, 106], ["folding stability", "OBSERVATION", 107, 124]]], ["These features make the EboV GP2 a-helical bundle an interesting system to study in the context of factors that are required to drive membrane fusion.IntroductionThe evidence for the extended intermediate in HIV-1 gp41 was obtained from designed peptides and proteins that bound the extended intermediate and prevented rearrangement to the six-helix bundle [''fusion inhibitors,'' Fig. 1(A) ].", [["membrane", "ANATOMY", 134, 142], ["membrane", "CELLULAR_COMPONENT", 134, 142], ["HIV-1", "ORGANISM", 208, 213], ["gp41", "ORGANISM", 214, 218], ["GP2", "PROTEIN", 29, 32], ["HIV-1 gp41", "PROTEIN", 208, 218], ["six-helix bundle", "PROTEIN", 340, 356], ["HIV-1", "SPECIES", 208, 213], ["HIV-1", "SPECIES", 208, 213], ["membrane fusion", "TREATMENT", 134, 149], ["the extended intermediate in HIV", "PROBLEM", 179, 211], ["the six-helix bundle", "TREATMENT", 336, 356], ["''fusion inhibitors", "TREATMENT", 358, 377]]], ["3, 4 Proteins, peptides, and small molecules that bind protein mimics of the HIV-1 gp41 extended intermediate have antiviral activity and have been exploited for design of viral entry inhibitors.", [["HIV-1", "ORGANISM", 77, 82], ["gp41", "ORGANISM", 83, 87], ["HIV-1 gp41", "PROTEIN", 77, 87], ["HIV-1", "SPECIES", 77, 82], ["HIV-1", "SPECIES", 77, 82], ["small molecules", "PROBLEM", 29, 44], ["the HIV", "PROBLEM", 73, 80], ["antiviral activity", "TREATMENT", 115, 133], ["viral entry inhibitors", "TREATMENT", 172, 194], ["small molecules", "OBSERVATION", 29, 44], ["antiviral activity", "OBSERVATION", 115, 133]]], ["[17] [18] [19] [20] Furthermore, appropriately designed protein mimics of the gp41 extended intermediate serve as targets for neutralizing antibodies and thus have potential as immunogens for vaccine discovery.", [["[17] [18] [19] [20", "SIMPLE_CHEMICAL", 0, 18], ["gp41", "PROTEIN", 78, 82], ["neutralizing antibodies", "PROTEIN", 126, 149], ["neutralizing antibodies", "PROBLEM", 126, 149]]], ["[21] [22] [23] [24] In theory, similar approaches could be adopted for EboV GP2, given the similarity in their proposed fusion mechanisms.", [["[21] [22] [23] [24]", "SIMPLE_CHEMICAL", 0, 19], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 71, 79], ["EboV GP2", "PROTEIN", 71, 79], ["EboV GP2", "PROBLEM", 71, 79]]], ["25 Our goal was to design protein mimics of the a-helical bundle segment of EboV GP2 that could be used as model systems to study folding stability and potentially aid in development of inhibitors of EboV membrane fusion.", [["membrane", "ANATOMY", 205, 213], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 76, 84], ["EboV", "GENE_OR_GENE_PRODUCT", 200, 204], ["membrane", "CELLULAR_COMPONENT", 205, 213], ["a-helical bundle segment", "PROTEIN", 48, 72], ["EboV GP2", "PROTEIN", 76, 84], ["EboV", "PROTEIN", 200, 204], ["EboV GP2", "TREATMENT", 76, 84], ["inhibitors", "TREATMENT", 186, 196], ["EboV membrane fusion", "TREATMENT", 200, 220], ["EboV membrane fusion", "OBSERVATION", 200, 220]]], ["To this end, we prepared model proteins consisting of the alternating NHR and CHR segments from EboV GP2 linked by short, flexible loops.", [["EboV GP2", "GENE_OR_GENE_PRODUCT", 96, 104], ["NHR", "PROTEIN", 70, 73], ["CHR segments", "PROTEIN", 78, 90], ["EboV GP2", "PROTEIN", 96, 104], ["the alternating NHR and CHR segments", "TREATMENT", 54, 90], ["flexible loops", "OBSERVATION", 122, 136]]], ["Biophysical characterization reveals that these proteins adopt stable a-helical structures consistent with their design.", [["Biophysical characterization", "TEST", 0, 28], ["stable", "OBSERVATION_MODIFIER", 63, 69], ["consistent with", "UNCERTAINTY", 91, 106]]], ["Further analysis provided interesting insights into factors that influence stability of the EboV GP2 six-helix bundle.Results and DiscussionDesign of protein mimics of the EboV GP2 ahelical bundleResults and DiscussionWe sought to analyze the folding properties of the ahelical bundle segment of the EboV GP2 ectodomain.", [["EboV GP2", "GENE_OR_GENE_PRODUCT", 92, 100], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 300, 308], ["EboV GP2 six-helix bundle", "PROTEIN", 92, 117], ["GP2", "PROTEIN", 177, 180], ["ahelical bundle segment", "PROTEIN", 269, 292], ["EboV GP2 ectodomain", "PROTEIN", 300, 319], ["Further analysis", "TEST", 0, 16], ["bundle", "ANATOMY_MODIFIER", 278, 284], ["segment", "ANATOMY_MODIFIER", 285, 292], ["EboV GP2 ectodomain", "OBSERVATION", 300, 319]]], ["The GP2 postfusion structure is distinct from that of HIV-1 gp41 in that GP2 contains a relatively small six-helix bundle segment but a long, triple stranded core NHR coiled-coil; much of the GP2 postfusion outer layer consists of the helix-turn-helix and loop segments [the six-helix bundle is boxed in Fig. 1(B) ].", [["outer layer", "ANATOMY", 207, 218], ["GP2", "GENE_OR_GENE_PRODUCT", 4, 7], ["HIV-1 gp41", "ORGANISM", 54, 64], ["GP2", "GENE_OR_GENE_PRODUCT", 73, 76], ["GP2", "GENE_OR_GENE_PRODUCT", 192, 195], ["GP2", "PROTEIN", 4, 7], ["HIV-1 gp41", "PROTEIN", 54, 64], ["GP2", "PROTEIN", 73, 76], ["six-helix bundle segment", "PROTEIN", 105, 129], ["NHR coiled-coil", "PROTEIN", 163, 178], ["GP2", "PROTEIN", 192, 195], ["helix-turn-helix", "PROTEIN", 235, 251], ["loop segments", "PROTEIN", 256, 269], ["six-helix bundle", "PROTEIN", 275, 291], ["HIV-1", "SPECIES", 54, 59], ["HIV", "TEST", 54, 57], ["a relatively small six-helix bundle segment", "PROBLEM", 86, 129], ["a long, triple stranded core NHR coiled-coil", "TREATMENT", 134, 178], ["helix and loop segments", "TREATMENT", 246, 269], ["the six-helix bundle", "TREATMENT", 271, 291], ["distinct", "OBSERVATION_MODIFIER", 32, 40], ["GP2", "ANATOMY_MODIFIER", 73, 76], ["relatively", "OBSERVATION_MODIFIER", 88, 98], ["small", "OBSERVATION_MODIFIER", 99, 104], ["six-helix", "OBSERVATION", 105, 114], ["bundle", "ANATOMY_MODIFIER", 115, 121], ["segment", "ANATOMY_MODIFIER", 122, 129], ["long", "OBSERVATION_MODIFIER", 136, 140], ["NHR", "OBSERVATION_MODIFIER", 163, 166], ["coiled", "OBSERVATION", 167, 173], ["coil", "OBSERVATION_MODIFIER", 174, 178], ["layer", "OBSERVATION_MODIFIER", 213, 218], ["helix", "ANATOMY_MODIFIER", 235, 240], ["turn", "OBSERVATION_MODIFIER", 241, 245], ["helix", "ANATOMY_MODIFIER", 246, 251], ["loop", "OBSERVATION_MODIFIER", 256, 260], ["segments", "OBSERVATION_MODIFIER", 261, 269], ["six-helix", "OBSERVATION_MODIFIER", 275, 284], ["bundle", "OBSERVATION_MODIFIER", 285, 291], ["boxed", "OBSERVATION_MODIFIER", 295, 300], ["Fig", "OBSERVATION_MODIFIER", 304, 307]]], ["8, 9 By contrast, the long, central NHR trimer of HIV-1 gp41 is surrounded by CHR a-helices of essentially equal length.", [["HIV-1 gp41", "GENE_OR_GENE_PRODUCT", 50, 60], ["NHR trimer", "PROTEIN", 36, 46], ["HIV-1 gp41", "PROTEIN", 50, 60], ["CHR a-helices", "PROTEIN", 78, 91], ["HIV-1", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 50, 55], ["essentially", "OBSERVATION_MODIFIER", 95, 106], ["equal", "OBSERVATION_MODIFIER", 107, 112], ["length", "OBSERVATION_MODIFIER", 113, 119]]], ["5, 6, [26] [27] [28] Previously, Wiley and coworkers 29 performed denaturation studies with pIIGp2(552-650) and found it to be highly thermostable (complete unfolding was not observed on heating to 98 C at pH 8).", [["[26] [27] [28", "SIMPLE_CHEMICAL", 6, 19], ["pIIGp2", "SIMPLE_CHEMICAL", 92, 98], ["denaturation studies", "TEST", 66, 86], ["pIIGp2", "TEST", 92, 98]]], ["Kim and coworkers 9 performed denaturation studies with two GP2 ectodomain constructs, a larger 95-residue construct containing essentially the entire GP2 ectodomain (''Ebo-95''), and the protease-resistant Ebo-74.", [["Ebo-74", "CHEMICAL", 207, 213], ["GP2", "GENE_OR_GENE_PRODUCT", 60, 63], ["GP2", "GENE_OR_GENE_PRODUCT", 151, 154], ["GP2 ectodomain constructs", "DNA", 60, 85], ["GP2 ectodomain", "PROTEIN", 151, 165], ["Ebo", "PROTEIN", 169, 172], ["protease", "PROTEIN", 188, 196], ["Ebo", "PROTEIN", 207, 210], ["denaturation studies", "TEST", 30, 50], ["two GP2 ectodomain constructs", "PROBLEM", 56, 85], ["Ebo", "TEST", 169, 172], ["the protease", "TEST", 184, 196], ["Ebo", "TEST", 207, 210]]], ["These proteins were also found to be thermostable (thermal midpoint, T m , of 88 C at pH 7.2 for Ebo-95 and 77 C at pH 4.5 for Ebo-74).", [["These proteins", "TEST", 0, 14], ["T m", "TEST", 69, 72], ["pH", "TEST", 86, 88], ["Ebo", "TEST", 97, 100], ["pH", "TEST", 116, 118], ["Ebo", "TEST", 127, 130]]], ["We wondered what contributions were provided by the GP2 six-helix bundle segment alone (i.e., in the absence of the helix-turn-helix and loop segments).", [["GP2", "GENE_OR_GENE_PRODUCT", 52, 55], ["GP2 six-helix bundle segment", "PROTEIN", 52, 80], ["helix-turn-helix", "PROTEIN", 116, 132], ["loop segments", "PROTEIN", 137, 150], ["helix and loop segments", "TREATMENT", 127, 150]]], ["Analysis of folding energetics for sixhelix bundle constructs from HIV-1 and simian immunodeficiency virus (SIV) gp41 has previously been performed using short hairpin proteins (i.e., a single NHR and a single CHR segment linked by a short linker that form a trimer).", [["simian immunodeficiency virus", "DISEASE", 77, 106], ["HIV-1", "ORGANISM", 67, 72], ["simian immunodeficiency virus", "ORGANISM", 77, 106], ["SIV", "ORGANISM", 108, 111], ["sixhelix bundle constructs", "DNA", 35, 61], ["gp41", "PROTEIN", 113, 117], ["short hairpin proteins", "PROTEIN", 154, 176], ["NHR", "PROTEIN", 193, 196], ["CHR segment", "PROTEIN", 210, 221], ["short linker", "PROTEIN", 234, 246], ["HIV-1", "SPECIES", 67, 72], ["simian immunodeficiency virus", "SPECIES", 77, 106], ["HIV-1", "SPECIES", 67, 72], ["simian immunodeficiency virus", "SPECIES", 77, 106], ["SIV", "SPECIES", 108, 111], ["folding energetics", "PROBLEM", 12, 30], ["sixhelix bundle constructs", "PROBLEM", 35, 61], ["HIV", "TEST", 67, 70], ["simian immunodeficiency virus (SIV) gp41", "PROBLEM", 77, 117], ["short hairpin proteins", "PROBLEM", 154, 176], ["a single NHR", "TREATMENT", 184, 196], ["a single CHR segment", "TREATMENT", 201, 221], ["a short linker", "TREATMENT", 232, 246]]], ["27, 28 However, such proteins typically display concentration-dependent behavior and therefore aggregation complicates thermodynamic analysis.", [["concentration-dependent behavior", "PROBLEM", 48, 80], ["thermodynamic analysis", "TEST", 119, 141]]], ["We reasoned that a single chain construct consisting of the EboV GP2 a-helical NHR and CHR segments alone would provide a useful system to examine folding stability of the GP2 six-helix bundle.Results and DiscussionWe designed two proteins consisting of alternating NHR and CHR segments of Zaire ebolavirus GP2: ''Ebo6H'' and ''Ebo5H'' (Fig. 2) .", [["GP2", "GENE_OR_GENE_PRODUCT", 172, 175], ["GP2", "PROTEIN", 65, 68], ["NHR", "PROTEIN", 79, 82], ["CHR segments", "PROTEIN", 87, 99], ["GP2 six-helix bundle", "PROTEIN", 172, 192], ["NHR", "PROTEIN", 266, 269], ["CHR segments", "PROTEIN", 274, 286], ["GP2", "PROTEIN", 307, 310], ["Zaire ebolavirus", "SPECIES", 290, 306], ["a single chain construct", "TREATMENT", 17, 41], ["the EboV GP2 a-helical NHR and CHR segments", "TREATMENT", 56, 99], ["alternating NHR and CHR segments", "TREATMENT", 254, 286]]], ["Ebo6H contains the segments each of the CHR region encompassing residues 615-633 (this segment is referred to as ''C19'') linked to the NHR segment consisting of residues 559-576 (''N18,'' which includes the unusual heptad repeat stutter) via short, flexible protein linkers.", [["Ebo6H", "CHEMICAL", 0, 5], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 0, 5], ["-633", "AMINO_ACID", 76, 80], ["Ebo6H", "PROTEIN", 0, 5], ["CHR region", "DNA", 40, 50], ["NHR segment", "PROTEIN", 136, 147], ["heptad repeat stutter", "PROTEIN", 216, 237], ["flexible protein linkers", "PROTEIN", 250, 274], ["short, flexible protein linkers", "TREATMENT", 243, 274], ["segments each", "ANATOMY_MODIFIER", 19, 32], ["CHR", "ANATOMY_MODIFIER", 40, 43], ["region", "ANATOMY_MODIFIER", 44, 50], ["NHR", "ANATOMY", 136, 139], ["segment", "ANATOMY_MODIFIER", 140, 147], ["protein linkers", "OBSERVATION", 259, 274]]], ["When properly folded, this polypeptide is predicted to adopt a six-helix bundle that mimics that of the GP2 postfusion core.", [["GP2", "GENE_OR_GENE_PRODUCT", 104, 107], ["six-helix bundle", "PROTEIN", 63, 79], ["GP2", "PROTEIN", 104, 107], ["a six-helix bundle", "TREATMENT", 61, 79]]], ["8, 9 Ebo5H is similar to Ebo6H but lacks one of the CHR regions.", [["Ebo6H", "CHEMICAL", 25, 30], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 5, 10], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 25, 30], ["Ebo5H", "PROTEIN", 5, 10], ["Ebo6H", "PROTEIN", 25, 30], ["CHR regions", "DNA", 52, 63]]], ["When folded, Ebo5H should adopt a structure similar to that of Ebo6H but lacking a single CHR segment.", [["Ebo5H", "GENE_OR_GENE_PRODUCT", 13, 18], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 63, 68], ["Ebo5H", "PROTEIN", 13, 18], ["Ebo6H", "PROTEIN", 63, 68], ["CHR segment", "DNA", 90, 101]]], ["Comparison of stabilities for Ebo5H and Ebo6H The regions corresponding to the NHR, CHR, and helix-turn-helix regions are indicated with cylinders whose colors match the structural elements depicted in Figure 1 (B).", [["Ebo6H", "CHEMICAL", 40, 45], ["Ebo5H", "CHEMICAL", 30, 35], ["Ebo6H", "CHEMICAL", 40, 45], ["Ebo5H", "SIMPLE_CHEMICAL", 30, 35], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 40, 45], ["NHR", "GENE_OR_GENE_PRODUCT", 79, 82], ["Ebo5H", "PROTEIN", 30, 35], ["Ebo6H", "PROTEIN", 40, 45], ["NHR, CHR, and helix-turn-helix regions", "DNA", 79, 117], ["Ebo5H", "TREATMENT", 30, 35], ["the NHR", "TEST", 75, 82], ["CHR", "TEST", 84, 87], ["structural elements", "OBSERVATION", 170, 189]]], ["The helix-turn-helix region contains three cysteines, two of which form an intramolecular disulfide bond and the third tethers GP1 to GP2.", [["cysteines", "CHEMICAL", 43, 52], ["disulfide", "CHEMICAL", 90, 99], ["GP1", "GENE_OR_GENE_PRODUCT", 127, 130], ["GP2", "GENE_OR_GENE_PRODUCT", 134, 137], ["helix-turn-helix region", "PROTEIN", 4, 27], ["GP1", "PROTEIN", 127, 130], ["GP2", "PROTEIN", 134, 137], ["The helix-turn-helix region", "TREATMENT", 0, 27], ["three cysteines", "TREATMENT", 37, 52], ["an intramolecular disulfide bond", "TREATMENT", 72, 104], ["helix", "ANATOMY_MODIFIER", 4, 9], ["turn", "OBSERVATION_MODIFIER", 10, 14], ["helix", "ANATOMY_MODIFIER", 15, 20], ["three cysteines", "OBSERVATION", 37, 52]]], ["The ectodomain contains two glycosylation sites, these are indicated with an ''o.''", [["ectodomain", "PROTEIN", 4, 14], ["glycosylation sites", "PROTEIN", 28, 47], ["The ectodomain", "TREATMENT", 0, 14], ["two glycosylation sites", "TREATMENT", 24, 47], ["two", "OBSERVATION_MODIFIER", 24, 27], ["glycosylation sites", "OBSERVATION", 28, 47]]], ["The T565 residue that gives rise to the unusual 3-4-4-3 hydrophobic stutter in the NHR is indicated with an ''\u00c2,'' other residues in the NHR that form core positions are denoted a and d.", [["3-4-4-3 hydrophobic stutter", "DNA", 48, 75], ["NHR", "PROTEIN", 83, 86], ["NHR", "PROTEIN", 137, 140], ["The T565 residue", "PROBLEM", 0, 16], ["'' other residues in the NHR", "PROBLEM", 112, 140]]], ["For comparison, the sequence of the related marburgvirus (MarV, Lake Victoria strain) is also shown; conserved residues are colored black.", [["marburgvirus", "GENE_OR_GENE_PRODUCT", 44, 56], ["Lake Victoria strain", "ORGANISM", 64, 84], ["the related marburgvirus", "PROBLEM", 32, 56], ["colored", "OBSERVATION_MODIFIER", 124, 131], ["black", "OBSERVATION_MODIFIER", 132, 137]]], ["The segments used in design of Ebo6H and Ebo5H (N18 and C19) are indicated with a black bar above.", [["Ebo5H (N18 and C19", "CHEMICAL", 41, 59], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 31, 36], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 41, 46], ["Ebo6H", "PROTEIN", 31, 36], ["Ebo5H", "PROTEIN", 41, 46], ["N18", "PROTEIN", 48, 51], ["C19", "PROTEIN", 56, 59], ["Ebo6H", "TEST", 31, 36], ["Ebo5H", "TEST", 41, 46], ["segments", "ANATOMY_MODIFIER", 4, 12], ["black bar", "OBSERVATION", 82, 91]]], ["B: Schematic representation of Ebo6H and Ebo5H design.", [["Ebo6H", "GENE_OR_GENE_PRODUCT", 31, 36], ["Ebo6H", "PROTEIN", 31, 36], ["Ebo5H", "PROTEIN", 41, 46]]], ["Ebo6H consists of alternating C19 and N18 segments linked by short linkers (CAN linker sequence AGSSGGA and NAC linker sequence AGGSGGA).", [["Ebo6H", "CHEMICAL", 0, 5], ["NAC", "CHEMICAL", 108, 111], ["NAC", "CHEMICAL", 108, 111], ["C19", "SIMPLE_CHEMICAL", 30, 33], ["Ebo6H", "PROTEIN", 0, 5], ["alternating C19 and N18 segments", "PROTEIN", 18, 50], ["CAN linker sequence", "PROTEIN", 76, 95], ["AGSSGGA", "PROTEIN", 96, 103], ["NAC linker sequence", "PROTEIN", 108, 127], ["AGGSGGA", "PROTEIN", 128, 135], ["Ebo6H", "TEST", 0, 5], ["alternating C19 and N18 segments", "TREATMENT", 18, 50], ["short linkers (CAN linker sequence AGSSGGA", "TREATMENT", 61, 103], ["NAC linker sequence AGGSGGA", "TREATMENT", 108, 135], ["C19", "ANATOMY_MODIFIER", 30, 33], ["short linkers", "OBSERVATION_MODIFIER", 61, 74]]], ["Ebo5H is similar but lacking the first C19 sequence.", [["Ebo5H", "CHEMICAL", 0, 5], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 0, 5], ["Ebo5H", "PROTEIN", 0, 5], ["C19 sequence", "PROTEIN", 39, 51]]], ["C: SDS-PAGE analysis of purified, refolded Ebo6H and Ebo5H.", [["Ebo6H", "GENE_OR_GENE_PRODUCT", 43, 48], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 53, 58], ["Ebo6H", "PROTEIN", 43, 48], ["Ebo5H", "PROTEIN", 53, 58], ["PAGE analysis", "TEST", 7, 20]]], ["In both cases, a single band was observed of expected molecular weight (16 kDa for Ebo6H and 15 kDa for Ebo5H).Results and Discussionshould therefore provide insight into contribution of stability of a single CHR segment.", [["Ebo5H", "GENE_OR_GENE_PRODUCT", 104, 109], ["Ebo6H", "PROTEIN", 83, 88], ["Ebo5H", "PROTEIN", 104, 109], ["CHR segment", "DNA", 209, 220], ["a single band", "TREATMENT", 15, 28], ["a single CHR segment", "PROBLEM", 200, 220], ["stability", "OBSERVATION", 187, 196]]], ["In addition, similar ''5-Helix'' constructs based on HIV-1 gp41 have been used as entry inhibitors and mimics of the extended intermediate.", [["HIV-1", "ORGANISM", 53, 58], ["gp41", "ORGANISM", 59, 63], ["''5-Helix'' constructs", "DNA", 21, 43], ["HIV-1 gp41", "PROTEIN", 53, 63], ["HIV-1", "SPECIES", 53, 58], ["HIV-1", "SPECIES", 53, 58], ["HIV-1 gp41", "TREATMENT", 53, 63], ["entry inhibitors", "TREATMENT", 82, 98]]], ["[18] [19] [20] [21] [22] [23] [24] Therefore, Ebo5H may be useful for development of EboV entry inhibitors.", [["Ebo5H", "CHEMICAL", 46, 51], ["[18] [19] [20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 0, 34], ["Ebo5H", "SIMPLE_CHEMICAL", 46, 51], ["EboV", "SIMPLE_CHEMICAL", 85, 89], ["EboV entry inhibitors", "TREATMENT", 85, 106], ["EboV", "OBSERVATION", 85, 89]]], ["Ebo6H and Ebo5H proteins containing hexahistidine tags were expressed in E. coli, purified from inclusion bodies, and then subjected to refolding conditions.", [["Ebo6H", "GENE_OR_GENE_PRODUCT", 0, 5], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 10, 15], ["hexahistidine", "GENE_OR_GENE_PRODUCT", 36, 49], ["E. coli", "ORGANISM", 73, 80], ["Ebo6H", "PROTEIN", 0, 5], ["Ebo5H proteins", "PROTEIN", 10, 24], ["E. coli", "SPECIES", 73, 80], ["E. coli", "SPECIES", 73, 80], ["Ebo6H", "TEST", 0, 5], ["Ebo5H proteins containing hexahistidine tags", "PROBLEM", 10, 54], ["E. coli", "PROBLEM", 73, 80], ["hexahistidine tags", "OBSERVATION", 36, 54], ["E. coli", "OBSERVATION", 73, 80]]], ["Both proteins were obtained in good yield and purity [ Fig. 1(C) ].Ebo6H and Ebo5H adopt stable a-helical conformationsCircular dichroism (CD) spectra for Ebo6H (2 lM) and Ebo5H (0.4 lM) in 20 mM sodium acetate (pH 5.3) exhibited double minima at 208 and 222 nm, characteristic of a-helical secondary structure and consistent with the intended design [ Fig. 3(A) ].", [["Ebo6H", "CHEMICAL", 67, 72], ["Ebo5H", "CHEMICAL", 77, 82], ["Ebo6H", "CHEMICAL", 155, 160], ["Ebo5H", "CHEMICAL", 172, 177], ["sodium acetate", "CHEMICAL", 196, 210], ["Ebo6H", "CHEMICAL", 67, 72], ["Ebo5H", "CHEMICAL", 77, 82], ["Ebo6H", "CHEMICAL", 155, 160], ["Ebo5H", "CHEMICAL", 172, 177], ["sodium acetate", "CHEMICAL", 196, 210], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 67, 72], ["Ebo5H", "SIMPLE_CHEMICAL", 77, 82], ["Ebo6H", "SIMPLE_CHEMICAL", 155, 160], ["Ebo5H", "SIMPLE_CHEMICAL", 172, 177], ["sodium acetate", "SIMPLE_CHEMICAL", 196, 210], ["Ebo6H", "PROTEIN", 67, 72], ["Ebo5H", "PROTEIN", 77, 82], ["a-helical conformations", "PROTEIN", 96, 119], ["Circular dichroism", "TEST", 119, 137], ["Ebo6H", "TEST", 155, 160], ["Ebo5H", "TEST", 172, 177], ["20 mM sodium acetate", "TREATMENT", 190, 210], ["pH", "TEST", 212, 214], ["double minima", "PROBLEM", 230, 243], ["a-helical secondary structure", "PROBLEM", 281, 310], ["stable", "OBSERVATION_MODIFIER", 89, 95], ["222 nm", "OBSERVATION_MODIFIER", 255, 261], ["secondary structure", "OBSERVATION", 291, 310], ["consistent with", "UNCERTAINTY", 315, 330]]], ["The CD signature (as judged by ratio of signal intensity at 208 and 222 nm) for both proteins was invariant across a 0.2-10 lM concentration range, indicating that a-helix formation was not driven by aggregation.", [["a-helix", "SIMPLE_CHEMICAL", 164, 171], ["The CD signature", "TEST", 0, 16], ["signal intensity", "TEST", 40, 56], ["a-helix formation", "PROBLEM", 164, 181], ["CD", "OBSERVATION", 4, 6]]], ["Gel filtration analysis at mid-micromolar protein concentrations (80 lM for Ebo6H and 50 lM for Ebo5H) yielded molecular weight estimates consistent with monomer for each protein, although a small amount of aggregate was observed in both cases [ Fig. 3(B) ].", [["Ebo6H", "PROTEIN", 76, 81], ["Ebo5H", "PROTEIN", 96, 101], ["Gel filtration analysis", "TEST", 0, 23], ["mid-micromolar protein concentrations", "TREATMENT", 27, 64], ["Ebo6H", "TEST", 76, 81], ["molecular weight estimates", "TEST", 111, 137], ["each protein", "PROBLEM", 166, 178], ["a small amount of aggregate", "PROBLEM", 189, 216], ["small", "OBSERVATION_MODIFIER", 191, 196], ["amount", "OBSERVATION_MODIFIER", 197, 203]]], ["Ebo6H underwent a cooperative unfolding transition on heating when monitored by CD at 222 nm ( Fig. 3) with T m of 86.8 6 2.0 C at pH 5.3 and 77.8 6 1.6 C at pH 5.8.", [["Ebo6H", "CHEMICAL", 0, 5], ["Ebo6H", "CHEMICAL", 0, 5], ["Ebo6H", "SIMPLE_CHEMICAL", 0, 5], ["Ebo6H", "PROTEIN", 0, 5], ["a cooperative unfolding transition", "PROBLEM", 16, 50], ["T m", "TEST", 108, 111], ["pH", "TEST", 131, 133], ["pH", "TEST", 158, 160]]], ["Ebo5H was less stable than Ebo6H at pH 5.3 (T m \u00bc 80.6 6 0.7 C); therefore, the additional CHR segment in Ebo6H provided 6.2 C of thermal stability under these conditions.", [["Ebo5H", "CHEMICAL", 0, 5], ["Ebo6H", "CHEMICAL", 27, 32], ["Ebo6H", "CHEMICAL", 106, 111], ["Ebo5H", "CHEMICAL", 0, 5], ["Ebo6H", "CHEMICAL", 27, 32], ["Ebo5H", "SIMPLE_CHEMICAL", 0, 5], ["Ebo6H", "SIMPLE_CHEMICAL", 27, 32], ["Ebo6H", "SIMPLE_CHEMICAL", 106, 111], ["CHR segment", "DNA", 91, 102], ["Ebo5H", "TEST", 0, 5], ["Ebo6H", "TEST", 27, 32], ["pH", "TEST", 36, 38], ["T m \u00bc", "TEST", 44, 49], ["the additional CHR segment in Ebo6H", "TREATMENT", 76, 111], ["less", "OBSERVATION_MODIFIER", 10, 14], ["stable", "OBSERVATION_MODIFIER", 15, 21], ["segment", "ANATOMY_MODIFIER", 95, 102]]], ["The reversibility of unfolding was confirmed by cooling heated samples to room temperature over 5 min; we found the intensity of the 222 nm signal returned to initial values during this process (data not shown).Ebo6H and Ebo5H adopt stable a-helical conformationsTo obtain insight into thermodynamic parameters of unfolding, we performed van't Hoff analysis of the thermal denaturation data.", [["Ebo6H", "CHEMICAL", 211, 216], ["Ebo5H", "CHEMICAL", 221, 226], ["Ebo6H", "CHEMICAL", 211, 216], ["Ebo5H", "CHEMICAL", 221, 226], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 211, 216], ["Ebo5H", "SIMPLE_CHEMICAL", 221, 226], ["Ebo6H", "PROTEIN", 211, 216], ["Ebo5H", "PROTEIN", 221, 226], ["a-helical conformations", "PROTEIN", 240, 263], ["unfolding", "PROBLEM", 21, 30], ["the thermal denaturation data", "TEST", 361, 390], ["reversibility", "OBSERVATION_MODIFIER", 4, 17], ["unfolding", "OBSERVATION", 21, 30], ["stable", "OBSERVATION_MODIFIER", 233, 239]]], ["[30] [31] [32] Assuming a simple two-state unfolding model \u00f0N\u00a2D\u00de with no intermediates, the equilibrium constant for the unfolding reaction (K unf ) is related to the fraction unfolded (F unf ) by Eq.", [["N\u00a2D\u00de", "CHEMICAL", 60, 64], ["K", "CHEMICAL", 141, 142], ["N\u00a2D\u00de", "CHEMICAL", 60, 64], ["[30] [31] [32", "SIMPLE_CHEMICAL", 0, 13], ["N\u00a2D\u00de", "SIMPLE_CHEMICAL", 60, 64], ["F unf", "PROTEIN", 186, 191], ["the unfolding reaction", "PROBLEM", 117, 139]]], ["(1).Ebo6H and Ebo5H adopt stable a-helical conformationsThe van't Hoff enthalpy (DH vH ) can be derived from nonlinear regression of K unf as a function of temperature (T) in accordance with Eq.", [["Ebo6H", "CHEMICAL", 4, 9], ["Ebo5H", "CHEMICAL", 14, 19], ["K", "CHEMICAL", 133, 134], ["Ebo6H", "CHEMICAL", 4, 9], ["Ebo5H", "CHEMICAL", 14, 19], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 4, 9], ["Ebo5H", "SIMPLE_CHEMICAL", 14, 19], ["Ebo6H", "PROTEIN", 4, 9], ["Ebo5H", "PROTEIN", 14, 19], ["a-helical conformations", "PROTEIN", 33, 56], ["Hoff enthalpy (DH vH", "TREATMENT", 66, 86], ["stable", "OBSERVATION_MODIFIER", 26, 32]]], ["(2) (where R is the gas constant).Ebo6H and Ebo5H adopt stable a-helical conformationsAlthough DH vH does not provide direct information about the free energy of unfolding (DG unf ), it nonetheless provides a rough parameter to assess folding stability.", [["Ebo6H", "CHEMICAL", 34, 39], ["Ebo5H", "CHEMICAL", 44, 49], ["Ebo6H", "CHEMICAL", 34, 39], ["Ebo5H", "CHEMICAL", 44, 49], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 34, 39], ["Ebo5H", "SIMPLE_CHEMICAL", 44, 49], ["Ebo6H", "PROTEIN", 34, 39], ["Ebo5H", "PROTEIN", 44, 49], ["a-helical conformations", "PROTEIN", 63, 86], ["DH vH", "PROTEIN", 95, 100], ["stable", "OBSERVATION_MODIFIER", 56, 62]]], ["This analysis yielded DH vH of \u00c028.2 6 1.0 kcal/mol for Ebo6H and \u00c027.6 6 0.4 kcal/mol for Ebo5H at pH 5.3.", [["Ebo6H", "CHEMICAL", 56, 61], ["Ebo5H", "CHEMICAL", 91, 96], ["Ebo6H", "CHEMICAL", 56, 61], ["Ebo5H", "SIMPLE_CHEMICAL", 91, 96], ["This analysis", "TEST", 0, 13], ["DH vH", "TEST", 22, 27], ["Ebo6H", "TEST", 56, 61], ["Ebo5H", "TEST", 91, 96], ["pH", "TEST", 100, 102]]], ["These values are lower than unfolding enthalpies obtained by differential scanning calorimetry of model six-helix bundle proteins of SIV gp41 (DH unf \u00bc \u00c042.3 kcal/mol).", [["SIV", "ORGANISM", 133, 136], ["six-helix bundle proteins", "PROTEIN", 104, 129], ["SIV gp41", "PROTEIN", 133, 141], ["DH", "PROTEIN", 143, 145], ["These values", "TEST", 0, 12], ["unfolding enthalpies", "TEST", 28, 48], ["differential scanning calorimetry", "TEST", 61, 94], ["model six-helix bundle proteins", "TREATMENT", 98, 129], ["lower", "OBSERVATION_MODIFIER", 17, 22]]], ["28 The SIV gp41 six-helix bundle segment is much longer than that of EboV GP2; therefore, it is not surprising that the unfolding enthalpy of SIV gp41 is larger than that of EboV GP2.Effects of pH on stabilityThe envelope glycoproteins of many viruses that enter via the endosome undergo large structural transitions on exposure to acidic pH.", [["endosome", "ANATOMY", 271, 279], ["SIV", "ORGANISM", 7, 10], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 69, 77], ["SIV", "ORGANISM", 142, 145], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 174, 182], ["endosome", "CELLULAR_COMPONENT", 271, 279], ["SIV gp41 six-helix bundle segment", "PROTEIN", 7, 40], ["EboV GP2", "PROTEIN", 69, 77], ["SIV gp41", "PROTEIN", 142, 150], ["EboV GP2", "PROTEIN", 174, 182], ["envelope glycoproteins", "PROTEIN", 213, 235], ["The SIV gp41 six-helix bundle segment", "TREATMENT", 3, 40], ["the unfolding enthalpy of SIV gp41", "PROBLEM", 116, 150], ["The envelope glycoproteins", "TREATMENT", 209, 235], ["many viruses", "PROBLEM", 239, 251], ["large structural transitions", "PROBLEM", 288, 316], ["acidic pH", "TEST", 332, 341], ["SIV gp41", "OBSERVATION", 7, 15], ["bundle", "OBSERVATION_MODIFIER", 26, 32], ["segment", "OBSERVATION_MODIFIER", 33, 40], ["much", "OBSERVATION_MODIFIER", 44, 48], ["longer", "OBSERVATION_MODIFIER", 49, 55], ["SIV gp41", "OBSERVATION", 142, 150], ["larger", "OBSERVATION_MODIFIER", 154, 160], ["stability", "OBSERVATION_MODIFIER", 200, 209], ["viruses", "OBSERVATION", 244, 251], ["large", "OBSERVATION_MODIFIER", 288, 293], ["structural transitions", "OBSERVATION", 294, 316], ["acidic pH", "OBSERVATION", 332, 341]]], ["1-3,16,33-37 These pH-dependent conformational changes are generally thought to control timing of the membrane fusion reaction such that it occurs only in endosomal compartments.", [["membrane", "ANATOMY", 102, 110], ["endosomal compartments", "ANATOMY", 155, 177], ["1-3,16,33-37", "CHEMICAL", 0, 12], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["endosomal compartments", "CELLULAR_COMPONENT", 155, 177], ["These pH", "TEST", 13, 21], ["dependent conformational changes", "PROBLEM", 22, 54], ["the membrane fusion reaction", "PROBLEM", 98, 126], ["dependent", "OBSERVATION_MODIFIER", 22, 31], ["conformational", "OBSERVATION", 32, 46], ["membrane fusion", "OBSERVATION", 102, 117], ["endosomal compartments", "OBSERVATION", 155, 177]]], ["For example, low pH triggers dissociation of the surface subunit (HA1) and HA2 subunits of influenza and extension of the central HA2 coiled-coil.", [["surface", "ANATOMY", 49, 56], ["influenza", "DISEASE", 91, 100], ["surface subunit", "PROTEIN", 49, 64], ["HA1", "PROTEIN", 66, 69], ["HA2 subunits", "PROTEIN", 75, 87], ["central HA2 coiled-coil", "PROTEIN", 122, 145], ["low pH triggers dissociation", "PROBLEM", 13, 41], ["influenza", "PROBLEM", 91, 100], ["the central HA2 coiled-coil", "TREATMENT", 118, 145], ["low pH", "OBSERVATION_MODIFIER", 13, 19], ["surface", "OBSERVATION_MODIFIER", 49, 56], ["influenza", "OBSERVATION", 91, 100], ["central", "OBSERVATION_MODIFIER", 122, 129], ["HA2", "OBSERVATION_MODIFIER", 130, 133], ["coil", "OBSERVATION_MODIFIER", 141, 145]]], ["1,3 A pH-de-pendent coil-to-helix transition in the midsection of the HA2 coiled-coil effectively jackknifes the N-terminal FP from the center of the envelope spike out toward the cell membrane.", [["cell membrane", "ANATOMY", 180, 193], ["cell membrane", "CELLULAR_COMPONENT", 180, 193], ["HA2 coiled-coil", "PROTEIN", 70, 85], ["N-terminal FP", "PROTEIN", 113, 126], ["A pH", "TEST", 4, 8], ["de-pendent coil", "TREATMENT", 9, 24], ["the HA2 coiled", "TREATMENT", 66, 80], ["N-terminal", "OBSERVATION_MODIFIER", 113, 123], ["FP", "OBSERVATION_MODIFIER", 124, 126], ["envelope spike", "OBSERVATION", 150, 164], ["cell membrane", "OBSERVATION", 180, 193]]], ["16, 33, 34 This rearrangement projects the FP into the cell membrane, leading to the extended intermediate.", [["cell membrane", "ANATOMY", 55, 68], ["cell membrane", "CELLULAR_COMPONENT", 55, 68], ["cell membrane", "OBSERVATION", 55, 68]]], ["In the envelope glycorproteins of viruses such as alphaviruses and flaviriruses that contain mostly b-sheet structures (the ''class II'' envelope glycoproteins), similar pH effects destabilize the inactive prefusion conformation and promote oligomerization of fusion-active components.", [["flaviriruses", "GENE_OR_GENE_PRODUCT", 67, 79], ["class II'' envelope glycoproteins", "GENE_OR_GENE_PRODUCT", 126, 159], ["class II'' envelope glycoproteins", "PROTEIN", 126, 159], ["fusion-active components", "PROTEIN", 260, 284], ["viruses", "PROBLEM", 34, 41], ["alphaviruses", "PROBLEM", 50, 62], ["flaviriruses", "PROBLEM", 67, 79], ["similar pH effects", "PROBLEM", 162, 180], ["the inactive prefusion conformation", "PROBLEM", 193, 228], ["fusion-active components", "TREATMENT", 260, 284], ["envelope", "OBSERVATION_MODIFIER", 7, 15], ["glycorproteins", "OBSERVATION", 16, 30], ["viruses", "OBSERVATION", 34, 41], ["inactive", "OBSERVATION_MODIFIER", 197, 205], ["prefusion conformation", "OBSERVATION", 206, 228], ["fusion", "OBSERVATION", 260, 266], ["active", "OBSERVATION_MODIFIER", 267, 273], ["components", "OBSERVATION_MODIFIER", 274, 284]]], ["35, 37 In EboV entry, proteolytic disassembly of GP1 by CatL and CatB, whose optimal catalytic activity is known to be at pH $5, is an essential step in early infection events.", [["infection", "DISEASE", 159, 168], ["EboV", "GENE_OR_GENE_PRODUCT", 10, 14], ["GP1", "GENE_OR_GENE_PRODUCT", 49, 52], ["CatL", "GENE_OR_GENE_PRODUCT", 56, 60], ["CatB", "GENE_OR_GENE_PRODUCT", 65, 69], ["GP1", "PROTEIN", 49, 52], ["CatL", "PROTEIN", 56, 60], ["CatB", "PROTEIN", 65, 69], ["early infection events", "PROBLEM", 153, 175], ["early", "OBSERVATION_MODIFIER", 153, 158], ["infection", "OBSERVATION", 159, 168]]], ["10, 11 However, pH-dependent structural transitions have not been reported for GP1 or the GP2 ectodomain.", [["GP1", "GENE_OR_GENE_PRODUCT", 79, 82], ["GP2", "GENE_OR_GENE_PRODUCT", 90, 93], ["GP1", "PROTEIN", 79, 82], ["GP2 ectodomain", "PROTEIN", 90, 104], ["pH-dependent structural transitions", "PROBLEM", 16, 51], ["GP1", "PROBLEM", 79, 82], ["the GP2 ectodomain", "PROBLEM", 86, 104], ["structural transitions", "OBSERVATION", 29, 51], ["GP2 ectodomain", "OBSERVATION", 90, 104]]], ["Very recently, Gregory et al. 38 demonstrated that the GP2 fusion loop undergoes pH-dependent conformational changes that promote fusogenic activity.Effects of pH on stabilityWe determined the effect of pH on a-helical bundle stability of Ebo6H and Ebo5H by performing spectroscopic analysis under various buffer conditions.", [["Ebo6H", "CHEMICAL", 239, 244], ["GP2", "GENE_OR_GENE_PRODUCT", 55, 58], ["Ebo6H", "SIMPLE_CHEMICAL", 239, 244], ["Ebo5H", "SIMPLE_CHEMICAL", 249, 254], ["GP2 fusion loop", "PROTEIN", 55, 70], ["Ebo6H", "PROTEIN", 239, 244], ["Ebo5H", "PROTEIN", 249, 254], ["the GP2 fusion loop", "TREATMENT", 51, 70], ["dependent conformational changes", "PROBLEM", 84, 116], ["pH", "TEST", 203, 205], ["spectroscopic analysis", "TEST", 269, 291], ["various buffer conditions", "TREATMENT", 298, 323], ["fusogenic activity", "OBSERVATION", 130, 148], ["stability", "OBSERVATION_MODIFIER", 166, 175]]], ["In conditions above pH 6.5, both proteins were poorly behaved and prone to aggregation.", [["aggregation", "DISEASE", 75, 86], ["pH", "TEST", 20, 22]]], ["However, in range of pH 4.8-6.1, we found that both proteins retained their wellbehaved, native-like properties.", [["pH", "TEST", 21, 23]]], ["We performed thermal denaturation of Ebo6H and Ebo5H under several buffering conditions and found that the T m was lower at higher pH for both proteins (Fig. 4 and Table I ).", [["Ebo6H", "CHEMICAL", 37, 42], ["Ebo5H", "CHEMICAL", 47, 52], ["Ebo6H", "CHEMICAL", 37, 42], ["Ebo5H", "CHEMICAL", 47, 52], ["Ebo6H", "SIMPLE_CHEMICAL", 37, 42], ["Ebo5H", "SIMPLE_CHEMICAL", 47, 52], ["T m", "GENE_OR_GENE_PRODUCT", 107, 110], ["Ebo6H", "PROTEIN", 37, 42], ["Ebo5H", "PROTEIN", 47, 52], ["Table I", "PROTEIN", 164, 171], ["thermal denaturation of Ebo6H", "TREATMENT", 13, 42], ["the T m", "TEST", 103, 110]]], ["The folding stability of small, globular proteins can be significantly influenced by pH; however, most proteins are most stably folded at neutral (physiologic) pH and become less stable in conditions below pH 6 (converse to the behavior observed here).", [["globular proteins", "PROTEIN", 32, 49], ["small, globular proteins", "PROBLEM", 25, 49], ["stability", "OBSERVATION_MODIFIER", 12, 21], ["small", "OBSERVATION_MODIFIER", 25, 30], ["globular", "OBSERVATION_MODIFIER", 32, 40], ["proteins", "OBSERVATION", 41, 49], ["less", "OBSERVATION_MODIFIER", 174, 178], ["stable", "OBSERVATION_MODIFIER", 179, 185]]], ["39 The effects of pH on T m were most pronounced in Ebo6H, where the T m differed by 37 C between pH 5.2 (T m \u00bc 86.8 6 2.0 C) and pH 6.1 (T m \u00bc 49.8 6 1.1 C), corresponding to a DDH vH of 7.8 kcal/mol over this range.", [["T m", "GENE_OR_GENE_PRODUCT", 24, 27], ["Ebo6H", "SIMPLE_CHEMICAL", 52, 57], ["T m", "GENE_OR_GENE_PRODUCT", 69, 72], ["pH on T m", "TEST", 18, 27], ["the T m", "TEST", 65, 72], ["pH", "TEST", 98, 100], ["T m \u00bc", "TEST", 106, 111], ["pH", "TEST", 130, 132], ["T m \u00bc", "TEST", 138, 143], ["a DDH vH", "TEST", 176, 184]]], ["In addition, heating to 100 C at pH 4.8 did not result in complete unfolding of Ebo6H [ Fig. 3(C) ].", [["Ebo6H", "CHEMICAL", 80, 85], ["Ebo6H", "SIMPLE_CHEMICAL", 80, 85], ["Ebo6H", "PROTEIN", 80, 85], ["pH", "TEST", 33, 35]]], ["Similar stability effects were observed for Ebo5H although they were less dramatic.", [["Ebo5H", "CHEMICAL", 44, 49], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 44, 49], ["Ebo5H", "PROTEIN", 44, 49], ["stability", "OBSERVATION", 8, 17], ["less", "OBSERVATION_MODIFIER", 69, 73], ["dramatic", "OBSERVATION_MODIFIER", 74, 82]]], ["The T m values ranged from 82.2 6 1.2 C at pH 4.8 to 72.6 6 1.9 C at pH 6.1; this corresponded to a DDH vH of Table I .", [["T m", "GENE_OR_GENE_PRODUCT", 4, 7], ["The T m values", "TEST", 0, 14], ["pH", "TEST", 43, 45], ["pH", "TEST", 69, 71], ["a DDH vH", "TEST", 98, 106]]], ["Both pIIGP2(552-650), the Wiley construct, and Ebo-95, the longer of the two Kim constructs, had high thermostability at neutral pH or higher.", [["Ebo-95", "CHEMICAL", 47, 53], ["pIIGP2", "GENE_OR_GENE_PRODUCT", 5, 11], ["Ebo-95", "GENE_OR_GENE_PRODUCT", 47, 53], ["Wiley construct", "DNA", 26, 41], ["Ebo-95", "DNA", 47, 53], ["Kim constructs", "DNA", 77, 91], ["Ebo", "TEST", 47, 50], ["high thermostability at neutral pH", "PROBLEM", 97, 131]]], ["9, 29 However, the shorter Ebo-74 construct was crystallized and characterized by CD at pH 4.5-4.6.", [["Ebo-74", "CHEMICAL", 27, 33], ["Ebo-74 construct", "DNA", 27, 43], ["the shorter Ebo", "TEST", 15, 30], ["pH", "TEST", 88, 90]]], ["9 Ebo6H and Ebo5H contain even less of the ectodomain than does Ebo-74, therefore the a-helical stability of shorter constructs may be more sensitive to environmental pH.", [["Ebo-74", "CHEMICAL", 64, 70], ["Ebo-74", "CHEMICAL", 64, 70], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 2, 7], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 12, 17], ["Ebo6H", "PROTEIN", 2, 7], ["Ebo5H", "PROTEIN", 12, 17], ["ectodomain", "PROTEIN", 43, 53], ["Ebo", "PROTEIN", 64, 67], ["Ebo", "TEST", 64, 67], ["shorter constructs", "PROBLEM", 109, 127], ["less", "OBSERVATION_MODIFIER", 31, 35]]], ["An examination of the six-helix bundle segment of the GP2 postfusion structure suggests that two side chain-side chain ionic interactions may be responsible for this pH-dependent behavior.", [["GP2", "GENE_OR_GENE_PRODUCT", 54, 57], ["six-helix bundle segment", "PROTEIN", 22, 46], ["GP2", "PROTEIN", 54, 57], ["An examination", "TEST", 0, 14], ["two side chain-side chain ionic interactions", "PROBLEM", 93, 137], ["this pH-dependent behavior", "PROBLEM", 161, 187], ["segment", "ANATOMY_MODIFIER", 39, 46], ["GP2", "ANATOMY_MODIFIER", 54, 57], ["two", "OBSERVATION_MODIFIER", 93, 96], ["side", "OBSERVATION_MODIFIER", 97, 101], ["chain", "OBSERVATION_MODIFIER", 102, 107], ["side chain", "OBSERVATION_MODIFIER", 108, 118]]], ["On the CHR a-helix, an intrahelical i ! i \u00fe 3 interaction between D621 and D624 could destabilize CHR a-helix formation at neutral pH due to repulsion between the carboxylate anions [ Fig. 5(A) ].", [["D621", "CHEMICAL", 66, 70], ["D624", "CHEMICAL", 75, 79], ["carboxylate", "CHEMICAL", 163, 174], ["D621", "CHEMICAL", 66, 70], ["D624", "CHEMICAL", 75, 79], ["CHR", "CHEMICAL", 98, 101], ["carboxylate", "CHEMICAL", 163, 174], ["\u00fe 3", "GENE_OR_GENE_PRODUCT", 42, 45], ["D621", "SIMPLE_CHEMICAL", 66, 70], ["D624", "SIMPLE_CHEMICAL", 75, 79], ["CHR a-helix", "SIMPLE_CHEMICAL", 98, 109], ["carboxylate anions", "SIMPLE_CHEMICAL", 163, 181], ["D621", "TREATMENT", 66, 70], ["the carboxylate anions", "TREATMENT", 159, 181]]], ["In other short a-helical bundle systems, overall folding stability can be greatly influenced by propensity of individual segments to adopt ahelical fold.", [["overall folding stability", "PROBLEM", 41, 66], ["short", "OBSERVATION_MODIFIER", 9, 14], ["overall", "OBSERVATION_MODIFIER", 41, 48], ["folding stability", "OBSERVATION", 49, 66]]], ["40 Electrostatic i ! i \u00fe 3 interactions can strongly influence a-helix formation and therefore ahelical bundle formation in systems containing segments as short as the GP2 CHR (three a-helical turns).", [["ahelical bundle", "ANATOMY", 95, 110], ["\u00fe 3", "GENE_OR_GENE_PRODUCT", 23, 26], ["a-helix", "SIMPLE_CHEMICAL", 63, 70], ["GP2", "GENE_OR_GENE_PRODUCT", 168, 171], ["GP2 CHR", "PROTEIN", 168, 175], ["ahelical bundle formation in systems", "PROBLEM", 95, 131], ["the GP2 CHR", "TEST", 164, 175]]], ["41, 42 In addition, a repulsive interaction between E564 of the NHR and D629 of the CHR may disrupt interhelical association at neutral pH [ Fig. 5(A) ].", [["E564", "CHEMICAL", 52, 56], ["NHR", "PROTEIN", 64, 67], ["D629", "PROTEIN", 72, 76], ["CHR", "PROTEIN", 84, 87], ["the CHR", "TREATMENT", 80, 87], ["repulsive", "OBSERVATION", 22, 31]]], ["To test this hypothesis, we prepared an Ebo6H variant with the mutations D621N, D624N, and D629N on the CHR segments, and E564Q on the NHR segments (''Ebo6H-QNNN'').", [["Ebo6H", "GENE_OR_GENE_PRODUCT", 40, 45], ["Ebo6H variant", "PROTEIN", 40, 53], ["CHR segments", "DNA", 104, 116], ["NHR segments", "DNA", 135, 147], ["Ebo6H", "PROTEIN", 151, 156], ["D624N", "TREATMENT", 80, 85], ["Ebo6H", "TEST", 151, 156]]], ["As Ebo6H contains a total of three NHR and CHR segments each, the GP2 NHR/CHR segments of Ebo6H-QNNN have 12 total substitutions relative to the analogous segments in Ebo6H.", [["Ebo6H", "GENE_OR_GENE_PRODUCT", 3, 8], ["NHR", "GENE_OR_GENE_PRODUCT", 35, 38], ["GP2", "GENE_OR_GENE_PRODUCT", 66, 69], ["Ebo6H-QNNN", "GENE_OR_GENE_PRODUCT", 90, 100], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 167, 172], ["Ebo6H", "PROTEIN", 3, 8], ["NHR", "PROTEIN", 35, 38], ["CHR segments", "PROTEIN", 43, 55], ["GP2 NHR", "PROTEIN", 66, 73], ["CHR segments", "PROTEIN", 74, 86], ["Ebo6H", "PROTEIN", 90, 95], ["QNNN", "PROTEIN", 96, 100], ["Ebo6H", "PROTEIN", 167, 172], ["the GP2 NHR", "TEST", 62, 73], ["Ebo6H", "TEST", 90, 95], ["12 total substitutions", "PROBLEM", 106, 128], ["CHR segments", "ANATOMY_MODIFIER", 43, 55]]], ["We found Ebo6H-QNNN to be a-helical by CD; thermal denaturation indicates that the T m s were similar at pH 4.8 and 5.3 [43.1 6 0.9 C and 46.2 6 1.0 C, respectively, Fig. 5(B) ] but was lower than Ebo6H under these conditions.", [["Ebo6H-QNNN", "CHEMICAL", 9, 19], ["Ebo6H-QNNN", "SIMPLE_CHEMICAL", 9, 19], ["T m", "GENE_OR_GENE_PRODUCT", 83, 86], ["Ebo6H", "SIMPLE_CHEMICAL", 197, 202], ["Ebo6H", "PROTEIN", 9, 14], ["QNNN", "PROTEIN", 15, 19], ["Ebo6H", "PROTEIN", 197, 202], ["Ebo6H", "TEST", 9, 14], ["thermal denaturation", "PROBLEM", 43, 63], ["the T m s", "TEST", 79, 88], ["pH", "TEST", 105, 107], ["C", "TEST", 132, 133], ["Fig.", "TEST", 166, 170]]], ["Furthermore, unfolding transition for Ebo6H-QNNN was much broader that of Ebo6H.", [["Ebo6H", "CHEMICAL", 38, 43], ["Ebo6H-QNNN", "CHEMICAL", 38, 48], ["Ebo6H-QNNN", "SIMPLE_CHEMICAL", 38, 48], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 74, 79], ["Ebo6H", "PROTEIN", 38, 43], ["QNNN", "PROTEIN", 44, 48], ["Ebo6H", "PROTEIN", 74, 79], ["Ebo6H", "TEST", 38, 43]]], ["These differences may reflect the fact that aspargine has lower a-helical propensity in coiled-coil proteins than does aspartic acid and therefore the nine Asp !", [["aspargine", "CHEMICAL", 44, 53], ["aspartic acid", "CHEMICAL", 119, 132], ["aspargine", "CHEMICAL", 44, 53], ["aspartic acid", "CHEMICAL", 119, 132], ["Asp", "CHEMICAL", 156, 159], ["aspargine", "SIMPLE_CHEMICAL", 44, 53], ["aspartic acid", "AMINO_ACID", 119, 132], ["coiled-coil proteins", "PROTEIN", 88, 108], ["lower a-helical propensity in coiled-coil proteins", "PROBLEM", 58, 108], ["aspartic acid", "PROBLEM", 119, 132], ["lower", "OBSERVATION_MODIFIER", 58, 63]]], ["Asn substitutions in the GP2 NHR/CHR regions have a cumulative effect on folding stability.", [["Asn", "CHEMICAL", 0, 3], ["Asn", "CHEMICAL", 0, 3], ["Asn", "AMINO_ACID", 0, 3], ["GP2", "GENE_OR_GENE_PRODUCT", 25, 28], ["GP2 NHR/CHR regions", "DNA", 25, 44], ["Asn substitutions in the GP2 NHR/CHR regions", "PROBLEM", 0, 44], ["cumulative effect", "OBSERVATION", 52, 69], ["folding stability", "OBSERVATION", 73, 90]]], ["40 Ebo6H-QNNN had higher stability at pH 6.1 (T m \u00bc 53.5 6 1.1 C) than at the lower pHs.", [["Ebo6H-QNNN", "CHEMICAL", 3, 13], ["Ebo6H-QNNN", "SIMPLE_CHEMICAL", 3, 13], ["Ebo6H", "TEST", 3, 8], ["higher stability", "PROBLEM", 18, 34], ["pH", "TEST", 38, 40], ["T m \u00bc", "TEST", 46, 51], ["higher", "OBSERVATION_MODIFIER", 18, 24], ["stability", "OBSERVATION_MODIFIER", 25, 34]]], ["This behavior contrasts with that of Ebo6H, which was significantly more stable under acidic conditions than at pH 6.1.", [["Ebo6H", "CHEMICAL", 37, 42], ["Ebo6H", "CHEMICAL", 37, 42], ["Ebo6H", "SIMPLE_CHEMICAL", 37, 42], ["pH", "TEST", 112, 114], ["stable", "OBSERVATION_MODIFIER", 73, 79]]], ["Furthermore, Ebo6H-QNNN had 3.7 C higher T m than did Ebo6H at pH 6.1, indicating that the ahelical fold of Ebo6H-QNNN is less sensitive to conditions near neutral pH.", [["Ebo6H", "CHEMICAL", 13, 18], ["Ebo6H-QNNN", "CHEMICAL", 108, 118], ["Ebo6H-QNNN", "CHEMICAL", 108, 118], ["Ebo6H-QNNN", "SIMPLE_CHEMICAL", 13, 23], ["Ebo6H", "SIMPLE_CHEMICAL", 54, 59], ["Ebo6H-QNNN", "SIMPLE_CHEMICAL", 108, 118], ["Ebo6H", "PROTEIN", 13, 18], ["Ebo6H", "PROTEIN", 108, 113], ["QNNN", "PROTEIN", 114, 118], ["Ebo6H", "TEST", 13, 18], ["QNNN", "TEST", 19, 23], ["pH", "TEST", 63, 65], ["Ebo6H", "TEST", 108, 113], ["less sensitive", "OBSERVATION_MODIFIER", 122, 136]]], ["In addition, Ebo6H was much less stable than Ebo5H at pH 6.1 (T m s of 49.8 6 1.1 C for Ebo6H and 72.6 6 1.9 C for Ebo5H) suggesting that repulsive interactions within the additional CHR segment in Ebo6H substantially affects global a-helical bundle fold stability under these conditions.", [["Ebo6H", "CHEMICAL", 198, 203], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 13, 18], ["Ebo5H", "SIMPLE_CHEMICAL", 45, 50], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 198, 203], ["Ebo6H", "PROTEIN", 13, 18], ["Ebo6H", "PROTEIN", 88, 93], ["Ebo5H", "PROTEIN", 115, 120], ["CHR segment", "DNA", 183, 194], ["Ebo6H", "PROTEIN", 198, 203], ["Ebo6H", "TEST", 13, 18], ["pH", "TEST", 54, 56], ["T m s", "TEST", 62, 67], ["Ebo6H", "TEST", 88, 93], ["repulsive interactions", "PROBLEM", 138, 160], ["stable", "OBSERVATION_MODIFIER", 33, 39], ["repulsive", "OBSERVATION", 138, 147], ["segment", "ANATOMY_MODIFIER", 187, 194], ["bundle fold", "OBSERVATION", 243, 254]]], ["Taken together, these results suggest that anionic side chain-side chain interactions mediate pH-dependent a-helical bundle stability in Ebo6H.Effects of pH on stabilityBoth Ebo6H and Ebo5H were purified with two hexahistidine tags, one at each terminus.", [["Ebo6H", "SIMPLE_CHEMICAL", 137, 142], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 174, 179], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 184, 189], ["Ebo6H", "PROTEIN", 137, 142], ["Ebo6H", "PROTEIN", 174, 179], ["Ebo5H", "PROTEIN", 184, 189], ["anionic side chain-side chain interactions", "PROBLEM", 43, 85], ["pH", "TEST", 94, 96], ["pH", "TEST", 154, 156], ["two hexahistidine tags", "TREATMENT", 209, 231], ["bundle stability", "OBSERVATION", 117, 133], ["pH", "OBSERVATION_MODIFIER", 154, 156], ["hexahistidine tags", "OBSERVATION", 213, 231]]], ["As the pKa of the imidazole side chain is approximately 6, it is possible that the histidine tags contribute to the pHsensitive behavior observed here.", [["imidazole", "CHEMICAL", 18, 27], ["histidine", "CHEMICAL", 83, 92], ["imidazole", "CHEMICAL", 18, 27], ["histidine", "CHEMICAL", 83, 92], ["the imidazole side chain", "TREATMENT", 14, 38], ["the histidine tags", "PROBLEM", 79, 97], ["the pHsensitive behavior", "PROBLEM", 112, 136]]], ["Unfortunately, attempts to isolate Ebo6H variants containing fewer than two histidine tags were unsuccessful and therefore we could not directly compare thermostability with and without these segments.", [["histidine", "CHEMICAL", 76, 85], ["histidine", "CHEMICAL", 76, 85], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 35, 40], ["Ebo6H variants", "DNA", 35, 49], ["Ebo6H variants", "PROBLEM", 35, 49], ["two histidine tags", "TEST", 72, 90]]], ["However, increased cationic charge density by protonation of histidine tags at the N-and C-terminal ends is predicted to disfavor folding due to repulsion between the N-and Cterminal ends in a compact, globular state.", [["histidine", "CHEMICAL", 61, 70], ["histidine", "CHEMICAL", 61, 70], ["N", "CHEMICAL", 83, 84], ["C", "CHEMICAL", 89, 90], ["N", "CHEMICAL", 167, 168], ["histidine", "AMINO_ACID", 61, 70], ["N-and C-terminal ends", "DNA", 83, 104], ["N-and Cterminal ends", "PROTEIN", 167, 187], ["increased cationic charge density", "PROBLEM", 9, 42], ["histidine tags", "TEST", 61, 75], ["the N", "TEST", 79, 84], ["repulsion", "TEST", 145, 154], ["increased", "OBSERVATION_MODIFIER", 9, 18], ["cationic charge density", "OBSERVATION", 19, 42], ["globular", "OBSERVATION_MODIFIER", 202, 210]]], ["Although we cannot rule out the possibility that the histidine tags play a role in the pH-dependent stability of Ebo6H and Ebo5H, it seems unlikely that the observed effects could be explained by these regions alone.", [["histidine", "CHEMICAL", 53, 62], ["histidine", "CHEMICAL", 53, 62], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 113, 118], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 123, 128], ["Ebo6H", "PROTEIN", 113, 118], ["Ebo5H", "PROTEIN", 123, 128], ["the histidine tags", "PROBLEM", 49, 67], ["the pH", "TEST", 83, 89]]], ["Although the pH range in which we see the most dramatic changes in Ebo6H and Ebo5H structural stability (pH 4.8-6.1) falls above the pKa of carboxylic acid side chains (pH $4), it is not unusual for side chain pKas to be elevated in situations where their deprotonation disfavors formation of a highly stable fold.", [["carboxylic acid", "CHEMICAL", 140, 155], ["carboxylic acid", "CHEMICAL", 140, 155], ["Ebo6H", "SIMPLE_CHEMICAL", 67, 72], ["carboxylic acid", "SIMPLE_CHEMICAL", 140, 155], ["the pH range", "TEST", 9, 21], ["pH", "TEST", 105, 107], ["the pKa", "TEST", 129, 136], ["carboxylic acid side chains", "TREATMENT", 140, 167], ["side chain pKas", "PROBLEM", 199, 214], ["pH range", "OBSERVATION_MODIFIER", 13, 21], ["dramatic", "OBSERVATION_MODIFIER", 47, 55], ["stability", "OBSERVATION_MODIFIER", 94, 103], ["highly", "OBSERVATION_MODIFIER", 295, 301], ["stable", "OBSERVATION", 302, 308]]], ["[43] [44] [45] [46] Such phenomena have been documented in other a-helical bundle proteins as well.", [["[43] [44] [45] [46]", "SIMPLE_CHEMICAL", 0, 19], ["a-helical bundle proteins", "PROTEIN", 65, 90], ["Such phenomena", "PROBLEM", 20, 34]]], ["[43] [44] [45] [46] Conclusions and implications for membrane fusion Our analysis with Ebo6H and Ebo5H provide new insight into folding and stability for the six-helix bundle of EboV GP2.", [["membrane", "ANATOMY", 53, 61], ["[43] [44] [45] [46", "SIMPLE_CHEMICAL", 0, 18], ["membrane", "CELLULAR_COMPONENT", 53, 61], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 87, 92], ["Ebo5H", "SIMPLE_CHEMICAL", 97, 102], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 178, 186], ["Ebo6H", "PROTEIN", 87, 92], ["Ebo5H", "PROTEIN", 97, 102], ["six-helix bundle", "PROTEIN", 158, 174], ["EboV GP2", "PROTEIN", 178, 186], ["membrane fusion", "TREATMENT", 53, 68], ["Our analysis", "TEST", 69, 81], ["Ebo6H", "TREATMENT", 87, 92]]], ["We found that Ebo6H, a designed protein mimic of the GP2 a-helical bundle, adopts a highly thermostable fold.", [["Ebo6H", "CHEMICAL", 14, 19], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 14, 19], ["GP2", "GENE_OR_GENE_PRODUCT", 53, 56], ["Ebo6H", "PROTEIN", 14, 19], ["GP2 a-helical bundle", "PROTEIN", 53, 73], ["a highly thermostable fold", "PROBLEM", 82, 108], ["highly", "OBSERVATION_MODIFIER", 84, 90], ["thermostable fold", "OBSERVATION", 91, 108]]], ["Among class I viral membrane fusion glycoproteins, the central ectodomain core NHR trimeric coiled-coil of EboV GP2 and analogous proteins from the structurally related MarV, MoMLV HTLV-1, and ASLV are relatively short in length.", [["membrane", "ANATOMY", 20, 28], ["class I viral membrane fusion glycoproteins", "GENE_OR_GENE_PRODUCT", 6, 49], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 107, 115], ["MarV", "GENE_OR_GENE_PRODUCT", 169, 173], ["MoMLV HTLV-1", "ORGANISM", 175, 187], ["ASLV", "GENE_OR_GENE_PRODUCT", 193, 197], ["class I viral membrane fusion glycoproteins", "PROTEIN", 6, 49], ["central ectodomain core NHR trimeric coiled-coil", "PROTEIN", 55, 103], ["EboV GP2", "PROTEIN", 107, 115], ["MarV", "PROTEIN", 169, 173], ["ASLV", "PROTEIN", 193, 197], ["class I", "SPECIES", 6, 13], ["HTLV-1", "SPECIES", 181, 187], ["Among class I viral membrane fusion glycoproteins", "TREATMENT", 0, 49], ["the central ectodomain core NHR trimeric coiled", "TREATMENT", 51, 98], ["EboV GP2", "TREATMENT", 107, 115], ["analogous proteins", "PROBLEM", 120, 138], ["MoMLV HTLV", "TEST", 175, 185], ["viral membrane fusion", "OBSERVATION", 14, 35], ["central", "ANATOMY_MODIFIER", 55, 62], ["EboV GP2", "OBSERVATION", 107, 115], ["MarV", "OBSERVATION", 169, 173], ["relatively", "OBSERVATION_MODIFIER", 202, 212], ["short", "OBSERVATION_MODIFIER", 213, 218]]], ["1, 2, 14 The core NHR trimers of influenza A virus HA2 and severe acute respiratory syndrome coronavirus S2 are longer than EboV GP2, but these ectodomains also contain loop or non-a-helical segments and therefore their six-helix bundle segments are also small in comparison to HIV-1 gp41.", [["acute respiratory syndrome coronavirus", "DISEASE", 66, 104], ["influenza A virus HA2", "ORGANISM", 33, 54], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 124, 132], ["HIV-1 gp41", "ORGANISM", 278, 288], ["core NHR trimers", "PROTEIN", 13, 29], ["EboV GP2", "PROTEIN", 124, 132], ["ectodomains", "PROTEIN", 144, 155], ["loop or non-a-helical segments", "PROTEIN", 169, 199], ["six-helix bundle segments", "PROTEIN", 220, 245], ["HIV-1 gp41", "PROTEIN", 278, 288], ["influenza A virus", "SPECIES", 33, 50], ["HIV-1", "SPECIES", 278, 283], ["influenza A virus", "SPECIES", 33, 50], ["severe acute respiratory syndrome coronavirus", "SPECIES", 59, 104], ["EboV", "SPECIES", 124, 128], ["HIV-1", "SPECIES", 278, 283], ["influenza A virus HA2", "PROBLEM", 33, 54], ["severe acute respiratory syndrome coronavirus S2", "PROBLEM", 59, 107], ["EboV GP2", "TEST", 124, 132], ["HIV", "TEST", 278, 281], ["influenza", "OBSERVATION", 33, 42], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory syndrome", "OBSERVATION", 72, 92], ["coronavirus S2", "OBSERVATION", 93, 107], ["loop", "OBSERVATION_MODIFIER", 169, 173], ["segments", "ANATOMY_MODIFIER", 191, 199], ["six-helix", "OBSERVATION_MODIFIER", 220, 229], ["bundle", "OBSERVATION_MODIFIER", 230, 236], ["segments", "OBSERVATION_MODIFIER", 237, 245], ["small", "OBSERVATION_MODIFIER", 255, 260]]], ["3 Our studies demonstrate that even the small a-helical bundle of EboV GP2 (consisting of a-helical segments containing just three to four turns) provides a large amount of energy to overcome barriers associated with membrane fusion.", [["membrane", "ANATOMY", 217, 225], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 66, 74], ["membrane", "CELLULAR_COMPONENT", 217, 225], ["EboV GP2", "PROTEIN", 66, 74], ["a-helical segments", "PROTEIN", 90, 108], ["Our studies", "TEST", 2, 13], ["the small a-helical bundle of EboV GP2", "PROBLEM", 36, 74], ["a-helical segments", "TREATMENT", 90, 108], ["membrane fusion", "TREATMENT", 217, 232], ["small", "OBSERVATION_MODIFIER", 40, 45], ["EboV GP2", "OBSERVATION", 66, 74], ["large", "OBSERVATION_MODIFIER", 157, 162], ["amount", "OBSERVATION_MODIFIER", 163, 169], ["membrane fusion", "OBSERVATION", 217, 232]]], ["Furthermore, we found that Ebo5H was less stable than Ebo6H (DT m \u00bc 6.2 C at pH 5.3) thereby demonstrating that a single CHR segment can enhance thermostability of the a-helical bundle by a significant amount.", [["Ebo5H", "CHEMICAL", 27, 32], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 27, 32], ["Ebo6H", "SIMPLE_CHEMICAL", 54, 59], ["Ebo5H", "PROTEIN", 27, 32], ["CHR segment", "DNA", 121, 132], ["a-helical bundle", "PROTEIN", 168, 184], ["Ebo5H", "TEST", 27, 32], ["Ebo6H", "TEST", 54, 59], ["DT m", "TEST", 61, 65], ["pH", "TEST", 77, 79], ["a single CHR segment", "PROBLEM", 112, 132], ["less", "OBSERVATION_MODIFIER", 37, 41], ["stable", "OBSERVATION_MODIFIER", 42, 48], ["significant", "OBSERVATION_MODIFIER", 190, 201], ["amount", "OBSERVATION_MODIFIER", 202, 208]]], ["Similar designed 5-Helix proteins based on HIV-1 gp41 act as potent inhibitors of entry by sequestering the CHR segment on the extended intermediate during infection.", [["infection", "DISEASE", 156, 165], ["HIV-1", "ORGANISM", 43, 48], ["gp41", "ORGANISM", 49, 53], ["5-Helix proteins", "PROTEIN", 17, 33], ["HIV-1 gp41", "PROTEIN", 43, 53], ["CHR segment", "DNA", 108, 119], ["HIV-1", "SPECIES", 43, 48], ["HIV-1", "SPECIES", 43, 48], ["Similar designed 5-Helix proteins", "PROBLEM", 0, 33], ["HIV", "TEST", 43, 46], ["infection", "PROBLEM", 156, 165], ["CHR segment", "ANATOMY_MODIFIER", 108, 119], ["intermediate", "OBSERVATION_MODIFIER", 136, 148], ["infection", "OBSERVATION", 156, 165]]], ["[18] [19] [20] [21] [22] [23] [24] We tested Ebo5H for entry inhibition using a recombinant vesicular stomatitis virus containing the EboV GP in place of the native envelope glycoprotein (VSV-GP).", [["Ebo5H", "CHEMICAL", 45, 50], ["vesicular stomatitis", "DISEASE", 92, 112], ["[18] [19] [20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 0, 34], ["Ebo5H", "SIMPLE_CHEMICAL", 45, 50], ["vesicular stomatitis virus", "ORGANISM", 92, 118], ["EboV GP", "GENE_OR_GENE_PRODUCT", 134, 141], ["VSV-GP", "ORGANISM", 188, 194], ["EboV GP", "PROTEIN", 134, 141], ["native envelope glycoprotein", "PROTEIN", 158, 186], ["VSV", "PROTEIN", 188, 191], ["GP", "PROTEIN", 192, 194], ["stomatitis virus", "SPECIES", 102, 118], ["entry inhibition", "PROBLEM", 55, 71], ["a recombinant vesicular stomatitis virus", "PROBLEM", 78, 118], ["the EboV GP", "TEST", 130, 141], ["vesicular stomatitis", "OBSERVATION", 92, 112]]], ["We found that Ebo5H was not able to inhibit infection of VSV-GP (Miller and Chandran, unpublished results) , although this result is likely because the extended intermediate is exposed only in the endosome.", [["endosome", "ANATOMY", 197, 205], ["Ebo5H", "CHEMICAL", 14, 19], ["infection", "DISEASE", 44, 53], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 14, 19], ["VSV-GP", "ORGANISM", 57, 63], ["endosome", "CELLULAR_COMPONENT", 197, 205], ["Ebo5H", "PROTEIN", 14, 19], ["VSV", "SPECIES", 57, 60], ["infection of VSV", "PROBLEM", 44, 60], ["infection", "OBSERVATION", 44, 53]]], ["7 We recently reported that antiviral activity of peptides corresponding to the GP2 CHR segment (C-peptides) can be enhanced by inclusion of an endosome-targeting sequence.", [["endosome", "ANATOMY", 144, 152], ["GP2", "GENE_OR_GENE_PRODUCT", 80, 83], ["C-peptides", "GENE_OR_GENE_PRODUCT", 97, 107], ["endosome", "CELLULAR_COMPONENT", 144, 152], ["GP2 CHR segment", "DNA", 80, 95], ["endosome-targeting sequence", "PROTEIN", 144, 171], ["antiviral activity of peptides", "PROBLEM", 28, 58], ["an endosome", "TEST", 141, 152], ["antiviral activity", "OBSERVATION", 28, 46], ["segment", "ANATOMY_MODIFIER", 88, 95]]], ["25 Further studies indicated that the folding stabilities of Ebo6H and Ebo5H were pH sensitive.", [["Ebo6H", "GENE_OR_GENE_PRODUCT", 61, 66], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 71, 76], ["Ebo6H", "PROTEIN", 61, 66], ["Ebo5H", "PROTEIN", 71, 76], ["Further studies", "TEST", 3, 18], ["Ebo6H", "TEST", 61, 66], ["Ebo5H", "TEST", 71, 76]]], ["The ahelical bundle stability as judged by T m and DH vH values was significantly lower in buffering conditions closer to neutral pH than in acidic conditions.", [["T m", "GENE_OR_GENE_PRODUCT", 43, 46], ["DH vH values", "TEST", 51, 63], ["bundle", "OBSERVATION_MODIFIER", 13, 19], ["stability", "OBSERVATION", 20, 29], ["neutral pH", "OBSERVATION_MODIFIER", 122, 132], ["acidic conditions", "OBSERVATION", 141, 158]]], ["Analysis with Ebo6H-QNNN suggested that anionic side chain-side chain interactions mediate this pHdependent stability in Ebo6H; this feature of the GP2 six-helix bundle may have implications in control of the fusion reaction.", [["Ebo6H-QNNN", "CHEMICAL", 14, 24], ["Ebo6H-QNNN", "CHEMICAL", 14, 24], ["Ebo6H-QNNN", "SIMPLE_CHEMICAL", 14, 24], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 121, 126], ["GP2", "GENE_OR_GENE_PRODUCT", 148, 151], ["Ebo6H", "PROTEIN", 14, 19], ["QNNN", "PROTEIN", 20, 24], ["Ebo6H", "PROTEIN", 121, 126], ["GP2 six-helix bundle", "PROTEIN", 148, 168], ["Analysis", "TEST", 0, 8], ["Ebo6H", "TEST", 14, 19], ["anionic side chain", "TREATMENT", 40, 58], ["side chain interactions", "PROBLEM", 59, 82], ["the GP2 six-helix bundle", "PROBLEM", 144, 168], ["the fusion reaction", "PROBLEM", 205, 224], ["fusion", "OBSERVATION", 209, 215]]], ["In the prevailing model for viral membrane fusion, it is thought that the transmembrane subunit is prevented from adopting the thermodynamically stable a-helical bundle structure by interactions with the surface subunit in the prefusion conformation.", [["membrane", "ANATOMY", 34, 42], ["transmembrane", "ANATOMY", 74, 87], ["surface", "ANATOMY", 204, 211], ["membrane", "CELLULAR_COMPONENT", 34, 42], ["transmembrane", "CELLULAR_COMPONENT", 74, 87], ["transmembrane subunit", "PROTEIN", 74, 95], ["a-helical bundle structure", "PROTEIN", 152, 178], ["surface subunit", "PROTEIN", 204, 219], ["viral membrane fusion", "TREATMENT", 28, 49], ["the transmembrane subunit", "PROBLEM", 70, 95], ["viral membrane fusion", "OBSERVATION", 28, 49], ["thermodynamically", "OBSERVATION_MODIFIER", 127, 144], ["stable", "OBSERVATION_MODIFIER", 145, 151], ["bundle structure", "OBSERVATION", 162, 178], ["prefusion conformation", "OBSERVATION", 227, 249]]], ["47, 48 Triggering events cause dissociation of the surface subunit and releases constraints on the transmembrane subunit ectodomain, allowing the eventual formation of the a-helical bundle that drives membrane fusion (the ''spring loaded clamp'' model).", [["surface", "ANATOMY", 51, 58], ["transmembrane", "ANATOMY", 99, 112], ["membrane", "ANATOMY", 201, 209], ["transmembrane", "CELLULAR_COMPONENT", 99, 112], ["membrane", "CELLULAR_COMPONENT", 201, 209], ["surface subunit", "PROTEIN", 51, 66], ["transmembrane subunit ectodomain", "PROTEIN", 99, 131], ["a-helical bundle", "PROTEIN", 172, 188], ["the surface subunit", "TREATMENT", 47, 66], ["the transmembrane subunit ectodomain", "TREATMENT", 95, 131], ["the a-helical bundle", "TREATMENT", 168, 188], ["membrane fusion", "TREATMENT", 201, 216], ["the ''spring loaded clamp'' model", "TREATMENT", 218, 251]]], ["In HIV-1 and influenza A virus, the events that trigger release of the transmembrane subunits (gp41 and HA2) from the prefusion confor-mation are well established.", [["transmembrane", "ANATOMY", 71, 84], ["HIV-1", "ORGANISM", 3, 8], ["influenza A virus", "ORGANISM", 13, 30], ["gp41", "GENE_OR_GENE_PRODUCT", 95, 99], ["HA2", "GENE_OR_GENE_PRODUCT", 104, 107], ["transmembrane subunits", "PROTEIN", 71, 93], ["gp41", "PROTEIN", 95, 99], ["HA2", "PROTEIN", 104, 107], ["HIV-1", "SPECIES", 3, 8], ["influenza A virus", "SPECIES", 13, 30], ["HIV-1", "SPECIES", 3, 8], ["influenza A virus", "SPECIES", 13, 30], ["influenza A virus", "PROBLEM", 13, 30], ["the transmembrane subunits", "TREATMENT", 67, 93], ["HA2", "PROBLEM", 104, 107], ["the prefusion confor-mation", "TREATMENT", 114, 141]]], ["For HIV-1, where membrane fusion is thought to occur at the cellular surface, a conformational change in gp120 on CD4 and coreceptor binding induces its dissociation from the spike.", [["membrane", "ANATOMY", 17, 25], ["cellular surface", "ANATOMY", 60, 76], ["HIV-1", "ORGANISM", 4, 9], ["membrane", "CELLULAR_COMPONENT", 17, 25], ["cellular surface", "CELLULAR_COMPONENT", 60, 76], ["gp120", "GENE_OR_GENE_PRODUCT", 105, 110], ["CD4", "GENE_OR_GENE_PRODUCT", 114, 117], ["gp120", "PROTEIN", 105, 110], ["CD4", "PROTEIN", 114, 117], ["HIV-1", "SPECIES", 4, 9], ["HIV-1", "SPECIES", 4, 9], ["HIV", "PROBLEM", 4, 7], ["membrane fusion", "PROBLEM", 17, 32], ["a conformational change in gp120", "PROBLEM", 78, 110], ["CD4 and coreceptor binding", "TREATMENT", 114, 140], ["its dissociation", "PROBLEM", 149, 165], ["the spike", "PROBLEM", 171, 180], ["fusion", "OBSERVATION", 26, 32], ["spike", "OBSERVATION_MODIFIER", 175, 180]]], ["49 In influenza A virus, which enters via the endosome, low pH destabilizes the prefusion conformation and leads to the extended intermediate.Effects of pH on stabilityA role for pH in structural transitions of GP1 or the GP2 ectodomain has not been established and the precise trigger for membrane fusion is still under investigation.", [["endosome", "ANATOMY", 46, 54], ["membrane", "ANATOMY", 290, 298], ["influenza A", "DISEASE", 6, 17], ["influenza A virus", "ORGANISM", 6, 23], ["endosome", "CELLULAR_COMPONENT", 46, 54], ["GP1", "GENE_OR_GENE_PRODUCT", 211, 214], ["GP2", "GENE_OR_GENE_PRODUCT", 222, 225], ["membrane", "CELLULAR_COMPONENT", 290, 298], ["GP1", "PROTEIN", 211, 214], ["GP2 ectodomain", "PROTEIN", 222, 236], ["influenza A virus", "SPECIES", 6, 23], ["influenza A virus", "SPECIES", 6, 23], ["influenza A virus", "PROBLEM", 6, 23], ["low pH", "PROBLEM", 56, 62], ["pH", "TEST", 179, 181], ["GP1", "PROBLEM", 211, 214], ["the GP2 ectodomain", "TEST", 218, 236], ["membrane fusion", "TREATMENT", 290, 305], ["influenza", "OBSERVATION", 6, 15], ["low pH", "OBSERVATION_MODIFIER", 56, 62], ["prefusion conformation", "OBSERVATION", 80, 102]]], ["Comparison of the NHR and CHR segments in the prefusion GP1-GP2 assembly demonstrates that the protein segment corresponding to the long a-helical NHR coiled-coil is interrupted into three shorter a-helices in the prefusion structure.", [["GP2", "GENE_OR_GENE_PRODUCT", 60, 63], ["NHR", "PROTEIN", 18, 21], ["CHR segments", "PROTEIN", 26, 38], ["prefusion GP1", "PROTEIN", 46, 59], ["GP2", "PROTEIN", 60, 63], ["protein segment", "PROTEIN", 95, 110], ["long a-helical NHR coiled-coil", "PROTEIN", 132, 162], ["a-helices", "PROTEIN", 197, 206], ["prefusion structure", "PROTEIN", 214, 233], ["the NHR", "TEST", 14, 21], ["the protein segment", "PROBLEM", 91, 110], ["the long a-helical NHR coiled-coil", "TREATMENT", 128, 162], ["CHR", "ANATOMY_MODIFIER", 26, 29], ["segments", "ANATOMY_MODIFIER", 30, 38], ["long", "OBSERVATION_MODIFIER", 132, 136], ["coiled", "OBSERVATION", 151, 157], ["coil", "OBSERVATION", 158, 162], ["three", "OBSERVATION_MODIFIER", 183, 188], ["shorter", "OBSERVATION_MODIFIER", 189, 196], ["prefusion structure", "OBSERVATION", 214, 233]]], ["7, 12 Electron density for the CHR segments was not observed in the prefusion structure, suggesting that this region is dynamic.", [["CHR segments", "DNA", 31, 43], ["density", "OBSERVATION", 15, 22], ["segments", "ANATOMY_MODIFIER", 35, 43], ["not observed", "UNCERTAINTY", 48, 60], ["prefusion structure", "OBSERVATION", 68, 87], ["dynamic", "OBSERVATION_MODIFIER", 120, 127]]], ["12 Recent mutational studies on the helix-turn-helix/loop segment of the ASLV transmembrane envelope glycoprotein (EnvA) have implicated a histidine residue in the pH dependence of EnvA-mediated viral entry.", [["histidine", "CHEMICAL", 139, 148], ["histidine", "CHEMICAL", 139, 148], ["ASLV transmembrane envelope glycoprotein", "GENE_OR_GENE_PRODUCT", 73, 113], ["EnvA", "GENE_OR_GENE_PRODUCT", 115, 119], ["EnvA", "GENE_OR_GENE_PRODUCT", 181, 185], ["helix-turn-helix/loop segment", "PROTEIN", 36, 65], ["ASLV transmembrane envelope glycoprotein", "PROTEIN", 73, 113], ["EnvA", "PROTEIN", 115, 119], ["EnvA", "PROTEIN", 181, 185], ["Recent mutational studies", "TEST", 3, 28], ["helix/loop segment of the ASLV transmembrane envelope glycoprotein", "TREATMENT", 47, 113], ["a histidine residue", "PROBLEM", 137, 156], ["the pH dependence", "PROBLEM", 160, 177], ["loop segment", "ANATOMY_MODIFIER", 53, 65], ["histidine residue", "OBSERVATION", 139, 156], ["pH dependence", "OBSERVATION", 164, 177], ["viral entry", "OBSERVATION", 195, 206]]], ["14 Mutation of residues in the analogous segment in EboV GP2 have an effect on viral entry but, in the absence of a fusion assay directed at the cell surface, it is not possible to determine whether these residues are involved in pH-dependent structural changes that promote membrane fusion.", [["cell surface", "ANATOMY", 145, 157], ["membrane", "ANATOMY", 275, 283], ["EboV GP2", "GENE_OR_GENE_PRODUCT", 52, 60], ["cell surface", "CELLULAR_COMPONENT", 145, 157], ["membrane", "CELLULAR_COMPONENT", 275, 283], ["EboV GP2", "PROTEIN", 52, 60], ["Mutation of residues in the analogous segment in EboV GP2", "PROBLEM", 3, 60], ["viral entry", "PROBLEM", 79, 90], ["a fusion assay", "TEST", 114, 128], ["these residues", "PROBLEM", 199, 213], ["dependent structural changes", "PROBLEM", 233, 261], ["membrane fusion", "TREATMENT", 275, 290], ["segment", "ANATOMY_MODIFIER", 41, 48], ["effect", "OBSERVATION_MODIFIER", 69, 75], ["viral entry", "OBSERVATION", 79, 90], ["fusion", "OBSERVATION", 116, 122], ["not possible", "UNCERTAINTY", 165, 177], ["membrane fusion", "OBSERVATION", 275, 290]]], ["14 Furthermore, a recent report suggests that the fusion loop of GP2 also undergoes a conformational transition between pH 7 and 5.5 that activates fusogenic activity under the lower pH condition.", [["GP2", "GENE_OR_GENE_PRODUCT", 65, 68], ["fusion loop", "PROTEIN", 50, 61], ["GP2", "PROTEIN", 65, 68], ["the fusion loop of GP2", "PROBLEM", 46, 68], ["pH", "TEST", 120, 122], ["the lower pH condition", "PROBLEM", 173, 195], ["fusion", "OBSERVATION", 50, 56], ["fusogenic activity", "OBSERVATION", 148, 166], ["lower pH", "OBSERVATION_MODIFIER", 177, 185]]], ["38 The results presented here suggest that pH-dependent ahelical bundle stability could also play a role in controlling the timing of membrane fusion.", [["membrane", "ANATOMY", 134, 142], ["membrane", "CELLULAR_COMPONENT", 134, 142], ["pH-dependent ahelical bundle stability", "PROBLEM", 43, 81], ["membrane fusion", "TREATMENT", 134, 149], ["bundle stability", "OBSERVATION", 65, 81], ["membrane fusion", "OBSERVATION", 134, 149]]], ["At neutral pH, the six-helix bundle is less stable and therefore the prefusion conformation is preferred.", [["six-helix bundle", "PROTEIN", 19, 35], ["less", "OBSERVATION_MODIFIER", 39, 43], ["stable", "OBSERVATION_MODIFIER", 44, 50], ["prefusion conformation", "OBSERVATION", 69, 91]]], ["However, once the virus particle is taken up into an endosome that undergoes acidification, the postfusion six-helix bundle becomes more stable and therefore the postfusion state becomes preferred.", [["endosome", "ANATOMY", 53, 61], ["endosome", "CELLULAR_COMPONENT", 53, 61], ["postfusion six-helix bundle", "PROTEIN", 96, 123], ["the virus particle", "PROBLEM", 14, 32], ["acidification", "PROBLEM", 77, 90], ["acidification", "OBSERVATION", 77, 90], ["more", "OBSERVATION_MODIFIER", 132, 136], ["stable", "OBSERVATION_MODIFIER", 137, 143]]], ["The pH range in which we see the most significant changes in stability (pH 4.8-6.1) corresponds to the pH of late endosomes and correlates closely with the optimal pH for acid-dependent cysteine cathepsin activity.", [["late endosomes", "ANATOMY", 109, 123], ["cysteine", "CHEMICAL", 186, 194], ["cysteine", "CHEMICAL", 186, 194], ["late endosomes", "CELLULAR_COMPONENT", 109, 123], ["cysteine", "AMINO_ACID", 186, 194], ["cathepsin", "GENE_OR_GENE_PRODUCT", 195, 204], ["cathepsin", "PROTEIN", 195, 204], ["The pH range", "TEST", 0, 12], ["pH", "TEST", 72, 74], ["the pH", "TEST", 99, 105], ["the optimal pH", "TEST", 152, 166], ["acid-dependent cysteine cathepsin activity", "TREATMENT", 171, 213], ["pH range", "OBSERVATION_MODIFIER", 4, 12], ["stability", "OBSERVATION_MODIFIER", 61, 70], ["cathepsin activity", "OBSERVATION", 195, 213]]], ["This proposed mechanism for conformational control is distinct from that of other endosomal viruses: in most cases, the pH change destabilizes the prefusion conformation rather than stabilizing the postfusion conformation.", [["endosomal", "ANATOMY", 82, 91], ["endosomal", "CELLULAR_COMPONENT", 82, 91], ["conformational control", "TREATMENT", 28, 50], ["other endosomal viruses", "PROBLEM", 76, 99], ["the pH change", "PROBLEM", 116, 129], ["the prefusion conformation", "PROBLEM", 143, 169], ["viruses", "OBSERVATION", 92, 99], ["prefusion conformation", "OBSERVATION", 147, 169]]], ["[1] [2] [3] [4] Further studies will be required to determine if this pH-dependent stability is relevant in the virus and whether other pH-induced structural changes occur.Materials and MethodsCloning, expression, purification, and refolding of Ebo5H and Ebo6HMaterials and MethodsSynthetic DNA encoding the genes for Ebo6H and Ebo5H codon optimized for E. coli were obtained from a commercial supplier (DNA 2.0, Menlo Park, CA) and cloned into pET28 using the NdeI and XhoI restriction sites.", [["[1] [2] [3", "SIMPLE_CHEMICAL", 0, 10], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 245, 250], ["Ebo6HMaterials", "GENE_OR_GENE_PRODUCT", 255, 269], ["DNA", "CELLULAR_COMPONENT", 291, 294], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 318, 323], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 328, 333], ["E. coli", "ORGANISM", 354, 361], ["DNA", "CELLULAR_COMPONENT", 404, 407], ["pET28", "GENE_OR_GENE_PRODUCT", 445, 450], ["NdeI", "GENE_OR_GENE_PRODUCT", 461, 465], ["XhoI", "GENE_OR_GENE_PRODUCT", 470, 474], ["Ebo5H", "PROTEIN", 245, 250], ["Ebo6HMaterials", "PROTEIN", 255, 269], ["MethodsSynthetic DNA", "DNA", 274, 294], ["Ebo6H", "DNA", 318, 323], ["Ebo5H codon", "DNA", 328, 339], ["pET28", "DNA", 445, 450], ["NdeI and XhoI restriction sites", "DNA", 461, 492], ["E. coli", "SPECIES", 354, 361], ["E. coli", "SPECIES", 354, 361], ["Further studies", "TEST", 16, 31], ["this pH", "TEST", 65, 72], ["dependent stability", "PROBLEM", 73, 92], ["the virus", "PROBLEM", 108, 117], ["other pH", "PROBLEM", 130, 138], ["structural changes", "PROBLEM", 147, 165], ["MethodsCloning", "TREATMENT", 186, 200], ["purification", "TREATMENT", 214, 226], ["Ebo5H", "TREATMENT", 245, 250], ["Ebo6HMaterials", "TREATMENT", 255, 269], ["MethodsSynthetic DNA", "TREATMENT", 274, 294], ["Ebo6H and Ebo5H codon", "TREATMENT", 318, 339], ["E. coli", "PROBLEM", 354, 361], ["DNA", "TEST", 404, 407], ["Menlo Park, CA)", "TREATMENT", 413, 428], ["the NdeI and XhoI restriction sites", "TREATMENT", 457, 492]]], ["Constructs of Ebo5H were prepared containing His 6 tags at the N-terminus, at the C-terminus, or at both the N-and C-termini and protein expression assessed in small-scale cultures.", [["His", "CHEMICAL", 45, 48], ["N", "CHEMICAL", 63, 64], ["C", "CHEMICAL", 82, 83], ["N", "CHEMICAL", 109, 110], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 14, 19], ["Ebo5H", "PROTEIN", 14, 19], ["N-terminus", "PROTEIN", 63, 73], ["C-terminus", "PROTEIN", 82, 92], ["N-and C-termini", "PROTEIN", 109, 124], ["small-scale cultures", "CELL_LINE", 160, 180], ["small-scale cultures", "TEST", 160, 180]]], ["We found that the construct containing His 6 tags at both the Nand C-termini was most abundantly expressed and therefore we used this format for large-scale expression of both Ebo6H and Ebo5H.", [["His", "CHEMICAL", 39, 42], ["C", "CHEMICAL", 67, 68], ["His 6", "GENE_OR_GENE_PRODUCT", 39, 44], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 176, 181], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 186, 191], ["His 6 tags", "DNA", 39, 49], ["Nand C-termini", "DNA", 62, 76], ["Ebo6H", "PROTEIN", 176, 181], ["Ebo5H", "PROTEIN", 186, 191], ["His 6 tags", "TEST", 39, 49], ["large-scale expression", "TREATMENT", 145, 167]]], ["E. coli BL21(DE3) (Invitrogen, Madison, WI) harboring expression plasmids for Ebo6H or Ebo5H were grown in Luria-Bertani (LB) broth at 37 C to an optical density (600 nm, OD 600 ) of 0.6 and then expression of the protein was induced by addition of 1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG).", [["isopropyl b-D-1-thiogalactopyranoside", "CHEMICAL", 254, 291], ["IPTG", "CHEMICAL", 293, 297], ["isopropyl b-D-1-thiogalactopyranoside", "CHEMICAL", 254, 291], ["IPTG", "CHEMICAL", 293, 297], ["E. coli BL21", "ORGANISM", 0, 12], ["DE3", "GENE_OR_GENE_PRODUCT", 13, 16], ["Invitrogen, Madison, WI", "ORGANISM", 19, 42], ["Ebo6H", "GENE_OR_GENE_PRODUCT", 78, 83], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 87, 92], ["isopropyl b-D-1-thiogalactopyranoside", "SIMPLE_CHEMICAL", 254, 291], ["IPTG", "SIMPLE_CHEMICAL", 293, 297], ["expression plasmids", "DNA", 54, 73], ["Ebo6H", "DNA", 78, 83], ["Ebo5H", "DNA", 87, 92], ["E. coli BL21", "SPECIES", 0, 12], ["E. coli BL21", "SPECIES", 0, 12], ["DE3", "SPECIES", 13, 16], ["Luria-Bertani", "SPECIES", 107, 120], ["E. coli BL21", "TEST", 0, 12], ["harboring expression plasmids", "TREATMENT", 44, 73], ["Ebo6H", "TEST", 78, 83], ["Ebo5H", "TEST", 87, 92], ["an optical density", "TEST", 143, 161], ["1 mM isopropyl b", "TREATMENT", 249, 265], ["thiogalactopyranoside (IPTG", "TREATMENT", 270, 297], ["coli BL21", "OBSERVATION", 3, 12]]], ["The cells were incubated overnight at 37 C, harvested by centrifugation, and then lysed in a French Pressure cell.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 109, 113], ["cells", "CELL", 4, 9], ["cell", "CELL", 109, 113], ["a French Pressure cell", "TREATMENT", 91, 113], ["Pressure cell", "OBSERVATION", 100, 113]]], ["The insoluble fraction was separated by ultracentrifugation, dissolved in 6 M guanidine HCl (GdnHCl) and applied to nickel-nitrilotriacetic acid (Ni-NTA) resin (Qiagen, Valencia, CA).", [["guanidine HCl", "CHEMICAL", 78, 91], ["GdnHCl", "CHEMICAL", 93, 99], ["nickel-nitrilotriacetic acid", "CHEMICAL", 116, 144], ["Ni-NTA", "CHEMICAL", 146, 152], ["guanidine HCl", "CHEMICAL", 78, 91], ["GdnHCl", "CHEMICAL", 93, 99], ["nickel-nitrilotriacetic acid", "CHEMICAL", 116, 144], ["Ni-NTA", "CHEMICAL", 146, 152], ["guanidine HCl", "SIMPLE_CHEMICAL", 78, 91], ["GdnHCl", "SIMPLE_CHEMICAL", 93, 99], ["nickel-nitrilotriacetic acid", "SIMPLE_CHEMICAL", 116, 144], ["Ni-NTA", "SIMPLE_CHEMICAL", 146, 152], ["The insoluble fraction", "PROBLEM", 0, 22], ["guanidine HCl (GdnHCl)", "TREATMENT", 78, 100], ["nickel-nitrilotriacetic acid (Ni-NTA) resin", "TREATMENT", 116, 159]]], ["The resin was washed with 10 column volumes of 15 mM imidazole containing 6 M GdnHCl and the protein was eluted with 250 mM imidazole containing 6 M GdnHCl.", [["imidazole", "CHEMICAL", 53, 62], ["GdnHCl", "CHEMICAL", 78, 84], ["imidazole", "CHEMICAL", 124, 133], ["GdnHCl", "CHEMICAL", 149, 155], ["imidazole", "CHEMICAL", 53, 62], ["GdnHCl", "CHEMICAL", 78, 84], ["imidazole", "CHEMICAL", 124, 133], ["GdnHCl", "CHEMICAL", 149, 155], ["imidazole", "SIMPLE_CHEMICAL", 53, 62], ["GdnHCl", "SIMPLE_CHEMICAL", 78, 84], ["imidazole", "SIMPLE_CHEMICAL", 124, 133], ["The resin", "TREATMENT", 0, 9], ["10 column volumes", "TREATMENT", 26, 43], ["15 mM imidazole", "TREATMENT", 47, 62], ["GdnHCl", "TREATMENT", 78, 84], ["the protein", "TREATMENT", 89, 100], ["250 mM imidazole", "TREATMENT", 117, 133]]], ["The fractions containing purified protein were pooled and refolded by two-step dialysis first into 100 mM glycine HCl (pH 3.5), then into 20 mM NaOAc pH 5.3 containing 150 mM NaCl.", [["fractions", "ANATOMY", 4, 13], ["glycine HCl", "CHEMICAL", 106, 117], ["NaCl", "CHEMICAL", 175, 179], ["glycine HCl", "CHEMICAL", 106, 117], ["NaOAc", "CHEMICAL", 144, 149], ["NaCl", "CHEMICAL", 175, 179], ["glycine HCl", "SIMPLE_CHEMICAL", 106, 117], ["purified protein", "PROTEIN", 25, 41], ["two-step dialysis", "TREATMENT", 70, 87], ["100 mM glycine HCl", "TREATMENT", 99, 117], ["pH", "TEST", 119, 121], ["mM NaOAc pH", "TEST", 141, 152], ["150 mM NaCl", "TREATMENT", 168, 179]]], ["Precipitated material was removed by centrifugation and the protein solution was used immediately for analysis or flash frozen and stored at \u00c080 C. Preparation of Ebo6H-QNNN was similar.Circular dichroism spectroscopyProtein samples were prepared in the appropriate buffer and measurements were performed on a Jasco J-815 spectrometer with a 1 cm quartz cuvette.", [["samples", "ANATOMY", 225, 232], ["Ebo6H-QNNN", "CHEMICAL", 163, 173], ["Ebo6H-QNNN", "CHEMICAL", 163, 173], ["Ebo6H-QNNN", "SIMPLE_CHEMICAL", 163, 173], ["Ebo6H", "PROTEIN", 163, 168], ["QNNN", "PROTEIN", 169, 173], ["the protein solution", "TREATMENT", 56, 76], ["analysis", "TEST", 102, 110], ["flash frozen", "PROBLEM", 114, 126], ["Ebo6H", "TEST", 163, 168], ["Circular dichroism spectroscopy", "TEST", 186, 217], ["Protein samples", "TEST", 217, 232], ["a Jasco J", "TREATMENT", 308, 317], ["a 1 cm quartz cuvette", "TREATMENT", 340, 361], ["1 cm", "OBSERVATION_MODIFIER", 342, 346], ["quartz cuvette", "OBSERVATION", 347, 361]]], ["Protein concentrations ranged from 0.4 to 10 lM as determined by absorbance at 280 nm.", [["Protein concentrations", "TEST", 0, 22], ["concentrations", "OBSERVATION_MODIFIER", 8, 22], ["ranged", "OBSERVATION_MODIFIER", 23, 29]]], ["CD wavelength scans were obtained with a 0.2 or 1 nm step size and a 2 s averaging time.", [["CD wavelength scans", "TEST", 0, 19], ["size", "OBSERVATION_MODIFIER", 58, 62]]], ["The signal was corrected for blank and then converted to mean residue ellipticity (y).", [["blank", "PROBLEM", 29, 34]]], ["Thermal denaturation data were obtained with a 3 C step size and 1 min equilibration at each temperature.", [["Thermal denaturation data", "TEST", 0, 25], ["size", "OBSERVATION_MODIFIER", 56, 60]]], ["The raw ellipticity signal was corrected for folded and unfolded baselines and then nonlinear least squares regression was performed using a standard four-parameter logistic equation.", [["The raw ellipticity signal", "TEST", 0, 26], ["folded and unfolded baselines", "PROBLEM", 45, 74], ["a standard four-parameter logistic equation", "TREATMENT", 139, 182], ["ellipticity", "OBSERVATION_MODIFIER", 8, 19]]], ["The T m values were derived from the inflection point of the curve.", [["T m", "GENE_OR_GENE_PRODUCT", 4, 7], ["The T m values", "TEST", 0, 14]]], ["For van't Hoff analysis, the baseline-corrected ellipticity was converted to F unf and then K unf was calculated at each temperature (in K) according to Eq.", [["F unf", "DNA", 77, 82], ["van't Hoff analysis", "TEST", 4, 23], ["corrected ellipticity", "PROBLEM", 38, 59], ["K unf", "TEST", 92, 97]]], ["Nonlinear least-squares regression of a K unf versus T curve was then performed in accordance with Eq.", [["K", "CHEMICAL", 40, 41], ["a K unf versus T curve", "TEST", 38, 60]]], ["(2) to obtain DH vH .Gel filtration analysisAnalysis was performed on a Sephadex S75 column (10/300) at 4 C in 20 mM NaOAc pH 5.3 containing 150 mM NaCl.", [["NaCl", "CHEMICAL", 148, 152], ["NaCl", "CHEMICAL", 148, 152], ["vH", "PROTEIN", 17, 19], ["Gel filtration analysisAnalysis", "TEST", 21, 52], ["a Sephadex S75 column", "TREATMENT", 70, 91], ["NaOAc pH", "TEST", 117, 125], ["150 mM NaCl", "TREATMENT", 141, 152]]], ["Protein samples were loaded at concentrations of 50-80 lM and elution was monitored by absorbance at 280 nm.", [["samples", "ANATOMY", 8, 15], ["Protein samples", "TEST", 0, 15]]], ["Both Ebo6H and Ebo5H eluted as a single peak.", [["Ebo6H", "GENE_OR_GENE_PRODUCT", 5, 10], ["Ebo5H", "GENE_OR_GENE_PRODUCT", 15, 20], ["Ebo6H", "PROTEIN", 5, 10], ["Ebo5H", "PROTEIN", 15, 20]]], ["Protein molecular weight standards (Bio-Rad Laboratories, Hercules, CA) were used to generate a standard curve and the Ebo6H and Ebo5H molecular weights were estimated by elution volume.", [["Ebo6H", "SIMPLE_CHEMICAL", 119, 124], ["Ebo5H", "PROTEIN", 129, 134], ["Protein molecular weight", "TEST", 0, 24], ["Bio-Rad Laboratories", "TEST", 36, 56], ["Hercules", "TEST", 58, 66], ["a standard curve", "TEST", 94, 110], ["the Ebo6H", "TEST", 115, 124], ["Ebo5H molecular weights", "TEST", 129, 152]]]], "b79bb7f22e362ed03016f943e6667a1edc880fad": [["The COVID-19 pandemic has impacted us at various levels.", [["The COVID", "TEST", 0, 9], ["impacted", "OBSERVATION_MODIFIER", 26, 34]]], ["In line with this policy, hospitals need to restrict patient numbers both in the outpatient clinics and inpatient wards.", [["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60]]]], "88395bf2fdca68c0eb033b14655275547bdcd714": [["IntroductionCoronaviruses are enveloped viruses with a long positive-stranded RNA genome of~30 kb.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["long positive-stranded RNA genome", "DNA", 55, 88], ["a long positive", "PROBLEM", 53, 68]]], ["Their replication occurs in the cytoplasm and has a profound impact on the endoplasmic reticulum (ER) [1, 2] .", [["cytoplasm", "ANATOMY", 32, 41], ["endoplasmic reticulum", "ANATOMY", 75, 96], ["ER", "ANATOMY", 98, 100], ["cytoplasm", "ORGANISM_SUBSTANCE", 32, 41], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 75, 96], ["ER", "CELLULAR_COMPONENT", 98, 100], ["cytoplasm", "OBSERVATION_MODIFIER", 32, 41], ["profound", "OBSERVATION_MODIFIER", 52, 60], ["impact", "OBSERVATION_MODIFIER", 61, 67], ["endoplasmic reticulum", "OBSERVATION", 75, 96]]], ["Particularly, extraordinarily large amounts of viral structural and non-structural proteins are synthesized and processed primarily in the ER.", [["ER", "ANATOMY", 139, 141], ["ER", "GENE_OR_GENE_PRODUCT", 139, 141], ["viral structural and non-structural proteins", "PROTEIN", 47, 91], ["ER", "PROTEIN", 139, 141], ["viral structural and non-structural proteins", "PROBLEM", 47, 91], ["extraordinarily", "OBSERVATION_MODIFIER", 14, 29], ["large", "OBSERVATION_MODIFIER", 30, 35], ["amounts", "OBSERVATION_MODIFIER", 36, 43], ["viral structural", "OBSERVATION", 47, 63], ["non-structural proteins", "OBSERVATION", 68, 91]]], ["To facilitate this process, coronaviruses have developed strategies to modulate signal transduction pathways that govern ER function.", [["ER", "ANATOMY", 121, 123], ["coronaviruses", "ORGANISM", 28, 41], ["ER", "GENE_OR_GENE_PRODUCT", 121, 123], ["ER", "PROTEIN", 121, 123], ["coronaviruses", "PROBLEM", 28, 41]]], ["We and others have previously shown that severe acute respiratory syndrome coronavirus (SARS-CoV) and mouse hepatitis virus (MHV) spike (S) proteins induce ER stress and activate cellular unfolded protein response (UPR) in the ER [3] [4] [5] .", [["cellular", "ANATOMY", 179, 187], ["acute respiratory syndrome coronavirus", "DISEASE", 48, 86], ["SARS", "DISEASE", 88, 92], ["hepatitis", "DISEASE", 108, 117], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 41, 86], ["SARS-CoV", "ORGANISM", 88, 96], ["mouse hepatitis virus", "ORGANISM", 102, 123], ["spike (S) proteins", "GENE_OR_GENE_PRODUCT", 130, 148], ["ER", "GENE_OR_GENE_PRODUCT", 156, 158], ["cellular unfolded protein response", "GENE_OR_GENE_PRODUCT", 179, 213], ["ER", "GENE_OR_GENE_PRODUCT", 227, 229], ["mouse hepatitis virus (MHV) spike (S) proteins", "PROTEIN", 102, 148], ["ER", "PROTEIN", 156, 158], ["UPR", "PROTEIN", 215, 218], ["mouse", "SPECIES", 102, 107], ["hepatitis virus", "SPECIES", 108, 123], ["severe acute respiratory syndrome coronavirus", "SPECIES", 41, 86], ["SARS-CoV", "SPECIES", 88, 96], ["mouse hepatitis virus", "SPECIES", 102, 123], ["MHV", "SPECIES", 125, 128], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 41, 86], ["mouse hepatitis virus", "PROBLEM", 102, 123], ["ER stress", "TEST", 156, 165], ["activate cellular unfolded protein response", "TEST", 170, 213], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["respiratory syndrome coronavirus", "OBSERVATION", 54, 86]]], ["Several other viral proteins of SARS-CoV are also known to be capable of activating the UPR [6] [7] [8] [9] .IntroductionCoronaviruses that are known to infect humans broadly include two categories of viruses.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 32, 40], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 121, 134], ["humans", "ORGANISM", 160, 166], ["viral proteins", "PROTEIN", 14, 28], ["humans", "SPECIES", 160, 166], ["SARS-CoV", "SPECIES", 32, 40], ["humans", "SPECIES", 160, 166], ["SARS", "PROBLEM", 32, 36], ["IntroductionCoronaviruses", "PROBLEM", 109, 134], ["viral", "OBSERVATION", 14, 19], ["viruses", "OBSERVATION", 201, 208]]], ["In the first category, the viruses commonly circulate in human populations and cause generally mild respiratory illnesses.", [["respiratory", "ANATOMY", 100, 111], ["respiratory illnesses", "DISEASE", 100, 121], ["human", "ORGANISM", 57, 62], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["the viruses", "PROBLEM", 23, 34], ["generally mild respiratory illnesses", "PROBLEM", 85, 121], ["viruses", "OBSERVATION", 27, 34], ["human populations", "OBSERVATION", 57, 74], ["mild", "OBSERVATION_MODIFIER", 95, 99], ["respiratory illnesses", "OBSERVATION", 100, 121]]], ["These viruses that are thought to be well adapted to humans include human coronavirus 229E (HCoV-229E), HCoV-OC43, HCoV-NL63 and HCoV-HKU1 [10] [11] [12] .", [["humans", "ORGANISM", 53, 59], ["human coronavirus 229E", "ORGANISM", 68, 90], ["HCoV-229E", "ORGANISM", 92, 101], ["HCoV-OC43", "CELL", 104, 113], ["HCoV-NL63", "CELL", 115, 124], ["humans", "SPECIES", 53, 59], ["human", "SPECIES", 68, 73], ["coronavirus", "SPECIES", 74, 85], ["humans", "SPECIES", 53, 59], ["human coronavirus 229E (HCoV-229E", "SPECIES", 68, 101], ["These viruses", "PROBLEM", 0, 13], ["human coronavirus", "TEST", 68, 85], ["HCoV", "TEST", 92, 96], ["HCoV", "TEST", 104, 108], ["HCoV", "TEST", 115, 119], ["HCoV", "TEST", 129, 133], ["HKU1", "TEST", 134, 138], ["viruses", "OBSERVATION", 6, 13]]], ["In the family Coronaviridae, HCoV-229E and HCoV-NL63 belong to the genus Alphacoronavirus, whereas HCoV-OC43 and HCoV-HKU1 are in the lineage A of the genus Betacoronavirus.", [["HCoV-229E", "ORGANISM", 29, 38], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 43, 52], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 73, 89], ["HCoV-OC43", "ORGANISM", 99, 108], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 113, 122], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 157, 172], ["HCoV", "PROTEIN", 29, 33], ["HCoV", "DNA", 43, 47], ["NL63", "DNA", 48, 52], ["HCoV", "DNA", 99, 103], ["OC43", "DNA", 104, 108], ["HCoV", "DNA", 113, 117], ["HKU1", "DNA", 118, 122], ["HCoV-229E", "SPECIES", 29, 38], ["HCoV-NL63", "SPECIES", 43, 52], ["HCoV", "TEST", 29, 33], ["HCoV", "TEST", 43, 47], ["the genus Alphacoronavirus", "TEST", 63, 89], ["HCoV", "TEST", 99, 103], ["OC43", "TEST", 104, 108], ["HCoV", "TEST", 113, 117], ["genus Alphacoronavirus", "ANATOMY", 67, 89], ["genus Betacoronavirus", "OBSERVATION", 151, 172]]], ["In the second category, the viruses accidentally or newly cross the species barrier to infect humans.", [["humans", "ORGANISM", 94, 100], ["humans", "SPECIES", 94, 100], ["humans", "SPECIES", 94, 100], ["the viruses", "PROBLEM", 24, 35], ["viruses", "OBSERVATION", 28, 35]]], ["SARS-CoV and the emerging Middle East respiratory syndrome coronavirus (MERS-CoV) are two well known examples in this category [13] [14] [15] [16] .", [["SARS", "DISEASE", 0, 4], ["Middle East respiratory syndrome coronavirus", "DISEASE", 26, 70], ["SARS-CoV", "ORGANISM", 0, 8], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 26, 70], ["MERS-CoV", "ORGANISM", 72, 80], ["[13] [14] [15] [16]", "SIMPLE_CHEMICAL", 127, 146], ["SARS-CoV", "SPECIES", 0, 8], ["Middle East respiratory syndrome coronavirus", "SPECIES", 26, 70], ["MERS-CoV", "SPECIES", 72, 80], ["SARS", "PROBLEM", 0, 4], ["the emerging Middle East respiratory syndrome coronavirus", "PROBLEM", 13, 70], ["Middle", "ANATOMY_MODIFIER", 26, 32], ["respiratory syndrome", "OBSERVATION", 38, 58]]], ["They are less well adapted to humans and cause severe and highly lethal diseases.", [["humans", "ORGANISM", 30, 36], ["humans", "SPECIES", 30, 36], ["humans", "SPECIES", 30, 36], ["severe and highly lethal diseases", "PROBLEM", 47, 80], ["highly", "OBSERVATION_MODIFIER", 58, 64], ["lethal", "OBSERVATION", 65, 71]]], ["Whereas SARS-CoV belongs to lineage B of the genus Betacoronavirus, MERS-CoV represents lineage C of the same genus.", [["SARS", "DISEASE", 8, 12], ["SARS-CoV", "ORGANISM", 8, 16], ["lineage B", "CELL", 28, 37], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 51, 66], ["MERS-CoV", "ORGANISM", 68, 76], ["lineage C", "CELL", 88, 97], ["MERS-CoV", "DNA", 68, 76], ["SARS-CoV", "SPECIES", 8, 16], ["MERS-CoV", "SPECIES", 68, 76], ["SARS", "PROBLEM", 8, 12], ["MERS", "PROBLEM", 68, 72], ["genus Betacoronavirus", "ANATOMY", 45, 66]]], ["The molecular mechanisms that determine the severity of diseases in coronavirus infection remain poorly understood.", [["coronavirus infection", "DISEASE", 68, 89], ["coronavirus", "ORGANISM", 68, 79], ["coronavirus", "SPECIES", 68, 79], ["diseases", "PROBLEM", 56, 64], ["coronavirus infection", "PROBLEM", 68, 89], ["diseases", "OBSERVATION", 56, 64], ["coronavirus infection", "OBSERVATION", 68, 89]]], ["Particularly, it is not known whether S proteins of human coronaviruses in the above two categories have similar UPR-activating activity.", [["human", "ORGANISM", 52, 57], ["coronaviruses", "ORGANISM", 58, 71], ["UPR", "GENE_OR_GENE_PRODUCT", 113, 116], ["S proteins", "PROTEIN", 38, 48], ["UPR", "PROTEIN", 113, 116], ["human", "SPECIES", 52, 57], ["human coronaviruses", "SPECIES", 52, 71], ["human coronaviruses", "PROBLEM", 52, 71], ["activating activity", "OBSERVATION", 117, 136]]], ["We therefore set out to compare S proteins of SARS-CoV and HCoV-HKU1 for their ability to modulate the UPR.", [["SARS-CoV", "ORGANISM", 46, 54], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 59, 68], ["S proteins", "PROTEIN", 32, 42], ["HCoV", "PROTEIN", 59, 63], ["HKU1", "PROTEIN", 64, 68], ["UPR", "PROTEIN", 103, 106], ["SARS-CoV", "SPECIES", 46, 54], ["HCoV", "SPECIES", 59, 63], ["SARS", "PROBLEM", 46, 50], ["CoV", "TEST", 51, 54], ["HCoV", "TREATMENT", 59, 63], ["HKU1", "TREATMENT", 64, 68]]], ["All three branches of the UPR, which are governed by ER-resident transmembrane proteins ATF6, IRE1 and PERK, respectively [17, 18] , were examined.IntroductionHCoV-HKU1 is a betacoronavirus initially identified in 2005 from a patient with community-acquired pneumonia [11] .", [["transmembrane", "ANATOMY", 65, 78], ["pneumonia", "DISEASE", 258, 267], ["UPR", "GENE_OR_GENE_PRODUCT", 26, 29], ["ER", "GENE_OR_GENE_PRODUCT", 53, 55], ["transmembrane", "CELLULAR_COMPONENT", 65, 78], ["ATF6", "GENE_OR_GENE_PRODUCT", 88, 92], ["IRE1", "GENE_OR_GENE_PRODUCT", 94, 98], ["PERK", "GENE_OR_GENE_PRODUCT", 103, 107], ["HKU1", "GENE_OR_GENE_PRODUCT", 164, 168], ["patient", "ORGANISM", 226, 233], ["UPR", "PROTEIN", 26, 29], ["ER", "PROTEIN", 53, 55], ["resident transmembrane proteins", "PROTEIN", 56, 87], ["ATF6", "PROTEIN", 88, 92], ["IRE1", "PROTEIN", 94, 98], ["PERK", "PROTEIN", 103, 107], ["HKU1", "DNA", 164, 168], ["patient", "SPECIES", 226, 233], ["ATF6", "TEST", 88, 92], ["IRE1", "TEST", 94, 98], ["PERK", "TEST", 103, 107], ["IntroductionHCoV", "TEST", 147, 163], ["a betacoronavirus", "PROBLEM", 172, 189], ["community-acquired pneumonia", "PROBLEM", 239, 267], ["three", "ANATOMY_MODIFIER", 4, 9], ["branches", "ANATOMY_MODIFIER", 10, 18], ["UPR", "ANATOMY_MODIFIER", 26, 29], ["pneumonia", "OBSERVATION", 258, 267]]], ["It was subsequently found to be commonly associated with respiratory tract infections worldwide [12, 19, 20] .", [["respiratory tract", "ANATOMY", 57, 74], ["respiratory tract infections", "DISEASE", 57, 85], ["tract", "ORGANISM_SUBDIVISION", 69, 74], ["respiratory tract infections", "PROBLEM", 57, 85], ["respiratory tract", "ANATOMY", 57, 74], ["infections", "OBSERVATION", 75, 85]]], ["However, molecular and cellular pathogenesis of HCoV-HKU1 in contrast to SARS-CoV remains elusive.", [["cellular", "ANATOMY", 23, 31], ["SARS", "DISEASE", 73, 77], ["cellular", "CELL", 23, 31], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 48, 57], ["SARS-CoV", "ORGANISM", 73, 81], ["HCoV", "PROTEIN", 48, 52], ["HKU1", "DNA", 53, 57], ["HCoV", "SPECIES", 48, 52], ["SARS-CoV", "SPECIES", 73, 81], ["molecular and cellular pathogenesis of HCoV", "PROBLEM", 9, 52], ["SARS", "PROBLEM", 73, 77], ["CoV", "PROBLEM", 78, 81], ["cellular", "OBSERVATION_MODIFIER", 23, 31], ["pathogenesis", "OBSERVATION", 32, 44]]], ["Although primary human ciliated airway epithelial cells and type II alveolar epithelial cells have been tested for culturing of HCoV-HKU1 with limited success [21] [22] [23] , HCoV-HKU1 remains a very-difficult-to-culture virus in most laboratories.", [["ciliated airway epithelial cells", "ANATOMY", 23, 55], ["type II alveolar epithelial cells", "ANATOMY", 60, 93], ["human", "ORGANISM", 17, 22], ["ciliated airway epithelial cells", "CELL", 23, 55], ["type II alveolar epithelial cells", "CELL", 60, 93], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 128, 137], ["HCoV-HKU1", "SIMPLE_CHEMICAL", 176, 185], ["primary human ciliated airway epithelial cells", "CELL_TYPE", 9, 55], ["type II alveolar epithelial cells", "CELL_TYPE", 60, 93], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["HCoV", "SPECIES", 128, 132], ["primary human ciliated airway epithelial cells", "PROBLEM", 9, 55], ["type II alveolar epithelial cells", "PROBLEM", 60, 93], ["culturing", "TEST", 115, 124], ["HCoV", "TEST", 128, 132], ["HCoV", "TEST", 176, 180], ["culture virus", "PROBLEM", 214, 227], ["ciliated", "ANATOMY_MODIFIER", 23, 31], ["airway", "ANATOMY", 32, 38], ["epithelial cells", "OBSERVATION", 39, 55], ["alveolar", "ANATOMY_MODIFIER", 68, 76], ["epithelial cells", "OBSERVATION", 77, 93]]], ["Worse still, an infectious clone of HCoV-HKU1 is not available.", [["clone", "CELL", 27, 32], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 36, 45], ["HCoV", "PROTEIN", 36, 40], ["HKU1", "DNA", 41, 45], ["HCoV", "SPECIES", 36, 40], ["an infectious clone of HCoV", "PROBLEM", 13, 40], ["infectious", "OBSERVATION", 16, 26]]], ["At this stage, analysis of cloned HCoV-HKU1 genes represents a major route for deriving mechanistic insight on HCoV-HKU1 pathogenesis.IntroductionCoronavirus S proteins mediate the interaction with host cell receptors, membrane fusion and the induction of humoral and cellular immune responses [1, 24] .", [["cell", "ANATOMY", 203, 207], ["membrane", "ANATOMY", 219, 227], ["cellular", "ANATOMY", 268, 276], ["HCoV", "GENE_OR_GENE_PRODUCT", 34, 38], ["HKU1", "GENE_OR_GENE_PRODUCT", 39, 43], ["HCoV", "GENE_OR_GENE_PRODUCT", 111, 115], ["HKU1", "GENE_OR_GENE_PRODUCT", 116, 120], ["Coronavirus S proteins", "GENE_OR_GENE_PRODUCT", 146, 168], ["host cell", "CELL", 198, 207], ["membrane", "CELLULAR_COMPONENT", 219, 227], ["cellular", "CELL", 268, 276], ["HCoV-HKU1 genes", "DNA", 34, 49], ["Coronavirus S proteins", "PROTEIN", 146, 168], ["host cell receptors", "PROTEIN", 198, 217], ["HCoV", "SPECIES", 34, 38], ["analysis", "TEST", 15, 23], ["cloned HCoV", "PROBLEM", 27, 38], ["HKU1 genes", "PROBLEM", 39, 49], ["HKU1 pathogenesis", "PROBLEM", 116, 133], ["IntroductionCoronavirus S proteins", "TREATMENT", 134, 168], ["host cell receptors", "TREATMENT", 198, 217], ["membrane fusion", "TREATMENT", 219, 234], ["host cell", "OBSERVATION", 198, 207], ["membrane fusion", "OBSERVATION", 219, 234]]], ["In addition, S proteins play an important role in coronaviral pathogenesis by modulating host protein synthesis, cytokine secretion and stress response [4, 5, [25] [26] [27] .", [["coronaviral", "ANATOMY", 50, 61], ["4, 5, [25] [26", "CHEMICAL", 153, 167], ["S proteins", "GENE_OR_GENE_PRODUCT", 13, 23], ["coronaviral", "CANCER", 50, 61], ["[25] [26] [27]", "SIMPLE_CHEMICAL", 159, 173], ["S proteins", "PROTEIN", 13, 23], ["cytokine", "PROTEIN", 113, 121], ["coronaviral pathogenesis", "PROBLEM", 50, 74], ["modulating host protein synthesis", "TREATMENT", 78, 111], ["cytokine secretion", "TEST", 113, 131], ["stress response", "TEST", 136, 151]]], ["Changes in S proteins are critical determinants in cross-species transmission [28] .", [["S proteins", "GENE_OR_GENE_PRODUCT", 11, 21], ["S proteins", "PROTEIN", 11, 21], ["Changes in S proteins", "PROBLEM", 0, 21], ["S proteins", "OBSERVATION_MODIFIER", 11, 21]]], ["In this context, comparison of the UPR-activating activity of SARS-CoV and HCoV-HKU1 S proteins might shed new light on their roles in coronavirus-host interaction.IntroductionIn this study, we provided the first evidence for the activation of ER stress and the UPR by HCoV-HKU1 S protein.", [["UPR", "GENE_OR_GENE_PRODUCT", 35, 38], ["SARS-CoV", "ORGANISM", 62, 70], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 75, 86], ["coronavirus", "ORGANISM", 135, 146], ["ER", "GENE_OR_GENE_PRODUCT", 244, 246], ["UPR", "GENE_OR_GENE_PRODUCT", 262, 265], ["HCoV-HKU1 S protein", "GENE_OR_GENE_PRODUCT", 269, 288], ["UPR", "PROTEIN", 35, 38], ["SARS-CoV and HCoV-HKU1 S proteins", "PROTEIN", 62, 95], ["ER", "PROTEIN", 244, 246], ["UPR", "PROTEIN", 262, 265], ["HCoV", "PROTEIN", 269, 273], ["HKU1 S protein", "PROTEIN", 274, 288], ["SARS-CoV", "SPECIES", 62, 70], ["the UPR", "TEST", 31, 38], ["SARS", "PROBLEM", 62, 66], ["CoV", "TEST", 67, 70], ["HCoV", "TEST", 75, 79], ["HKU1 S proteins", "PROBLEM", 80, 95], ["this study", "TEST", 179, 189], ["ER stress", "PROBLEM", 244, 253], ["the UPR", "TEST", 258, 265], ["HCoV", "TEST", 269, 273]]], ["We compared the UPR-activating activity of SARS-CoV and HCoV-HKU1 S proteins in terms of their influence on the expression of UPR effectors Grp78, Grp94, CHOP and PERK.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 43, 51], ["HCoV-HKU1 S proteins", "GENE_OR_GENE_PRODUCT", 56, 76], ["UPR", "GENE_OR_GENE_PRODUCT", 126, 129], ["Grp78", "GENE_OR_GENE_PRODUCT", 140, 145], ["Grp94", "GENE_OR_GENE_PRODUCT", 147, 152], ["CHOP", "GENE_OR_GENE_PRODUCT", 154, 158], ["PERK", "GENE_OR_GENE_PRODUCT", 163, 167], ["UPR", "PROTEIN", 16, 19], ["SARS-CoV and HCoV-HKU1 S proteins", "PROTEIN", 43, 76], ["UPR effectors", "PROTEIN", 126, 139], ["Grp78", "PROTEIN", 140, 145], ["Grp94", "PROTEIN", 147, 152], ["CHOP", "PROTEIN", 154, 158], ["PERK", "PROTEIN", 163, 167], ["SARS-CoV", "SPECIES", 43, 51], ["the UPR", "TEST", 12, 19], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["HCoV", "TEST", 56, 60], ["HKU1 S proteins", "PROBLEM", 61, 76], ["UPR effectors", "TEST", 126, 139], ["Grp78", "TEST", 140, 145], ["Grp94", "TEST", 147, 152], ["CHOP", "TEST", 154, 158], ["PERK", "TEST", 163, 167]]], ["We also assessed the impact of N-linked glycosylation on the activation of UPR signaling by S proteins.", [["N", "CHEMICAL", 31, 32], ["UPR", "GENE_OR_GENE_PRODUCT", 75, 78], ["S proteins", "GENE_OR_GENE_PRODUCT", 92, 102], ["UPR", "PROTEIN", 75, 78], ["S proteins", "PROTEIN", 92, 102], ["N-linked glycosylation", "TREATMENT", 31, 53]]], ["Furthermore, we defined a minimal domain in S1 subunit required for the UPRactivating activity of SARS-CoV S protein.", [["S1", "GENE_OR_GENE_PRODUCT", 44, 46], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 98, 108], ["S1 subunit", "PROTEIN", 44, 54], ["SARS-CoV S protein", "PROTEIN", 98, 116], ["SARS-CoV", "SPECIES", 98, 106], ["a minimal domain in S1 subunit", "TREATMENT", 24, 54], ["SARS", "PROBLEM", 98, 102], ["CoV S protein", "TEST", 103, 116], ["minimal", "OBSERVATION_MODIFIER", 26, 33]]], ["Our findings provide new molecular details for UPR activation by SARS-CoV and HCoV-HKU1 S proteins.ResultsExpression, localization and cleavage of SARS-CoV and HCoV-HKU1 S proteins Before we compared the UPR-activating activity of SARS-CoV and HCoV-HKU1 S proteins, we expressed them in 293FT cells.", [["293FT cells", "ANATOMY", 287, 298], ["UPR", "GENE_OR_GENE_PRODUCT", 47, 50], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 65, 73], ["HCoV-HKU1 S proteins", "GENE_OR_GENE_PRODUCT", 78, 98], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 147, 155], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 160, 171], ["UPR", "GENE_OR_GENE_PRODUCT", 204, 207], ["SARS-CoV", "ORGANISM", 231, 239], ["HCoV-HKU1 S proteins", "GENE_OR_GENE_PRODUCT", 244, 264], ["293FT cells", "CELL", 287, 298], ["UPR", "PROTEIN", 47, 50], ["SARS-CoV and HCoV-HKU1 S proteins", "PROTEIN", 65, 98], ["SARS-CoV and HCoV-HKU1 S proteins", "PROTEIN", 147, 180], ["UPR", "PROTEIN", 204, 207], ["SARS-CoV and HCoV-HKU1 S proteins", "PROTEIN", 231, 264], ["293FT cells", "CELL_LINE", 287, 298], ["SARS-CoV", "SPECIES", 65, 73], ["SARS-CoV", "SPECIES", 147, 155], ["SARS-CoV", "SPECIES", 231, 239], ["UPR activation", "TEST", 47, 61], ["SARS", "TEST", 65, 69], ["CoV", "TEST", 70, 73], ["HCoV", "TEST", 78, 82], ["SARS", "TEST", 147, 151], ["CoV", "TEST", 152, 155], ["HCoV", "TEST", 160, 164], ["HKU1 S proteins", "PROBLEM", 165, 180], ["the UPR", "TEST", 200, 207], ["SARS", "PROBLEM", 231, 235], ["CoV", "TEST", 236, 239], ["HCoV", "TEST", 244, 248], ["HKU1 S proteins", "PROBLEM", 249, 264]]], ["Both Western blotting ( Figure 1A ) and confocal immunofluorescence microscopy ( Figure 1B ) indicated effective expression of both proteins to similar levels.", [["confocal immunofluorescence microscopy", "TEST", 40, 78]]], ["The molecular sizes of both S proteins were~155 kDa, indicative of post-translational modifications.", [["S proteins", "PROTEIN", 28, 38], ["both S proteins", "TEST", 23, 38], ["post-translational modifications", "PROBLEM", 67, 99], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["sizes", "OBSERVATION_MODIFIER", 14, 19], ["both", "OBSERVATION_MODIFIER", 23, 27], ["155 kDa", "OBSERVATION_MODIFIER", 44, 51], ["indicative of", "UNCERTAINTY", 53, 66], ["post-translational modifications", "OBSERVATION", 67, 99]]], ["This was generally consistent with the reported size of SARS-CoV S protein [2] [3] [4] .", [["SARS", "DISEASE", 56, 60], ["[2] [3] [4]", "SIMPLE_CHEMICAL", 75, 86], ["SARS-CoV S protein", "PROTEIN", 56, 74], ["SARS-CoV", "SPECIES", 56, 64], ["SARS", "TEST", 56, 60], ["CoV S protein", "TEST", 61, 74], ["size", "OBSERVATION_MODIFIER", 48, 52]]], ["With the help of the fluorescent ER marker of DsRed-ER, we confirmed that both S proteins resided largely in the ER ( Figure 1B , panels 3 and 6).ResultsSARS-CoV S protein is proteolytically processed into S1 and S2 subunits by host proteases such as cathepsin L, factor Xa, trypsin and transmembrane serine protease TMPRSS2 [29] [30] [31] [32] [33] [34] .", [["ER", "ANATOMY", 113, 115], ["serine", "CHEMICAL", 301, 307], ["ER", "GENE_OR_GENE_PRODUCT", 33, 35], ["DsRed-ER", "GENE_OR_GENE_PRODUCT", 46, 54], ["ER", "GENE_OR_GENE_PRODUCT", 113, 115], ["ResultsSARS-CoV S", "GENE_OR_GENE_PRODUCT", 146, 163], ["S1", "GENE_OR_GENE_PRODUCT", 206, 208], ["S2", "GENE_OR_GENE_PRODUCT", 213, 215], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 251, 262], ["factor Xa", "GENE_OR_GENE_PRODUCT", 264, 273], ["trypsin", "GENE_OR_GENE_PRODUCT", 275, 282], ["transmembrane serine protease TMPRSS2 [29] [30] [31] [32] [33] [34]", "SIMPLE_CHEMICAL", 287, 354], ["ER", "PROTEIN", 33, 35], ["DsRed", "PROTEIN", 46, 51], ["ER", "PROTEIN", 52, 54], ["S proteins", "PROTEIN", 79, 89], ["ER", "PROTEIN", 113, 115], ["panels 3 and 6", "PROTEIN", 130, 144], ["ResultsSARS-CoV S protein", "PROTEIN", 146, 171], ["S1 and S2 subunits", "PROTEIN", 206, 224], ["host proteases", "PROTEIN", 228, 242], ["cathepsin L", "PROTEIN", 251, 262], ["factor Xa", "PROTEIN", 264, 273], ["trypsin", "PROTEIN", 275, 282], ["transmembrane serine protease", "PROTEIN", 287, 316], ["both S proteins", "TEST", 74, 89], ["panels", "TEST", 130, 136], ["ResultsSARS", "TEST", 146, 157], ["CoV S protein", "TEST", 158, 171], ["host proteases", "TEST", 228, 242], ["cathepsin", "TEST", 251, 260], ["factor Xa", "TEST", 264, 273], ["trypsin", "TEST", 275, 282], ["transmembrane serine protease TMPRSS2", "TEST", 287, 324]]], ["Particularly, TMPRSS2 efficiently activates S proteins of SARS-CoV as well as MERS-CoV and HCoV-229E [32] [33] [34] [35] [36] .", [["TMPRSS2", "GENE_OR_GENE_PRODUCT", 14, 21], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 58, 66], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 78, 86], ["HCoV-229E [32] [33] [34] [35", "SIMPLE_CHEMICAL", 91, 119], ["TMPRSS2", "PROTEIN", 14, 21], ["S proteins", "PROTEIN", 44, 54], ["SARS-CoV", "PROTEIN", 58, 66], ["MERS", "PROTEIN", 78, 82], ["SARS-CoV", "SPECIES", 58, 66], ["MERS-CoV", "SPECIES", 78, 86], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66], ["MERS", "TEST", 78, 82], ["HCoV", "TEST", 91, 95]]], ["Moreover, TMPRSS2 and related proteases TMPRSS4, which are abundantly expressed in human alveolar epithelial cells, are capable of activating influenza virus hemagglutinin [37] .", [["alveolar epithelial cells", "ANATOMY", 89, 114], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 10, 17], ["TMPRSS4", "GENE_OR_GENE_PRODUCT", 40, 47], ["human", "ORGANISM", 83, 88], ["alveolar epithelial cells", "CELL", 89, 114], ["influenza virus hemagglutinin", "ORGANISM", 142, 171], ["TMPRSS2", "PROTEIN", 10, 17], ["TMPRSS4", "PROTEIN", 40, 47], ["human alveolar epithelial cells", "CELL_TYPE", 83, 114], ["human", "SPECIES", 83, 88], ["influenza virus hemagglutinin", "SPECIES", 142, 171], ["human", "SPECIES", 83, 88], ["TMPRSS2", "TEST", 10, 17], ["related proteases TMPRSS4", "PROBLEM", 22, 47], ["human alveolar epithelial cells", "PROBLEM", 83, 114], ["activating influenza virus hemagglutinin", "PROBLEM", 131, 171], ["alveolar epithelial cells", "OBSERVATION", 89, 114]]], ["To investigate whether they might also proteolytically activate HCoV-HKU1 S protein, we expressed them together in 293FT cells.", [["293FT cells", "ANATOMY", 115, 126], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 64, 75], ["293FT cells", "CELL", 115, 126], ["HCoV", "PROTEIN", 64, 68], ["HKU1 S protein", "PROTEIN", 69, 83], ["293FT cells", "CELL_LINE", 115, 126], ["HCoV", "TEST", 64, 68]]], ["Coexpression of TMPRSS2 with SARS-CoV S protein resulted in the appearance of S1 subunit, indicative of proteolytic cleavage ( Figure 2 , lane 3).", [["TMPRSS2", "GENE_OR_GENE_PRODUCT", 16, 23], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 29, 39], ["S1", "GENE_OR_GENE_PRODUCT", 78, 80], ["TMPRSS2", "PROTEIN", 16, 23], ["SARS-CoV S protein", "PROTEIN", 29, 47], ["S1 subunit", "PROTEIN", 78, 88], ["SARS-CoV", "SPECIES", 29, 37], ["TMPRSS2", "PROBLEM", 16, 23], ["SARS", "PROBLEM", 29, 33], ["CoV S protein", "TEST", 34, 47], ["S1 subunit", "PROBLEM", 78, 88], ["proteolytic cleavage", "PROBLEM", 104, 124], ["S1", "ANATOMY", 78, 80], ["indicative of", "UNCERTAINTY", 90, 103], ["proteolytic cleavage", "OBSERVATION", 104, 124]]], ["Although a V5 tag was added to the N-terminus of SARS-CoV S protein, the cleavage was not affected.", [["V5", "GENE_OR_GENE_PRODUCT", 11, 13], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 49, 59], ["V5 tag", "DNA", 11, 17], ["N-terminus", "PROTEIN", 35, 45], ["SARS-CoV S protein", "PROTEIN", 49, 67], ["SARS-CoV", "SPECIES", 49, 57], ["a V5 tag", "TEST", 9, 17], ["SARS", "PROBLEM", 49, 53], ["CoV S protein", "TEST", 54, 67], ["the cleavage", "PROBLEM", 69, 81]]], ["The action of TMPRSS2 on SARS-CoV S was highly specific since TMPRSS1 and TMPRSS4 had no activity under the same condition ( Figure 2 , lanes 1 and 2).", [["TMPRSS2", "GENE_OR_GENE_PRODUCT", 14, 21], ["TMPRSS1", "GENE_OR_GENE_PRODUCT", 62, 69], ["TMPRSS4", "GENE_OR_GENE_PRODUCT", 74, 81], ["TMPRSS2", "PROTEIN", 14, 21], ["TMPRSS1", "PROTEIN", 62, 69], ["TMPRSS4", "PROTEIN", 74, 81], ["TMPRSS2", "PROBLEM", 14, 21], ["SARS-CoV S", "TEST", 25, 35], ["TMPRSS1", "TEST", 62, 69], ["TMPRSS4", "TEST", 74, 81]]], ["In contrast, none of the three proteases cleaved HCoV-HKU1 S protein ( Figure 2 , lanes 4-6).", [["HCoV-HKU1 S protein", "GENE_OR_GENE_PRODUCT", 49, 68], ["proteases", "PROTEIN", 31, 40], ["HCoV", "PROTEIN", 49, 53], ["HKU1 S protein", "PROTEIN", 54, 68], ["Figure 2 , lanes 4-6", "PROTEIN", 71, 91], ["the three proteases", "TEST", 21, 40], ["HCoV", "TEST", 49, 53], ["S protein", "TEST", 59, 68], ["Figure", "TEST", 71, 77], ["lanes", "TEST", 82, 87]]], ["Thus, HCoV-HKU1 S protein is not processed by TMPRSS1, TMPRSS2 or TMPRSS4.S proteins from both SARS-CoV and HCoV-HKU1 activate UPRWe and others have previously demonstrated transcriptional activation of Grp78 and Grp94 promoters by SARS-CoV S protein [3] [4] [5] .", [["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 6, 17], ["TMPRSS1", "GENE_OR_GENE_PRODUCT", 46, 53], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 55, 62], ["TMPRSS4", "GENE_OR_GENE_PRODUCT", 66, 73], ["SARS-CoV", "ORGANISM", 95, 103], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 108, 117], ["UPRWe", "GENE_OR_GENE_PRODUCT", 127, 132], ["Grp78", "GENE_OR_GENE_PRODUCT", 203, 208], ["Grp94", "GENE_OR_GENE_PRODUCT", 213, 218], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 232, 240], ["HCoV", "PROTEIN", 6, 10], ["HKU1 S protein", "PROTEIN", 11, 25], ["TMPRSS1", "PROTEIN", 46, 53], ["TMPRSS2", "PROTEIN", 55, 62], ["TMPRSS4", "PROTEIN", 66, 73], ["S proteins", "PROTEIN", 74, 84], ["HCoV", "PROTEIN", 108, 112], ["HKU1", "DNA", 113, 117], ["UPRWe", "DNA", 127, 132], ["Grp78 and Grp94 promoters", "DNA", 203, 228], ["SARS-CoV S protein", "PROTEIN", 232, 250], ["SARS-CoV", "SPECIES", 95, 103], ["HCoV", "TEST", 6, 10], ["HKU1 S protein", "TEST", 11, 25], ["TMPRSS1", "TEST", 46, 53], ["TMPRSS2", "TEST", 55, 62], ["TMPRSS4", "TEST", 66, 73], ["S proteins", "TEST", 74, 84], ["both SARS", "PROBLEM", 90, 99], ["CoV", "TEST", 100, 103], ["HCoV", "TEST", 108, 112], ["Grp78", "TEST", 203, 208], ["Grp94 promoters", "TREATMENT", 213, 228], ["SARS", "TEST", 232, 236], ["CoV S protein", "TEST", 237, 250]]], ["Grp78 and Grp94 are molecular chaperones that are drastically induced in response to ER stress.", [["Grp78", "GENE_OR_GENE_PRODUCT", 0, 5], ["Grp94", "GENE_OR_GENE_PRODUCT", 10, 15], ["ER", "GENE_OR_GENE_PRODUCT", 85, 87], ["Grp78", "PROTEIN", 0, 5], ["Grp94", "PROTEIN", 10, 15], ["molecular chaperones", "PROTEIN", 20, 40], ["ER", "PROTEIN", 85, 87], ["Grp78", "TEST", 0, 5]]], ["The promoter activity of Grp78 and Grp94 was activated by S proteins of SARS-CoV and HCoV-HKU1 to similar levels ( Figure 3A and B).", [["Grp78", "GENE_OR_GENE_PRODUCT", 25, 30], ["Grp94", "GENE_OR_GENE_PRODUCT", 35, 40], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 72, 80], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 85, 94], ["Grp78", "PROTEIN", 25, 30], ["Grp94", "PROTEIN", 35, 40], ["S proteins", "PROTEIN", 58, 68], ["HCoV", "PROTEIN", 85, 89], ["HKU1", "PROTEIN", 90, 94], ["SARS-CoV", "SPECIES", 72, 80], ["Grp94", "TEST", 35, 40], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80], ["HCoV", "TEST", 85, 89]]], ["The stimulatory effect of HCoV-HKU1 S protein is dose-dependent and equally potent compared to that of SARS-CoV S protein.", [["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 26, 37], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 103, 113], ["HCoV", "PROTEIN", 26, 30], ["HKU1 S protein", "PROTEIN", 31, 45], ["SARS-CoV S protein", "PROTEIN", 103, 121], ["SARS-CoV", "SPECIES", 103, 111], ["HCoV", "TEST", 26, 30], ["HKU1 S protein", "TREATMENT", 31, 45], ["SARS", "TEST", 103, 107], ["CoV S protein", "TEST", 108, 121], ["equally potent", "OBSERVATION_MODIFIER", 68, 82]]], ["In contrast, overexpression of \u03b2-galactosidase, a large foreign protein, had minimal or very mild effect on Grp78 and Grp94 promoter activity.", [["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 31, 46], ["Grp78", "GENE_OR_GENE_PRODUCT", 108, 113], ["Grp94", "GENE_OR_GENE_PRODUCT", 118, 123], ["\u03b2-galactosidase", "PROTEIN", 31, 46], ["Grp78", "PROTEIN", 108, 113], ["Grp94", "PROTEIN", 118, 123], ["\u03b2-galactosidase", "TREATMENT", 31, 46], ["a large foreign protein", "PROBLEM", 48, 71], ["very mild effect on Grp78", "PROBLEM", 88, 113], ["large", "OBSERVATION_MODIFIER", 50, 55], ["foreign protein", "OBSERVATION", 56, 71], ["mild", "OBSERVATION_MODIFIER", 93, 97], ["effect", "OBSERVATION", 98, 104], ["promoter activity", "OBSERVATION", 124, 141]]], ["Thus, S proteins from both viruses might induce ER stress and activate the UPR.S proteins from both SARS-CoV and HCoV-HKU1 activate UPRWe next tested the influence of S proteins on the transcriptional activity driven by CHOP promoter and UPRE.", [["S proteins", "GENE_OR_GENE_PRODUCT", 6, 16], ["ER", "GENE_OR_GENE_PRODUCT", 48, 50], ["UPR", "GENE_OR_GENE_PRODUCT", 75, 78], ["SARS-CoV", "ORGANISM", 100, 108], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 113, 122], ["UPRWe", "GENE_OR_GENE_PRODUCT", 132, 137], ["S proteins", "GENE_OR_GENE_PRODUCT", 167, 177], ["CHOP", "GENE_OR_GENE_PRODUCT", 220, 224], ["S proteins", "PROTEIN", 6, 16], ["ER", "PROTEIN", 48, 50], ["UPR", "PROTEIN", 75, 78], ["S proteins", "PROTEIN", 79, 89], ["HCoV", "PROTEIN", 113, 117], ["HKU1", "DNA", 118, 122], ["UPRWe", "DNA", 132, 137], ["S proteins", "PROTEIN", 167, 177], ["CHOP promoter", "DNA", 220, 233], ["UPRE", "DNA", 238, 242], ["SARS-CoV", "SPECIES", 100, 108], ["S proteins", "PROBLEM", 6, 16], ["both viruses", "PROBLEM", 22, 34], ["S proteins", "TEST", 79, 89], ["both SARS", "PROBLEM", 95, 104], ["CoV", "TEST", 105, 108], ["HCoV", "TEST", 113, 117], ["S proteins", "PROBLEM", 167, 177]]], ["CHOP is a proapoptotic transcription factor activated in the UPR [38, 39] .", [["CHOP", "GENE_OR_GENE_PRODUCT", 0, 4], ["CHOP", "PROTEIN", 0, 4], ["proapoptotic transcription factor", "PROTEIN", 10, 43], ["CHOP", "TREATMENT", 0, 4], ["a proapoptotic transcription factor", "TREATMENT", 8, 43]]], ["UPRE is an enhancer element responsive to ATF6, XBP1 and CREB3-related transcription factors [40] [41] [42] [43] .", [["UPRE", "GENE_OR_GENE_PRODUCT", 0, 4], ["ATF6", "GENE_OR_GENE_PRODUCT", 42, 46], ["XBP1", "GENE_OR_GENE_PRODUCT", 48, 52], ["CREB3", "GENE_OR_GENE_PRODUCT", 57, 62], ["UPRE", "DNA", 0, 4], ["enhancer element", "DNA", 11, 27], ["ATF6", "PROTEIN", 42, 46], ["XBP1", "PROTEIN", 48, 52], ["CREB3", "PROTEIN", 57, 62], ["transcription factors", "PROTEIN", 71, 92], ["ATF6", "TEST", 42, 46], ["XBP1", "TEST", 48, 52], ["CREB3", "TEST", 57, 62]]], ["UPRE mediates the activation of a subset of UPR genes distinct from Grp78 and Grp94 [44, 45] .", [["UPRE", "CHEMICAL", 0, 4], ["UPRE", "GENE_OR_GENE_PRODUCT", 0, 4], ["UPR", "GENE_OR_GENE_PRODUCT", 44, 47], ["Grp78", "GENE_OR_GENE_PRODUCT", 68, 73], ["Grp94", "GENE_OR_GENE_PRODUCT", 78, 83], ["UPRE", "PROTEIN", 0, 4], ["UPR genes", "DNA", 44, 53], ["Grp78", "PROTEIN", 68, 73], ["Grp94", "PROTEIN", 78, 83], ["Grp78", "TEST", 68, 73], ["Grp94", "TEST", 78, 83]]], ["S proteins of both viruses exhibited the same activity profile not only on Grp78 and Grp94 promoters, but also on CHOP promoter and UPRE.", [["Grp78", "GENE_OR_GENE_PRODUCT", 75, 80], ["Grp94", "GENE_OR_GENE_PRODUCT", 85, 90], ["CHOP", "GENE_OR_GENE_PRODUCT", 114, 118], ["S proteins", "PROTEIN", 0, 10], ["Grp78 and Grp94 promoters", "DNA", 75, 100], ["CHOP promoter", "DNA", 114, 127], ["UPRE", "DNA", 132, 136], ["both viruses", "PROBLEM", 14, 26], ["CHOP promoter", "TREATMENT", 114, 127], ["both", "ANATOMY_MODIFIER", 14, 18], ["viruses", "OBSERVATION", 19, 26]]], ["They activated CHOP promoter mildly but did not affect the activity of UPRE ( Figure 3C and D).", [["CHOP", "GENE_OR_GENE_PRODUCT", 15, 19], ["D", "GENE_OR_GENE_PRODUCT", 92, 93], ["CHOP promoter", "DNA", 15, 28], ["UPRE", "PROTEIN", 71, 75]]], ["Thus, S proteins of SARS-CoV and HCoV-HKU1 showed the same pattern of modulatory activity on UPR effector genes.S proteins from both SARS-CoV and HCoV-HKU1 activate UPRPERK is a protein kinase that controls the expression of many UPR effector genes including Grp78 and Grp94 [17, 46, 47] .", [["SARS-CoV", "ORGANISM", 20, 28], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 33, 42], ["UPR", "GENE_OR_GENE_PRODUCT", 93, 96], ["SARS-CoV", "ORGANISM", 133, 141], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 146, 155], ["UPRPERK", "GENE_OR_GENE_PRODUCT", 165, 172], ["UPR", "GENE_OR_GENE_PRODUCT", 230, 233], ["Grp78", "GENE_OR_GENE_PRODUCT", 259, 264], ["Grp94", "GENE_OR_GENE_PRODUCT", 269, 274], ["S proteins", "PROTEIN", 6, 16], ["HCoV", "PROTEIN", 33, 37], ["HKU1", "PROTEIN", 38, 42], ["UPR effector genes", "DNA", 93, 111], ["S proteins", "PROTEIN", 112, 122], ["HCoV", "PROTEIN", 146, 150], ["HKU1", "DNA", 151, 155], ["UPRPERK", "PROTEIN", 165, 172], ["protein kinase", "PROTEIN", 178, 192], ["UPR effector genes", "DNA", 230, 248], ["Grp78", "DNA", 259, 264], ["Grp94", "DNA", 269, 274], ["SARS-CoV", "SPECIES", 20, 28], ["SARS-CoV", "SPECIES", 133, 141], ["SARS", "PROBLEM", 20, 24], ["CoV", "TEST", 25, 28], ["HCoV", "TEST", 33, 37], ["HKU1", "TEST", 38, 42], ["S proteins", "TEST", 112, 122], ["both SARS", "PROBLEM", 128, 137], ["CoV", "TEST", 138, 141], ["HCoV", "TEST", 146, 150], ["a protein kinase", "TEST", 176, 192], ["Grp78", "TEST", 259, 264], ["Grp94", "TEST", 269, 274], ["modulatory activity", "OBSERVATION", 70, 89], ["effector genes", "OBSERVATION", 97, 111], ["UPR effector genes", "OBSERVATION", 230, 248]]], ["To analyze further whether PERK activity is required for transcriptional activation of Grp78 and Grp94 promoters by SARS-CoV and HCoV-HKU1 S proteins, we made use of a dominant negative (DN) mutant of PERK which constitutively inhibits PERK kinase activity [48] .", [["PERK", "GENE_OR_GENE_PRODUCT", 27, 31], ["Grp78", "GENE_OR_GENE_PRODUCT", 87, 92], ["Grp94", "GENE_OR_GENE_PRODUCT", 97, 102], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 116, 124], ["HCoV-HKU1 S proteins", "GENE_OR_GENE_PRODUCT", 129, 149], ["PERK", "GENE_OR_GENE_PRODUCT", 201, 205], ["PERK", "GENE_OR_GENE_PRODUCT", 236, 240], ["PERK", "PROTEIN", 27, 31], ["Grp78 and Grp94 promoters", "DNA", 87, 112], ["SARS-CoV and HCoV-HKU1 S proteins", "PROTEIN", 116, 149], ["dominant negative (DN) mutant", "PROTEIN", 168, 197], ["PERK", "PROTEIN", 201, 205], ["PERK kinase", "PROTEIN", 236, 247], ["SARS-CoV", "SPECIES", 116, 124], ["PERK activity", "PROBLEM", 27, 40], ["Grp78", "TEST", 87, 92], ["Grp94 promoters", "TREATMENT", 97, 112], ["SARS", "TEST", 116, 120], ["CoV", "TEST", 121, 124], ["HCoV", "TEST", 129, 133], ["PERK kinase activity", "TEST", 236, 256]]], ["If the activation of Grp78 and Grp94 proteins by S proteins requires PERK, their stimulatory effect would be reversed in the presence of PERK-DN.", [["Grp78", "GENE_OR_GENE_PRODUCT", 21, 26], ["Grp94", "GENE_OR_GENE_PRODUCT", 31, 36], ["S proteins", "GENE_OR_GENE_PRODUCT", 49, 59], ["PERK", "GENE_OR_GENE_PRODUCT", 69, 73], ["PERK", "GENE_OR_GENE_PRODUCT", 137, 141], ["Grp78", "PROTEIN", 21, 26], ["Grp94 proteins", "PROTEIN", 31, 45], ["S proteins", "PROTEIN", 49, 59], ["PERK", "PROTEIN", 69, 73], ["PERK", "PROTEIN", 137, 141], ["Grp78", "PROBLEM", 21, 26], ["Grp94 proteins", "TEST", 31, 45], ["S proteins", "TEST", 49, 59], ["PERK", "PROBLEM", 69, 73]]], ["Consistent with our previous findings [3] , activation of Grp78 and Grp94 promoters by SARS-CoV S protein was enhanced by wild-type PERK (PERK-WT) and dampened by PERK-DN ( Figure 4A and B).", [["Grp78", "GENE_OR_GENE_PRODUCT", 58, 63], ["Grp94", "GENE_OR_GENE_PRODUCT", 68, 73], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 87, 97], ["PERK", "GENE_OR_GENE_PRODUCT", 132, 136], ["PERK", "GENE_OR_GENE_PRODUCT", 138, 142], ["PERK-DN ( Figure 4A", "GENE_OR_GENE_PRODUCT", 163, 182], ["B", "GENE_OR_GENE_PRODUCT", 187, 188], ["Grp78 and Grp94 promoters", "DNA", 58, 83], ["SARS-CoV S protein", "PROTEIN", 87, 105], ["wild-type PERK", "PROTEIN", 122, 136], ["PERK", "PROTEIN", 138, 142], ["WT", "PROTEIN", 143, 145], ["PERK", "PROTEIN", 163, 167], ["DN", "PROTEIN", 168, 170], ["Figure 4A and B", "PROTEIN", 173, 188], ["SARS-CoV", "SPECIES", 87, 95], ["Grp78", "TEST", 58, 63], ["Grp94 promoters", "TEST", 68, 83], ["SARS", "TEST", 87, 91], ["CoV S protein", "TEST", 92, 105], ["PERK", "TEST", 138, 142], ["WT", "TEST", 143, 145], ["PERK", "TEST", 163, 167]]], ["A very similar pattern was also observed for HCoV-HKU1 S protein.", [["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 45, 56], ["HCoV", "PROTEIN", 45, 49], ["HKU1 S protein", "PROTEIN", 50, 64], ["HCoV", "TEST", 45, 49]]], ["In other words, PERK-WT and PERK-DN exerted opposite effects on the activation of Grp78 and Grp94 promoters by S proteins from both viruses ( Figure 4A and B).", [["PERK", "GENE_OR_GENE_PRODUCT", 16, 20], ["PERK-DN", "GENE_OR_GENE_PRODUCT", 28, 35], ["Grp78", "GENE_OR_GENE_PRODUCT", 82, 87], ["Grp94", "GENE_OR_GENE_PRODUCT", 92, 97], ["S proteins", "GENE_OR_GENE_PRODUCT", 111, 121], ["B", "GENE_OR_GENE_PRODUCT", 156, 157], ["PERK", "PROTEIN", 16, 20], ["PERK", "PROTEIN", 28, 32], ["Grp78 and Grp94 promoters", "DNA", 82, 107], ["S proteins", "PROTEIN", 111, 121], ["PERK", "TEST", 16, 20], ["WT", "TEST", 21, 23], ["PERK", "TEST", 28, 32], ["Grp94 promoters", "TREATMENT", 92, 107], ["S proteins", "TEST", 111, 121]]], ["Thus, the activation of Grp78 and Grp94 expression by S proteins is mediated through PERK.N-linked glycosylation is not required for UPR activation by S proteinsGlycosylation might affect the folding, stability, sorting and function of viral structural proteins [49] .", [["N", "CHEMICAL", 90, 91], ["Grp78", "GENE_OR_GENE_PRODUCT", 24, 29], ["Grp94", "GENE_OR_GENE_PRODUCT", 34, 39], ["S proteins", "GENE_OR_GENE_PRODUCT", 54, 64], ["PERK", "GENE_OR_GENE_PRODUCT", 85, 89], ["UPR", "GENE_OR_GENE_PRODUCT", 133, 136], ["S proteins", "GENE_OR_GENE_PRODUCT", 151, 161], ["Grp78", "PROTEIN", 24, 29], ["Grp94", "PROTEIN", 34, 39], ["S proteins", "PROTEIN", 54, 64], ["PERK", "PROTEIN", 85, 89], ["UPR", "PROTEIN", 133, 136], ["S proteins", "PROTEIN", 151, 161], ["viral structural proteins", "PROTEIN", 236, 261], ["Grp78", "PROBLEM", 24, 29], ["S proteins", "TEST", 54, 64], ["glycosylation", "TREATMENT", 99, 112], ["UPR activation", "PROBLEM", 133, 147], ["S proteinsGlycosylation", "TREATMENT", 151, 174]]], ["Coronavirus S protein is heavily glycosylated.", [["Coronavirus S protein", "GENE_OR_GENE_PRODUCT", 0, 21], ["Coronavirus S protein", "PROTEIN", 0, 21], ["Coronavirus S protein", "TEST", 0, 21], ["heavily glycosylated", "PROBLEM", 25, 45]]], ["N-linked glycosylation of SARS-CoV S protein is known to be critical to receptor binding, viral entry and infectivity [50] [51] [52] .", [["N", "CHEMICAL", 0, 1], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 26, 36], ["SARS-CoV S protein", "PROTEIN", 26, 44], ["SARS-CoV", "SPECIES", 26, 34], ["SARS", "PROBLEM", 26, 30], ["CoV S protein", "TEST", 31, 44]]], ["Since N-linked glycosylation of S protein might overload the ER leading to the activation of the UPR, it will be of interest to see whether N-linked glycosylation of SARS-CoV and HCoV-HKU1 S proteins might be influential in their induction of ER stress.", [["ER", "ANATOMY", 61, 63], ["SARS", "DISEASE", 166, 170], ["N", "CHEMICAL", 6, 7], ["N", "CHEMICAL", 140, 141], ["S protein", "GENE_OR_GENE_PRODUCT", 32, 41], ["ER", "GENE_OR_GENE_PRODUCT", 61, 63], ["UPR", "GENE_OR_GENE_PRODUCT", 97, 100], ["SARS-CoV", "ORGANISM", 166, 174], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 179, 190], ["ER", "GENE_OR_GENE_PRODUCT", 243, 245], ["S protein", "PROTEIN", 32, 41], ["ER", "PROTEIN", 61, 63], ["UPR", "PROTEIN", 97, 100], ["SARS-CoV and HCoV-HKU1 S proteins", "PROTEIN", 166, 199], ["ER", "PROTEIN", 243, 245], ["SARS-CoV", "SPECIES", 166, 174], ["S protein", "TREATMENT", 32, 41], ["overload the ER", "PROBLEM", 48, 63], ["SARS", "PROBLEM", 166, 170], ["CoV", "TEST", 171, 174], ["HCoV", "TREATMENT", 179, 183], ["HKU1 S proteins", "PROBLEM", 184, 199]]], ["N-linked glycosylation sites in SARS-CoV S protein has been documented [50] [51] [52] .", [["N", "CHEMICAL", 0, 1], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 32, 42], ["N-linked glycosylation sites", "PROTEIN", 0, 28], ["SARS-CoV S protein", "PROTEIN", 32, 50], ["SARS-CoV", "SPECIES", 32, 40], ["linked glycosylation sites", "PROBLEM", 2, 28], ["SARS", "PROBLEM", 32, 36], ["CoV S protein", "TEST", 37, 50]]], ["Based on comparison and prediction with the help of a computer program, ten major N-linked glycosylation sites in SARS-CoV S protein and nine sites in HCoV- 4) .", [["N", "CHEMICAL", 82, 83], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 114, 124], ["HCoV- 4", "CELL", 151, 158], ["N-linked glycosylation sites", "PROTEIN", 82, 110], ["SARS-CoV S protein", "PROTEIN", 114, 132], ["HCoV", "PROTEIN", 151, 155], ["SARS-CoV", "SPECIES", 114, 122], ["a computer program", "TREATMENT", 52, 70], ["linked glycosylation sites", "PROBLEM", 84, 110], ["SARS", "PROBLEM", 114, 118], ["CoV S protein", "TEST", 119, 132], ["HCoV", "TEST", 151, 155]]], ["DsRed-ER was used as an ER marker (panels 2 and 5).", [["ER", "ANATOMY", 24, 26], ["DsRed", "GENE_OR_GENE_PRODUCT", 0, 5], ["ER", "GENE_OR_GENE_PRODUCT", 6, 8], ["ER", "GENE_OR_GENE_PRODUCT", 24, 26], ["DsRed", "PROTEIN", 0, 5], ["ER", "PROTEIN", 6, 8], ["ER", "PROTEIN", 24, 26], ["an ER marker", "TEST", 21, 33]]], ["The S (green) and DsRed-ER (red) fluorescent signals are overlaid and colocalization is in yellow (panels 3 and 6).", [["S (green)", "GENE_OR_GENE_PRODUCT", 4, 13], ["DsRed-ER", "GENE_OR_GENE_PRODUCT", 18, 26], ["DsRed", "PROTEIN", 18, 23], ["ER", "PROTEIN", 24, 26], ["fluorescent signals", "TEST", 33, 52], ["yellow (panels", "TEST", 91, 105], ["yellow", "OBSERVATION_MODIFIER", 91, 97]]], ["Nuclear morphology was visualized with DAPI and is in blue.", [["Nuclear", "ANATOMY", 0, 7], ["DAPI", "CHEMICAL", 39, 43], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["DAPI", "SIMPLE_CHEMICAL", 39, 43], ["Nuclear morphology", "TEST", 0, 18], ["DAPI", "TEST", 39, 43], ["DAPI", "OBSERVATION", 39, 43]]], ["Figure 2 Proteolytic cleavage of SARS-CoV S protein by TMPRSS2.", [["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 33, 43], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 55, 62], ["SARS-CoV S protein", "PROTEIN", 33, 51], ["TMPRSS2", "PROTEIN", 55, 62], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 33, 37], ["CoV S protein", "TEST", 38, 51], ["TMPRSS2", "TEST", 55, 62]]], ["293FT cells were cotransfected with FLAG-tagged TMPRSS1/4/2 and V5-tagged S proteins.", [["293FT cells", "ANATOMY", 0, 11], ["293FT cells", "CELL", 0, 11], ["FLAG", "GENE_OR_GENE_PRODUCT", 36, 40], ["TMPRSS1", "GENE_OR_GENE_PRODUCT", 48, 55], ["4/2", "GENE_OR_GENE_PRODUCT", 56, 59], ["V5-tagged S proteins", "GENE_OR_GENE_PRODUCT", 64, 84], ["293FT cells", "CELL_LINE", 0, 11], ["FLAG", "PROTEIN", 36, 40], ["TMPRSS1", "PROTEIN", 48, 55], ["4/2", "PROTEIN", 56, 59], ["V5", "PROTEIN", 64, 66], ["tagged S proteins", "PROTEIN", 67, 84], ["FLAG", "TEST", 36, 40], ["TMPRSS1", "TEST", 48, 55], ["V5", "TEST", 64, 66]]], ["Western blotting was performed with anti-V5 and anti-FLAG antibodies.", [["anti-V5", "GENE_OR_GENE_PRODUCT", 36, 43], ["anti-FLAG", "GENE_OR_GENE_PRODUCT", 48, 57], ["anti-V5", "PROTEIN", 36, 43], ["anti-FLAG antibodies", "PROTEIN", 48, 68], ["Western blotting", "TEST", 0, 16], ["anti-V5", "TREATMENT", 36, 43], ["anti-FLAG antibodies", "TREATMENT", 48, 68]]], ["Arrow points to S1 subunit of SARS-CoV.", [["SARS", "DISEASE", 30, 34], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 30, 38], ["S1 subunit", "PROTEIN", 16, 26], ["SARS-CoV", "SPECIES", 30, 38], ["CoV", "PROBLEM", 35, 38]]], ["HKU1 S protein were chosen for further analysis.", [["HKU1 S", "GENE_OR_GENE_PRODUCT", 0, 6], ["HKU1 S protein", "PROTEIN", 0, 14], ["HKU1 S protein", "TEST", 0, 14], ["further analysis", "TEST", 31, 47]]], ["When all these sites were mutated, electrophoretic mobility of the mutant S proteins on SDS-PAGE gel was no long shifted upon treatment of cell lysates with endoglycosidase PNGase F ( Figure 5A and B), indicating their deficiency in N-linked glycosylation.", [["cell lysates", "ANATOMY", 139, 151], ["SDS-PAGE", "CHEMICAL", 88, 96], ["N", "CHEMICAL", 233, 234], ["SDS-PAGE", "SIMPLE_CHEMICAL", 88, 96], ["cell lysates", "ORGANISM_SUBSTANCE", 139, 151], ["endoglycosidase PNGase F", "GENE_OR_GENE_PRODUCT", 157, 181], ["B", "GENE_OR_GENE_PRODUCT", 198, 199], ["mutant S proteins", "PROTEIN", 67, 84], ["endoglycosidase PNGase F", "PROTEIN", 157, 181], ["Figure 5A and B", "PROTEIN", 184, 199], ["the mutant S proteins", "PROBLEM", 63, 84], ["SDS", "TEST", 88, 91], ["cell lysates", "PROBLEM", 139, 151], ["endoglycosidase PNGase F", "TEST", 157, 181], ["Figure 5A", "TEST", 184, 193], ["their deficiency in N-linked glycosylation", "PROBLEM", 213, 255]]], ["However, compared to the wildtype proteins, these mutants were equally competent in the activation of Grp78 and Grp94 promoters ( Figure 5C -F).", [["Grp78", "GENE_OR_GENE_PRODUCT", 102, 107], ["Grp94", "GENE_OR_GENE_PRODUCT", 112, 117], ["wildtype proteins", "PROTEIN", 25, 42], ["Grp78", "PROTEIN", 102, 107], ["Grp94 promoters", "DNA", 112, 127], ["the wildtype proteins", "TEST", 21, 42], ["Grp94 promoters", "TREATMENT", 112, 127]]], ["Hence, N-linked glycosylation is not influential in UPR activation by SARS-CoV and HCoV-HKU1 S proteins.N-linked glycosylation is not required for UPR activation by S proteinsMapping of UPR-activating domain in SARS-CoV S protein SARS-CoV S protein is cleaved into S1 and S2 subunits [29] [30] [31] [32] [33] [34] .", [["N", "CHEMICAL", 7, 8], ["N", "CHEMICAL", 104, 105], ["UPR", "GENE_OR_GENE_PRODUCT", 52, 55], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 70, 78], ["HCoV-HKU1 S proteins", "GENE_OR_GENE_PRODUCT", 83, 103], ["UPR", "GENE_OR_GENE_PRODUCT", 147, 150], ["S proteins", "GENE_OR_GENE_PRODUCT", 165, 175], ["UPR", "GENE_OR_GENE_PRODUCT", 186, 189], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 211, 219], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 230, 240], ["[29] [30] [31] [32] [33] [34]", "SIMPLE_CHEMICAL", 284, 313], ["SARS-CoV and HCoV-HKU1 S proteins", "PROTEIN", 70, 103], ["UPR", "PROTEIN", 147, 150], ["S proteins", "PROTEIN", 165, 175], ["UPR-activating domain", "PROTEIN", 186, 207], ["SARS-CoV S protein SARS-CoV S protein", "PROTEIN", 211, 248], ["S1", "PROTEIN", 265, 267], ["S2", "PROTEIN", 272, 274], ["SARS-CoV", "SPECIES", 70, 78], ["SARS-CoV", "SPECIES", 211, 219], ["N-linked glycosylation", "TREATMENT", 7, 29], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78], ["HCoV", "TEST", 83, 87], ["HKU1 S proteins", "PROBLEM", 88, 103], ["UPR activation", "PROBLEM", 147, 161], ["UPR", "TEST", 186, 189], ["activating domain", "PROBLEM", 190, 207], ["SARS", "TEST", 211, 215], ["CoV S protein SARS", "TEST", 216, 234], ["CoV S protein", "TEST", 235, 248], ["S1 and S2 subunits", "TEST", 265, 283]]], ["Above we showed the proteolytic cleavage of Progressively escalating amounts of expression plasmids for \u03b2-galactosidase (\u03b2-gal) and S proteins were used.", [["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 104, 119], ["\u03b2-gal", "GENE_OR_GENE_PRODUCT", 121, 126], ["S proteins", "GENE_OR_GENE_PRODUCT", 132, 142], ["expression plasmids", "DNA", 80, 99], ["\u03b2-galactosidase", "PROTEIN", 104, 119], ["\u03b2", "PROTEIN", 121, 122], ["gal", "PROTEIN", 123, 126], ["S proteins", "PROTEIN", 132, 142], ["the proteolytic cleavage", "PROBLEM", 16, 40], ["expression plasmids", "TREATMENT", 80, 99], ["\u03b2-galactosidase (\u03b2-gal) and S proteins", "TREATMENT", 104, 142], ["Progressively", "OBSERVATION_MODIFIER", 44, 57], ["escalating", "OBSERVATION_MODIFIER", 58, 68]]], ["Fold activation was calculated from readouts of firefly luciferase activity normalized to those of Renilla luciferase activity.", [["luciferase", "GENE_OR_GENE_PRODUCT", 56, 66], ["Renilla", "GENE_OR_GENE_PRODUCT", 99, 106], ["luciferase", "GENE_OR_GENE_PRODUCT", 107, 117], ["luciferase", "PROTEIN", 56, 66], ["luciferase", "PROTEIN", 107, 117], ["Fold activation", "PROBLEM", 0, 15], ["firefly luciferase activity", "TEST", 48, 75]]], ["Activity recovered from cells transfected with pLenti vector alone was set as 1.", [["cells", "ANATOMY", 24, 29], ["cells", "CELL", 24, 29], ["pLenti vector", "DNA", 47, 60], ["pLenti vector", "TREATMENT", 47, 60]]], ["Means from triplicate experiments are presented and error bars indicate SD.", [["SD", "DISEASE", 72, 74], ["SD", "PROBLEM", 72, 74]]], ["In panel D, there is no statistically significant difference between groups \u03b2-gal and SCV-S or between groups \u03b2-gal and HKU1-S (p > 0.05).", [["\u03b2-gal", "SIMPLE_CHEMICAL", 76, 81], ["\u03b2-gal", "GENE_OR_GENE_PRODUCT", 110, 115], ["HKU1-S", "GENE_OR_GENE_PRODUCT", 120, 126], ["\u03b2-gal", "TEST", 76, 81], ["SCV", "TEST", 86, 89], ["gal", "TEST", 112, 115], ["HKU1", "TEST", 120, 124], ["no", "UNCERTAINTY", 21, 23], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["difference", "OBSERVATION", 50, 60], ["SCV", "ANATOMY", 86, 89]]], ["SARS-CoV S protein by TMPRSS2 protease (Figure 2 ), but the processing of HCoV-HKU1 S protein is not mediated by this enzyme and remains elusive.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 0, 10], ["TMPRSS2 protease", "GENE_OR_GENE_PRODUCT", 22, 38], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 74, 85], ["SARS-CoV S protein", "PROTEIN", 0, 18], ["TMPRSS2 protease", "PROTEIN", 22, 38], ["HCoV", "PROTEIN", 74, 78], ["HKU1 S protein", "PROTEIN", 79, 93], ["enzyme", "PROTEIN", 118, 124], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "TEST", 0, 4], ["CoV S protein", "TEST", 5, 18], ["TMPRSS2 protease (Figure", "TREATMENT", 22, 46], ["HCoV", "TEST", 74, 78], ["HKU1 S protein", "TEST", 79, 93], ["this enzyme", "TEST", 113, 124]]], ["To determine whether the UPR-activating property of SARS-CoV S protein is mediated by S1 (amino acids 1-770) or S2 (amino acids 771-1255) subunit, we expressed them in 293FT cells ( Figure 6A, lanes 2 and 3) .", [["293FT cells", "ANATOMY", 168, 179], ["SARS", "DISEASE", 52, 56], ["amino acids 1-770", "CHEMICAL", 90, 107], ["amino acids 771-1255", "CHEMICAL", 116, 136], ["amino acids", "CHEMICAL", 90, 101], ["amino acids", "CHEMICAL", 116, 127], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 52, 62], ["amino acids 1-770", "AMINO_ACID", 90, 107], ["S2", "GENE_OR_GENE_PRODUCT", 112, 114], ["amino acids", "AMINO_ACID", 116, 127], ["771-1255", "AMINO_ACID", 128, 136], ["293FT cells", "CELL", 168, 179], ["UPR", "PROTEIN", 25, 28], ["SARS-CoV S protein", "PROTEIN", 52, 70], ["S1", "PROTEIN", 86, 88], ["amino acids 1-770", "PROTEIN", 90, 107], ["S2", "PROTEIN", 112, 114], ["amino acids 771-1255) subunit", "PROTEIN", 116, 145], ["293FT cells", "CELL_LINE", 168, 179], ["SARS-CoV", "SPECIES", 52, 60], ["the UPR", "TEST", 21, 28], ["SARS", "PROBLEM", 52, 56], ["CoV S protein", "TEST", 57, 70], ["amino acids", "TEST", 90, 101], ["S2 (amino acids", "TEST", 112, 127]]], ["Whereas S2 has no influence on the activation of Grp78 and Grp94 promoters, S1 was fully competent in this activation ( Figure 6B and D) .", [["S2", "GENE_OR_GENE_PRODUCT", 8, 10], ["Grp78", "GENE_OR_GENE_PRODUCT", 49, 54], ["Grp94", "GENE_OR_GENE_PRODUCT", 59, 64], ["S1", "GENE_OR_GENE_PRODUCT", 76, 78], ["S2", "PROTEIN", 8, 10], ["Grp78 and Grp94 promoters", "DNA", 49, 74], ["S1", "PROTEIN", 76, 78], ["Grp94 promoters", "TREATMENT", 59, 74], ["no", "UNCERTAINTY", 15, 17]]], ["To compare the two S proteins, we also expressed the polypeptides corresponding to S1 (amino acids 1-869) and S2 (amino acids 870-1255) of HCoV-HKU1 ( Figure 6A, lanes 8 and 9) , although we had no evidence in support of the cleavage of S in that virus.", [["amino acids 1-869", "CHEMICAL", 87, 104], ["amino acids 870-1255", "CHEMICAL", 114, 134], ["amino acids", "CHEMICAL", 87, 98], ["amino acids", "CHEMICAL", 114, 125], ["amino acids", "AMINO_ACID", 87, 98], ["amino acids", "AMINO_ACID", 114, 125], ["S proteins", "PROTEIN", 19, 29], ["S1", "PROTEIN", 83, 85], ["amino acids 1-869", "PROTEIN", 87, 104], ["S2", "PROTEIN", 110, 112], ["HCoV", "PROTEIN", 139, 143], ["HKU1", "PROTEIN", 144, 148], ["the polypeptides", "TEST", 49, 65], ["S1 (amino acids", "TEST", 83, 98], ["S2 (amino acids", "TEST", 110, 125], ["HCoV", "TEST", 139, 143], ["HKU1", "PROBLEM", 144, 148], ["Figure 6A", "TEST", 151, 160], ["lanes", "TEST", 162, 167], ["the cleavage of S in that virus", "PROBLEM", 221, 252], ["no evidence in", "UNCERTAINTY", 195, 209]]], ["To our surprise, neither S1 nor S2 of HCoV-HKU1 was able to activate Grp78 or Grp94 promoter ( Figure 6C and E) .N-linked glycosylation is not required for UPR activation by S proteinsTo further dissect the UPR-activating domain in SARS-CoV S1 subunit, we constructed three truncated mutants S1-M1 (amino acids 201-770), S1-M2 (amino acids 401-770) and S1-M3 (amino acids 534-770).", [["amino acids", "CHEMICAL", 299, 310], ["amino acids 401-770", "CHEMICAL", 328, 347], ["amino acids 534-770", "CHEMICAL", 360, 379], ["amino acids", "CHEMICAL", 299, 310], ["amino acids", "CHEMICAL", 328, 339], ["amino acids", "CHEMICAL", 360, 371], ["S2", "GENE_OR_GENE_PRODUCT", 32, 34], ["HCoV", "GENE_OR_GENE_PRODUCT", 38, 42], ["HKU1", "GENE_OR_GENE_PRODUCT", 43, 47], ["Grp78", "GENE_OR_GENE_PRODUCT", 69, 74], ["Grp94", "GENE_OR_GENE_PRODUCT", 78, 83], ["UPR", "GENE_OR_GENE_PRODUCT", 156, 159], ["S proteins", "GENE_OR_GENE_PRODUCT", 174, 184], ["SARS-CoV S1", "GENE_OR_GENE_PRODUCT", 232, 243], ["amino acids", "AMINO_ACID", 299, 310], ["201-770", "AMINO_ACID", 311, 318], ["amino acids", "AMINO_ACID", 328, 339], ["401-770", "AMINO_ACID", 340, 347], ["amino acids", "AMINO_ACID", 360, 371], ["534-770", "AMINO_ACID", 372, 379], ["S1", "PROTEIN", 25, 27], ["S2", "PROTEIN", 32, 34], ["HCoV", "PROTEIN", 38, 42], ["HKU1", "PROTEIN", 43, 47], ["Grp78", "PROTEIN", 69, 74], ["Grp94 promoter", "DNA", 78, 92], ["E", "DNA", 109, 110], ["UPR", "PROTEIN", 156, 159], ["S proteins", "PROTEIN", 174, 184], ["UPR-activating domain", "PROTEIN", 207, 228], ["SARS-CoV S1 subunit", "PROTEIN", 232, 251], ["S1", "PROTEIN", 292, 294], ["M1", "PROTEIN", 295, 297], ["amino acids 201-770", "PROTEIN", 299, 318], ["S1", "PROTEIN", 321, 323], ["M2", "PROTEIN", 324, 326], ["amino acids 401-770", "PROTEIN", 328, 347], ["S1", "PROTEIN", 353, 355], ["M3", "PROTEIN", 356, 358], ["amino acids 534-770", "PROTEIN", 360, 379], ["SARS-CoV", "SPECIES", 232, 240], ["HKU1", "PROBLEM", 43, 47], ["Grp78", "TEST", 69, 74], ["Grp94 promoter", "TEST", 78, 92], ["N-linked glycosylation", "TREATMENT", 113, 135], ["UPR activation", "PROBLEM", 156, 170], ["amino acids", "TEST", 299, 310], ["S1", "TEST", 321, 323], ["amino acids", "TEST", 328, 339], ["S1", "TEST", 353, 355], ["amino acids", "TEST", 360, 371], ["M1", "ANATOMY", 295, 297], ["M2", "ANATOMY", 324, 326]]], ["These mutants were expressed in 293FT cells ( Figure 6A , lanes 4-6).", [["293FT cells", "ANATOMY", 32, 43], ["293FT cells", "CELL", 32, 43], ["293FT cells", "CELL_LINE", 32, 43]]], ["Among them only S1-M1 was capable of activating the transcriptional activity of Grp78 and Grp94 promoters ( Figure 6B and D) .", [["S1-M1", "GENE_OR_GENE_PRODUCT", 16, 21], ["Grp78", "GENE_OR_GENE_PRODUCT", 80, 85], ["Grp94", "GENE_OR_GENE_PRODUCT", 90, 95], ["Figure 6B", "GENE_OR_GENE_PRODUCT", 108, 117], ["D", "GENE_OR_GENE_PRODUCT", 122, 123], ["S1", "PROTEIN", 16, 18], ["M1", "PROTEIN", 19, 21], ["Grp78 and Grp94 promoters", "DNA", 80, 105], ["Grp78", "TEST", 80, 85], ["Grp94 promoters", "TEST", 90, 105], ["S1", "ANATOMY", 16, 18], ["M1", "ANATOMY", 19, 21]]], ["Neither S1-M2 nor S1-M3 was active in the same assay.", [["S1-M2", "GENE_OR_GENE_PRODUCT", 8, 13], ["S1-M3", "GENE_OR_GENE_PRODUCT", 18, 23], ["S1", "PROTEIN", 8, 10], ["M2", "PROTEIN", 11, 13], ["S1", "PROTEIN", 18, 20], ["M3", "PROTEIN", 21, 23], ["S1", "ANATOMY", 8, 10], ["M2", "ANATOMY_MODIFIER", 11, 13], ["S1", "ANATOMY", 18, 20], ["M3", "ANATOMY_MODIFIER", 21, 23], ["active", "OBSERVATION", 28, 34]]], ["Thus, the central region (amino acids 201-400) of SARS-CoV S1 subunit is indispensable for the UPR-activating activity.DiscussionIn this study we compared and contrasted the UPRactivating activity of S proteins of SARS-CoV and HCoV-HKU1.", [["amino acids 201-400", "CHEMICAL", 26, 45], ["SARS", "DISEASE", 214, 218], ["amino acids", "CHEMICAL", 26, 37], ["amino acids", "AMINO_ACID", 26, 37], ["SARS-CoV S1", "GENE_OR_GENE_PRODUCT", 50, 61], ["UPR", "GENE_OR_GENE_PRODUCT", 95, 98], ["SARS-CoV", "ORGANISM", 214, 222], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 227, 236], ["amino acids 201-400", "PROTEIN", 26, 45], ["SARS-CoV S1 subunit", "PROTEIN", 50, 69], ["UPR", "PROTEIN", 95, 98], ["S proteins", "PROTEIN", 200, 210], ["HCoV", "PROTEIN", 227, 231], ["HKU1", "PROTEIN", 232, 236], ["SARS-CoV", "SPECIES", 50, 58], ["SARS-CoV", "SPECIES", 214, 222], ["amino acids", "TEST", 26, 37], ["SARS", "PROBLEM", 50, 54], ["this study", "TEST", 132, 142], ["SARS", "PROBLEM", 214, 218], ["CoV", "TEST", 219, 222], ["HCoV", "TEST", 227, 231], ["central", "ANATOMY_MODIFIER", 10, 17], ["region", "ANATOMY_MODIFIER", 18, 24]]], ["We found that the two S proteins share the following three properties in common.", [["S proteins", "PROTEIN", 22, 32], ["the two S proteins", "PROBLEM", 14, 32]]], ["First, they localize predominantly to the ER (Figure 1 ).", [["ER", "GENE_OR_GENE_PRODUCT", 42, 44], ["ER", "PROTEIN", 42, 44]]], ["Second, they display a similar profile of UPR-activating properties with the ability to activate Grp78, Grp94 and CHOP promoters but not UPRE enhancer ( Figure 3 ).", [["UPR", "GENE_OR_GENE_PRODUCT", 42, 45], ["Grp78", "GENE_OR_GENE_PRODUCT", 97, 102], ["Grp94", "GENE_OR_GENE_PRODUCT", 104, 109], ["CHOP", "GENE_OR_GENE_PRODUCT", 114, 118], ["UPRE enhancer ( Figure 3", "GENE_OR_GENE_PRODUCT", 137, 161], ["UPR", "PROTEIN", 42, 45], ["Grp78", "PROTEIN", 97, 102], ["Grp94", "PROTEIN", 104, 109], ["CHOP promoters", "DNA", 114, 128], ["UPRE enhancer", "DNA", 137, 150], ["Grp78", "TEST", 97, 102], ["CHOP promoters", "TREATMENT", 114, 128]]], ["Third, their activation of Grp78 and Grp94 promoters requires catalytic activity of PERK (Figure 4) but not N-linked glycosylation ( Figure 5 ).", [["N", "CHEMICAL", 108, 109], ["Grp78", "GENE_OR_GENE_PRODUCT", 27, 32], ["Grp94", "GENE_OR_GENE_PRODUCT", 37, 42], ["PERK", "GENE_OR_GENE_PRODUCT", 84, 88], ["Figure 4", "GENE_OR_GENE_PRODUCT", 90, 98], ["Grp78 and Grp94 promoters", "DNA", 27, 52], ["PERK", "PROTEIN", 84, 88], ["Figure 4", "PROTEIN", 90, 98], ["Grp78", "PROBLEM", 27, 32], ["Grp94 promoters", "TREATMENT", 37, 52]]], ["On the other hand, the two S proteins also exhibit distinct properties in protease cleavability and UPR-activating domain.", [["UPR", "GENE_OR_GENE_PRODUCT", 100, 103], ["S proteins", "PROTEIN", 27, 37], ["protease", "PROTEIN", 74, 82], ["UPR-activating domain", "PROTEIN", 100, 121], ["protease cleavability", "TREATMENT", 74, 95], ["distinct", "OBSERVATION_MODIFIER", 51, 59], ["properties", "OBSERVATION_MODIFIER", 60, 70]]], ["TMPRSS2 protease is capable of cleaving SARS-CoV S protein into S1 and S2 subunits, but has no proteolytic activity on HCoV-HKU1 S protein (Figure 2 ).", [["TMPRSS2 protease", "GENE_OR_GENE_PRODUCT", 0, 16], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 40, 48], ["S1", "GENE_OR_GENE_PRODUCT", 64, 66], ["S2", "GENE_OR_GENE_PRODUCT", 71, 73], ["HCoV-HKU1 S protein", "GENE_OR_GENE_PRODUCT", 119, 138], ["TMPRSS2 protease", "PROTEIN", 0, 16], ["SARS-CoV S protein", "PROTEIN", 40, 58], ["S1 and S2 subunits", "PROTEIN", 64, 82], ["HCoV", "PROTEIN", 119, 123], ["HKU1 S protein", "PROTEIN", 124, 138], ["SARS-CoV", "SPECIES", 40, 48], ["TMPRSS2 protease", "TEST", 0, 16], ["cleaving SARS", "PROBLEM", 31, 44], ["CoV S protein", "TEST", 45, 58], ["proteolytic activity", "PROBLEM", 95, 115], ["HCoV", "TEST", 119, 123], ["no", "UNCERTAINTY", 92, 94]]], ["The S1 subunit of SARS-CoV sufficiently activates the UPR, but its counterpart in HCoV-HKU1 has no UPR-modulating activity ( Figure 6 ).", [["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 18, 26], ["UPR", "GENE_OR_GENE_PRODUCT", 54, 57], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 82, 91], ["UPR", "GENE_OR_GENE_PRODUCT", 99, 102], ["S1 subunit", "PROTEIN", 4, 14], ["UPR", "PROTEIN", 54, 57], ["HCoV", "PROTEIN", 82, 86], ["HKU1", "DNA", 87, 91], ["UPR", "PROTEIN", 99, 102], ["SARS-CoV", "SPECIES", 18, 26], ["SARS", "PROBLEM", 18, 22], ["the UPR", "TEST", 50, 57], ["HCoV", "TEST", 82, 86], ["UPR", "PROBLEM", 99, 102], ["SARS", "OBSERVATION", 18, 22], ["no", "UNCERTAINTY", 96, 98]]], ["Thus, although the UPR-activating domains in SARS-CoV and HCoV-HKU1 S proteins are distinct, their modulatory effects on UPR signaling are similar.DiscussionWe provided the first evidence for the ability of HCoV-HKU1 S protein to modulate the UPR.", [["UPR", "GENE_OR_GENE_PRODUCT", 19, 22], ["SARS-CoV", "ORGANISM", 45, 53], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 58, 69], ["UPR", "GENE_OR_GENE_PRODUCT", 121, 124], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 207, 218], ["UPR", "GENE_OR_GENE_PRODUCT", 243, 246], ["UPR-activating domains", "PROTEIN", 19, 41], ["SARS-CoV and HCoV-HKU1 S proteins", "PROTEIN", 45, 78], ["UPR", "PROTEIN", 121, 124], ["HCoV", "PROTEIN", 207, 211], ["HKU1 S protein", "PROTEIN", 212, 226], ["UPR", "PROTEIN", 243, 246], ["SARS-CoV", "SPECIES", 45, 53], ["the UPR", "TEST", 15, 22], ["SARS", "TEST", 45, 49], ["CoV", "TEST", 50, 53], ["HCoV", "TEST", 58, 62], ["HKU1 S proteins", "TEST", 63, 78], ["UPR signaling", "TEST", 121, 134], ["HCoV", "TEST", 207, 211], ["distinct", "OBSERVATION_MODIFIER", 83, 91], ["modulatory effects", "OBSERVATION", 99, 117], ["similar", "OBSERVATION_MODIFIER", 139, 146]]], ["This adds HCoV-HKU1 to the list of coronaviruses including SARS-CoV and MHV, which use S protein to activate the UPR [3] [4] [5] .", [["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 10, 19], ["coronaviruses", "ORGANISM", 35, 48], ["SARS-CoV", "ORGANISM", 59, 67], ["MHV", "ORGANISM", 72, 75], ["HCoV", "PROTEIN", 10, 14], ["HKU1", "PROTEIN", 15, 19], ["S protein", "PROTEIN", 87, 96], ["SARS-CoV", "SPECIES", 59, 67], ["MHV", "SPECIES", 72, 75], ["HCoV", "TEST", 10, 14], ["coronaviruses", "PROBLEM", 35, 48], ["SARS", "PROBLEM", 59, 63], ["MHV", "TREATMENT", 72, 75], ["S protein", "TREATMENT", 87, 96]]], ["Although the direct evidence remains to be seen, HCoV-OC43, another human betacoronavirus of lineage A, might also use S protein to modulate the UPR, since a mutant HCoV-OC43 carrying two persistence-associated mutations in S was able to activate the UPR more potently [53] .", [["lineage A", "ANATOMY", 93, 102], ["HCoV-OC43", "ORGANISM", 49, 58], ["human", "ORGANISM", 68, 73], ["lineage A", "CELL", 93, 102], ["UPR", "GENE_OR_GENE_PRODUCT", 145, 148], ["HCoV-OC43", "ORGANISM", 165, 174], ["UPR", "GENE_OR_GENE_PRODUCT", 251, 254], ["HCoV", "PROTEIN", 49, 53], ["OC43", "PROTEIN", 54, 58], ["S protein", "PROTEIN", 119, 128], ["UPR", "PROTEIN", 145, 148], ["HCoV", "PROTEIN", 165, 169], ["OC43", "PROTEIN", 170, 174], ["UPR", "PROTEIN", 251, 254], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["HCoV", "TEST", 49, 53], ["S protein", "TREATMENT", 119, 128], ["a mutant HCoV", "PROBLEM", 156, 169], ["mutations in S", "PROBLEM", 211, 225]]], ["It will be of interest to see whether other coronaviruses including the emerging MERS-CoV might also employ S protein to activate the UPR.", [["coronaviruses", "ORGANISM", 44, 57], ["MERS-CoV", "ORGANISM", 81, 89], ["S protein", "GENE_OR_GENE_PRODUCT", 108, 117], ["UPR", "GENE_OR_GENE_PRODUCT", 134, 137], ["S protein", "PROTEIN", 108, 117], ["UPR", "PROTEIN", 134, 137], ["MERS-CoV", "SPECIES", 81, 89], ["other coronaviruses", "PROBLEM", 38, 57]]], ["More importantly, new investigations should be directed towards understanding the biological significance of UPR activation in coronavirus life cycle.DiscussionWhereas the UPR-activating domain maps to a central region (amino acids 201-400) in SARS-CoV S protein, the S1 fragment (amino acids 1-869) of HCoV-HKU1 S protein was unable to activate the UPR (Figure 6 ).", [["amino acids 201-400", "CHEMICAL", 220, 239], ["amino acids 1-869", "CHEMICAL", 281, 298], ["amino acids", "CHEMICAL", 220, 231], ["amino acids", "CHEMICAL", 281, 292], ["UPR", "GENE_OR_GENE_PRODUCT", 109, 112], ["coronavirus", "ORGANISM", 127, 138], ["amino acids", "AMINO_ACID", 220, 231], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 244, 254], ["amino acids", "AMINO_ACID", 281, 292], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 303, 314], ["UPR", "PROTEIN", 109, 112], ["UPR-activating domain", "PROTEIN", 172, 193], ["amino acids 201-400", "PROTEIN", 220, 239], ["SARS-CoV S protein", "PROTEIN", 244, 262], ["S1 fragment", "PROTEIN", 268, 279], ["amino acids 1-869", "PROTEIN", 281, 298], ["HCoV", "PROTEIN", 303, 307], ["HKU1 S protein", "PROTEIN", 308, 322], ["UPR", "PROTEIN", 350, 353], ["SARS-CoV", "SPECIES", 244, 252], ["new investigations", "TEST", 18, 36], ["amino acids", "TEST", 220, 231], ["SARS", "TEST", 244, 248], ["CoV S protein", "TEST", 249, 262], ["the S1 fragment", "TEST", 264, 279], ["amino acids", "TEST", 281, 292], ["HCoV", "TEST", 303, 307], ["HKU1 S protein", "TEST", 308, 322], ["central", "ANATOMY_MODIFIER", 204, 211], ["S1", "ANATOMY", 268, 270]]], ["The central regions of the two S proteins are relatively less conserved.", [["S proteins", "PROTEIN", 31, 41], ["central", "ANATOMY_MODIFIER", 4, 11], ["regions", "ANATOMY_MODIFIER", 12, 19], ["two S", "ANATOMY_MODIFIER", 27, 32], ["proteins", "OBSERVATION", 33, 41], ["relatively", "OBSERVATION_MODIFIER", 46, 56], ["less", "OBSERVATION_MODIFIER", 57, 61]]], ["It remains to be seen whether HCoV-HKU1 S protein might use one part of S1 and another part of S2 to perform its function in UPR modulation.", [["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 30, 41], ["S1", "GENE_OR_GENE_PRODUCT", 72, 74], ["S2", "GENE_OR_GENE_PRODUCT", 95, 97], ["UPR", "GENE_OR_GENE_PRODUCT", 125, 128], ["HCoV", "PROTEIN", 30, 34], ["HKU1 S protein", "PROTEIN", 35, 49], ["S1", "PROTEIN", 72, 74], ["S2", "PROTEIN", 95, 97], ["HCoV", "TEST", 30, 34], ["HKU1 S protein", "PROBLEM", 35, 49], ["UPR modulation", "OBSERVATION", 125, 139]]], ["Another possibility is that some regions in the S1 fragment of Figure 6 Mapping of UPR-activating domain in SARS-CoV and HCoV-HKU1 S proteins.", [["UPR", "GENE_OR_GENE_PRODUCT", 83, 86], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 108, 116], ["HCoV-HKU1 S proteins", "GENE_OR_GENE_PRODUCT", 121, 141], ["S1 fragment", "PROTEIN", 48, 59], ["UPR-activating domain", "PROTEIN", 83, 104], ["SARS-CoV and HCoV-HKU1 S proteins", "PROTEIN", 108, 141], ["SARS-CoV", "SPECIES", 108, 116], ["some regions in the S1 fragment", "PROBLEM", 28, 59], ["UPR", "TEST", 83, 86], ["activating domain", "PROBLEM", 87, 104], ["SARS", "TEST", 108, 112], ["CoV", "TEST", 113, 116], ["HCoV", "TEST", 121, 125], ["HKU1 S proteins", "PROBLEM", 126, 141], ["S1", "ANATOMY", 48, 50], ["fragment", "OBSERVATION_MODIFIER", 51, 59]]], ["(A) Truncated mutants.", [["Truncated mutants", "PROTEIN", 4, 21]]], ["SARS-CoV (SCV) S protein and its truncated mutants S1 (amino acids 1-770), S2 (amino acids 771-1255), S1-M1 (amino acids 201-770), S1-M2 (amino acids 401-770) and S1-M3 (amino acids 534-770) as well as HCoV-HKU1 S protein and its truncated mutants S1 (amino acids 1-869) and S2 (amino acids 870-1356) were expressed in 293FT cells.", [["293FT cells", "ANATOMY", 319, 330], ["SARS", "DISEASE", 0, 4], ["amino acids 1-770", "CHEMICAL", 55, 72], ["amino acids 771-1255", "CHEMICAL", 79, 99], ["amino acids 201-770", "CHEMICAL", 109, 128], ["amino acids 401-770", "CHEMICAL", 138, 157], ["amino acids 534-770", "CHEMICAL", 170, 189], ["amino acids 1-869", "CHEMICAL", 252, 269], ["amino acids 870-1356", "CHEMICAL", 279, 299], ["amino acids", "CHEMICAL", 55, 66], ["amino acids", "CHEMICAL", 79, 90], ["amino acids", "CHEMICAL", 109, 120], ["amino acids", "CHEMICAL", 138, 149], ["amino acids", "CHEMICAL", 170, 181], ["amino acids", "CHEMICAL", 252, 263], ["amino acids", "CHEMICAL", 279, 290], ["SARS-CoV (SCV) S protein", "GENE_OR_GENE_PRODUCT", 0, 24], ["amino acids 1-770", "AMINO_ACID", 55, 72], ["S2", "GENE_OR_GENE_PRODUCT", 75, 77], ["amino acids", "AMINO_ACID", 79, 90], ["771-1255", "AMINO_ACID", 91, 99], ["amino acids", "AMINO_ACID", 109, 120], ["201-770", "AMINO_ACID", 121, 128], ["S1-M2", "GENE_OR_GENE_PRODUCT", 131, 136], ["amino acids", "AMINO_ACID", 138, 149], ["401-770", "AMINO_ACID", 150, 157], ["S1-M3", "GENE_OR_GENE_PRODUCT", 163, 168], ["amino acids", "AMINO_ACID", 170, 181], ["534-770", "AMINO_ACID", 182, 189], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 202, 213], ["amino acids 1-869", "AMINO_ACID", 252, 269], ["amino acids", "AMINO_ACID", 279, 290], ["870-1356", "AMINO_ACID", 291, 299], ["293FT cells", "CELL", 319, 330], ["SARS-CoV (SCV) S protein", "PROTEIN", 0, 24], ["S1", "PROTEIN", 51, 53], ["amino acids 1-770", "PROTEIN", 55, 72], ["S2", "PROTEIN", 75, 77], ["amino acids 771-1255", "PROTEIN", 79, 99], ["S1", "PROTEIN", 102, 104], ["M1", "PROTEIN", 105, 107], ["amino acids 201-770", "PROTEIN", 109, 128], ["S1", "PROTEIN", 131, 133], ["M2", "PROTEIN", 134, 136], ["amino acids 401-770", "PROTEIN", 138, 157], ["S1", "PROTEIN", 163, 165], ["M3", "PROTEIN", 166, 168], ["amino acids 534-770", "PROTEIN", 170, 189], ["HCoV", "PROTEIN", 202, 206], ["HKU1 S protein", "PROTEIN", 207, 221], ["S1", "PROTEIN", 248, 250], ["amino acids 1-869", "PROTEIN", 252, 269], ["S2", "PROTEIN", 275, 277], ["amino acids 870-1356", "PROTEIN", 279, 299], ["293FT cells", "CELL_LINE", 319, 330], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "TEST", 0, 4], ["CoV (SCV) S protein", "TEST", 5, 24], ["amino acids", "TEST", 55, 66], ["amino acids", "TEST", 79, 90], ["S1", "TEST", 102, 104], ["amino acids", "TEST", 109, 120], ["S1", "TEST", 131, 133], ["amino acids", "TEST", 138, 149], ["S1", "TEST", 163, 165], ["amino acids", "TEST", 170, 181], ["HCoV", "TEST", 202, 206], ["HKU1 S protein", "TEST", 207, 221], ["amino acids", "TEST", 252, 263], ["S2 (amino acids", "TEST", 275, 290], ["SCV", "ANATOMY", 10, 13], ["M1", "ANATOMY", 105, 107], ["M2", "ANATOMY", 134, 136], ["S1", "ANATOMY", 163, 165]]], ["(B-E) Luciferase reporter assay.", [["B-E", "GENE_OR_GENE_PRODUCT", 1, 4], ["Luciferase reporter assay", "TEST", 6, 31]]], ["S protein and its truncated mutants in escalating doses were compared for the activity to activate luciferase reporter expression driven by Grp78 and Grp94 promoters.DiscussionHCoV-HKU1 could exert suppressive effect on UPR activation.", [["HKU1", "CHEMICAL", 181, 185], ["S protein", "GENE_OR_GENE_PRODUCT", 0, 9], ["luciferase", "GENE_OR_GENE_PRODUCT", 99, 109], ["Grp78", "GENE_OR_GENE_PRODUCT", 140, 145], ["Grp94", "GENE_OR_GENE_PRODUCT", 150, 155], ["DiscussionHCoV-HKU1", "GENE_OR_GENE_PRODUCT", 166, 185], ["UPR", "GENE_OR_GENE_PRODUCT", 220, 223], ["S protein", "PROTEIN", 0, 9], ["luciferase", "PROTEIN", 99, 109], ["Grp78 and Grp94 promoters", "DNA", 140, 165], ["HKU1", "PROTEIN", 181, 185], ["S protein", "TEST", 0, 9], ["its truncated mutants", "PROBLEM", 14, 35], ["escalating doses", "TREATMENT", 39, 55], ["UPR activation", "PROBLEM", 220, 234]]], ["Further experiments are required to define the UPR-activating domain in HCoV-HKU1 S protein.DiscussionElevated expression of molecular chaperones such as Grp78 and Grp94 would plausibly increase the capacity of ER to fold and process coronaviral proteins produced in extraordinarily high amounts during viral replication.", [["ER", "ANATOMY", 211, 213], ["HCoV-HKU1 S protein", "GENE_OR_GENE_PRODUCT", 72, 91], ["Grp78", "GENE_OR_GENE_PRODUCT", 154, 159], ["Grp94", "GENE_OR_GENE_PRODUCT", 164, 169], ["ER", "GENE_OR_GENE_PRODUCT", 211, 213], ["UPR-activating domain", "PROTEIN", 47, 68], ["HCoV", "PROTEIN", 72, 76], ["HKU1 S protein", "PROTEIN", 77, 91], ["molecular chaperones", "PROTEIN", 125, 145], ["Grp78", "PROTEIN", 154, 159], ["Grp94", "PROTEIN", 164, 169], ["ER", "PROTEIN", 211, 213], ["coronaviral proteins", "PROTEIN", 234, 254], ["the UPR", "TEST", 43, 50], ["HCoV", "TEST", 72, 76], ["molecular chaperones", "PROBLEM", 125, 145], ["Grp78", "PROBLEM", 154, 159], ["Grp94", "PROBLEM", 164, 169], ["coronaviral proteins", "PROBLEM", 234, 254], ["viral replication", "TREATMENT", 303, 320], ["viral replication", "OBSERVATION", 303, 320]]], ["This might explain why Grp78 and Grp94 promoters are activated potently by S proteins.", [["Grp78", "GENE_OR_GENE_PRODUCT", 23, 28], ["Grp94", "GENE_OR_GENE_PRODUCT", 33, 38], ["S proteins", "GENE_OR_GENE_PRODUCT", 75, 85], ["Grp78 and Grp94 promoters", "DNA", 23, 48], ["S proteins", "PROTEIN", 75, 85], ["Grp78", "PROBLEM", 23, 28], ["Grp94 promoters", "TREATMENT", 33, 48]]], ["On the other hand, CHOP mediates ER stress-induced apoptosis and UPRE controls the transcription of some UPR effector genes involved in ER-associated protein degradation, such as EDEM [38, 45] .", [["CHOP", "GENE_OR_GENE_PRODUCT", 19, 23], ["ER", "GENE_OR_GENE_PRODUCT", 33, 35], ["UPRE", "GENE_OR_GENE_PRODUCT", 65, 69], ["UPR", "GENE_OR_GENE_PRODUCT", 105, 108], ["ER", "GENE_OR_GENE_PRODUCT", 136, 138], ["CHOP", "PROTEIN", 19, 23], ["ER", "PROTEIN", 33, 35], ["UPRE", "PROTEIN", 65, 69], ["UPR effector genes", "DNA", 105, 123], ["ER", "PROTEIN", 136, 138], ["ER stress", "PROBLEM", 33, 42], ["apoptosis", "PROBLEM", 51, 60], ["UPRE controls", "TREATMENT", 65, 78], ["some UPR effector genes", "PROBLEM", 100, 123], ["protein degradation", "PROBLEM", 150, 169], ["protein degradation", "OBSERVATION", 150, 169]]], ["Compared to Grp78 and Grp94 promoters, the activation of CHOP promoter by S proteins was very modest ( Figure 3C ).", [["Grp78", "GENE_OR_GENE_PRODUCT", 12, 17], ["Grp94", "GENE_OR_GENE_PRODUCT", 22, 27], ["CHOP", "GENE_OR_GENE_PRODUCT", 57, 61], ["S proteins", "GENE_OR_GENE_PRODUCT", 74, 84], ["Grp78 and Grp94 promoters", "DNA", 12, 37], ["CHOP promoter", "DNA", 57, 70], ["S proteins", "PROTEIN", 74, 84], ["Grp78", "TEST", 12, 17], ["Grp94 promoters", "TREATMENT", 22, 37], ["CHOP promoter", "TREATMENT", 57, 70], ["S proteins", "TEST", 74, 84]]], ["Moreover, S proteins did not activate UPRE-dependent transcription ( Figure 3D ).", [["UPRE", "GENE_OR_GENE_PRODUCT", 38, 42], ["S proteins", "PROTEIN", 10, 20], ["UPRE", "PROTEIN", 38, 42]]], ["Hence, UPR activation by S proteins is highly selective and in the benefit of the viruses.", [["UPR", "GENE_OR_GENE_PRODUCT", 7, 10], ["S proteins", "GENE_OR_GENE_PRODUCT", 25, 35], ["UPR", "PROTEIN", 7, 10], ["S proteins", "PROTEIN", 25, 35], ["the viruses", "PROBLEM", 78, 89], ["viruses", "OBSERVATION", 82, 89]]], ["This is in line with the idea that ER stress-induced apoptosis or ER-associated protein degradation would be undesirable in the early phase of SARS-CoV and HCoV-HKU1 replication.", [["SARS", "DISEASE", 143, 147], ["ER", "GENE_OR_GENE_PRODUCT", 35, 37], ["ER", "GENE_OR_GENE_PRODUCT", 66, 68], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 143, 151], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 156, 165], ["ER", "PROTEIN", 35, 37], ["ER", "PROTEIN", 66, 68], ["SARS-CoV", "SPECIES", 143, 151], ["HCoV", "SPECIES", 156, 160], ["ER stress-induced apoptosis", "PROBLEM", 35, 62], ["protein degradation", "PROBLEM", 80, 99], ["SARS", "TEST", 143, 147], ["CoV", "TEST", 148, 151], ["HCoV", "TEST", 156, 160], ["HKU1 replication", "TREATMENT", 161, 177]]], ["Exactly how S proteins differentially modulate UPR signaling to facilitate viral replication merits further analysis.DiscussionHCoV-HKU1 remains unculturable except in primary human airway or alveolar epithelial cells [21] [22] [23] .", [["airway", "ANATOMY", 182, 188], ["alveolar epithelial cells", "ANATOMY", 192, 217], ["S proteins", "GENE_OR_GENE_PRODUCT", 12, 22], ["UPR", "GENE_OR_GENE_PRODUCT", 47, 50], ["HKU1", "GENE_OR_GENE_PRODUCT", 132, 136], ["human", "ORGANISM", 176, 181], ["airway", "CELL", 182, 188], ["alveolar epithelial cells", "CELL", 192, 217], ["S proteins", "PROTEIN", 12, 22], ["UPR", "PROTEIN", 47, 50], ["HKU1", "DNA", 132, 136], ["primary human airway or alveolar epithelial cells", "CELL_TYPE", 168, 217], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 176, 181], ["UPR signaling", "PROBLEM", 47, 60], ["viral replication", "TREATMENT", 75, 92], ["further analysis", "TEST", 100, 116], ["DiscussionHCoV", "TEST", 117, 131], ["alveolar epithelial cells", "TEST", 192, 217], ["airway", "ANATOMY", 182, 188], ["alveolar epithelial", "ANATOMY", 192, 211]]], ["This and the lack of an infectious HCoV-HKU1 clone prevented us from analyzing UPR activation in infected cells.", [["cells", "ANATOMY", 106, 111], ["HCoV", "GENE_OR_GENE_PRODUCT", 35, 39], ["HKU1 clone", "CELL", 40, 50], ["UPR", "GENE_OR_GENE_PRODUCT", 79, 82], ["cells", "CELL", 106, 111], ["infectious HCoV-HKU1 clone", "CELL_LINE", 24, 50], ["UPR", "PROTEIN", 79, 82], ["infected cells", "CELL_TYPE", 97, 111], ["an infectious HCoV", "PROBLEM", 21, 39], ["HKU1 clone", "PROBLEM", 40, 50], ["infected cells", "PROBLEM", 97, 111], ["infectious", "OBSERVATION", 24, 34], ["infected cells", "OBSERVATION", 97, 111]]], ["Establishing a more accessible and efficient culture system and an animal model for the study of HCoV-HKU1 infection is the next challenge in the field.", [["infection", "DISEASE", 107, 116], ["HCoV-HKU1", "ORGANISM", 97, 106], ["HCoV", "SPECIES", 97, 101], ["efficient culture system", "TEST", 35, 59], ["the study", "TEST", 84, 93], ["HCoV", "TEST", 97, 101], ["HKU1 infection", "PROBLEM", 102, 116], ["infection", "OBSERVATION", 107, 116]]], ["In addition, a recombinant lentivirus pseudotyped with HCoV-HKU1 S protein can also be used to study the roles of S protein in viral entry and pathogenesis.", [["lentivirus", "ORGANISM", 27, 37], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 55, 66], ["S protein", "GENE_OR_GENE_PRODUCT", 114, 123], ["HCoV", "PROTEIN", 55, 59], ["HKU1 S protein", "PROTEIN", 60, 74], ["S protein", "PROTEIN", 114, 123], ["lentivirus", "SPECIES", 27, 37], ["HCoV", "SPECIES", 55, 59], ["a recombinant lentivirus pseudotyped", "TREATMENT", 13, 49], ["HCoV", "TEST", 55, 59], ["HKU1 S protein", "TREATMENT", 60, 74], ["pathogenesis", "PROBLEM", 143, 155], ["viral entry", "OBSERVATION", 127, 138]]], ["Particularly, such a pseudotyped virus might prove useful in the analysis of UPR activation by HCoV-HKU1 S protein.DiscussionSARS-CoV is a highly pathogenic coronavirus in humans, whereas human infection with HCoV-HKU1 is more common but causes less severe disease [12, 19, 20] .", [["coronavirus", "DISEASE", 157, 168], ["infection", "DISEASE", 194, 203], ["pseudotyped", "ORGANISM", 21, 32], ["UPR", "GENE_OR_GENE_PRODUCT", 77, 80], ["HCoV-HKU1 S protein", "GENE_OR_GENE_PRODUCT", 95, 114], ["DiscussionSARS-CoV", "GENE_OR_GENE_PRODUCT", 115, 133], ["coronavirus", "ORGANISM", 157, 168], ["humans", "ORGANISM", 172, 178], ["human", "ORGANISM", 188, 193], ["HCoV-HKU1", "ORGANISM", 209, 218], ["UPR", "PROTEIN", 77, 80], ["HCoV", "PROTEIN", 95, 99], ["HKU1 S protein", "PROTEIN", 100, 114], ["coronavirus", "SPECIES", 157, 168], ["humans", "SPECIES", 172, 178], ["human", "SPECIES", 188, 193], ["humans", "SPECIES", 172, 178], ["human", "SPECIES", 188, 193], ["HCoV", "SPECIES", 209, 213], ["a pseudotyped virus", "PROBLEM", 19, 38], ["UPR activation", "TEST", 77, 91], ["HCoV", "TEST", 95, 99], ["a highly pathogenic coronavirus in humans", "PROBLEM", 137, 178], ["human infection", "PROBLEM", 188, 203], ["HCoV", "TEST", 209, 213], ["less severe disease", "PROBLEM", 245, 264], ["coronavirus", "OBSERVATION", 157, 168], ["infection", "OBSERVATION", 194, 203], ["less", "OBSERVATION_MODIFIER", 245, 249], ["severe", "OBSERVATION_MODIFIER", 250, 256], ["disease", "OBSERVATION", 257, 264]]], ["Because S proteins from both viruses are equally competent in the activation of the UPR, the UPR-modulating property of S proteins is unlikely a critical determinant in the severity of disease associated with SARS-CoV and HCoV-HKU1.", [["SARS", "DISEASE", 209, 213], ["S proteins", "GENE_OR_GENE_PRODUCT", 8, 18], ["UPR", "GENE_OR_GENE_PRODUCT", 84, 87], ["UPR", "GENE_OR_GENE_PRODUCT", 93, 96], ["S proteins", "GENE_OR_GENE_PRODUCT", 120, 130], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 209, 217], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 222, 231], ["S proteins", "PROTEIN", 8, 18], ["UPR", "PROTEIN", 84, 87], ["UPR", "PROTEIN", 93, 96], ["S proteins", "PROTEIN", 120, 130], ["HKU1", "PROTEIN", 227, 231], ["SARS-CoV", "SPECIES", 209, 217], ["S proteins from both viruses", "PROBLEM", 8, 36], ["the UPR", "TEST", 89, 96], ["disease", "PROBLEM", 185, 192], ["SARS", "PROBLEM", 209, 213], ["CoV", "TEST", 214, 217], ["HCoV", "TEST", 222, 226], ["viruses", "OBSERVATION", 29, 36], ["disease", "OBSERVATION", 185, 192]]], ["However, TMPRSS2 protease was capable of cleaving SARS-CoV S protein, but not HCoV-HKU1 S protein, into S1 and S1 subunits ( Figure 2) .", [["TMPRSS2 protease", "GENE_OR_GENE_PRODUCT", 9, 25], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 50, 60], ["HCoV-HKU1 S protein", "GENE_OR_GENE_PRODUCT", 78, 97], ["TMPRSS2 protease", "PROTEIN", 9, 25], ["SARS-CoV S protein", "PROTEIN", 50, 68], ["HCoV", "PROTEIN", 78, 82], ["HKU1 S protein", "PROTEIN", 83, 97], ["S1", "PROTEIN", 104, 106], ["S1 subunits", "PROTEIN", 111, 122], ["SARS-CoV", "SPECIES", 50, 58], ["TMPRSS2 protease", "PROBLEM", 9, 25], ["cleaving SARS", "PROBLEM", 41, 54], ["CoV S protein", "TEST", 55, 68], ["HCoV", "TEST", 78, 82], ["S protein", "TEST", 88, 97], ["S1", "ANATOMY", 104, 106]]], ["Moreover, SARS-CoV S1 protein, but not its counterpart in HCoV-HKU1, was required and sufficient for UPR activation ( Figure 6 ).", [["SARS-CoV S1", "GENE_OR_GENE_PRODUCT", 10, 21], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 58, 67], ["SARS-CoV S1 protein", "PROTEIN", 10, 29], ["HCoV", "PROTEIN", 58, 62], ["HKU1", "PROTEIN", 63, 67], ["UPR", "PROTEIN", 101, 104], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "TEST", 10, 14], ["CoV S1 protein", "TEST", 15, 29]]], ["Cleavability of surface proteins by host proteases is an important virulence determinant in coronaviruses and other viruses such as influenza [1, 14, 37] .", [["surface", "ANATOMY", 16, 23], ["influenza", "DISEASE", 132, 141], ["coronaviruses", "ORGANISM", 92, 105], ["surface proteins", "PROTEIN", 16, 32], ["host proteases", "PROTEIN", 36, 50], ["surface proteins", "PROBLEM", 16, 32], ["host proteases", "PROBLEM", 36, 50], ["coronaviruses", "PROBLEM", 92, 105], ["other viruses", "PROBLEM", 110, 123], ["influenza", "PROBLEM", 132, 141]]], ["In this connection, it will not be too surprising if the inability of TMPRSS2 to cleave HCoV-HKU1 might affect pathogenesis.", [["TMPRSS2", "GENE_OR_GENE_PRODUCT", 70, 77], ["HCoV", "GENE_OR_GENE_PRODUCT", 88, 92], ["HKU1", "GENE_OR_GENE_PRODUCT", 93, 97], ["TMPRSS2", "PROTEIN", 70, 77], ["HCoV", "PROTEIN", 88, 92], ["HKU1", "PROTEIN", 93, 97], ["TMPRSS2", "TEST", 70, 77], ["HCoV", "TEST", 88, 92], ["pathogenesis", "PROBLEM", 111, 123]]], ["It will be even more interesting to see whether the ability of S1 to activate the UPR might be related to viral replication and pathogenesis.DiscussionOur findings that SARS-CoV and HCoV-HKU1 S proteins activate ER stress and the UPR might have implications in therapeutic intervention.", [["SARS", "DISEASE", 169, 173], ["S1", "GENE_OR_GENE_PRODUCT", 63, 65], ["UPR", "GENE_OR_GENE_PRODUCT", 82, 85], ["SARS-CoV", "ORGANISM", 169, 177], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 182, 193], ["ER", "GENE_OR_GENE_PRODUCT", 212, 214], ["UPR", "GENE_OR_GENE_PRODUCT", 230, 233], ["S1", "PROTEIN", 63, 65], ["UPR", "PROTEIN", 82, 85], ["SARS-CoV and HCoV-HKU1 S proteins", "PROTEIN", 169, 202], ["ER", "PROTEIN", 212, 214], ["UPR", "PROTEIN", 230, 233], ["SARS-CoV", "SPECIES", 169, 177], ["viral replication", "PROBLEM", 106, 123], ["pathogenesis", "PROBLEM", 128, 140], ["SARS", "TEST", 169, 173], ["CoV", "TEST", 174, 177], ["HCoV", "TEST", 182, 186], ["ER stress", "PROBLEM", 212, 221], ["therapeutic intervention", "TREATMENT", 261, 285], ["might be related to", "UNCERTAINTY", 86, 105], ["viral replication", "OBSERVATION", 106, 123]]], ["Pharmaceutical modulators of ER stress and the UPR have been developed and tested for various disease conditions including viral infection [54, 55] .", [["viral infection", "DISEASE", 123, 138], ["ER", "GENE_OR_GENE_PRODUCT", 29, 31], ["UPR", "GENE_OR_GENE_PRODUCT", 47, 50], ["ER", "PROTEIN", 29, 31], ["UPR", "PROTEIN", 47, 50], ["ER stress", "PROBLEM", 29, 38], ["the UPR", "TEST", 43, 50], ["various disease conditions", "PROBLEM", 86, 112], ["viral infection", "PROBLEM", 123, 138]]], ["Interestingly, whereas inhibition of PERK kinase has been found to inhibit cytomegalovirus replication [56] , activation of the UPR with a small-molecule compound also has broad-spectrum antiviral activity [57] .", [["PERK", "GENE_OR_GENE_PRODUCT", 37, 41], ["cytomegalovirus", "ORGANISM", 75, 90], ["UPR", "GENE_OR_GENE_PRODUCT", 128, 131], ["PERK kinase", "PROTEIN", 37, 48], ["UPR", "PROTEIN", 128, 131], ["PERK kinase", "TEST", 37, 48], ["cytomegalovirus replication", "PROBLEM", 75, 102], ["a small-molecule compound", "PROBLEM", 137, 162], ["small", "OBSERVATION_MODIFIER", 139, 144], ["antiviral activity", "OBSERVATION", 187, 205]]], ["Thus, our demonstration of the activation of the UPR by S proteins might pave the way for further evaluation of the utility of UPRmodulating agents for the treatment of diseases associated with SARS-CoV and HCoV-HKU1 infection.Plasmids and antibodiesExpression plasmids for human PERK and its DN mutant K621M were obtained from Ronald Wek [48] .", [["SARS-CoV", "DISEASE", 194, 202], ["infection", "DISEASE", 217, 226], ["UPR", "GENE_OR_GENE_PRODUCT", 49, 52], ["S proteins", "GENE_OR_GENE_PRODUCT", 56, 66], ["SARS-CoV", "ORGANISM", 194, 202], ["HCoV-HKU1", "ORGANISM", 207, 216], ["human", "ORGANISM", 274, 279], ["PERK", "GENE_OR_GENE_PRODUCT", 280, 284], ["DN", "GENE_OR_GENE_PRODUCT", 293, 295], ["UPR", "PROTEIN", 49, 52], ["S proteins", "PROTEIN", 56, 66], ["antibodiesExpression plasmids", "DNA", 240, 269], ["human PERK", "PROTEIN", 274, 284], ["DN mutant K621M", "PROTEIN", 293, 308], ["human", "SPECIES", 274, 279], ["SARS-CoV", "SPECIES", 194, 202], ["HCoV", "SPECIES", 207, 211], ["human", "SPECIES", 274, 279], ["further evaluation", "TEST", 90, 108], ["UPRmodulating agents", "TREATMENT", 127, 147], ["diseases", "PROBLEM", 169, 177], ["SARS", "PROBLEM", 194, 198], ["CoV", "PROBLEM", 199, 202], ["HCoV", "PROBLEM", 207, 211], ["HKU1 infection", "PROBLEM", 212, 226], ["Plasmids", "TREATMENT", 227, 235], ["antibodiesExpression plasmids", "TREATMENT", 240, 269], ["human PERK", "TEST", 274, 284], ["diseases", "OBSERVATION", 169, 177], ["infection", "OBSERVATION", 217, 226]]], ["Reporter plasmid pCHOP-Luc, in which luciferase expression is driven by human CHOP promoter (\u2212644 to +91), was provided by Nai Sum Wong [23] .", [["pCHOP-Luc", "GENE_OR_GENE_PRODUCT", 17, 26], ["luciferase", "GENE_OR_GENE_PRODUCT", 37, 47], ["human", "ORGANISM", 72, 77], ["CHOP", "GENE_OR_GENE_PRODUCT", 78, 82], ["pCHOP", "DNA", 17, 22], ["Luc", "DNA", 23, 26], ["luciferase", "PROTEIN", 37, 47], ["human CHOP promoter", "DNA", 72, 91], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77]]], ["Reporter plasmids pGRP78-Luc and pGRP94-Luc were gifts from Kazutoshi Mori [40, 58] .", [["pGRP78", "GENE_OR_GENE_PRODUCT", 18, 24], ["Luc", "GENE_OR_GENE_PRODUCT", 25, 28], ["pGRP94-Luc", "GENE_OR_GENE_PRODUCT", 33, 43], ["Reporter plasmids", "DNA", 0, 17], ["pGRP78", "DNA", 18, 24], ["Luc", "DNA", 25, 28], ["pGRP94", "DNA", 33, 39], ["Luc", "DNA", 40, 43], ["Reporter plasmids", "TEST", 0, 17]]], ["The Grp78 and Grp94 promoters are derived from \u2212304 to +34 of human Grp78 gene and \u2212363 to +34 of human Grp94 gene, respectively.", [["Grp78", "GENE_OR_GENE_PRODUCT", 4, 9], ["Grp94", "GENE_OR_GENE_PRODUCT", 14, 19], ["human", "ORGANISM", 62, 67], ["Grp78", "GENE_OR_GENE_PRODUCT", 68, 73], ["+34", "GENE_OR_GENE_PRODUCT", 91, 94], ["human", "ORGANISM", 98, 103], ["Grp94", "GENE_OR_GENE_PRODUCT", 104, 109], ["Grp78 and Grp94 promoters", "DNA", 4, 29], ["human Grp78 gene", "DNA", 62, 78], ["\u2212363 to +34", "DNA", 83, 94], ["human Grp94 gene", "DNA", 98, 114], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 98, 103], ["The Grp78", "TEST", 0, 9], ["human Grp78 gene", "TEST", 62, 78], ["Grp94 promoters", "OBSERVATION", 14, 29]]], ["Both promoters harbor multiple copies of ER stress response element [58] . pUPRE-Luc reporter plasmid has been described elsewhere [41, 42] .Plasmids and antibodiesMouse monoclonal anti-V5 antibody was purchased from Invitrogen.", [["ER", "GENE_OR_GENE_PRODUCT", 41, 43], ["pUPRE-Luc", "GENE_OR_GENE_PRODUCT", 75, 84], ["Mouse", "ORGANISM", 164, 169], ["anti-V5", "GENE_OR_GENE_PRODUCT", 181, 188], ["promoters", "DNA", 5, 14], ["ER stress response element", "DNA", 41, 67], ["pUPRE-Luc reporter plasmid", "DNA", 75, 101], ["antibodiesMouse monoclonal anti-V5 antibody", "PROTEIN", 154, 197], ["Mouse", "SPECIES", 164, 169], ["Mouse", "SPECIES", 164, 169], ["ER stress response element", "PROBLEM", 41, 67], ["Plasmids", "TREATMENT", 141, 149], ["antibodiesMouse monoclonal anti-V5 antibody", "TREATMENT", 154, 197]]], ["Mouse anti-FLAG antibody (clone M2) was from Sigma-Aldrich.Cell culture and transfection293FT and HeLa cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and antibiotics.", [["Cell", "ANATOMY", 59, 63], ["293FT", "ANATOMY", 88, 93], ["HeLa cells", "ANATOMY", 98, 108], ["fetal bovine serum", "ANATOMY", 173, 191], ["Mouse", "ORGANISM", 0, 5], ["anti-FLAG antibody (clone M2", "GENE_OR_GENE_PRODUCT", 6, 34], ["Sigma-Aldrich", "ORGANISM", 45, 58], ["Cell", "CELL", 59, 63], ["transfection293FT", "CELL", 76, 93], ["HeLa cells", "CELL", 98, 108], ["bovine", "ORGANISM", 179, 185], ["serum", "ORGANISM_SUBSTANCE", 186, 191], ["Mouse anti-FLAG antibody", "PROTEIN", 0, 24], ["clone M2", "PROTEIN", 26, 34], ["transfection293FT", "CELL_LINE", 76, 93], ["HeLa cells", "CELL_LINE", 98, 108], ["Mouse", "SPECIES", 0, 5], ["bovine", "SPECIES", 179, 185], ["Mouse", "SPECIES", 0, 5], ["bovine", "SPECIES", 179, 185], ["Mouse anti-FLAG antibody", "TEST", 0, 24], ["Cell culture", "TEST", 59, 71], ["transfection", "TEST", 76, 88], ["HeLa cells", "TEST", 98, 108], ["10% fetal bovine serum", "TREATMENT", 169, 191], ["antibiotics", "TREATMENT", 196, 207]]], ["Cells were transfected with Gene-Juice transfection reagent (Novagen) as described [42, 59] .", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Novagen", "GENE_OR_GENE_PRODUCT", 61, 68], ["Gene-Juice transfection reagent", "TREATMENT", 28, 59]]], ["The SV40 large T antigen is constitutively expressed in 293FT cells.Western blotting and luciferase reporter assayWestern blotting and dual luciferase reporter assay were carried out as described [42, 59] .", [["293FT cells", "ANATOMY", 56, 67], ["SV40", "ORGANISM", 4, 8], ["large T antigen", "GENE_OR_GENE_PRODUCT", 9, 24], ["293FT cells", "CELL", 56, 67], ["luciferase", "GENE_OR_GENE_PRODUCT", 89, 99], ["luciferase", "GENE_OR_GENE_PRODUCT", 140, 150], ["SV40 large T antigen", "PROTEIN", 4, 24], ["293FT cells", "CELL_LINE", 56, 67], ["The SV40 large T antigen", "TEST", 0, 24], ["luciferase reporter", "TEST", 89, 108], ["dual luciferase reporter assay", "TEST", 135, 165], ["large", "OBSERVATION_MODIFIER", 9, 14]]], ["Control plasmid pRLSV40 expressing Renilla luciferase (Promega) was cotransfected into cells and firefly luciferase activity was normalized to that of Renilla luciferase in all experiments.Laser-scanning confocal microscopyConfocal immunofluorescence microscopy was performed on LSM510 (Carl-Zeiss) as described [60, 61] .", [["plasmid", "ANATOMY", 8, 15], ["cells", "ANATOMY", 87, 92], ["Renilla", "GENE_OR_GENE_PRODUCT", 35, 42], ["luciferase", "GENE_OR_GENE_PRODUCT", 43, 53], ["Promega", "GENE_OR_GENE_PRODUCT", 55, 62], ["cells", "CELL", 87, 92], ["luciferase", "GENE_OR_GENE_PRODUCT", 105, 115], ["Renilla", "GENE_OR_GENE_PRODUCT", 151, 158], ["luciferase", "GENE_OR_GENE_PRODUCT", 159, 169], ["pRLSV40", "DNA", 16, 23], ["Renilla luciferase", "DNA", 35, 53], ["Promega", "PROTEIN", 55, 62], ["luciferase", "PROTEIN", 105, 115], ["Renilla luciferase", "DNA", 151, 169], ["Control plasmid", "TREATMENT", 0, 15], ["Renilla luciferase (Promega)", "TREATMENT", 35, 63], ["firefly luciferase activity", "TEST", 97, 124], ["Renilla luciferase", "TEST", 151, 169], ["Laser-scanning confocal microscopy", "TEST", 189, 223], ["Confocal immunofluorescence microscopy", "TEST", 223, 261], ["Renilla luciferase", "OBSERVATION", 35, 53], ["Renilla luciferase", "OBSERVATION", 151, 169]]], ["HeLa cells were transfected with an S-expressing plasmid and pDsRed-ER (Clontech) for 36 h.", [["HeLa cells", "ANATOMY", 0, 10], ["plasmid", "ANATOMY", 49, 56], ["HeLa cells", "CELL", 0, 10], ["pDsRed-ER", "GENE_OR_GENE_PRODUCT", 61, 70], ["Clontech", "GENE_OR_GENE_PRODUCT", 72, 80], ["HeLa cells", "CELL_LINE", 0, 10], ["S-expressing plasmid", "DNA", 36, 56], ["pDsRed", "PROTEIN", 61, 67], ["ER", "PROTEIN", 68, 70], ["Clontech", "PROTEIN", 72, 80], ["HeLa cells", "PROBLEM", 0, 10], ["an S", "TEST", 33, 37], ["expressing plasmid", "TREATMENT", 38, 56], ["pDsRed-ER (Clontech)", "TREATMENT", 61, 81]]], ["Cells were then fixed and stained with anti-V5 antibody.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["anti-V5", "GENE_OR_GENE_PRODUCT", 39, 46], ["anti-V5 antibody", "PROTEIN", 39, 55], ["Cells", "TEST", 0, 5], ["anti-V5 antibody", "TEST", 39, 55]]], ["Nuclei were counter-stained with 4', 6-diamidino-2-phenylindole (DAPI) before mounting.Site-directed mutagenesisN-linked glycosylation mutants of S proteins were constructed by using a site-directed mutagenesis kit (Agilent).", [["Nuclei", "ANATOMY", 0, 6], ["4', 6-diamidino-2-phenylindole", "CHEMICAL", 33, 63], ["4', 6-diamidino-2-phenylindole", "CHEMICAL", 33, 63], ["DAPI", "CHEMICAL", 65, 69], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["4', 6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 33, 63], ["DAPI", "SIMPLE_CHEMICAL", 65, 69], ["S proteins", "GENE_OR_GENE_PRODUCT", 146, 156], ["Site-directed mutagenesisN-linked glycosylation mutants", "PROTEIN", 87, 142], ["S proteins", "PROTEIN", 146, 156], ["Nuclei", "TEST", 0, 6], ["diamidino", "TEST", 39, 48], ["phenylindole (DAPI", "TREATMENT", 51, 69], ["glycosylation mutants of S proteins", "PROBLEM", 121, 156], ["a site-directed mutagenesis kit (Agilent)", "TREATMENT", 183, 224]]], ["Potential N-linked glycosylation sites were analyzed online by the NetNGlyc program (website: http:// www.cbs.dtu.dk/services/NetNGlyc/).", [["N", "CHEMICAL", 10, 11], ["N-linked glycosylation sites", "PROTEIN", 10, 38], ["Potential N-linked glycosylation sites", "TREATMENT", 0, 38]]], ["For SARS-CoV S protein, asparagine residues at positions 29, 65, 119, 227, 318, 330, 357, 589, 669 and 783 were mutated to glutamine.", [["asparagine", "CHEMICAL", 24, 34], ["glutamine", "CHEMICAL", 123, 132], ["asparagine", "CHEMICAL", 24, 34], ["glutamine", "CHEMICAL", 123, 132], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 4, 14], ["asparagine", "AMINO_ACID", 24, 34], ["glutamine", "AMINO_ACID", 123, 132], ["SARS-CoV S protein", "PROTEIN", 4, 22], ["SARS-CoV", "SPECIES", 4, 12], ["SARS", "PROBLEM", 4, 8], ["CoV S protein", "TEST", 9, 22], ["asparagine residues", "TEST", 24, 43], ["glutamine", "TEST", 123, 132]]], ["For HCoV-HKU1 S protein, asparagine residues at positions 19, 29, 192, 335, 433, 454, 664 , 684 and 725 were mutated to glutamine.Endoglycosidase treatmentN-linked glycans were removed from S protein by endoglycosidase treatment as described [42] .", [["asparagine", "CHEMICAL", 25, 35], ["glutamine", "CHEMICAL", 120, 129], ["asparagine", "CHEMICAL", 25, 35], ["glutamine", "CHEMICAL", 120, 129], ["HCoV-HKU1 S", "GENE_OR_GENE_PRODUCT", 4, 15], ["asparagine", "AMINO_ACID", 25, 35], ["glutamine", "AMINO_ACID", 120, 129], ["Endoglycosidase treatmentN-linked glycans", "GENE_OR_GENE_PRODUCT", 130, 171], ["endoglycosidase", "GENE_OR_GENE_PRODUCT", 203, 218], ["HCoV", "PROTEIN", 4, 8], ["HKU1 S protein", "PROTEIN", 9, 23], ["S protein", "PROTEIN", 190, 199], ["HCoV", "TEST", 4, 8], ["HKU1 S protein", "TEST", 9, 23], ["asparagine residues at positions", "TEST", 25, 57], ["glutamine", "TEST", 120, 129], ["Endoglycosidase treatmentN-linked glycans", "TREATMENT", 130, 171], ["endoglycosidase treatment", "TREATMENT", 203, 228]]], ["In brief, cell lysates were incubated with endoglycosidase PNGase F (New England BioLabs) for 1 h at 37\u00b0C.", [["cell lysates", "ANATOMY", 10, 22], ["cell lysates", "CELL", 10, 22], ["cell lysates", "TEST", 10, 22], ["endoglycosidase PNGase", "TREATMENT", 43, 65], ["New England BioLabs", "TREATMENT", 69, 88]]]], "PMC6462090": [["Structure of the USP9X CD. ::: ResultsUSP9X is a large protein of over 2,500 aa, with little domain annotation outside the CD (Fig. 1A).", [["ResultsUSP9X", "GENE_OR_GENE_PRODUCT", 31, 43], ["USP9X CD", "PROTEIN", 17, 25], ["ResultsUSP9X", "PROTEIN", 31, 43], ["a large protein", "PROBLEM", 47, 62], ["USP9X CD", "OBSERVATION", 17, 25], ["large", "OBSERVATION_MODIFIER", 49, 54], ["protein", "OBSERVATION", 55, 62]]], ["The crystal structure of the USP9X CD (amino acids 1,551\u20131,970) was solved at 2.5-\u00c5 resolution in space group P21 using the USP7 CD as a molecular replacement search model.", [["amino acids 1,551\u20131,970", "CHEMICAL", 39, 62], ["USP9X CD", "CHEMICAL", 29, 37], ["amino acids", "CHEMICAL", 39, 50], ["USP9X", "GENE_OR_GENE_PRODUCT", 29, 34], ["amino acids", "AMINO_ACID", 39, 50], ["USP7", "GENE_OR_GENE_PRODUCT", 124, 128], ["USP9X CD", "PROTEIN", 29, 37], ["USP7 CD", "PROTEIN", 124, 131], ["amino acids", "TEST", 39, 50], ["space group P21", "TREATMENT", 98, 113], ["the USP7 CD", "TREATMENT", 120, 131], ["a molecular replacement search model", "TREATMENT", 135, 171], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["USP9X CD", "OBSERVATION", 29, 37], ["replacement", "OBSERVATION", 147, 158]]], ["The asymmetric unit contains four copies of USP9X that show a noncrystallographic pseudo C2 symmetry.", [["USP9X", "GENE_OR_GENE_PRODUCT", 44, 49], ["USP9X", "PROTEIN", 44, 49], ["USP9X", "TEST", 44, 49], ["a noncrystallographic pseudo C2 symmetry", "PROBLEM", 60, 100], ["asymmetric", "OBSERVATION_MODIFIER", 4, 14], ["C2 symmetry", "OBSERVATION", 89, 100]]], ["Electron density for residues 1,593\u20131,631, 1,839\u20131,858, 1,891\u20131,895, and 1,959\u20131,960 of chain A and similar regions in chains B, C, and D is not observed, and these regions are presumably disordered (Fig. 1 A and B).", [["C", "GENE_OR_GENE_PRODUCT", 129, 130], ["B", "PROTEIN", 126, 127], ["C", "PROTEIN", 129, 130], ["D", "PROTEIN", 136, 137], ["B", "PROTEIN", 213, 214], ["residues", "TEST", 21, 29], ["chain A and similar regions in chains B, C, and D", "PROBLEM", 88, 137], ["density", "OBSERVATION", 9, 16], ["chains", "ANATOMY_MODIFIER", 119, 125]]], ["Chain A in the asymmetric unit was used in structural analysis unless otherwise specified.", [["Chain A", "SIMPLE_CHEMICAL", 0, 7], ["structural analysis", "TEST", 43, 62]]], ["A Dali search (25) revealed the core structure of USP9X is closest to the USP7 CD, with an rmsd of about 2.4 \u00c5 over 350 aligned amino acids and a z-score of 34.", [["amino acids", "CHEMICAL", 128, 139], ["amino acids", "CHEMICAL", 128, 139], ["USP9X", "GENE_OR_GENE_PRODUCT", 50, 55], ["USP7", "GENE_OR_GENE_PRODUCT", 74, 78], ["amino acids", "AMINO_ACID", 128, 139], ["USP9X", "PROTEIN", 50, 55], ["USP7 CD", "PROTEIN", 74, 81], ["A Dali search", "TEST", 0, 13], ["an rmsd", "TEST", 88, 95], ["amino acids", "TEST", 128, 139], ["a z-score", "TEST", 144, 153], ["USP9X", "OBSERVATION", 50, 55]]], ["The overall structure represents a canonical USP fold, comprising thumb, palm, and fingers subdomains (Fig. 1B).", [["thumb", "ANATOMY", 66, 71], ["thumb", "ORGANISM_SUBDIVISION", 66, 71], ["palm", "ORGANISM_SUBDIVISION", 73, 77], ["USP fold", "PROTEIN", 45, 53], ["thumb, palm, and fingers subdomains", "PROTEIN", 66, 101], ["Fig. 1B", "PROTEIN", 103, 110], ["overall structure", "OBSERVATION", 4, 21], ["canonical USP fold", "OBSERVATION", 35, 53], ["thumb", "ANATOMY", 66, 71], ["palm", "ANATOMY_MODIFIER", 73, 77], ["fingers", "ANATOMY", 83, 90]]], ["Additional features common to other USP CDs are also found in USP9X.", [["USP CDs", "GENE_OR_GENE_PRODUCT", 36, 43], ["USP9X", "GENE_OR_GENE_PRODUCT", 62, 67], ["USP CDs", "DNA", 36, 43], ["USP9X", "DNA", 62, 67], ["other USP CDs", "TEST", 30, 43]]], ["For example, the tip of the fingers subdomain contains a CHC2-type ZnF motif with a zinc ion coordinated by residues Cys1727, His1729, Cys1771, and Cys1774 arranged in a tetrahedron (SI Appendix, Fig. S1A).", [["zinc", "CHEMICAL", 84, 88], ["zinc", "CHEMICAL", 84, 88], ["Cys", "CHEMICAL", 117, 120], ["His", "CHEMICAL", 126, 129], ["Cys", "CHEMICAL", 135, 138], ["Cys1774", "CHEMICAL", 148, 155], ["Cys1727", "AMINO_ACID", 117, 124], ["Cys1771", "AMINO_ACID", 135, 142], ["Cys1774", "AMINO_ACID", 148, 155], ["fingers subdomain", "PROTEIN", 28, 45], ["CHC2", "PROTEIN", 57, 61], ["ZnF motif", "PROTEIN", 67, 76], ["the fingers subdomain", "PROBLEM", 24, 45], ["a CHC2-type ZnF motif", "TREATMENT", 55, 76], ["a zinc ion", "TREATMENT", 82, 92], ["Cys", "TEST", 117, 120], ["Cys", "TEST", 135, 138], ["a tetrahedron (SI Appendix", "TREATMENT", 168, 194], ["tip", "OBSERVATION_MODIFIER", 17, 20], ["fingers", "ANATOMY", 28, 35]]], ["Unexpectedly, a nearby Cys1724 is not involved, as seen in other known USP structures, where the zinc is coordinated by four cysteines.Structure of the USP9X CD. ::: ResultsStructural alignment of USP9X with a USP7/Ub-aldehyde covalent complex (PDB ID code 1NBF) reveals that the catalytic triad (Cys1566, His1879, Asp1901) superimposes well with the catalytic triad of USP7 in the active conformation (Fig. 1C).", [["zinc", "CHEMICAL", 97, 101], ["aldehyde", "CHEMICAL", 218, 226], ["zinc", "CHEMICAL", 97, 101], ["cysteines", "CHEMICAL", 125, 134], ["aldehyde", "CHEMICAL", 218, 226], ["Cys1566", "CHEMICAL", 297, 304], ["His", "CHEMICAL", 306, 309], ["Asp", "CHEMICAL", 315, 318], ["Cys1724", "GENE_OR_GENE_PRODUCT", 23, 30], ["zinc", "SIMPLE_CHEMICAL", 97, 101], ["USP9X", "GENE_OR_GENE_PRODUCT", 197, 202], ["USP7", "GENE_OR_GENE_PRODUCT", 210, 214], ["Ub", "GENE_OR_GENE_PRODUCT", 215, 217], ["USP7", "GENE_OR_GENE_PRODUCT", 370, 374], ["Cys1724", "PROTEIN", 23, 30], ["USP structures", "PROTEIN", 71, 85], ["USP9X CD", "PROTEIN", 152, 160], ["USP9X", "PROTEIN", 197, 202], ["USP7", "PROTEIN", 210, 214], ["Ub", "PROTEIN", 215, 217], ["aldehyde covalent complex", "PROTEIN", 218, 243], ["PDB ID code 1NBF", "PROTEIN", 245, 261], ["catalytic triad", "PROTEIN", 280, 295], ["catalytic triad", "PROTEIN", 351, 366], ["USP7", "PROTEIN", 370, 374], ["a USP7", "TEST", 208, 214], ["the catalytic triad", "PROBLEM", 276, 295], ["Asp", "TEST", 315, 318], ["the catalytic triad of USP7", "PROBLEM", 347, 374], ["not involved", "UNCERTAINTY", 34, 46], ["USP9X CD", "OBSERVATION", 152, 160]]], ["Notably, a Gln1683 residue is positioned close (3.6 \u00c5) to the catalytic Cys1566 in the apo structure (SI Appendix, Fig. S1B).", [["Cys1566", "CHEMICAL", 72, 79], ["Gln1683", "CHEMICAL", 11, 18], ["Cys", "CHEMICAL", 72, 75], ["Gln1683", "GENE_OR_GENE_PRODUCT", 11, 18], ["apo", "AMINO_ACID", 87, 90], ["catalytic Cys1566", "PROTEIN", 62, 79], ["apo structure", "PROTEIN", 87, 100], ["a Gln1683 residue", "PROBLEM", 9, 26], ["the catalytic Cys", "TEST", 58, 75], ["SI Appendix", "ANATOMY", 102, 113]]], ["It must adopt a different rotamer conformation to accommodate the C terminus of a Ub substrate as observed for an equivalent Gln293 in the USP7\u2013Ub complex structure (SI Appendix, Fig. S1C).", [["C", "CHEMICAL", 66, 67], ["Ub", "GENE_OR_GENE_PRODUCT", 82, 84], ["Gln293", "GENE_OR_GENE_PRODUCT", 125, 131], ["USP7", "GENE_OR_GENE_PRODUCT", 139, 143], ["Ub", "GENE_OR_GENE_PRODUCT", 144, 146], ["S1C", "GENE_OR_GENE_PRODUCT", 184, 187], ["C terminus", "PROTEIN", 66, 76], ["Ub substrate", "PROTEIN", 82, 94], ["Gln293", "PROTEIN", 125, 131], ["USP7", "PROTEIN", 139, 143], ["Ub complex structure", "PROTEIN", 144, 164], ["a different rotamer conformation", "TREATMENT", 14, 46], ["the C terminus", "TREATMENT", 62, 76], ["a Ub substrate", "TREATMENT", 80, 94], ["complex", "OBSERVATION_MODIFIER", 147, 154], ["SI Appendix", "OBSERVATION", 166, 177]]], ["Interestingly, Gln1683 is conserved among USP DUBs and often with a juxtaposed second Gln residue.", [["Gln", "CHEMICAL", 86, 89], ["Gln", "CHEMICAL", 86, 89], ["Gln1683", "GENE_OR_GENE_PRODUCT", 15, 22], ["USP DUBs", "GENE_OR_GENE_PRODUCT", 42, 50], ["Gln", "AMINO_ACID", 86, 89], ["Gln1683", "PROTEIN", 15, 22], ["USP DUBs", "PROTEIN", 42, 50], ["a juxtaposed second Gln residue", "PROBLEM", 66, 97], ["Gln residue", "OBSERVATION", 86, 97]]], ["Close to the active site, USP9X contains two blocking loops, BL1 (1,801\u20131,810) connecting \u03b213 and \u03b214 and BL2 (1,872\u20131,879) connecting \u03b216 and \u03b217 (Fig. 1B and SI Appendix, Fig. S2), similar to those in USP7 (5\u20137, 26) that form the binding cleft for the C-terminal tail of Ub.", [["C", "CHEMICAL", 254, 255], ["USP9X", "GENE_OR_GENE_PRODUCT", 26, 31], ["\u03b213", "GENE_OR_GENE_PRODUCT", 90, 93], ["\u03b214", "GENE_OR_GENE_PRODUCT", 98, 101], ["\u03b216", "GENE_OR_GENE_PRODUCT", 135, 138], ["Fig. S2", "GENE_OR_GENE_PRODUCT", 173, 180], ["USP7", "GENE_OR_GENE_PRODUCT", 203, 207], ["USP9X", "DNA", 26, 31], ["\u03b213", "DNA", 90, 93], ["BL2", "DNA", 106, 109], ["\u03b216", "DNA", 135, 138], ["\u03b217", "DNA", 143, 146], ["USP7", "PROTEIN", 203, 207], ["C-terminal tail", "PROTEIN", 254, 269], ["Ub.", "PROTEIN", 273, 276], ["USP9X", "TEST", 26, 31], ["BL1", "TEST", 61, 64], ["BL2", "TEST", 106, 109], ["USP7", "TEST", 203, 207], ["the binding cleft", "PROBLEM", 228, 245], ["active", "OBSERVATION_MODIFIER", 13, 19], ["two", "OBSERVATION_MODIFIER", 41, 44], ["blocking loops", "OBSERVATION", 45, 59], ["SI Appendix", "ANATOMY", 160, 171], ["Fig. S2", "OBSERVATION_MODIFIER", 173, 180], ["terminal tail", "ANATOMY", 256, 269]]], ["A unique USP9X \u03b2-hairpin insertion is located next to the two blocking loops (Fig. 1B), suggesting the insertion may have some effect on the recognition of the Ub tail.", [["USP9X", "GENE_OR_GENE_PRODUCT", 9, 14], ["Ub", "GENE_OR_GENE_PRODUCT", 160, 162], ["USP9X \u03b2-hairpin insertion", "DNA", 9, 34], ["Ub tail", "PROTEIN", 160, 167], ["A unique USP9X \u03b2-hairpin insertion", "TREATMENT", 0, 34], ["the insertion", "TREATMENT", 99, 112], ["USP9X \u03b2-hairpin", "OBSERVATION", 9, 24], ["loops", "ANATOMY_MODIFIER", 71, 76], ["Ub", "ANATOMY_MODIFIER", 160, 162], ["tail", "ANATOMY", 163, 167]]], ["Interestingly, a loop connecting helices \u03b14 and \u03b15, which corresponds to the switching loop of USP7 (6), is 2 aa longer than that of USP7, and protrudes into space otherwise occupied by the C-terminal activating tail in USP7 (SI Appendix, Fig. S1D).", [["C", "CHEMICAL", 190, 191], ["helices \u03b14", "GENE_OR_GENE_PRODUCT", 33, 43], ["\u03b15", "GENE_OR_GENE_PRODUCT", 48, 50], ["USP7 (6)", "GENE_OR_GENE_PRODUCT", 95, 103], ["USP7", "GENE_OR_GENE_PRODUCT", 133, 137], ["USP7", "GENE_OR_GENE_PRODUCT", 220, 224], ["loop connecting helices \u03b14", "PROTEIN", 17, 43], ["\u03b15", "PROTEIN", 48, 50], ["USP7 (6)", "PROTEIN", 95, 103], ["USP7", "PROTEIN", 133, 137], ["C-terminal activating tail", "PROTEIN", 190, 216], ["USP7", "PROTEIN", 220, 224], ["SI Appendix, Fig. S1D", "PROTEIN", 226, 247], ["a loop connecting helices \u03b1", "TREATMENT", 15, 42], ["USP7", "TEST", 133, 137], ["the C-terminal activating tail in USP7", "PROBLEM", 186, 224], ["loop", "OBSERVATION", 17, 21], ["loop", "OBSERVATION_MODIFIER", 87, 91], ["USP7", "OBSERVATION", 133, 137], ["terminal", "ANATOMY_MODIFIER", 192, 200], ["tail", "OBSERVATION_MODIFIER", 212, 216]]], ["The extension may exclude a regulatory mechanism similar to that of USP7 (6).Structure of the USP9X CD. ::: ResultsThe USP9X CD contains three large insertions in the sequence.", [["USP7", "GENE_OR_GENE_PRODUCT", 68, 72], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 119, 127], ["USP7 (6)", "PROTEIN", 68, 76], ["USP9X CD", "PROTEIN", 94, 102], ["USP9X CD", "DNA", 119, 127], ["a regulatory mechanism", "PROBLEM", 26, 48], ["USP7", "TEST", 68, 72], ["The USP9X CD", "TREATMENT", 115, 127], ["three large insertions in the sequence", "TREATMENT", 137, 175], ["may exclude", "UNCERTAINTY", 14, 25], ["USP9X CD", "OBSERVATION", 94, 102], ["USP9X CD", "OBSERVATION", 119, 127], ["three", "OBSERVATION_MODIFIER", 137, 142], ["large", "OBSERVATION_MODIFIER", 143, 148], ["insertions", "OBSERVATION_MODIFIER", 149, 159]]], ["Two of them are located at the common insertion points of the core domain (2).", [["common", "OBSERVATION_MODIFIER", 31, 37], ["insertion", "OBSERVATION_MODIFIER", 38, 47]]], ["A 39-aa insertion (1,593\u20131,631) between boxes 1 and 2 (helices \u03b12 and \u03b13), and a 22-aa insertion (1,838\u20131,859) between boxes 4 and 5 (helix \u03b18 and strand \u03b216) (Fig. 1A and SI Appendix, Fig. S2) cannot be traced in the electron density map and are presumably disordered.", [["\u03b12", "GENE_OR_GENE_PRODUCT", 63, 65], ["\u03b13", "GENE_OR_GENE_PRODUCT", 70, 72], ["39-aa insertion", "DNA", 2, 17], ["boxes 1 and 2", "DNA", 40, 53], ["helices \u03b12 and \u03b13", "DNA", 55, 72], ["22-aa insertion", "DNA", 81, 96], ["boxes 4 and 5", "DNA", 119, 132], ["helix \u03b18", "DNA", 134, 142], ["strand \u03b216", "DNA", 147, 157], ["S2", "PROTEIN", 190, 192], ["A 39-aa insertion", "TREATMENT", 0, 17], ["boxes", "TEST", 40, 45], ["a 22-aa insertion", "TREATMENT", 79, 96], ["boxes", "TEST", 119, 124], ["helix", "TEST", 134, 139], ["SI Appendix", "ANATOMY", 172, 183], ["Fig", "OBSERVATION_MODIFIER", 185, 188]]], ["The importance of these loops remains unclear, but a high percentage of negatively charged Asp and Glu residues in the \u03b12\u2013\u03b13 loop may be of significance.", [["Asp", "CHEMICAL", 91, 94], ["Glu", "CHEMICAL", 99, 102], ["Asp", "CHEMICAL", 91, 94], ["Glu", "CHEMICAL", 99, 102], ["Asp", "AMINO_ACID", 91, 94], ["Glu", "AMINO_ACID", 99, 102], ["\u03b12\u2013\u03b13", "GENE_OR_GENE_PRODUCT", 119, 124], ["\u03b12\u2013\u03b13 loop", "PROTEIN", 119, 129], ["Glu residues in the \u03b12\u2013\u03b13 loop", "PROBLEM", 99, 129], ["loops", "OBSERVATION", 24, 29], ["Glu residues", "OBSERVATION", 99, 111], ["\u03b12\u2013\u03b13 loop", "ANATOMY", 119, 129], ["may be of", "UNCERTAINTY", 130, 139]]], ["A third 20-aa insertion (1,924\u20131,943) between \u03b19 and \u03b222 within box 6 forms an unexpected \u03b2-hairpin structure in the palm subdomain of the USP fold.", [["\u03b19", "GENE_OR_GENE_PRODUCT", 46, 48], ["20-aa insertion", "DNA", 8, 23], ["\u03b19 and \u03b222 within box 6", "DNA", 46, 69], ["\u03b2-hairpin structure", "PROTEIN", 90, 109], ["palm subdomain", "PROTEIN", 117, 131], ["USP fold", "PROTEIN", 139, 147], ["A third 20-aa insertion", "TREATMENT", 0, 23], ["an unexpected \u03b2-hairpin structure", "PROBLEM", 76, 109], ["unexpected", "OBSERVATION_MODIFIER", 79, 89], ["\u03b2-hairpin structure", "OBSERVATION", 90, 109], ["palm", "ANATOMY_MODIFIER", 117, 121], ["USP fold", "OBSERVATION", 139, 147]]], ["Sequence alignment revealed the \u03b2-hairpin insertion is completely conserved among USP9X from different species, as well as in the related USP9Y, whereas the two other insertions are not (SI Appendix, Fig. S2).", [["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 32, 41], ["USP9X", "GENE_OR_GENE_PRODUCT", 82, 87], ["USP9Y", "GENE_OR_GENE_PRODUCT", 138, 143], ["\u03b2-hairpin insertion", "DNA", 32, 51], ["USP9X", "DNA", 82, 87], ["USP9Y", "DNA", 138, 143], ["S2", "PROTEIN", 205, 207], ["Sequence alignment", "TEST", 0, 18], ["the \u03b2-hairpin insertion", "TREATMENT", 28, 51], ["different", "OBSERVATION_MODIFIER", 93, 102], ["species", "OBSERVATION_MODIFIER", 103, 110]]], ["This suggests the \u03b2-hairpin insertion may be functionally important.", [["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 18, 27], ["\u03b2-hairpin insertion", "DNA", 18, 37], ["the \u03b2-hairpin insertion", "TREATMENT", 14, 37]]], ["Analysis of the evolutionary conservation profile of USP9X CD using ConSurf algorithm (27) indicates the active site, the Ub C-terminal tail binding region, and a patch of the fingers subdomain, are highly conserved (SI Appendix, Fig. S3).Structure of the USP9X CD. ::: ResultsA survey of USP domain structural features reveals the ZnF and \u03b2-hairpin insertion in USP9X may be functionally significant (SI Appendix, Fig. S4).", [["USP9X CD", "GENE_OR_GENE_PRODUCT", 53, 61], ["Ub", "GENE_OR_GENE_PRODUCT", 122, 124], ["ZnF", "GENE_OR_GENE_PRODUCT", 332, 335], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 340, 349], ["USP9X", "GENE_OR_GENE_PRODUCT", 363, 368], ["USP9X CD", "DNA", 53, 61], ["Ub C-terminal tail binding region", "PROTEIN", 122, 155], ["fingers subdomain", "PROTEIN", 176, 193], ["USP9X CD", "PROTEIN", 256, 264], ["USP domain", "PROTEIN", 289, 299], ["ZnF and \u03b2-hairpin insertion", "DNA", 332, 359], ["USP9X", "PROTEIN", 363, 368], ["USP9X CD", "TEST", 53, 61], ["ConSurf algorithm", "TEST", 68, 85], ["the active site", "PROBLEM", 101, 116], ["the Ub C-terminal tail binding region", "PROBLEM", 118, 155], ["a patch of the fingers subdomain", "TREATMENT", 161, 193], ["ResultsA survey of USP domain structural features", "TEST", 270, 319], ["the ZnF", "TREATMENT", 328, 335], ["\u03b2-hairpin insertion in USP9X", "TREATMENT", 340, 368], ["active site", "OBSERVATION", 105, 116], ["Ub", "ANATOMY_MODIFIER", 122, 124], ["C-terminal tail", "ANATOMY", 125, 140], ["fingers", "ANATOMY", 176, 183], ["subdomain", "ANATOMY_MODIFIER", 184, 193], ["SI Appendix", "OBSERVATION", 217, 228], ["Fig", "OBSERVATION_MODIFIER", 230, 233], ["USP9X CD", "OBSERVATION", 256, 264], ["may be", "UNCERTAINTY", 369, 375], ["significant", "OBSERVATION_MODIFIER", 389, 400], ["SI Appendix", "OBSERVATION", 402, 413]]], ["Both USP9X and the K63 and M1 dual-specific USP, CYLD, have a large insertion within sequence box 6.", [["USP9X", "GENE_OR_GENE_PRODUCT", 5, 10], ["K63", "GENE_OR_GENE_PRODUCT", 19, 22], ["USP", "GENE_OR_GENE_PRODUCT", 44, 47], ["CYLD", "GENE_OR_GENE_PRODUCT", 49, 53], ["USP9X", "PROTEIN", 5, 10], ["K63", "PROTEIN", 19, 22], ["M1", "PROTEIN", 27, 29], ["USP", "PROTEIN", 44, 47], ["CYLD", "PROTEIN", 49, 53], ["sequence box 6", "DNA", 85, 99], ["USP9X", "TEST", 5, 10], ["the K63", "TEST", 15, 22], ["a large insertion within sequence box", "TREATMENT", 60, 97], ["large", "OBSERVATION_MODIFIER", 62, 67], ["insertion", "OBSERVATION", 68, 77]]], ["The insertion in CYLD forms helices/bend structural elements (28) located next to the two blocking loops and also extends a \u03b2-hairpin in the palm subdomain that contributes to proximal Ub recognition (8).", [["CYLD", "GENE_OR_GENE_PRODUCT", 17, 21], ["Ub", "GENE_OR_GENE_PRODUCT", 185, 187], ["CYLD", "PROTEIN", 17, 21], ["\u03b2-hairpin", "PROTEIN", 124, 133], ["palm subdomain", "PROTEIN", 141, 155], ["Ub", "PROTEIN", 185, 187], ["The insertion in CYLD forms helices/bend structural elements", "TREATMENT", 0, 60], ["a \u03b2-hairpin in the palm subdomain", "PROBLEM", 122, 155], ["insertion", "OBSERVATION_MODIFIER", 4, 13], ["loops", "OBSERVATION", 99, 104], ["palm", "ANATOMY_MODIFIER", 141, 145], ["proximal", "ANATOMY_MODIFIER", 176, 184], ["Ub", "ANATOMY_MODIFIER", 185, 187]]], ["Similarly, the insertion in USP9X may also be involved in polyUb chain specificity.", [["USP9X", "GENE_OR_GENE_PRODUCT", 28, 33], ["polyUb chain", "GENE_OR_GENE_PRODUCT", 58, 70], ["USP9X", "DNA", 28, 33], ["polyUb chain", "PROTEIN", 58, 70], ["the insertion in USP9X", "TREATMENT", 11, 33], ["insertion", "OBSERVATION_MODIFIER", 15, 24], ["may also be involved", "UNCERTAINTY", 34, 54]]], ["Furthermore, the fingers subdomain of some USPs is known to bind to a distal Ub of a polyUb chain, as shown in the USP21-linear diUb complex (9).", [["USPs", "GENE_OR_GENE_PRODUCT", 43, 47], ["Ub", "GENE_OR_GENE_PRODUCT", 77, 79], ["fingers subdomain", "PROTEIN", 17, 34], ["USPs", "PROTEIN", 43, 47], ["distal Ub", "PROTEIN", 70, 79], ["polyUb chain", "PROTEIN", 85, 97], ["USP21", "PROTEIN", 115, 120], ["diUb complex", "PROTEIN", 128, 140], ["some USPs", "PROBLEM", 38, 47], ["fingers", "ANATOMY", 17, 24], ["some", "OBSERVATION_MODIFIER", 38, 42], ["USPs", "OBSERVATION", 43, 47], ["distal", "ANATOMY_MODIFIER", 70, 76], ["Ub", "ANATOMY_MODIFIER", 77, 79], ["polyUb", "ANATOMY", 85, 91], ["chain", "ANATOMY_MODIFIER", 92, 97]]], ["Based on structural modeling and comparison with other USPs, we postulate that the USP9X CD may harbor three Ub binding sites (S2, S1, and S1\u2032) (Fig. 1B) and cleave a polyUb chain linkage-dependently.DUB Activity of USP9X. ::: ResultsWe first measured the DUB activity of USP9X CD against fluorogenic 7-amido-4-methylcoumarin (AMC)-derived Ub and Ub-like modifiers (UBLs).", [["USP9X", "CHEMICAL", 272, 277], ["7-amido-4-methylcoumarin", "CHEMICAL", 301, 325], ["AMC", "CHEMICAL", 327, 330], ["7-amido-4-methylcoumarin", "CHEMICAL", 301, 325], ["AMC", "CHEMICAL", 327, 330], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 83, 91], ["Ub", "GENE_OR_GENE_PRODUCT", 109, 111], ["Fig. 1B", "GENE_OR_GENE_PRODUCT", 145, 152], ["DUB", "GENE_OR_GENE_PRODUCT", 200, 203], ["USP9X", "GENE_OR_GENE_PRODUCT", 216, 221], ["DUB", "GENE_OR_GENE_PRODUCT", 256, 259], ["USP9X CD", "SIMPLE_CHEMICAL", 272, 280], ["fluorogenic 7-amido-4-methylcoumarin", "SIMPLE_CHEMICAL", 289, 325], ["AMC", "SIMPLE_CHEMICAL", 327, 330], [")-derived Ub", "SIMPLE_CHEMICAL", 330, 342], ["Ub-like modifiers", "SIMPLE_CHEMICAL", 347, 364], ["USPs", "PROTEIN", 55, 59], ["USP9X CD", "DNA", 83, 91], ["Ub binding sites", "DNA", 109, 125], ["S2", "PROTEIN", 127, 129], ["S1", "PROTEIN", 131, 133], ["polyUb chain", "PROTEIN", 167, 179], ["DUB", "PROTEIN", 200, 203], ["USP9X", "PROTEIN", 216, 221], ["DUB", "PROTEIN", 256, 259], ["Ub", "PROTEIN", 340, 342], ["Ub", "PROTEIN", 347, 349], ["other USPs", "TEST", 49, 59], ["S2", "TEST", 127, 129], ["S1", "TEST", 131, 133], ["fluorogenic", "TEST", 289, 300], ["amido", "TEST", 303, 308], ["methylcoumarin (AMC)", "TREATMENT", 311, 331], ["binding sites", "OBSERVATION", 112, 125], ["S1", "ANATOMY", 131, 133], ["S1", "ANATOMY", 139, 141], ["dependently", "OBSERVATION_MODIFIER", 188, 199]]], ["Unlike some other USPs that show cross-activities toward UBLs, such as SUMO and ISG15 (29, 30), USP9X is only active toward Ub, with no measurable activity for SUMO1-, NEDD8-, or ISG15-AMC (Fig. 1D).", [["USPs", "GENE_OR_GENE_PRODUCT", 18, 22], ["UBLs", "GENE_OR_GENE_PRODUCT", 57, 61], ["SUMO", "GENE_OR_GENE_PRODUCT", 71, 75], ["ISG15", "GENE_OR_GENE_PRODUCT", 80, 85], ["USP9X", "GENE_OR_GENE_PRODUCT", 96, 101], ["Ub", "GENE_OR_GENE_PRODUCT", 124, 126], ["SUMO1", "GENE_OR_GENE_PRODUCT", 160, 165], ["NEDD8", "GENE_OR_GENE_PRODUCT", 168, 173], ["ISG15", "GENE_OR_GENE_PRODUCT", 179, 184], ["USPs", "PROTEIN", 18, 22], ["UBLs", "PROTEIN", 57, 61], ["SUMO", "PROTEIN", 71, 75], ["ISG15", "PROTEIN", 80, 85], ["USP9X", "PROTEIN", 96, 101], ["Ub", "PROTEIN", 124, 126], ["SUMO1", "PROTEIN", 160, 165], ["NEDD8", "PROTEIN", 168, 173], ["ISG15", "PROTEIN", 179, 184], ["AMC", "PROTEIN", 185, 188], ["some other USPs", "PROBLEM", 7, 22], ["cross-activities toward UBLs", "PROBLEM", 33, 61], ["ISG15", "TEST", 80, 85], ["USP9X", "TEST", 96, 101], ["SUMO1", "TEST", 160, 165], ["NEDD8", "TEST", 168, 173], ["ISG15", "TEST", 179, 184]]], ["Using the Ub-AMC substrate, we determined the kinetic parameters for USP9X CD with kcat = 0.25 \u00b1 0.01 min\u22121 and Km = 0.10 \u00b1 0.02 \u00b5M (SI Appendix, Fig. S5A and Table S1).", [["USP9X CD", "CHEMICAL", 69, 77], ["Ub", "GENE_OR_GENE_PRODUCT", 10, 12], ["Ub", "PROTEIN", 10, 12], ["the kinetic parameters", "TEST", 42, 64], ["USP9X CD", "TEST", 69, 77], ["kcat", "TEST", 83, 87], ["Km", "TEST", 112, 114]]], ["The kcat and Km of USP9X CD are vastly different from those of the USP7 CD (kcat = 4.6 min\u22121 and Km = 44.2 \u00b5M) (31).", [["USP9X CD", "CHEMICAL", 19, 27], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 19, 27], ["USP7", "GENE_OR_GENE_PRODUCT", 67, 71], ["USP9X CD", "PROTEIN", 19, 27], ["USP7 CD", "PROTEIN", 67, 74], ["The kcat", "TEST", 0, 8], ["USP9X CD", "TEST", 19, 27], ["kcat", "TEST", 76, 80], ["Km", "TEST", 97, 99]]], ["The specificity constant (kcat/Km) of USP9X (2.5 min\u22121\u00b5M\u22121) is 25-fold higher than that of USP7 CD (0.10 min\u22121\u00b5M\u22121).", [["USP9X", "CHEMICAL", 38, 43], ["USP7", "GENE_OR_GENE_PRODUCT", 91, 95], ["USP7", "PROTEIN", 91, 95], ["The specificity", "TEST", 0, 15], ["USP9X", "TEST", 38, 43], ["USP7 CD", "TEST", 91, 98]]], ["We next assessed the activity of USP9X CD toward eight diUb substrates of different linkages.", [["USP9X CD", "GENE_OR_GENE_PRODUCT", 33, 41], ["USP9X CD", "PROTEIN", 33, 41]]], ["USP9X CD displayed various cleavage efficiencies, with a preference for K11-, K63-, K48-, and K6-linkages (Fig. 1E and SI Appendix, Fig. S5B).", [["USP9X", "CHEMICAL", 0, 5], ["K11", "CHEMICAL", 72, 75], ["USP9X", "GENE_OR_GENE_PRODUCT", 0, 5], ["K11", "GENE_OR_GENE_PRODUCT", 72, 75], ["K63", "SIMPLE_CHEMICAL", 78, 81], ["K48", "SIMPLE_CHEMICAL", 84, 87], ["K6-linkages", "SIMPLE_CHEMICAL", 94, 105], ["USP9X CD", "PROTEIN", 0, 8], ["K11", "PROTEIN", 72, 75], ["K6", "PROTEIN", 94, 96], ["various cleavage efficiencies", "PROBLEM", 19, 48], ["K11", "TEST", 72, 75], ["K63", "TEST", 78, 81], ["K48", "TEST", 84, 87], ["cleavage efficiencies", "OBSERVATION", 27, 48], ["SI Appendix", "ANATOMY", 119, 130]]], ["Low level of cleavage was observed for K27-, K29-, and K33-diUbs and no cleavage observed for M1-linked diUb (Fig. 1E).", [["K27", "GENE_OR_GENE_PRODUCT", 39, 42], ["K29", "GENE_OR_GENE_PRODUCT", 45, 48], ["K33-diUbs", "GENE_OR_GENE_PRODUCT", 55, 64], ["K27", "PROTEIN", 39, 42], ["K29", "PROTEIN", 45, 48], ["K33", "PROTEIN", 55, 58], ["diUbs", "PROTEIN", 59, 64], ["M1", "PROTEIN", 94, 96], ["diUb", "PROTEIN", 104, 108], ["Fig. 1E", "PROTEIN", 110, 117], ["Low level of cleavage", "PROBLEM", 0, 21], ["K27", "TEST", 39, 42], ["K29", "TEST", 45, 48], ["K33", "TEST", 55, 58], ["cleavage", "PROBLEM", 72, 80]]], ["We further assessed the cleavage of K6-, K11-, K63-, K48-linked tetraUb substrates and observed that K11-linked tetraUb was processed more efficiently than K63- or K48-linked chains, with poor cleavage of K6-linked tetraUb (SI Appendix, Fig. S5C).PolyUb Probes for Interrogating USPs. ::: ResultsABPs capture DUBs in action.", [["K6", "GENE_OR_GENE_PRODUCT", 36, 38], ["K11", "GENE_OR_GENE_PRODUCT", 41, 44], ["K63", "GENE_OR_GENE_PRODUCT", 47, 50], ["K48", "SIMPLE_CHEMICAL", 53, 56], ["tetraUb", "GENE_OR_GENE_PRODUCT", 64, 71], ["K11", "GENE_OR_GENE_PRODUCT", 101, 104], ["tetraUb", "GENE_OR_GENE_PRODUCT", 112, 119], ["K63", "SIMPLE_CHEMICAL", 156, 159], ["K6", "GENE_OR_GENE_PRODUCT", 205, 207], ["ResultsABPs", "SIMPLE_CHEMICAL", 289, 300], ["DUBs", "GENE_OR_GENE_PRODUCT", 309, 313], ["K6", "PROTEIN", 36, 38], ["K11", "PROTEIN", 41, 44], ["K63", "PROTEIN", 47, 50], ["K48", "PROTEIN", 53, 56], ["tetraUb substrates", "PROTEIN", 64, 82], ["K11", "PROTEIN", 101, 104], ["tetraUb", "PROTEIN", 112, 119], ["K63", "PROTEIN", 156, 159], ["K48", "PROTEIN", 164, 167], ["K6", "PROTEIN", 205, 207], ["tetraUb", "PROTEIN", 215, 222], ["SI Appendix", "PROTEIN", 224, 235], ["S5C", "PROTEIN", 242, 245], ["PolyUb Probes", "PROTEIN", 247, 260], ["ResultsABPs", "PROTEIN", 289, 300], ["DUBs", "PROTEIN", 309, 313], ["K6", "TEST", 36, 38], ["K11", "TEST", 41, 44], ["K63", "TEST", 47, 50], ["K11", "TEST", 101, 104], ["K63", "TEST", 156, 159], ["K48-linked chains", "PROBLEM", 164, 181], ["poor cleavage of K6", "PROBLEM", 188, 207], ["DUBs", "OBSERVATION", 309, 313]]], ["To study the three potential binding sites of USP9X, we generated a set of ABPs.", [["USP9X", "GENE_OR_GENE_PRODUCT", 46, 51], ["ABPs", "GENE_OR_GENE_PRODUCT", 75, 79], ["USP9X", "PROTEIN", 46, 51], ["ABPs", "PROTEIN", 75, 79], ["ABPs", "TEST", 75, 79]]], ["We systematically name the ABPs based on the chemical bond subjected to DUB cleavage, which can be a cleavable native peptide bond (CL), a noncleavable linker (NC), a Michael acceptor (MA) warhead, or the abbreviation of a specific reactive group, followed by a number to indicate the location of the bond of interest.", [["DUB", "GENE_OR_GENE_PRODUCT", 72, 75], ["CL", "SIMPLE_CHEMICAL", 132, 134], ["Michael acceptor", "SIMPLE_CHEMICAL", 167, 183], ["DUB", "PROTEIN", 72, 75], ["the ABPs", "TEST", 23, 31], ["DUB cleavage", "PROBLEM", 72, 84], ["a noncleavable linker (NC", "TREATMENT", 137, 162], ["a Michael acceptor", "TREATMENT", 165, 183]]], ["We previously reported K48- and K63-diUb probes with an internal MA (32), which are now denoted K48- or K63-diUb-MA1.", [["K48", "GENE_OR_GENE_PRODUCT", 23, 26], ["K48", "GENE_OR_GENE_PRODUCT", 96, 99], ["K48- and K63-diUb probes", "DNA", 23, 47], ["K48", "PROTEIN", 96, 99], ["K63", "DNA", 104, 107], ["diUb", "DNA", 108, 112], ["MA1", "DNA", 113, 116], ["K48", "TEST", 23, 26], ["K63", "TEST", 32, 35], ["K48", "TEST", 96, 99], ["K63", "TEST", 104, 107]]], ["In this study, we additionally generated K6- and K11-diUb-MA1 ABPs (SI Appendix, Fig. S6).", [["K6", "GENE_OR_GENE_PRODUCT", 41, 43], ["S6", "GENE_OR_GENE_PRODUCT", 86, 88], ["K6", "PROTEIN", 41, 43], ["K11", "PROTEIN", 49, 52], ["diUb", "PROTEIN", 53, 57], ["S6", "PROTEIN", 86, 88], ["this study", "TEST", 3, 13], ["K6", "TEST", 41, 43], ["K11", "TEST", 49, 52], ["diUb", "TEST", 53, 57], ["Appendix", "ANATOMY", 71, 79]]], ["These diUb-MA1 ABPs interrogate the Ub binding to the S1 site and a potential S1\u2032 (proximal) site in the DUB catalytic core.", [["diUb-MA1", "GENE_OR_GENE_PRODUCT", 6, 14], ["Ub", "GENE_OR_GENE_PRODUCT", 36, 38], ["DUB", "GENE_OR_GENE_PRODUCT", 105, 108], ["diUb-MA1 ABPs", "DNA", 6, 19], ["Ub", "PROTEIN", 36, 38], ["S1 site", "DNA", 54, 61], ["S1\u2032 (proximal) site", "DNA", 78, 97], ["DUB catalytic core", "DNA", 105, 123], ["These diUb", "TEST", 0, 10], ["a potential S1\u2032 (proximal) site", "PROBLEM", 66, 97], ["S1", "ANATOMY", 54, 56], ["proximal", "OBSERVATION_MODIFIER", 83, 91], ["DUB", "OBSERVATION", 105, 108]]], ["To probe the Ub binding at a potential S2 site in DUBs, we prepared K6-, K11-, K48-, and K63-linked diUb probes that contain an NC linker (33) and a terminal propargylamine (PA) warhead (diUb-NC1-PA2) (Fig. 2A and SI Appendix, Fig. S6).", [["propargylamine", "CHEMICAL", 158, 172], ["propargylamine", "CHEMICAL", 158, 172], ["Ub", "GENE_OR_GENE_PRODUCT", 13, 15], ["DUBs", "GENE_OR_GENE_PRODUCT", 50, 54], ["K6", "GENE_OR_GENE_PRODUCT", 68, 70], ["K11", "SIMPLE_CHEMICAL", 73, 76], ["K48", "SIMPLE_CHEMICAL", 79, 82], ["K63", "SIMPLE_CHEMICAL", 89, 92], ["propargylamine", "SIMPLE_CHEMICAL", 158, 172], ["PA", "SIMPLE_CHEMICAL", 174, 176], ["S6", "GENE_OR_GENE_PRODUCT", 232, 234], ["Ub", "PROTEIN", 13, 15], ["S2 site", "DNA", 39, 46], ["DUBs", "PROTEIN", 50, 54], ["K6-, K11-, K48-, and K63-linked diUb probes", "DNA", 68, 111], ["diUb", "PROTEIN", 187, 191], ["NC1", "PROTEIN", 192, 195], ["PA2", "PROTEIN", 196, 199], ["S6", "PROTEIN", 232, 234], ["K6", "TEST", 68, 70], ["K11", "TEST", 73, 76], ["K48", "TEST", 79, 82], ["K63", "TEST", 89, 92], ["an NC linker", "TREATMENT", 125, 137], ["a terminal propargylamine", "TEST", 147, 172], ["diUb", "TEST", 187, 191], ["NC1", "TEST", 192, 195], ["SI Appendix", "ANATOMY", 214, 225]]], ["For enzymatic kinetics quantification, we generated fluorogenic AMC derivatives of diUbs (diUb-NC1-AMC2) (Fig. 2A and SI Appendix, Fig. S7).PolyUb Probes for Interrogating USPs. ::: ResultsWe also designed and synthesized two classes of hybrid triUb probes (Fig. 2B and SI Appendix, Fig. S8) (see Methods for details).", [["diUbs", "SIMPLE_CHEMICAL", 83, 88], ["S7", "GENE_OR_GENE_PRODUCT", 136, 138], ["triUb", "GENE_OR_GENE_PRODUCT", 244, 249], ["diUbs", "PROTEIN", 83, 88], ["diUb", "PROTEIN", 90, 94], ["NC1", "PROTEIN", 95, 98], ["AMC2", "PROTEIN", 99, 103], ["S7", "PROTEIN", 136, 138], ["PolyUb Probes", "PROTEIN", 140, 153], ["enzymatic kinetics quantification", "PROBLEM", 4, 37], ["fluorogenic AMC derivatives", "TREATMENT", 52, 79], ["diUbs", "TEST", 83, 88], ["hybrid triUb probes", "TREATMENT", 237, 256], ["SI Appendix", "ANATOMY", 118, 129], ["SI Appendix", "ANATOMY", 270, 281]]], ["TriUb-NC1-CL2 (Fig. 2B) ensures that DUB-catalyzed cleavage only occurs when the middle Ub binds to the DUB S1 site, while the distal and proximal Ubs occupy the potential S2 and S1\u2032 sites, respectively.", [["TriUb-NC1-CL2 (Fig. 2B", "GENE_OR_GENE_PRODUCT", 0, 22], ["DUB", "GENE_OR_GENE_PRODUCT", 37, 40], ["Ub", "GENE_OR_GENE_PRODUCT", 88, 90], ["DUB S1", "GENE_OR_GENE_PRODUCT", 104, 110], ["Ubs", "GENE_OR_GENE_PRODUCT", 147, 150], ["TriUb", "PROTEIN", 0, 5], ["NC1", "PROTEIN", 6, 9], ["CL2", "PROTEIN", 10, 13], ["Fig. 2B", "PROTEIN", 15, 22], ["DUB", "PROTEIN", 37, 40], ["middle Ub", "PROTEIN", 81, 90], ["DUB S1 site", "DNA", 104, 115], ["distal and proximal Ubs", "DNA", 127, 150], ["potential S2 and S1\u2032 sites", "DNA", 162, 188], ["TriUb", "TEST", 0, 5], ["DUB-catalyzed cleavage", "TREATMENT", 37, 59], ["middle", "ANATOMY_MODIFIER", 81, 87], ["DUB S1", "ANATOMY", 104, 110], ["distal", "ANATOMY_MODIFIER", 127, 133], ["proximal", "ANATOMY_MODIFIER", 138, 146], ["potential S2", "OBSERVATION", 162, 174], ["S1", "ANATOMY", 179, 181]]], ["TriUb-MA1-CL2 (Fig. 2B) differentiates two binding modes in one assay.", [["TriUb-MA1-CL2", "CHEMICAL", 0, 13], ["Fig. 2B", "GENE_OR_GENE_PRODUCT", 15, 22], ["TriUb", "PROTEIN", 0, 5], ["MA1", "PROTEIN", 6, 9], ["CL2", "PROTEIN", 10, 13], ["Fig. 2B", "PROTEIN", 15, 22], ["TriUb", "TEST", 0, 5]]], ["If the DUB S1 site engages the middle Ub of a triUb-MA1-CL2, we expect a cleavage at the native isopeptide bond to produce a diUb-MA1 and a Ub.", [["DUB S1", "GENE_OR_GENE_PRODUCT", 7, 13], ["Ub", "GENE_OR_GENE_PRODUCT", 38, 40], ["diUb-MA1", "GENE_OR_GENE_PRODUCT", 125, 133], ["DUB S1 site", "DNA", 7, 18], ["middle Ub", "PROTEIN", 31, 40], ["triUb", "PROTEIN", 46, 51], ["MA1", "PROTEIN", 52, 55], ["CL2", "PROTEIN", 56, 59], ["diUb", "PROTEIN", 125, 129], ["MA1", "PROTEIN", 130, 133], ["the DUB S1 site", "PROBLEM", 3, 18], ["a cleavage", "PROBLEM", 71, 81], ["DUB", "ANATOMY", 7, 10], ["S1", "ANATOMY_MODIFIER", 11, 13], ["middle", "ANATOMY_MODIFIER", 31, 37]]], ["If the DUB S1 site engages the distal Ub, we expect labeling of the DUB active site cysteine by the probe\u2019s MA that gives a triUb conjugated product.", [["cysteine", "CHEMICAL", 84, 92], ["DUB S1", "GENE_OR_GENE_PRODUCT", 7, 13], ["Ub", "GENE_OR_GENE_PRODUCT", 38, 40], ["DUB", "GENE_OR_GENE_PRODUCT", 68, 71], ["cysteine", "AMINO_ACID", 84, 92], ["DUB S1 site", "DNA", 7, 18], ["distal Ub", "PROTEIN", 31, 40], ["DUB active site", "PROTEIN", 68, 83], ["triUb conjugated product", "PROTEIN", 124, 148], ["the DUB S1 site", "PROBLEM", 3, 18], ["the DUB active site cysteine", "TREATMENT", 64, 92], ["a triUb conjugated product", "TREATMENT", 122, 148], ["DUB", "ANATOMY", 7, 10], ["S1", "ANATOMY_MODIFIER", 11, 13], ["distal", "OBSERVATION_MODIFIER", 31, 37], ["DUB", "ANATOMY", 68, 71]]], ["These ABPs were synthesized and the identity characterized by mass spectrometry (SI Appendix, Fig. S8).The USP9X Zinc-Finger Is a Crucial Structural Motif. ::: ResultsA ZnF motif in the fingers subdomain is found in many USPs, although its function is not entirely clear.", [["USPs", "ANATOMY", 221, 225], ["ABPs", "SIMPLE_CHEMICAL", 6, 10], ["S8", "GENE_OR_GENE_PRODUCT", 99, 101], ["ZnF", "GENE_OR_GENE_PRODUCT", 169, 172], ["USPs", "GENE_OR_GENE_PRODUCT", 221, 225], ["ABPs", "PROTEIN", 6, 10], ["S8", "PROTEIN", 99, 101], ["Crucial Structural Motif", "PROTEIN", 130, 154], ["ZnF motif", "PROTEIN", 169, 178], ["fingers subdomain", "PROTEIN", 186, 203], ["USPs", "PROTEIN", 221, 225], ["These ABPs", "TEST", 0, 10], ["mass spectrometry", "PROBLEM", 62, 79], ["mass", "OBSERVATION", 62, 66], ["not entirely", "UNCERTAINTY", 252, 264], ["clear", "OBSERVATION", 265, 270]]], ["The ZnF of USP21 is important for binding the distal Ub in a linear diUb (SI Appendix, Fig. S9A) as well as the distal UBL domain in ISG15 (9).", [["USP21", "CHEMICAL", 11, 16], ["ZnF", "GENE_OR_GENE_PRODUCT", 4, 7], ["USP21", "GENE_OR_GENE_PRODUCT", 11, 16], ["Ub", "GENE_OR_GENE_PRODUCT", 53, 55], ["S9A", "GENE_OR_GENE_PRODUCT", 92, 95], ["ISG15", "GENE_OR_GENE_PRODUCT", 133, 138], ["ZnF", "PROTEIN", 4, 7], ["USP21", "PROTEIN", 11, 16], ["distal Ub", "PROTEIN", 46, 55], ["S9A", "PROTEIN", 92, 95], ["distal UBL domain", "PROTEIN", 112, 129], ["ISG15 (9)", "PROTEIN", 133, 142], ["The ZnF of USP21", "TREATMENT", 0, 16], ["the distal UBL domain in ISG15", "TREATMENT", 108, 138], ["distal", "ANATOMY_MODIFIER", 46, 52], ["Ub", "ANATOMY_MODIFIER", 53, 55], ["SI Appendix", "ANATOMY", 74, 85], ["distal", "ANATOMY_MODIFIER", 112, 118]]], ["To evaluate the role of the ZnF of USP9X, we mutated residues chelating the zinc ion, C1727A, or H1729A, and measured their activities.The USP9X Zinc-Finger Is a Crucial Structural Motif. ::: ResultsFor Ub-AMC substrate, the C1727A and H1729A mutants showed a five- and sevenfold increase in Km compared with WT, respectively, without substantial change in kcat (SI Appendix, Fig. S9B and Table S1).", [["zinc", "CHEMICAL", 76, 80], ["Zinc", "CHEMICAL", 145, 149], ["K", "CHEMICAL", 292, 293], ["zinc", "CHEMICAL", 76, 80], ["Zinc", "CHEMICAL", 145, 149], ["ZnF", "GENE_OR_GENE_PRODUCT", 28, 31], ["USP9X", "GENE_OR_GENE_PRODUCT", 35, 40], ["Ub", "GENE_OR_GENE_PRODUCT", 203, 205], ["Km", "GENE_OR_GENE_PRODUCT", 292, 294], ["Table S1", "GENE_OR_GENE_PRODUCT", 389, 397], ["ZnF", "PROTEIN", 28, 31], ["USP9X", "PROTEIN", 35, 40], ["Crucial Structural Motif", "PROTEIN", 162, 186], ["Ub", "PROTEIN", 203, 205], ["C1727A and H1729A mutants", "PROTEIN", 225, 250], ["S9B", "PROTEIN", 381, 384], ["the ZnF of USP9X", "TREATMENT", 24, 40], ["Ub", "TEST", 203, 205], ["sevenfold increase in Km", "PROBLEM", 270, 294], ["WT", "TEST", 309, 311], ["substantial change in kcat (SI Appendix", "PROBLEM", 335, 374], ["Finger", "ANATOMY", 150, 156], ["increase", "OBSERVATION_MODIFIER", 280, 288], ["without", "UNCERTAINTY", 327, 334], ["substantial", "OBSERVATION_MODIFIER", 335, 346], ["change", "OBSERVATION", 347, 353], ["Appendix", "ANATOMY", 366, 374]]], ["We next used internally quenched fluorescence (IQF)-diUb substrates of K11- and K63-linkage to monitor the continuous isopeptide cleavage and observed reduced cleavage activity of the C1727A mutant (SI Appendix, Fig. S9C), again supporting the importance of the ZnF in the S1 site Ub binding.", [["K11", "SIMPLE_CHEMICAL", 71, 74], ["K63", "SIMPLE_CHEMICAL", 80, 83], ["ZnF", "GENE_OR_GENE_PRODUCT", 262, 265], ["Ub", "GENE_OR_GENE_PRODUCT", 281, 283], ["K11", "PROTEIN", 71, 74], ["K63", "PROTEIN", 80, 83], ["C1727A mutant", "PROTEIN", 184, 197], ["Fig. S9C", "PROTEIN", 212, 220], ["ZnF", "PROTEIN", 262, 265], ["Ub", "PROTEIN", 281, 283], ["K11", "TEST", 71, 74], ["K63", "TREATMENT", 80, 83], ["the continuous isopeptide cleavage", "TREATMENT", 103, 137], ["reduced cleavage activity", "PROBLEM", 151, 176], ["S1", "ANATOMY", 273, 275]]], ["This is also consistent with the reduced labeling of the ZnF mutants by monoUb-based ABP (SI Appendix, Fig. S10A).The USP9X Zinc-Finger Is a Crucial Structural Motif. ::: ResultsTo measure the effect of the ZnF on S2-S1 diUb binding, we interrogated the USP9X CD using diUb-NC1-PA2 (Fig. 2A) and observed reduced labeling of the ZnF mutants compared with WT at a single time point (2 h) by K6-, K11-, and K48-probes, but with little change for the K63-linked probe (SI Appendix, Fig. S10B).", [["Zinc", "CHEMICAL", 124, 128], ["Zinc", "CHEMICAL", 124, 128], ["ZnF", "CHEMICAL", 207, 210], ["ZnF", "GENE_OR_GENE_PRODUCT", 57, 60], ["monoUb", "SIMPLE_CHEMICAL", 72, 78], ["ZnF", "SIMPLE_CHEMICAL", 207, 210], ["diUb", "GENE_OR_GENE_PRODUCT", 220, 224], ["diUb-NC1", "GENE_OR_GENE_PRODUCT", 269, 277], ["ZnF", "GENE_OR_GENE_PRODUCT", 329, 332], ["K6", "GENE_OR_GENE_PRODUCT", 390, 392], ["K11", "GENE_OR_GENE_PRODUCT", 395, 398], ["ZnF mutants", "PROTEIN", 57, 68], ["monoUb", "PROTEIN", 72, 78], ["ABP", "PROTEIN", 85, 88], ["Fig. S10A", "PROTEIN", 103, 112], ["Crucial Structural Motif", "PROTEIN", 141, 165], ["ZnF", "PROTEIN", 207, 210], ["S2", "PROTEIN", 214, 216], ["diUb", "PROTEIN", 220, 224], ["USP9X CD", "DNA", 254, 262], ["diUb", "PROTEIN", 269, 273], ["NC1", "PROTEIN", 274, 277], ["PA2", "PROTEIN", 278, 281], ["ZnF mutants", "PROTEIN", 329, 340], ["K6-, K11-, and K48-probes", "DNA", 390, 415], ["K63", "PROTEIN", 448, 451], ["monoUb", "TEST", 72, 78], ["the USP9X CD", "TEST", 250, 262], ["diUb", "TEST", 269, 273], ["NC1", "TEST", 274, 277], ["the ZnF mutants", "PROBLEM", 325, 340], ["WT", "TEST", 355, 357], ["K6", "TEST", 390, 392], ["K11", "TEST", 395, 398], ["K48", "TEST", 405, 408], ["the K63", "TEST", 444, 451], ["consistent with", "UNCERTAINTY", 13, 28], ["reduced", "OBSERVATION_MODIFIER", 33, 40], ["Finger", "ANATOMY", 129, 135]]], ["The results show a clear reduction in the labeling efficiency for the K11-diUb-NC1-PA2 probe but little change for the K63-diUb probe (SI Appendix, Fig. S10C).", [["K11", "PROTEIN", 70, 73], ["diUb", "PROTEIN", 74, 78], ["NC1", "PROTEIN", 79, 82], ["PA2", "PROTEIN", 83, 86], ["K63-diUb probe", "DNA", 119, 133], ["the labeling efficiency", "PROBLEM", 38, 61], ["the K11", "TEST", 66, 73], ["NC1", "TREATMENT", 79, 82], ["PA2 probe", "TREATMENT", 83, 92], ["the K63", "TEST", 115, 122], ["clear", "OBSERVATION_MODIFIER", 19, 24], ["reduction", "OBSERVATION_MODIFIER", 25, 34], ["labeling efficiency", "OBSERVATION", 42, 61]]], ["These results reveal that the ZnF in USP9X plays an important role in chain linkage-specific recognition of diUb.Role of the USP9X \u03b2-Hairpin Insertion on Catalysis. ::: ResultsAn insertion in CYLD sequence box 6 is important for the recognition of the proximal Ub in M1- and K63-diUbs (8).", [["ZnF", "CHEMICAL", 30, 33], ["USP9X", "CHEMICAL", 37, 42], ["ZnF", "GENE_OR_GENE_PRODUCT", 30, 33], ["USP9X", "GENE_OR_GENE_PRODUCT", 37, 42], ["diUb", "GENE_OR_GENE_PRODUCT", 108, 112], ["CYLD", "GENE_OR_GENE_PRODUCT", 192, 196], ["Ub", "GENE_OR_GENE_PRODUCT", 261, 263], ["ZnF", "PROTEIN", 30, 33], ["USP9X", "PROTEIN", 37, 42], ["diUb", "PROTEIN", 108, 112], ["CYLD sequence box 6", "DNA", 192, 211], ["proximal Ub", "PROTEIN", 252, 263], ["M1", "PROTEIN", 267, 269], ["K63", "DNA", 275, 278], ["the ZnF in USP9X", "TREATMENT", 26, 42], ["Hairpin Insertion on Catalysis", "TREATMENT", 133, 163], ["ResultsAn insertion in CYLD sequence box", "TREATMENT", 169, 209], ["K63", "TEST", 275, 278], ["Hairpin Insertion", "OBSERVATION", 133, 150], ["proximal", "ANATOMY_MODIFIER", 252, 260], ["Ub", "ANATOMY_MODIFIER", 261, 263], ["M1", "ANATOMY", 267, 269]]], ["The insertion in box 6 of the USP9X CD could play a similar role.", [["USP9X CD", "GENE_OR_GENE_PRODUCT", 30, 38], ["box 6", "DNA", 17, 22], ["USP9X CD", "DNA", 30, 38], ["The insertion in box", "TREATMENT", 0, 20], ["insertion", "OBSERVATION_MODIFIER", 4, 13]]], ["Unlike the CYLD insertion that is partially disordered in the apo structure and induced into an extended \u03b2-hairpin upon substrate binding (8, 28), the USP9X \u03b2-hairpin insertion is ordered in the apo structure.", [["CYLD", "GENE_OR_GENE_PRODUCT", 11, 15], ["apo", "AMINO_ACID", 62, 65], ["\u03b2-hairpin", "SIMPLE_CHEMICAL", 105, 114], ["USP9X \u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 151, 166], ["apo", "AMINO_ACID", 195, 198], ["CYLD", "PROTEIN", 11, 15], ["apo structure", "PROTEIN", 62, 75], ["\u03b2-hairpin", "PROTEIN", 105, 114], ["USP9X \u03b2-hairpin insertion", "DNA", 151, 176], ["apo structure", "PROTEIN", 195, 208], ["the CYLD insertion", "TREATMENT", 7, 25], ["the USP9X \u03b2-hairpin insertion", "TREATMENT", 147, 176], ["CYLD", "OBSERVATION", 11, 15], ["apo structure", "OBSERVATION_MODIFIER", 62, 75]]], ["Crystal packing analysis revealed the \u03b2-hairpin pairs with the \u03b2-strands of the fingers subdomain of a symmetry-related molecule (SI Appendix, Fig. S11A).", [["\u03b2-hairpin pairs", "PROTEIN", 38, 53], ["\u03b2-strands", "PROTEIN", 63, 72], ["fingers subdomain", "PROTEIN", 80, 97], ["symmetry-related molecule", "PROTEIN", 103, 128], ["SI Appendix", "PROTEIN", 130, 141], ["Fig. S11A", "PROTEIN", 143, 152], ["Crystal packing analysis", "TEST", 0, 24], ["the \u03b2-hairpin pairs", "PROBLEM", 34, 53], ["fingers", "ANATOMY", 80, 87], ["symmetry", "OBSERVATION", 103, 111], ["molecule", "OBSERVATION_MODIFIER", 120, 128]]], ["Secondary structure (34) and disorder (35) predictions suggest this insertion has no strong propensity to adopt an \u03b1-helix, \u03b2-strand, or disordered conformation (SI Appendix, Fig. S11 B and C).", [["\u03b1-helix", "SIMPLE_CHEMICAL", 115, 122], ["S11 B", "GENE_OR_GENE_PRODUCT", 180, 185], ["C", "GENE_OR_GENE_PRODUCT", 190, 191], ["S11 B and C", "PROTEIN", 180, 191], ["Secondary structure (34) and disorder", "PROBLEM", 0, 37], ["this insertion", "TREATMENT", 63, 77], ["disordered conformation", "PROBLEM", 137, 160], ["Appendix", "ANATOMY", 165, 173]]], ["This implicates that the observed conformation of the \u03b2-hairpin could have been influenced by crystal packing, and it may adopt a different conformation upon substrate binding.", [["\u03b2-hairpin", "CHEMICAL", 54, 63], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 54, 63], ["\u03b2-hairpin", "PROTEIN", 54, 63], ["crystal packing", "TREATMENT", 94, 109], ["a different conformation upon substrate binding", "PROBLEM", 128, 175], ["crystal packing", "OBSERVATION", 94, 109]]], ["Structure overlay of USP9X CD with CYLD CD in complex with diUb (PDB ID code 3WXE) shows that the USP9X \u03b2-hairpin is close to, but on the opposite side of a modeled S1\u2032 Ub compared with the CYLD \u03b2-hairpin (Fig. 3A).Role of the USP9X \u03b2-Hairpin Insertion on Catalysis. ::: ResultsTo understand the role of the USP9X \u03b2-hairpin insertion, we generated a deletion mutant \u0394(1924\u20131943) and assessed its activity.", [["USP9X CD", "GENE_OR_GENE_PRODUCT", 21, 29], ["CYLD CD", "GENE_OR_GENE_PRODUCT", 35, 42], ["USP9X \u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 98, 113], ["Ub", "GENE_OR_GENE_PRODUCT", 169, 171], ["CYLD", "GENE_OR_GENE_PRODUCT", 190, 194], ["USP9X", "GENE_OR_GENE_PRODUCT", 308, 313], ["USP9X CD", "PROTEIN", 21, 29], ["CYLD CD", "PROTEIN", 35, 42], ["diUb", "PROTEIN", 59, 63], ["PDB ID code 3WXE", "PROTEIN", 65, 81], ["USP9X \u03b2-hairpin", "PROTEIN", 98, 113], ["S1", "PROTEIN", 165, 167], ["Ub", "PROTEIN", 169, 171], ["CYLD \u03b2-hairpin", "DNA", 190, 204], ["USP9X \u03b2-hairpin insertion", "DNA", 308, 333], ["the USP9X \u03b2-hairpin", "PROBLEM", 94, 113], ["Hairpin Insertion on Catalysis", "TREATMENT", 235, 265], ["the USP9X \u03b2-hairpin insertion", "TREATMENT", 304, 333], ["USP9X CD", "OBSERVATION", 21, 29], ["CYLD CD", "OBSERVATION", 35, 42], ["USP9X", "OBSERVATION", 98, 103], ["Hairpin Insertion", "OBSERVATION", 235, 252]]], ["We only observed a slight change of the mutant in kcat and Km toward Ub-AMC (SI Appendix, Table S1), and monoUb-based Ub-PA probe labeling compared with WT (SI Appendix, Fig. S12 A and B).", [["Km", "GENE_OR_GENE_PRODUCT", 59, 61], ["Ub", "GENE_OR_GENE_PRODUCT", 69, 71], ["monoUb", "SIMPLE_CHEMICAL", 105, 111], ["Ub-PA", "GENE_OR_GENE_PRODUCT", 118, 123], ["B", "GENE_OR_GENE_PRODUCT", 185, 186], ["Ub", "PROTEIN", 69, 71], ["monoUb", "PROTEIN", 105, 111], ["Ub", "PROTEIN", 118, 120], ["B", "PROTEIN", 185, 186], ["a slight change of the mutant", "PROBLEM", 17, 46], ["kcat", "TEST", 50, 54], ["Km", "TEST", 59, 61], ["Ub", "TEST", 69, 71], ["AMC", "PROBLEM", 72, 75], ["monoUb", "TEST", 105, 111], ["slight", "OBSERVATION_MODIFIER", 19, 25], ["change", "OBSERVATION_MODIFIER", 26, 32], ["Appendix", "ANATOMY", 160, 168]]], ["Furthermore, labeling with diUb-NC1-PA2 probes, which measures S2-S1 binding, also only showed slightly reduced labeling efficiency for the deletion mutant (SI Appendix, Fig. S12C).", [["diUb-NC1", "GENE_OR_GENE_PRODUCT", 27, 35], ["S2-S1", "GENE_OR_GENE_PRODUCT", 63, 68], ["diUb", "PROTEIN", 27, 31], ["NC1", "PROTEIN", 32, 35], ["PA2", "PROTEIN", 36, 39], ["S2", "PROTEIN", 63, 65], ["S1", "PROTEIN", 66, 68], ["Fig. S12C", "PROTEIN", 170, 179], ["labeling", "TEST", 13, 21], ["diUb", "TEST", 27, 31], ["PA2 probes", "TEST", 36, 46], ["slightly reduced labeling efficiency", "PROBLEM", 95, 131], ["the deletion mutant", "PROBLEM", 136, 155], ["slightly", "OBSERVATION_MODIFIER", 95, 103], ["reduced", "OBSERVATION_MODIFIER", 104, 111], ["labeling efficiency", "OBSERVATION", 112, 131]]], ["Together, these observations suggest that removal of the \u03b2-hairpin insertion has a minimal impact on S2-S1 Ub binding.Role of the USP9X \u03b2-Hairpin Insertion on Catalysis. ::: ResultsWe next accessed S1-S1\u2032 site engagement using diUb-MA1 probes.", [["\u03b2-hairpin", "CHEMICAL", 57, 66], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 57, 66], ["S2-S1", "GENE_OR_GENE_PRODUCT", 101, 106], ["Ub", "GENE_OR_GENE_PRODUCT", 107, 109], ["diUb-MA1", "GENE_OR_GENE_PRODUCT", 227, 235], ["\u03b2-hairpin insertion", "DNA", 57, 76], ["S2", "PROTEIN", 101, 103], ["Ub", "PROTEIN", 107, 109], ["S1-S1\u2032 site", "DNA", 198, 209], ["diUb-MA1 probes", "DNA", 227, 242], ["removal", "TREATMENT", 42, 49], ["the \u03b2-hairpin insertion", "TREATMENT", 53, 76], ["Hairpin Insertion on Catalysis", "TREATMENT", 138, 168], ["diUb", "TEST", 227, 231], ["removal", "OBSERVATION_MODIFIER", 42, 49], ["minimal", "OBSERVATION_MODIFIER", 83, 90], ["impact", "OBSERVATION_MODIFIER", 91, 97], ["S1 Ub", "ANATOMY_MODIFIER", 104, 109], ["Hairpin Insertion", "OBSERVATION", 138, 155]]], ["The WT USP9X CD is most strongly labeled by K48- followed by K63- and K11-diUb-MA1 probes, but not by K6-diUb-MA1 in the time frame treated (1 h) (SI Appendix, Fig. S12D).", [["USP9X", "GENE_OR_GENE_PRODUCT", 7, 12], ["K48", "SIMPLE_CHEMICAL", 44, 47], ["K63", "SIMPLE_CHEMICAL", 61, 64], ["K11", "GENE_OR_GENE_PRODUCT", 70, 73], ["K6-diUb-MA1", "GENE_OR_GENE_PRODUCT", 102, 113], ["WT USP9X CD", "DNA", 4, 15], ["K48", "PROTEIN", 44, 47], ["K63- and K11-diUb-MA1 probes", "DNA", 61, 89], ["K6", "PROTEIN", 102, 104], ["diUb", "PROTEIN", 105, 109], ["MA1", "DNA", 110, 113], ["The WT USP9X CD", "TEST", 0, 15], ["K48", "TEST", 44, 47], ["K63", "TEST", 61, 64], ["K11", "TEST", 70, 73], ["Appendix", "ANATOMY", 150, 158]]], ["Labeling of USP9X \u0394(1924\u20131943) showed similar linkage preference (SI Appendix, Fig. S12D).", [["USP9X", "GENE_OR_GENE_PRODUCT", 12, 17], ["USP9X \u0394", "DNA", 12, 19], ["similar linkage preference", "PROBLEM", 38, 64]]], ["Using a gel-based DUB assay, the deletion mutant showed reduced cleavage of K11-, K48-, and K63-linked diUb (SI Appendix, Fig. S5B) and triUb substrates (SI Appendix, Fig. S12E) compared with WT.", [["K11", "GENE_OR_GENE_PRODUCT", 76, 79], ["K48", "GENE_OR_GENE_PRODUCT", 82, 85], ["K63", "SIMPLE_CHEMICAL", 92, 95], ["S5B", "GENE_OR_GENE_PRODUCT", 127, 130], ["DUB", "PROTEIN", 18, 21], ["K11", "PROTEIN", 76, 79], ["K48", "PROTEIN", 82, 85], ["K63", "PROTEIN", 92, 95], ["diUb", "DNA", 103, 107], ["S5B", "PROTEIN", 127, 130], ["S12E", "PROTEIN", 172, 176], ["a gel-based DUB assay", "TEST", 6, 27], ["the deletion mutant", "TEST", 29, 48], ["reduced cleavage", "PROBLEM", 56, 72], ["K11", "TEST", 76, 79], ["K48", "TEST", 82, 85], ["K63", "TEST", 92, 95], ["WT", "TEST", 192, 194], ["Appendix", "ANATOMY", 112, 120], ["Appendix", "ANATOMY", 157, 165]]], ["To quantify the activity, we used the IQF-diUb substrates for continuous monitoring of diUb cleavage.", [["diUb", "GENE_OR_GENE_PRODUCT", 87, 91], ["IQF", "PROTEIN", 38, 41], ["the IQF-diUb substrates", "TREATMENT", 34, 57], ["continuous monitoring of diUb cleavage", "TREATMENT", 62, 100]]], ["With K11- and K63-linked IQF-diUb, the \u03b2-hairpin deletion reduced the cleavage efficiency significantly (Fig. 3B).", [["K11", "GENE_OR_GENE_PRODUCT", 5, 8], ["K63", "GENE_OR_GENE_PRODUCT", 14, 17], ["IQF-diUb", "GENE_OR_GENE_PRODUCT", 25, 33], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 39, 48], ["K11", "PROTEIN", 5, 8], ["K63", "PROTEIN", 14, 17], ["IQF", "PROTEIN", 25, 28], ["diUb", "DNA", 29, 33], ["\u03b2-hairpin deletion", "DNA", 39, 57], ["K11", "TEST", 5, 8], ["K63", "TEST", 14, 17], ["the \u03b2-hairpin deletion", "PROBLEM", 35, 57], ["the cleavage efficiency", "PROBLEM", 66, 89], ["cleavage efficiency", "OBSERVATION", 70, 89]]], ["Overall, the \u03b2-hairpin insertion is important for the S1-S1\u2032 cleavage activity.Labeling by K11 DiUb-MA1 Probe Reveals the Reactivity of a Noncatalytic Cysteine. ::: ResultsIn the WT USP9X CD labeling experiment with diUb-MA1 probes of different linkages, we observed an interesting difference in the labeling pattern.", [["Cysteine", "CHEMICAL", 151, 159], ["Cysteine", "CHEMICAL", 151, 159], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 13, 22], ["Noncatalytic Cysteine", "SIMPLE_CHEMICAL", 138, 159], ["diUb-MA1", "GENE_OR_GENE_PRODUCT", 216, 224], ["\u03b2-hairpin insertion", "DNA", 13, 32], ["S1", "PROTEIN", 54, 56], ["S1", "PROTEIN", 57, 59], ["K11 DiUb", "PROTEIN", 91, 99], ["diUb-MA1 probes", "DNA", 216, 231], ["the \u03b2-hairpin insertion", "TREATMENT", 9, 32], ["diUb", "TEST", 216, 220], ["cleavage activity", "OBSERVATION", 61, 78], ["interesting", "OBSERVATION_MODIFIER", 270, 281], ["difference", "OBSERVATION_MODIFIER", 282, 292], ["labeling pattern", "OBSERVATION", 300, 316]]], ["As expected, the K48- and K63-diUb-MA1 probes yield one upshifted product band.", [["K48", "GENE_OR_GENE_PRODUCT", 17, 20], ["K63", "SIMPLE_CHEMICAL", 26, 29], ["K48- and K63-diUb-MA1 probes", "DNA", 17, 45], ["the K48", "TEST", 13, 20], ["K63", "TEST", 26, 29], ["product band", "OBSERVATION", 66, 78]]], ["Surprisingly, with the K11-diUb-MA1 probe, we observed two labeling bands with comparable intensities (Fig. 3C), which we denoted HMW and LMW bands (for high- and low-molecular weights).Labeling by K11 DiUb-MA1 Probe Reveals the Reactivity of a Noncatalytic Cysteine. ::: ResultsTo understand the nature of the labeling products, we subjected the HMW and LMW bands to tryptic digestion and MS/MS analysis.", [["Cysteine", "CHEMICAL", 258, 266], ["Cysteine", "CHEMICAL", 258, 266], ["K11", "GENE_OR_GENE_PRODUCT", 23, 26], ["HMW", "GENE_OR_GENE_PRODUCT", 130, 133], ["Noncatalytic Cysteine", "SIMPLE_CHEMICAL", 245, 266], ["K11", "DNA", 23, 26], ["diUb", "DNA", 27, 31], ["MA1 probe", "DNA", 32, 41], ["HMW", "PROTEIN", 130, 133], ["LMW bands", "PROTEIN", 138, 147], ["K11 DiUb", "PROTEIN", 198, 206], ["HMW", "PROTEIN", 347, 350], ["the K11", "TEST", 19, 26], ["two labeling bands", "PROBLEM", 55, 73], ["LMW bands", "TEST", 138, 147], ["the HMW", "PROBLEM", 343, 350], ["LMW bands", "PROBLEM", 355, 364], ["tryptic digestion", "PROBLEM", 368, 385], ["MS/MS analysis", "TEST", 390, 404]]], ["The results suggest that conjugation of Cys1808 on the blocking loop BL1 by the K11 diUb-MA1 probe results in the HMW band, while the labeling of the catalytic Cys1566 leads to the LMW band.", [["Cys1808", "CHEMICAL", 40, 47], ["Cys1566", "CHEMICAL", 160, 167], ["Cys1808", "CHEMICAL", 40, 47], ["Cys1566", "CHEMICAL", 160, 167], ["Cys1808", "SIMPLE_CHEMICAL", 40, 47], ["BL1", "GENE_OR_GENE_PRODUCT", 69, 72], ["BL1", "PROTEIN", 69, 72], ["K11 diUb-MA1 probe", "DNA", 80, 98], ["HMW band", "PROTEIN", 114, 122], ["catalytic Cys1566", "PROTEIN", 150, 167], ["LMW band", "PROTEIN", 181, 189], ["the catalytic Cys", "TEST", 146, 163], ["LMW band", "OBSERVATION", 181, 189]]], ["Subsequent mutational analysis confirmed the finding (Fig. 4A).", [["Subsequent mutational analysis", "TEST", 0, 30]]], ["Specifically, labeling of the active site mutant C1566S by the K11-diUb-MA1 probe showed only the HMW band, whereas the C1808S mutant showed only the LMW band.", [["K11", "GENE_OR_GENE_PRODUCT", 63, 66], ["K11-diUb-MA1 probe", "DNA", 63, 81], ["HMW band", "PROTEIN", 98, 106], ["C1808S mutant", "PROTEIN", 120, 133], ["LMW band", "PROTEIN", 150, 158], ["the K11", "TEST", 59, 66], ["the HMW band", "TEST", 94, 106], ["the LMW band", "PROBLEM", 146, 158], ["active", "OBSERVATION_MODIFIER", 30, 36], ["LMW band", "OBSERVATION", 150, 158]]], ["Notably, when the C1566S mutant was incubated with HA-Ub-vinyl methyl ester (VME), which bears the same MA as that in the diUb-MA1 probes, no labeling band was observed (Fig. 4B).", [["HA-Ub-vinyl methyl ester", "CHEMICAL", 51, 75], ["VME", "CHEMICAL", 77, 80], ["Ub-vinyl methyl ester", "CHEMICAL", 54, 75], ["VME", "CHEMICAL", 77, 80], ["HA-Ub-vinyl methyl ester", "SIMPLE_CHEMICAL", 51, 75], ["VME", "SIMPLE_CHEMICAL", 77, 80], ["C1566S mutant", "PROTEIN", 18, 31], ["Ub", "PROTEIN", 54, 56], ["diUb", "PROTEIN", 122, 126], ["MA1", "PROTEIN", 127, 130], ["HA", "PROBLEM", 51, 53], ["vinyl methyl ester (VME)", "TREATMENT", 57, 81], ["labeling band", "PROBLEM", 142, 155]]], ["This indicates the proximal Ub in the K11-diUb-MA1 is required for the alternate labeling of Cys1808 in USP9X CD.Labeling by K11 DiUb-MA1 Probe Reveals the Reactivity of a Noncatalytic Cysteine. ::: ResultsWe also subjected the ZnF mutant C1727A and the \u03b2-hairpin deletion mutant \u0394(1924\u20131943) to the same labeling assay with a K11 diUb-MA1 probe.", [["Cysteine", "CHEMICAL", 185, 193], ["Cysteine", "CHEMICAL", 185, 193], ["Ub", "GENE_OR_GENE_PRODUCT", 28, 30], ["K11", "GENE_OR_GENE_PRODUCT", 38, 41], ["Cys1808", "GENE_OR_GENE_PRODUCT", 93, 100], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 104, 112], ["ZnF", "GENE_OR_GENE_PRODUCT", 228, 231], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 254, 263], ["proximal Ub", "PROTEIN", 19, 30], ["K11", "PROTEIN", 38, 41], ["diUb", "PROTEIN", 42, 46], ["MA1", "DNA", 47, 50], ["Cys1808", "PROTEIN", 93, 100], ["K11 DiUb", "PROTEIN", 125, 133], ["ZnF mutant C1727A", "PROTEIN", 228, 245], ["\u03b2-hairpin deletion mutant", "DNA", 254, 279], ["K11 diUb-MA1 probe", "DNA", 327, 345], ["proximal", "ANATOMY_MODIFIER", 19, 27], ["Ub", "ANATOMY_MODIFIER", 28, 30]]], ["Interestingly, of the two labeling bands, the LMW band was diminished for the ZnF mutant (Fig. 4A).", [["LMW", "GENE_OR_GENE_PRODUCT", 46, 49], ["ZnF", "GENE_OR_GENE_PRODUCT", 78, 81], ["LMW band", "PROTEIN", 46, 54], ["ZnF mutant", "PROTEIN", 78, 88], ["Fig. 4A", "PROTEIN", 90, 97], ["the two labeling bands", "PROBLEM", 18, 40], ["the LMW band", "TEST", 42, 54], ["diminished", "OBSERVATION", 59, 69]]], ["The opposite was observed for the deletion mutant \u0394(1924\u20131943) with a reduced HMW band.Labeling by K11 DiUb-MA1 Probe Reveals the Reactivity of a Noncatalytic Cysteine. ::: ResultsWe generated a Q1683A mutation to unblock the access to the catalytic triad (SI Appendix, Fig. S1C) and subjected the mutant to labeling with the K11-diUb-MA1 probe.", [["Cysteine", "CHEMICAL", 159, 167], ["Cysteine", "CHEMICAL", 159, 167], ["Noncatalytic Cysteine", "SIMPLE_CHEMICAL", 146, 167], ["S1C", "GENE_OR_GENE_PRODUCT", 275, 278], ["K11", "GENE_OR_GENE_PRODUCT", 326, 329], ["HMW band", "PROTEIN", 78, 86], ["K11 DiUb", "PROTEIN", 99, 107], ["K11-diUb-MA1 probe", "DNA", 326, 344], ["a reduced HMW band", "PROBLEM", 68, 86], ["the K11", "TEST", 322, 329], ["SI Appendix", "ANATOMY", 257, 268]]], ["Notably, the LMW band (labeling of catalytic Cys1566) showed a more increased intensity than the HMW band (SI Appendix, Fig. S13A), suggesting improved access to the active site.", [["Cys1566", "CHEMICAL", 45, 52], ["Cys", "CHEMICAL", 45, 48], ["LMW band", "PROTEIN", 13, 21], ["catalytic Cys1566", "PROTEIN", 35, 52], ["HMW band", "PROTEIN", 97, 105], ["the LMW band", "TEST", 9, 21], ["catalytic Cys", "TEST", 35, 48], ["a more increased intensity", "PROBLEM", 61, 87], ["more", "OBSERVATION_MODIFIER", 63, 67], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["intensity", "OBSERVATION_MODIFIER", 78, 87], ["improved", "OBSERVATION_MODIFIER", 143, 151], ["access", "OBSERVATION", 152, 158], ["active", "OBSERVATION_MODIFIER", 166, 172], ["site", "OBSERVATION_MODIFIER", 173, 177]]], ["The Q1683A mutant also showed a large increase in Km and little decrease in kcat for Ub-AMC substrate compared with the WT (SI Appendix, Fig. S13B and Table S1).", [["K", "CHEMICAL", 50, 51], ["Q1683A", "GENE_OR_GENE_PRODUCT", 4, 10], ["Km", "GENE_OR_GENE_PRODUCT", 50, 52], ["Ub", "GENE_OR_GENE_PRODUCT", 85, 87], ["S13B", "GENE_OR_GENE_PRODUCT", 142, 146], ["Table S1", "GENE_OR_GENE_PRODUCT", 151, 159], ["Q1683A mutant", "PROTEIN", 4, 17], ["Ub", "PROTEIN", 85, 87], ["S13B", "PROTEIN", 142, 146], ["Table S1", "PROTEIN", 151, 159], ["a large increase in Km", "PROBLEM", 30, 52], ["little decrease", "PROBLEM", 57, 72], ["kcat", "TEST", 76, 80], ["Ub", "TEST", 85, 87], ["AMC substrate", "PROBLEM", 88, 101], ["the WT", "TEST", 116, 122], ["large", "OBSERVATION_MODIFIER", 32, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["Km", "OBSERVATION_MODIFIER", 50, 52], ["decrease", "OBSERVATION_MODIFIER", 64, 72], ["Appendix", "ANATOMY", 127, 135], ["Table S1", "ANATOMY", 151, 159]]], ["However, no significant change in kcat and Km values was observed for the IQF-K11-diUb substrate (SI Appendix, Fig. S13C).USP9X Displays Linkage-Specific Endo- and Exo-DUB Activities. ::: ResultsThe multiple Ub binding sites and linkage specificity of USP9X CD prompted us to investigate its endo- and exo-Ub chain cleavage activity.", [["Km", "GENE_OR_GENE_PRODUCT", 43, 45], ["Ub", "GENE_OR_GENE_PRODUCT", 208, 210], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 252, 260], ["Ub", "GENE_OR_GENE_PRODUCT", 306, 308], ["IQF", "PROTEIN", 74, 77], ["K11", "PROTEIN", 78, 81], ["diUb substrate", "PROTEIN", 82, 96], ["Fig. S13C", "PROTEIN", 111, 120], ["USP9X", "PROTEIN", 122, 127], ["Endo", "PROTEIN", 154, 158], ["multiple Ub binding sites", "DNA", 199, 224], ["USP9X CD", "PROTEIN", 252, 260], ["Ub chain", "PROTEIN", 306, 314], ["significant change", "PROBLEM", 12, 30], ["kcat", "TEST", 34, 38], ["Km values", "TEST", 43, 52], ["the IQF", "TEST", 70, 77], ["K11", "TEST", 78, 81], ["Linkage", "TEST", 137, 144], ["Endo", "TEST", 154, 158], ["The multiple Ub binding sites", "PROBLEM", 195, 224], ["USP9X CD", "PROBLEM", 252, 260], ["endo", "TEST", 292, 296], ["exo-Ub chain cleavage activity", "TREATMENT", 302, 332], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["change", "OBSERVATION", 24, 30], ["multiple", "OBSERVATION_MODIFIER", 199, 207], ["Ub", "OBSERVATION_MODIFIER", 208, 210], ["binding sites", "OBSERVATION", 211, 224], ["cleavage activity", "OBSERVATION", 315, 332]]], ["Using the diUb-NC1-AMC2 substrates (Fig. 2A), we performed a kinetic analysis of S2-S1 diUb cleavage and found that USP9X CD possesses robust endo-DUB activity for K11- and K63-diUb substrates.", [["USP9X", "CHEMICAL", 116, 121], ["diUb-NC1", "GENE_OR_GENE_PRODUCT", 10, 18], ["diUb", "GENE_OR_GENE_PRODUCT", 87, 91], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 116, 124], ["DUB", "GENE_OR_GENE_PRODUCT", 147, 150], ["K11", "GENE_OR_GENE_PRODUCT", 164, 167], ["K63-diUb", "GENE_OR_GENE_PRODUCT", 173, 181], ["diUb", "PROTEIN", 10, 14], ["NC1", "PROTEIN", 15, 18], ["AMC2 substrates", "PROTEIN", 19, 34], ["Fig. 2A", "PROTEIN", 36, 43], ["S2", "PROTEIN", 81, 83], ["diUb", "PROTEIN", 87, 91], ["USP9X CD", "PROTEIN", 116, 124], ["DUB", "PROTEIN", 147, 150], ["K11", "PROTEIN", 164, 167], ["K63", "PROTEIN", 173, 176], ["diUb substrates", "PROTEIN", 177, 192], ["a kinetic analysis", "TEST", 59, 77], ["S1 diUb cleavage", "TREATMENT", 84, 100], ["K11", "TEST", 164, 167], ["K63", "TEST", 173, 176]]], ["USP9X CD showed a twofold higher catalytic activity (kcat/Km) for K11- compared with K63-linked diUb-NC1-AMC2 (SI Appendix, Table S2).", [["USP9X", "CHEMICAL", 0, 5], ["USP9X", "GENE_OR_GENE_PRODUCT", 0, 5], ["K11", "SIMPLE_CHEMICAL", 66, 69], ["K63", "SIMPLE_CHEMICAL", 85, 88], ["diUb-NC1", "GENE_OR_GENE_PRODUCT", 96, 104], ["USP9X CD", "PROTEIN", 0, 8], ["K11", "PROTEIN", 66, 69], ["K63", "PROTEIN", 85, 88], ["diUb", "PROTEIN", 96, 100], ["NC1", "PROTEIN", 101, 104], ["AMC2", "PROTEIN", 105, 109], ["USP9X CD", "TEST", 0, 8], ["a twofold higher catalytic activity", "PROBLEM", 16, 51], ["kcat/Km", "TEST", 53, 60], ["K11", "TEST", 66, 69], ["K63", "TEST", 85, 88], ["diUb", "TEST", 96, 100], ["NC1", "TEST", 101, 104]]], ["Notably, USP9X CD is much less active against K48-diUb-NC1-AMC2 with an eightfold lower kcat/Km, suggesting that the positioning of the distal Ub influences the endo-cleavage activity.USP9X Displays Linkage-Specific Endo- and Exo-DUB Activities. ::: ResultsWe then used the hybrid triUb probes that mimic polyUb chain substrates (Fig. 2B).", [["USP9X CD", "GENE_OR_GENE_PRODUCT", 9, 17], ["K48", "GENE_OR_GENE_PRODUCT", 46, 49], ["NC1", "GENE_OR_GENE_PRODUCT", 55, 58], ["Ub", "GENE_OR_GENE_PRODUCT", 143, 145], ["USP9X CD", "PROTEIN", 9, 17], ["K48", "PROTEIN", 46, 49], ["diUb", "PROTEIN", 50, 54], ["NC1", "PROTEIN", 55, 58], ["AMC2", "PROTEIN", 59, 63], ["distal Ub", "PROTEIN", 136, 145], ["USP9X", "PROTEIN", 184, 189], ["Endo", "PROTEIN", 216, 220], ["hybrid triUb probes", "DNA", 274, 293], ["polyUb chain substrates", "PROTEIN", 305, 328], ["USP9X CD", "TEST", 9, 17], ["K48", "TEST", 46, 49], ["Linkage", "TEST", 199, 206], ["Endo", "TEST", 216, 220], ["the hybrid triUb probes", "TREATMENT", 270, 293], ["distal", "ANATOMY_MODIFIER", 136, 142], ["endo", "OBSERVATION", 161, 165], ["cleavage activity", "OBSERVATION", 166, 183]]], ["Three binding modes are possible with two of them leading to chain cleavage (endo and exo) (Fig. 5A).", [["endo and exo", "PROTEIN", 77, 89], ["chain cleavage", "PROBLEM", 61, 75]]], ["To probe the effect of simultaneous binding of a polyUb substrate to all three potential DUB Ub binding sites (S2, S1, and S1\u2032, mode 1), we used the triUb-NC1-CL2 probes (Fig. 2B), cleavage of which indicates an endo-mode.", [["polyUb", "CHEMICAL", 49, 55], ["DUB Ub", "GENE_OR_GENE_PRODUCT", 89, 95], ["polyUb substrate", "PROTEIN", 49, 65], ["DUB Ub binding sites", "PROTEIN", 89, 109], ["S2", "PROTEIN", 111, 113], ["S1", "PROTEIN", 115, 117], ["triUb", "PROTEIN", 149, 154], ["NC1", "PROTEIN", 155, 158], ["CL2", "PROTEIN", 159, 162], ["endo-mode", "PROTEIN", 212, 221], ["a polyUb substrate", "TREATMENT", 47, 65], ["the triUb-NC1", "TREATMENT", 145, 158], ["S1", "ANATOMY", 115, 117], ["S1", "ANATOMY", 123, 125], ["endo-mode", "OBSERVATION", 212, 221]]], ["We found that USP9X CD endo-cleaved K11- and K63-triUb-NC1-CL2 into diUb and monoUb efficiently (Fig. 5B and SI Appendix, Fig. S14 A and B).", [["USP9X", "GENE_OR_GENE_PRODUCT", 14, 19], ["K11", "GENE_OR_GENE_PRODUCT", 36, 39], ["K63", "GENE_OR_GENE_PRODUCT", 45, 48], ["diUb", "GENE_OR_GENE_PRODUCT", 68, 72], ["B", "GENE_OR_GENE_PRODUCT", 137, 138], ["USP9X CD endo", "PROTEIN", 14, 27], ["K11", "PROTEIN", 36, 39], ["K63", "PROTEIN", 45, 48], ["triUb", "PROTEIN", 49, 54], ["NC1", "PROTEIN", 55, 58], ["CL2", "DNA", 59, 62], ["diUb", "DNA", 68, 72], ["monoUb", "DNA", 77, 83], ["B", "PROTEIN", 137, 138], ["USP9X", "TEST", 14, 19], ["endo", "TEST", 23, 27], ["K11", "TEST", 36, 39], ["K63", "TEST", 45, 48], ["triUb", "TEST", 49, 54], ["NC1", "TEST", 55, 58], ["SI Appendix", "ANATOMY", 109, 120]]], ["However, little cleavage of K48 triUb-NC1-CL2 was detected (Fig. 5B and SI Appendix, Fig. S14C).", [["K48 triUb-NC1-CL2", "GENE_OR_GENE_PRODUCT", 28, 45], ["K48 triUb", "PROTEIN", 28, 37], ["NC1", "PROTEIN", 38, 41], ["CL2", "PROTEIN", 42, 45], ["Fig. S14C", "PROTEIN", 85, 94], ["SI Appendix", "ANATOMY", 72, 83]]], ["These assays were run in parallel with native diUb substrates, and for all linkages (K11, K48, and K63) efficient cleavage by the USP9X CD was observed (SI Appendix, Fig. S14).", [["diUb", "GENE_OR_GENE_PRODUCT", 46, 50], ["K63", "PROTEIN", 99, 102], ["USP9X CD", "DNA", 130, 138], ["These assays", "TEST", 0, 12], ["native diUb substrates", "TREATMENT", 39, 61], ["K11", "TEST", 85, 88], ["K48", "TEST", 90, 93], ["efficient cleavage", "PROBLEM", 104, 122], ["the USP9X CD", "TEST", 126, 138]]], ["We also used USP2 CD, which is permissive for different Ub chain linkages, as a comparison and observed efficient cleavage of triUb-NC1-CL2 of all three linkages (K11, K48, and K63) (SI Appendix, Fig. S14).USP9X Displays Linkage-Specific Endo- and Exo-DUB Activities. ::: ResultsNext, the triUb-MA1-CL2 probes (Fig. 2B) were used to detect both endo- and exo-cleavage modes by DUBs in one assay.", [["USP2 CD", "GENE_OR_GENE_PRODUCT", 13, 20], ["triUb-NC1", "GENE_OR_GENE_PRODUCT", 126, 135], ["USP2 CD", "PROTEIN", 13, 20], ["Ub chain", "PROTEIN", 56, 64], ["triUb", "PROTEIN", 126, 131], ["NC1", "PROTEIN", 132, 135], ["CL2", "PROTEIN", 136, 139], ["K11", "PROTEIN", 163, 166], ["K48", "PROTEIN", 168, 171], ["K63", "PROTEIN", 177, 180], ["USP9X", "PROTEIN", 206, 211], ["Endo", "PROTEIN", 238, 242], ["triUb", "DNA", 289, 294], ["MA1", "DNA", 295, 298], ["CL2 probes", "DNA", 299, 309], ["DUBs", "PROTEIN", 377, 381], ["USP2 CD", "TEST", 13, 20], ["triUb", "TEST", 126, 131], ["K11", "TEST", 163, 166], ["K48", "TEST", 168, 171], ["Linkage", "TEST", 221, 228], ["Endo", "TEST", 238, 242], ["the triUb", "TEST", 285, 294], ["endo", "TEST", 345, 349], ["chain linkages", "OBSERVATION", 59, 73]]], ["We envisioned three possible outcomes (SI Appendix, Fig. S15A) In scenario 1, the DUB engages the triUb substrate in a binding mode that leads to endo-cleavage of the triUb-MA1-CL2 to yield di- and monoUb species.", [["DUB", "GENE_OR_GENE_PRODUCT", 82, 85], ["triUb", "GENE_OR_GENE_PRODUCT", 167, 172], ["CL2", "GENE_OR_GENE_PRODUCT", 177, 180], ["monoUb species", "SIMPLE_CHEMICAL", 198, 212], ["S15A", "PROTEIN", 57, 61], ["DUB", "PROTEIN", 82, 85], ["triUb substrate", "PROTEIN", 98, 113], ["triUb", "PROTEIN", 167, 172], ["MA1", "PROTEIN", 173, 176], ["CL2", "PROTEIN", 177, 180], ["di- and monoUb species", "PROTEIN", 190, 212], ["endo", "TEST", 146, 150], ["the triUb", "TEST", 163, 172], ["di", "TEST", 190, 192], ["monoUb species", "PROBLEM", 198, 212], ["Appendix", "ANATOMY", 42, 50]]], ["The resulting diUb-MA1 probe may in turn label the DUB.", [["diUb", "GENE_OR_GENE_PRODUCT", 14, 18], ["DUB", "GENE_OR_GENE_PRODUCT", 51, 54], ["diUb-MA1 probe", "DNA", 14, 28], ["DUB", "PROTEIN", 51, 54], ["The resulting diUb-MA1 probe", "TREATMENT", 0, 28], ["DUB", "OBSERVATION", 51, 54]]], ["In scenario 2, the DUB engages the triUb substrate exclusively in an exo-binding mode that leads to the labeling of DUB by the triUb probe.", [["DUB", "GENE_OR_GENE_PRODUCT", 19, 22], ["DUB", "GENE_OR_GENE_PRODUCT", 116, 119], ["triUb", "GENE_OR_GENE_PRODUCT", 127, 132], ["DUB", "PROTEIN", 19, 22], ["triUb substrate", "PROTEIN", 35, 50], ["DUB", "PROTEIN", 116, 119], ["triUb probe", "DNA", 127, 138], ["an exo-binding mode", "TREATMENT", 66, 85]]], ["In scenario 3, both endo- or exo-binding modes are possible, and it will lead to simultaneous cleavage of the triUb at the native isopeptide bond and labeling by the warhead in the triUb probe.", [["isopeptide", "CHEMICAL", 130, 140], ["triUb", "GENE_OR_GENE_PRODUCT", 110, 115], ["triUb", "PROTEIN", 110, 115], ["triUb probe", "DNA", 181, 192], ["both endo", "TREATMENT", 15, 24]]], ["For K48 triUb-MA1-CL2, we observed no cleavage by USP9X CD but a robust labeling product in a time-course experiment (Fig. 5C).", [["USP9X CD", "GENE_OR_GENE_PRODUCT", 50, 58], ["K48 triUb", "PROTEIN", 4, 13], ["MA1", "PROTEIN", 14, 17], ["CL2", "PROTEIN", 18, 21], ["USP9X CD", "PROTEIN", 50, 58], ["K48", "TEST", 4, 7], ["triUb", "TEST", 8, 13], ["MA1", "TEST", 14, 17], ["cleavage", "PROBLEM", 38, 46]]], ["The identity of the upshifted labeling product band was confirmed by comparison with labeling of USP9X CD using K48-diUb-MA1 probe (SI Appendix, Fig. S15B), consistent with scenario 2.", [["USP9X CD", "GENE_OR_GENE_PRODUCT", 97, 105], ["K48-diUb-MA1 probe", "DNA", 112, 130], ["USP9X CD", "TEST", 97, 105], ["K48", "TEST", 112, 115], ["diUb", "TEST", 116, 120], ["MA1 probe", "TREATMENT", 121, 130], ["Appendix", "ANATOMY", 135, 143], ["consistent with", "UNCERTAINTY", 157, 172]]], ["For K63-triUb-MA1-CL2, both cleavages of and labeling by the triUb were observed (Fig. 5D), agreeing with scenario 3.", [["K63", "GENE_OR_GENE_PRODUCT", 4, 7], ["triUb", "GENE_OR_GENE_PRODUCT", 61, 66], ["K63", "PROTEIN", 4, 7], ["triUb", "PROTEIN", 8, 13], ["MA1", "PROTEIN", 14, 17], ["CL2", "DNA", 18, 21], ["triUb", "DNA", 61, 66], ["K63", "TEST", 4, 7], ["triUb", "TEST", 8, 13], ["MA1", "TEST", 14, 17]]], ["For K11-triUb-MA1-CL2, a robust cleavage of the triUb probe was observed with a low level of labeling product (Fig. 5D), suggesting a dominant scenario 2.USP9X Displays Linkage-Specific Endo- and Exo-DUB Activities. ::: ResultsWe further compared the cleavage of K11- and K63-triUb-NC1-CL2 by WT, the ZnF mutant (C1721A), and the deletion mutant \u0394(1924\u20131943) of USP9X CD.", [["K11", "GENE_OR_GENE_PRODUCT", 4, 7], ["triUb", "GENE_OR_GENE_PRODUCT", 48, 53], ["K11", "GENE_OR_GENE_PRODUCT", 263, 266], ["K63-triUb-NC1-CL2", "GENE_OR_GENE_PRODUCT", 272, 289], ["ZnF", "GENE_OR_GENE_PRODUCT", 301, 304], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 362, 370], ["K11", "PROTEIN", 4, 7], ["triUb", "PROTEIN", 8, 13], ["MA1", "PROTEIN", 14, 17], ["CL2", "DNA", 18, 21], ["triUb probe", "DNA", 48, 59], ["USP9X", "PROTEIN", 154, 159], ["Endo", "PROTEIN", 186, 190], ["DUB", "PROTEIN", 200, 203], ["K11", "PROTEIN", 263, 266], ["K63", "PROTEIN", 272, 275], ["triUb", "PROTEIN", 276, 281], ["NC1", "PROTEIN", 282, 285], ["CL2", "PROTEIN", 286, 289], ["ZnF mutant", "PROTEIN", 301, 311], ["C1721A", "PROTEIN", 313, 319], ["USP9X CD", "PROTEIN", 362, 370], ["K11", "TEST", 4, 7], ["triUb", "TEST", 8, 13], ["MA1", "TEST", 14, 17], ["a robust cleavage of the triUb probe", "TREATMENT", 23, 59], ["USP9X", "TEST", 154, 159], ["Linkage", "TEST", 169, 176], ["Endo", "TEST", 186, 190], ["the cleavage", "TEST", 247, 259], ["K11", "TEST", 263, 266], ["K63", "TEST", 272, 275], ["triUb", "TEST", 276, 281], ["NC1", "TEST", 282, 285], ["WT", "TEST", 293, 295], ["robust", "OBSERVATION_MODIFIER", 25, 31], ["cleavage", "OBSERVATION", 32, 40], ["dominant scenario", "OBSERVATION", 134, 151]]], ["Although little effect was observed for the ZnF mutation, we observed a clear reduction in cleavage efficiency for the \u03b2-hairpin deletion mutant for both linkages of triUb (Fig. 5 E and F).", [["ZnF", "GENE_OR_GENE_PRODUCT", 44, 47], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 119, 128], ["ZnF", "PROTEIN", 44, 47], ["\u03b2-hairpin deletion mutant", "PROTEIN", 119, 144], ["triUb", "PROTEIN", 166, 171], ["the ZnF mutation", "PROBLEM", 40, 56], ["cleavage efficiency", "PROBLEM", 91, 110], ["the \u03b2-hairpin deletion mutant", "TREATMENT", 115, 144], ["cleavage efficiency", "OBSERVATION", 91, 110]]], ["In contrast, the effect of the \u03b2-hairpin deletion was less pronounced toward K11- and K63-diUb substrates (SI Appendix, Fig. S5B).DiscussionThe USP family of deubiquitinating enzymes show an extraordinary diversity of sequences and structural elements.", [["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 31, 40], ["K11", "SIMPLE_CHEMICAL", 77, 80], ["\u03b2-hairpin deletion", "DNA", 31, 49], ["K11", "PROTEIN", 77, 80], ["K63", "PROTEIN", 86, 89], ["diUb substrates", "PROTEIN", 90, 105], ["USP family", "PROTEIN", 144, 154], ["deubiquitinating enzymes", "PROTEIN", 158, 182], ["structural elements", "DNA", 232, 251], ["the \u03b2-hairpin deletion", "PROBLEM", 27, 49], ["K11", "TEST", 77, 80], ["K63", "TEST", 86, 89], ["deubiquitinating enzymes", "TEST", 158, 182], ["structural elements", "OBSERVATION", 232, 251]]], ["The consensus sequence of USP CD can be divided into six boxes, with possible insertions in several regions (2).", [["USP CD", "GENE_OR_GENE_PRODUCT", 26, 32], ["consensus sequence", "DNA", 4, 22], ["USP CD", "DNA", 26, 32], ["The consensus sequence of USP CD", "TEST", 0, 32]]], ["Our crystal structure of the USP9X CD confirms a conserved, canonical core USP fold with additional structural features that include a CHC2-type ZnF in the fingers subdomain and a unique \u03b2-hairpin insertion in sequence box 6.", [["USP9X CD", "GENE_OR_GENE_PRODUCT", 29, 37], ["ZnF", "GENE_OR_GENE_PRODUCT", 145, 148], ["USP9X CD", "PROTEIN", 29, 37], ["CHC2", "PROTEIN", 135, 139], ["ZnF", "PROTEIN", 145, 148], ["fingers subdomain", "PROTEIN", 156, 173], ["\u03b2-hairpin", "PROTEIN", 187, 196], ["sequence box 6", "PROTEIN", 210, 224], ["the USP9X CD", "TEST", 25, 37], ["a conserved, canonical core USP fold", "PROBLEM", 47, 83], ["additional structural features", "PROBLEM", 89, 119], ["a CHC2-type ZnF in the fingers subdomain", "PROBLEM", 133, 173], ["a unique \u03b2-hairpin insertion in sequence box", "TREATMENT", 178, 222], ["core USP fold", "OBSERVATION", 70, 83], ["fingers", "ANATOMY", 156, 163], ["\u03b2-hairpin insertion", "OBSERVATION", 187, 206]]], ["The structure of USP9X CD and the functional studies using novel Ub-based probes implicate three potential Ub binding sites (S1, S2, and S1\u2032) in USP9X CD.", [["USP9X CD", "GENE_OR_GENE_PRODUCT", 17, 25], ["Ub", "GENE_OR_GENE_PRODUCT", 65, 67], ["Ub", "GENE_OR_GENE_PRODUCT", 107, 109], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 145, 153], ["USP9X CD", "PROTEIN", 17, 25], ["Ub", "PROTEIN", 65, 67], ["Ub binding sites", "DNA", 107, 123], ["S1, S2, and S1\u2032", "DNA", 125, 140], ["USP9X CD", "DNA", 145, 153], ["the functional studies", "TEST", 30, 52], ["novel Ub", "TEST", 59, 67], ["USP9X CD", "OBSERVATION", 17, 25], ["binding sites", "OBSERVATION", 110, 123], ["S1", "ANATOMY", 125, 127], ["S2", "ANATOMY", 129, 131], ["S1", "ANATOMY", 137, 139], ["USP9X CD", "OBSERVATION", 145, 153]]], ["Some USPs contain a C4-type ZnF at the tip of the fingers subdomain.", [["USPs", "GENE_OR_GENE_PRODUCT", 5, 9], ["ZnF", "GENE_OR_GENE_PRODUCT", 28, 31], ["USPs", "PROTEIN", 5, 9], ["C4-type ZnF", "PROTEIN", 20, 31], ["fingers subdomain", "PROTEIN", 50, 67], ["Some USPs", "TEST", 0, 9], ["a C4-type ZnF", "TREATMENT", 18, 31], ["C4", "OBSERVATION_MODIFIER", 20, 22], ["tip", "ANATOMY_MODIFIER", 39, 42], ["fingers", "ANATOMY", 50, 57], ["subdomain", "ANATOMY_MODIFIER", 58, 67]]], ["Only in USP21 was it shown structurally that the ZnF is involved in binding the S2 Ub in a polyUb chain.", [["ZnF", "CHEMICAL", 49, 52], ["USP21", "GENE_OR_GENE_PRODUCT", 8, 13], ["ZnF", "GENE_OR_GENE_PRODUCT", 49, 52], ["S2 Ub", "GENE_OR_GENE_PRODUCT", 80, 85], ["USP21", "PROTEIN", 8, 13], ["ZnF", "PROTEIN", 49, 52], ["S2 Ub", "PROTEIN", 80, 85], ["polyUb chain", "PROTEIN", 91, 103]]], ["Our ZnF mutagenesis and ABP labeling data suggest that an S2 Ub binding site likely exists in USP9X.", [["ZnF", "GENE_OR_GENE_PRODUCT", 4, 7], ["S2 Ub", "GENE_OR_GENE_PRODUCT", 58, 63], ["USP9X", "GENE_OR_GENE_PRODUCT", 94, 99], ["S2 Ub binding site", "DNA", 58, 76], ["USP9X", "PROTEIN", 94, 99], ["Our ZnF mutagenesis", "TEST", 0, 19], ["ABP labeling data", "TEST", 24, 41], ["an S2 Ub binding site", "PROBLEM", 55, 76], ["S2", "OBSERVATION", 58, 60]]], ["CYLD contains a distinctive truncated fingers subdomain without a ZnF motif and a large insertion in box 6.", [["CYLD", "GENE_OR_GENE_PRODUCT", 0, 4], ["CYLD", "PROTEIN", 0, 4], ["distinctive truncated fingers subdomain", "PROTEIN", 16, 55], ["ZnF motif", "PROTEIN", 66, 75], ["box 6", "PROTEIN", 101, 106], ["a distinctive truncated fingers subdomain", "PROBLEM", 14, 55], ["a ZnF motif", "TREATMENT", 64, 75], ["a large insertion in box", "TREATMENT", 80, 104], ["distinctive", "OBSERVATION_MODIFIER", 16, 27], ["truncated", "OBSERVATION_MODIFIER", 28, 37], ["fingers", "OBSERVATION_MODIFIER", 38, 45], ["subdomain", "OBSERVATION_MODIFIER", 46, 55], ["without", "UNCERTAINTY", 56, 63], ["large", "OBSERVATION_MODIFIER", 82, 87], ["insertion", "OBSERVATION_MODIFIER", 88, 97]]], ["The reduced binding surface of the fingers subdomain and the insertion render specificities for the more flexible linear and K63-linked polyUbs through S1 and S1\u2032 sites.", [["poly", "CHEMICAL", 136, 140], ["poly", "CHEMICAL", 136, 140], ["K63", "SIMPLE_CHEMICAL", 125, 128], ["poly", "SIMPLE_CHEMICAL", 136, 140], ["Ubs", "GENE_OR_GENE_PRODUCT", 140, 143], ["\u2032", "GENE_OR_GENE_PRODUCT", 161, 162], ["fingers subdomain", "PROTEIN", 35, 52], ["K63", "PROTEIN", 125, 128], ["Ubs", "DNA", 140, 143], ["S1 and S1\u2032 sites", "DNA", 152, 168], ["The reduced binding surface of the fingers subdomain", "PROBLEM", 0, 52], ["the more flexible linear and K63-linked poly", "TREATMENT", 96, 140], ["reduced", "OBSERVATION_MODIFIER", 4, 11], ["binding", "OBSERVATION_MODIFIER", 12, 19], ["surface", "OBSERVATION_MODIFIER", 20, 27], ["fingers", "ANATOMY", 35, 42], ["S1", "ANATOMY", 152, 154], ["S1", "ANATOMY", 159, 161]]], ["Similarly, a large, conserved insertion of USP9X within box 6 is also involved in the specific recognition of the proximal Ub of a polyUb chain.", [["USP9X", "GENE_OR_GENE_PRODUCT", 43, 48], ["Ub", "GENE_OR_GENE_PRODUCT", 123, 125], ["USP9X", "PROTEIN", 43, 48], ["box 6", "DNA", 56, 61], ["Ub", "PROTEIN", 123, 125], ["polyUb chain", "PROTEIN", 131, 143], ["a large, conserved insertion of USP9X within box", "TREATMENT", 11, 59], ["a polyUb chain", "TREATMENT", 129, 143], ["large", "OBSERVATION_MODIFIER", 13, 18], ["insertion", "OBSERVATION_MODIFIER", 30, 39], ["proximal", "ANATOMY_MODIFIER", 114, 122], ["polyUb", "ANATOMY", 131, 137], ["chain", "ANATOMY_MODIFIER", 138, 143]]], ["There exist two other less conserved, large insertions in the USP9X CD that are disordered in the crystal structure, located farther away from the catalytic binding cleft and may have other unknown functions.DiscussionIn contrast to the broadly conserved ZnF motif in USPs, a structured \u03b2-hairpin insertion within box 6 of the USP catalytic core was somewhat unexpected.", [["USP9X CD", "GENE_OR_GENE_PRODUCT", 62, 70], ["ZnF", "GENE_OR_GENE_PRODUCT", 255, 258], ["USPs", "GENE_OR_GENE_PRODUCT", 268, 272], ["USP", "GENE_OR_GENE_PRODUCT", 327, 330], ["USP9X CD", "DNA", 62, 70], ["ZnF motif", "DNA", 255, 264], ["USPs", "PROTEIN", 268, 272], ["\u03b2-hairpin insertion within box 6", "DNA", 287, 319], ["USP catalytic core", "DNA", 327, 345], ["large insertions in the USP9X CD", "PROBLEM", 38, 70], ["the catalytic binding cleft", "PROBLEM", 143, 170], ["a structured \u03b2-hairpin insertion within box", "TREATMENT", 274, 317], ["the USP catalytic core", "TEST", 323, 345], ["less conserved", "OBSERVATION_MODIFIER", 22, 36], ["large", "OBSERVATION_MODIFIER", 38, 43], ["insertions", "OBSERVATION_MODIFIER", 44, 54], ["USP9X CD", "OBSERVATION", 62, 70], ["crystal", "OBSERVATION_MODIFIER", 98, 105], ["structure", "OBSERVATION_MODIFIER", 106, 115], ["catalytic binding cleft", "OBSERVATION", 147, 170]]], ["Previous bioinformatics analyses revealed such insertion of about 20 residues exist in USP9X, USP9Y, USP24, USP34, USP47, USP48, and CYLD (2).", [["USP9X", "GENE_OR_GENE_PRODUCT", 87, 92], ["USP9Y", "GENE_OR_GENE_PRODUCT", 94, 99], ["USP24", "GENE_OR_GENE_PRODUCT", 101, 106], ["USP34", "GENE_OR_GENE_PRODUCT", 108, 113], ["USP47", "GENE_OR_GENE_PRODUCT", 115, 120], ["USP48", "GENE_OR_GENE_PRODUCT", 122, 127], ["CYLD", "GENE_OR_GENE_PRODUCT", 133, 137], ["USP9X, USP9Y, USP24, USP34, USP47, USP48, and CYLD (2)", "DNA", 87, 141], ["Previous bioinformatics analyses", "TEST", 0, 32], ["such insertion", "TREATMENT", 42, 56], ["USP9X", "TEST", 87, 92], ["USP9Y", "TEST", 94, 99], ["USP24", "TEST", 101, 106], ["USP34", "TEST", 108, 113], ["USP47", "TEST", 115, 120], ["CYLD", "TEST", 133, 137]]], ["However, only CYLD crystal structures were known, and the insertion plays an important role in binding to a proximal Ub.", [["CYLD", "GENE_OR_GENE_PRODUCT", 14, 18], ["CYLD", "PROTEIN", 14, 18], ["CYLD crystal structures", "PROBLEM", 14, 37]]], ["It remains to be determined whether the box 6 insertion in other USPs also plays a role in proximal Ub recognition or is unique to CYLD and USP9X (and likely USP9Y).DiscussionIn assessing USP9X activity, we observed that USP9X is specific for Ub but not for other UBL modifiers.", [["USPs", "GENE_OR_GENE_PRODUCT", 65, 69], ["Ub", "GENE_OR_GENE_PRODUCT", 100, 102], ["CYLD", "GENE_OR_GENE_PRODUCT", 131, 135], ["USP9X", "GENE_OR_GENE_PRODUCT", 140, 145], ["USP9Y", "GENE_OR_GENE_PRODUCT", 158, 163], ["USP9X", "GENE_OR_GENE_PRODUCT", 188, 193], ["USP9X", "GENE_OR_GENE_PRODUCT", 221, 226], ["Ub", "GENE_OR_GENE_PRODUCT", 243, 245], ["UBL", "GENE_OR_GENE_PRODUCT", 264, 267], ["box 6 insertion", "DNA", 40, 55], ["USPs", "DNA", 65, 69], ["Ub", "PROTEIN", 100, 102], ["CYLD", "PROTEIN", 131, 135], ["USP9X", "PROTEIN", 140, 145], ["USP9Y", "PROTEIN", 158, 163], ["USP9X", "PROTEIN", 188, 193], ["USP9X", "PROTEIN", 221, 226], ["Ub", "PROTEIN", 243, 245], ["UBL", "PROTEIN", 264, 267], ["the box 6 insertion", "TREATMENT", 36, 55], ["proximal Ub recognition", "PROBLEM", 91, 114], ["USP9X", "TEST", 140, 145], ["other UBL modifiers", "TREATMENT", 258, 277]]], ["Conversely, several other USPs showed cross-reactivity toward ISG15 and SUMO (29, 30).", [["USPs", "GENE_OR_GENE_PRODUCT", 26, 30], ["ISG15", "GENE_OR_GENE_PRODUCT", 62, 67], ["SUMO", "GENE_OR_GENE_PRODUCT", 72, 76], ["USPs", "PROTEIN", 26, 30], ["ISG15", "PROTEIN", 62, 67], ["SUMO", "PROTEIN", 72, 76], ["several other USPs", "TEST", 12, 30], ["ISG15", "TEST", 62, 67]]], ["The recent crystal structure of USP18 in complex with ISG15 provided a structure-based explanation (10).", [["USP18", "CHEMICAL", 32, 37], ["USP18", "GENE_OR_GENE_PRODUCT", 32, 37], ["ISG15", "GENE_OR_GENE_PRODUCT", 54, 59], ["USP18", "PROTEIN", 32, 37], ["ISG15", "PROTEIN", 54, 59], ["crystal structure", "OBSERVATION", 11, 28]]], ["A hydrophobic patch in ISG15 centered on Trp121, Pro128, and His149 interacts with complementary hydrophobic residues in USP18.", [["Pro128", "CHEMICAL", 49, 55], ["His149", "CHEMICAL", 61, 67], ["ISG15", "GENE_OR_GENE_PRODUCT", 23, 28], ["Trp121", "GENE_OR_GENE_PRODUCT", 41, 47], ["Pro128", "GENE_OR_GENE_PRODUCT", 49, 55], ["His149", "GENE_OR_GENE_PRODUCT", 61, 67], ["USP18", "GENE_OR_GENE_PRODUCT", 121, 126], ["ISG15", "PROTEIN", 23, 28], ["Trp121", "PROTEIN", 41, 47], ["His149", "PROTEIN", 61, 67], ["USP18", "PROTEIN", 121, 126], ["A hydrophobic patch in ISG15", "TREATMENT", 0, 28], ["complementary hydrophobic residues in USP18", "PROBLEM", 83, 126], ["hydrophobic patch", "OBSERVATION", 2, 19], ["hydrophobic residues", "OBSERVATION", 97, 117]]], ["Unlike ISG15, Ub contains polar residues (Arg42, Gln49, and Val70) at these ISG15 equivalent sites, which would complement polar residues found in Ub-reactive USPs such as USP7 (10).", [["Arg42", "CHEMICAL", 42, 47], ["Gln49", "CHEMICAL", 49, 54], ["Val70", "CHEMICAL", 60, 65], ["ISG15", "GENE_OR_GENE_PRODUCT", 7, 12], ["Ub", "GENE_OR_GENE_PRODUCT", 14, 16], ["Arg42", "GENE_OR_GENE_PRODUCT", 42, 47], ["Gln49", "GENE_OR_GENE_PRODUCT", 49, 54], ["Val70", "GENE_OR_GENE_PRODUCT", 60, 65], ["ISG15", "GENE_OR_GENE_PRODUCT", 76, 81], ["Ub", "GENE_OR_GENE_PRODUCT", 147, 149], ["USP7", "GENE_OR_GENE_PRODUCT", 172, 176], ["ISG15", "PROTEIN", 7, 12], ["Ub", "PROTEIN", 14, 16], ["Gln49", "PROTEIN", 49, 54], ["Val70", "PROTEIN", 60, 65], ["ISG15 equivalent sites", "PROTEIN", 76, 98], ["Ub", "PROTEIN", 147, 149], ["USPs", "PROTEIN", 159, 163], ["USP7", "PROTEIN", 172, 176], ["polar residues", "TEST", 26, 40], ["Arg42", "TEST", 42, 47], ["Gln49", "TEST", 49, 54], ["USP7", "TEST", 172, 176], ["polar residues", "OBSERVATION", 26, 40], ["reactive USPs", "OBSERVATION", 150, 163]]], ["Like USP7, USP9X also contains polar residues at this binding interface that would be unfavorable for ISG15 (SI Appendix, Fig. S16).", [["USP7", "GENE_OR_GENE_PRODUCT", 5, 9], ["USP9X", "GENE_OR_GENE_PRODUCT", 11, 16], ["ISG15", "GENE_OR_GENE_PRODUCT", 102, 107], ["USP7", "PROTEIN", 5, 9], ["USP9X", "PROTEIN", 11, 16], ["ISG15", "PROTEIN", 102, 107], ["USP9X", "TEST", 11, 16], ["polar residues at this binding interface", "PROBLEM", 31, 71], ["ISG15 (SI Appendix", "PROBLEM", 102, 120], ["polar residues", "OBSERVATION", 31, 45]]], ["Neither is USP9X active against NEDD8, the most homologous UBL to Ub.", [["USP9X", "GENE_OR_GENE_PRODUCT", 11, 16], ["NEDD8", "GENE_OR_GENE_PRODUCT", 32, 37], ["USP9X", "PROTEIN", 11, 16], ["NEDD8", "PROTEIN", 32, 37], ["UBL", "PROTEIN", 59, 62], ["NEDD8", "PROBLEM", 32, 37]]], ["The complex structure of USP21 with linear diUb provided insight into how USP21 distinguishes Ub from NEDD8 (9).", [["USP21", "GENE_OR_GENE_PRODUCT", 25, 30], ["diUb", "GENE_OR_GENE_PRODUCT", 43, 47], ["USP21", "GENE_OR_GENE_PRODUCT", 74, 79], ["Ub", "GENE_OR_GENE_PRODUCT", 94, 96], ["NEDD8", "GENE_OR_GENE_PRODUCT", 102, 107], ["USP21", "PROTEIN", 25, 30], ["diUb", "PROTEIN", 43, 47], ["USP21", "PROTEIN", 74, 79], ["Ub", "PROTEIN", 94, 96], ["NEDD8 (9)", "PROTEIN", 102, 111], ["complex", "OBSERVATION_MODIFIER", 4, 11], ["structure", "OBSERVATION_MODIFIER", 12, 21]]], ["A conserved Glu304 residue in USP21 interacts specifically with the guanidinium group of Arg72 of Ub C-terminal tail.", [["USP21", "CHEMICAL", 30, 35], ["guanidinium", "CHEMICAL", 68, 79], ["Glu304", "CHEMICAL", 12, 18], ["guanidinium", "CHEMICAL", 68, 79], ["Arg72", "CHEMICAL", 89, 94], ["Glu304", "GENE_OR_GENE_PRODUCT", 12, 18], ["USP21", "AMINO_ACID", 30, 35], ["Arg72", "AMINO_ACID", 89, 94], ["Ub", "GENE_OR_GENE_PRODUCT", 98, 100], ["USP21", "PROTEIN", 30, 35], ["Arg72", "PROTEIN", 89, 94], ["Ub C-terminal tail", "PROTEIN", 98, 116], ["A conserved Glu304 residue", "PROBLEM", 0, 26], ["Glu304 residue", "OBSERVATION", 12, 26], ["Ub", "ANATOMY_MODIFIER", 98, 100], ["C-terminal tail", "ANATOMY", 101, 116]]], ["The equivalent position in NEDD8 is an Ala.", [["Ala", "CHEMICAL", 39, 42], ["NEDD8", "GENE_OR_GENE_PRODUCT", 27, 32], ["NEDD8", "PROTEIN", 27, 32], ["equivalent", "OBSERVATION_MODIFIER", 4, 14], ["position", "OBSERVATION_MODIFIER", 15, 23], ["NEDD8", "OBSERVATION", 27, 32], ["Ala", "OBSERVATION_MODIFIER", 39, 42]]], ["A secondary polar patch of USP21 (Glu427 and Lys448) in the fingers subdomain interact with the \u03b21/\u03b22 loop of Ub but would clash sterically with and repel the larger, charged residues in NEDD8.", [["USP21", "CHEMICAL", 27, 32], ["Glu427", "CHEMICAL", 34, 40], ["Lys448", "CHEMICAL", 45, 51], ["USP21", "GENE_OR_GENE_PRODUCT", 27, 32], ["Glu427", "GENE_OR_GENE_PRODUCT", 34, 40], ["Lys448", "AMINO_ACID", 45, 51], ["\u03b21", "GENE_OR_GENE_PRODUCT", 96, 98], ["Ub", "GENE_OR_GENE_PRODUCT", 110, 112], ["NEDD8", "GENE_OR_GENE_PRODUCT", 187, 192], ["USP21", "PROTEIN", 27, 32], ["Lys448", "PROTEIN", 45, 51], ["fingers subdomain", "PROTEIN", 60, 77], ["\u03b21", "PROTEIN", 96, 98], ["\u03b22 loop", "PROTEIN", 99, 106], ["Ub", "PROTEIN", 110, 112], ["NEDD8", "PROTEIN", 187, 192], ["A secondary polar patch of USP21", "TREATMENT", 0, 32], ["the \u03b21/\u03b22 loop of Ub", "TREATMENT", 92, 112], ["secondary", "OBSERVATION_MODIFIER", 2, 11], ["polar patch", "OBSERVATION", 12, 23], ["fingers", "ANATOMY", 60, 67], ["larger", "OBSERVATION_MODIFIER", 159, 165], ["charged residues", "OBSERVATION", 167, 183]]], ["Not surprisingly, USP9X is conserved at both sites (Glu1688 and Asp1761/Lys1782), which explains why NEDD8 is not a substrate for USP9X.DiscussionAlthough the catalytic triad in the apo USP9X structure is properly aligned, both the turnover number kcat and the Michaelis constant Km of USP9X CD toward Ub-AMC are much lower than those of USP7 CD (4).", [["Glu1688", "CHEMICAL", 52, 59], ["Asp", "CHEMICAL", 64, 67], ["USP9X", "GENE_OR_GENE_PRODUCT", 18, 23], ["NEDD8", "GENE_OR_GENE_PRODUCT", 101, 106], ["USP9X", "GENE_OR_GENE_PRODUCT", 130, 135], ["apo USP9X", "GENE_OR_GENE_PRODUCT", 182, 191], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 286, 294], ["Ub-AMC", "GENE_OR_GENE_PRODUCT", 302, 308], ["USP7", "GENE_OR_GENE_PRODUCT", 338, 342], ["USP9X", "PROTEIN", 18, 23], ["NEDD8", "PROTEIN", 101, 106], ["USP9X", "PROTEIN", 130, 135], ["catalytic triad", "PROTEIN", 159, 174], ["apo USP9X structure", "PROTEIN", 182, 201], ["Ub", "PROTEIN", 302, 304], ["AMC", "PROTEIN", 305, 308], ["USP7", "PROTEIN", 338, 342], ["USP9X", "TEST", 18, 23], ["Glu1688", "TEST", 52, 59], ["Asp", "TEST", 64, 67], ["Lys", "TEST", 72, 75], ["USP9X", "PROBLEM", 130, 135], ["the catalytic triad in the apo USP9X structure", "PROBLEM", 155, 201], ["USP9X CD", "TEST", 286, 294], ["Ub", "TEST", 302, 304], ["USP7 CD", "TEST", 338, 345], ["USP9X", "OBSERVATION", 18, 23]]], ["This suggests additional structural restraints may play a role.", [["additional structural restraints", "TREATMENT", 14, 46], ["structural restraints", "OBSERVATION", 25, 46]]], ["We noticed the side chain of Gln1683 in the switching loop forms hydrogen bonds with the side chain of the catalytic Cys1566 and the main-chain carbonyl group of Gly1878 in the neighboring blocking loop BL2 and blocks the entrance of Ub C terminus to the active site cleft (SI Appendix, Fig. S1B).", [["Gln1683", "CHEMICAL", 29, 36], ["Cys1566", "CHEMICAL", 117, 124], ["Gly1878", "CHEMICAL", 162, 169], ["Gln1683", "CHEMICAL", 29, 36], ["hydrogen", "CHEMICAL", 65, 73], ["Cys", "CHEMICAL", 117, 120], ["carbonyl", "CHEMICAL", 144, 152], ["Gly", "CHEMICAL", 162, 165], ["C", "CHEMICAL", 237, 238], ["Gln1683", "AMINO_ACID", 29, 36], ["Cys1566", "AMINO_ACID", 117, 124], ["Gly1878", "AMINO_ACID", 162, 169], ["Gln1683", "PROTEIN", 29, 36], ["catalytic Cys1566", "PROTEIN", 107, 124], ["BL2", "PROTEIN", 203, 206], ["Ub C terminus", "PROTEIN", 234, 247], ["the catalytic Cys", "TEST", 103, 120], ["Ub C terminus", "TREATMENT", 234, 247], ["side chain", "OBSERVATION_MODIFIER", 15, 25], ["hydrogen bonds", "OBSERVATION", 65, 79], ["main", "OBSERVATION_MODIFIER", 133, 137], ["blocking loop", "OBSERVATION", 189, 202], ["entrance", "OBSERVATION_MODIFIER", 222, 230], ["active", "OBSERVATION_MODIFIER", 255, 261], ["site", "OBSERVATION_MODIFIER", 262, 266], ["cleft", "OBSERVATION", 267, 272], ["SI Appendix", "OBSERVATION", 274, 285]]], ["For comparison, in the USP7/Ub-aldehyde complex structure, the switching loop in USP7 adopts an \u201cout-conformation\u201d (6), and the equivalent Gln293 is positioned away from the catalytic cysteine (SI Appendix, Fig. S1C).", [["aldehyde", "CHEMICAL", 31, 39], ["aldehyde", "CHEMICAL", 31, 39], ["Gln293", "CHEMICAL", 139, 145], ["cysteine", "CHEMICAL", 184, 192], ["USP7", "GENE_OR_GENE_PRODUCT", 23, 27], ["Ub", "GENE_OR_GENE_PRODUCT", 28, 30], ["USP7", "GENE_OR_GENE_PRODUCT", 81, 85], ["Gln293", "GENE_OR_GENE_PRODUCT", 139, 145], ["cysteine", "AMINO_ACID", 184, 192], ["S1C", "GENE_OR_GENE_PRODUCT", 212, 215], ["USP7", "PROTEIN", 23, 27], ["Ub", "PROTEIN", 28, 30], ["aldehyde complex", "PROTEIN", 31, 47], ["USP7", "PROTEIN", 81, 85], ["Gln293", "PROTEIN", 139, 145], ["the switching loop in USP7", "TREATMENT", 59, 85], ["catalytic cysteine", "OBSERVATION", 174, 192], ["Appendix", "ANATOMY", 197, 205]]], ["Gln1683Ala mutation did not increase the kcat of USP9X CD, but rather significantly increased Km toward monoUb substrate.", [["Gln", "CHEMICAL", 0, 3], ["K", "CHEMICAL", 94, 95], ["Gln", "CHEMICAL", 0, 3], ["Gln1683Ala", "GENE_OR_GENE_PRODUCT", 0, 10], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 49, 57], ["Km", "GENE_OR_GENE_PRODUCT", 94, 96], ["USP9X CD", "PROTEIN", 49, 57], ["monoUb substrate", "PROTEIN", 104, 120], ["Gln", "TEST", 0, 3], ["USP9X CD", "PROBLEM", 49, 57], ["monoUb substrate", "PROBLEM", 104, 120]]], ["Kinetics of cleavage assay of IQF-K11 diUb substrate did not show any significant differences between the Q1683A mutant and the WT (SI Appendix, Fig. S13C).", [["IQF-K11", "GENE_OR_GENE_PRODUCT", 30, 37], ["IQF", "PROTEIN", 30, 33], ["K11 diUb substrate", "PROTEIN", 34, 52], ["Q1683A mutant", "PROTEIN", 106, 119], ["Fig. S13C", "PROTEIN", 145, 154], ["cleavage assay", "TEST", 12, 26], ["IQF", "TEST", 30, 33]]], ["These observations suggest that Gln1683 is more important for the binding of the Ub tail of a monoUb to the catalytic cleft than for the native isopeptide in diUb or polyUb substrates.", [["Gln1683", "CHEMICAL", 32, 39], ["Gln1683", "GENE_OR_GENE_PRODUCT", 32, 39], ["Ub", "GENE_OR_GENE_PRODUCT", 81, 83], ["monoUb", "GENE_OR_GENE_PRODUCT", 94, 100], ["diUb", "SIMPLE_CHEMICAL", 158, 162], ["Gln1683", "PROTEIN", 32, 39], ["Ub tail", "PROTEIN", 81, 88], ["monoUb", "PROTEIN", 94, 100], ["catalytic cleft", "PROTEIN", 108, 123], ["diUb", "PROTEIN", 158, 162], ["These observations", "TEST", 0, 18], ["polyUb substrates", "PROBLEM", 166, 183]]], ["Instead, the interaction between the proximal Ub and the potential USP9X CD S1\u2032 site may help to orient the isopeptide of a diUb in the catalytic cleft for cleavage.DiscussionAnother notable finding in this study is that a noncatalytic cysteine 1808 in USP9X was specifically labeled by an MA warhead introduced in the K11-diUb-MA1 probe.", [["cysteine 1808", "CHEMICAL", 236, 249], ["cysteine", "CHEMICAL", 236, 244], ["Ub", "GENE_OR_GENE_PRODUCT", 46, 48], ["USP9X", "GENE_OR_GENE_PRODUCT", 67, 72], ["diUb", "GENE_OR_GENE_PRODUCT", 124, 128], ["cysteine", "AMINO_ACID", 236, 244], ["USP9X", "GENE_OR_GENE_PRODUCT", 253, 258], ["K11", "GENE_OR_GENE_PRODUCT", 319, 322], ["proximal Ub", "PROTEIN", 37, 48], ["USP9X CD S1\u2032 site", "DNA", 67, 84], ["diUb", "PROTEIN", 124, 128], ["USP9X", "PROTEIN", 253, 258], ["K11-diUb-MA1 probe", "DNA", 319, 337], ["a diUb in the catalytic cleft", "TREATMENT", 122, 151], ["this study", "TEST", 202, 212], ["a noncatalytic cysteine", "TEST", 221, 244], ["USP9X", "TEST", 253, 258], ["an MA warhead", "TREATMENT", 287, 300], ["the K11", "TEST", 315, 322], ["proximal", "ANATOMY_MODIFIER", 37, 45], ["Ub", "ANATOMY_MODIFIER", 46, 48]]], ["Cys1808 is in blocking loop BL1 and 19 \u00c5 away from the catalytic cysteine.", [["Cys1808", "CHEMICAL", 0, 7], ["Cys", "CHEMICAL", 0, 3], ["cysteine", "CHEMICAL", 65, 73], ["Cys", "AMINO_ACID", 0, 3], ["cysteine", "AMINO_ACID", 65, 73], ["loop BL1", "PROTEIN", 23, 31], ["19 \u00c5", "PROTEIN", 36, 40], ["Cys", "TEST", 0, 3]]], ["A groove between BL1 and BL2 loops likely traps the diUb isopeptide in a nonproductive conformation (Fig. 4C) and places Cys1808 in proximity to the warhead for labeling.", [["Cys1808", "CHEMICAL", 121, 128], ["diUb", "CHEMICAL", 52, 56], ["Cys", "CHEMICAL", 121, 124], ["BL1", "GENE_OR_GENE_PRODUCT", 17, 20], ["BL1 and BL2 loops", "PROTEIN", 17, 34], ["diUb isopeptide", "PROTEIN", 52, 67], ["A groove between BL1 and BL2 loops", "PROBLEM", 0, 34], ["groove", "ANATOMY_MODIFIER", 2, 8], ["likely", "UNCERTAINTY", 35, 41], ["traps", "OBSERVATION", 42, 47], ["nonproductive", "OBSERVATION_MODIFIER", 73, 86]]], ["This specific labeling event by a noncatalytic cysteine residue revealed a possible search motion of the flexible S1 Ub C-terminal tail and the attached proximal Ub during active site engagement (Fig. 4C).", [["cysteine", "CHEMICAL", 47, 55], ["cysteine", "AMINO_ACID", 47, 55], ["Ub", "GENE_OR_GENE_PRODUCT", 162, 164], ["flexible S1 Ub C-terminal tail", "PROTEIN", 105, 135], ["proximal Ub", "PROTEIN", 153, 164], ["a noncatalytic cysteine residue", "TEST", 32, 63], ["active site engagement", "TREATMENT", 172, 194], ["possible", "UNCERTAINTY", 75, 83], ["search motion", "OBSERVATION", 84, 97], ["flexible", "ANATOMY_MODIFIER", 105, 113], ["S1", "ANATOMY_MODIFIER", 114, 116], ["Ub", "ANATOMY_MODIFIER", 117, 119], ["C-terminal tail", "ANATOMY", 120, 135], ["proximal", "ANATOMY_MODIFIER", 153, 161], ["Ub", "ANATOMY_MODIFIER", 162, 164], ["active", "OBSERVATION_MODIFIER", 172, 178], ["site engagement", "OBSERVATION", 179, 194]]], ["The elongated \u03b2-hairpin insertion likely restricts the motion of the proximal Ub and entraps the isopeptide into the groove between BL1 and BL2, leading to the labeling of Cys1808 by the MA warhead in the K11-diUb-MA1 probe (Fig. 4C).", [["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 14, 23], ["Ub", "GENE_OR_GENE_PRODUCT", 78, 80], ["BL1", "GENE_OR_GENE_PRODUCT", 132, 135], ["BL2", "GENE_OR_GENE_PRODUCT", 140, 143], ["Cys1808", "GENE_OR_GENE_PRODUCT", 172, 179], ["\u03b2-hairpin", "PROTEIN", 14, 23], ["proximal Ub", "PROTEIN", 69, 80], ["BL1", "PROTEIN", 132, 135], ["BL2", "PROTEIN", 140, 143], ["Cys1808", "PROTEIN", 172, 179], ["K11-diUb-MA1 probe", "DNA", 205, 223], ["The elongated \u03b2-hairpin insertion", "TREATMENT", 0, 33], ["the K11", "TEST", 201, 208], ["elongated", "OBSERVATION_MODIFIER", 4, 13], ["\u03b2-hairpin insertion", "OBSERVATION", 14, 33], ["motion", "OBSERVATION_MODIFIER", 55, 61], ["proximal", "ANATOMY_MODIFIER", 69, 77], ["Ub", "ANATOMY_MODIFIER", 78, 80], ["groove", "ANATOMY_MODIFIER", 117, 123]]], ["By this notion, the removal of \u03b2-hairpin insertion in USP9X CD resulted in reduced labeling efficiency of Cys1808 by the K11-diUb-MA1 probe (Fig. 4A), likely due to reduced contact time of the MA warhead with Cys1808.", [["USP9X", "CHEMICAL", 54, 59], ["Cys1808", "CHEMICAL", 106, 113], ["Cys1808", "CHEMICAL", 209, 216], ["\u03b2-hairpin", "CHEMICAL", 31, 40], ["USP9X CD", "CHEMICAL", 54, 62], ["Cys", "CHEMICAL", 106, 109], ["Cys1808", "CHEMICAL", 209, 216], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 31, 40], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 54, 62], ["Cys1808", "AMINO_ACID", 106, 113], ["MA", "GENE_OR_GENE_PRODUCT", 193, 195], ["Cys1808", "SIMPLE_CHEMICAL", 209, 216], ["\u03b2-hairpin insertion", "DNA", 31, 50], ["USP9X CD", "DNA", 54, 62], ["K11-diUb-MA1 probe", "DNA", 121, 139], ["Cys1808", "PROTEIN", 209, 216], ["the removal of \u03b2-hairpin insertion in USP9X CD", "TREATMENT", 16, 62], ["reduced labeling efficiency of Cys", "PROBLEM", 75, 109], ["the K11", "TEST", 117, 124], ["reduced", "OBSERVATION_MODIFIER", 75, 82], ["labeling efficiency", "OBSERVATION", 83, 102], ["likely due to", "UNCERTAINTY", 151, 164]]], ["Furthermore, a Gln1683Ala mutation in USP9X, intended to unblock the active site cleft, improved the active site Cys1566 labeling markedly (SI Appendix, Fig. S13A), mimicking the effect of \u03b2-hairpin deletion albeit with greater efficiency.", [["USP9X", "CHEMICAL", 38, 43], ["Cys1566", "CHEMICAL", 113, 120], ["Cys", "CHEMICAL", 113, 116], ["Gln1683Ala", "GENE_OR_GENE_PRODUCT", 15, 25], ["USP9X", "GENE_OR_GENE_PRODUCT", 38, 43], ["Cys1566", "AMINO_ACID", 113, 120], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 189, 198], ["USP9X", "PROTEIN", 38, 43], ["\u03b2-hairpin deletion", "DNA", 189, 207], ["a Gln1683Ala mutation in USP9X", "PROBLEM", 13, 43], ["the active site cleft", "PROBLEM", 65, 86], ["\u03b2-hairpin deletion", "PROBLEM", 189, 207], ["active", "OBSERVATION_MODIFIER", 69, 75], ["site", "OBSERVATION_MODIFIER", 76, 80], ["cleft", "OBSERVATION", 81, 86], ["improved", "OBSERVATION_MODIFIER", 88, 96], ["active", "OBSERVATION_MODIFIER", 101, 107], ["greater efficiency", "OBSERVATION_MODIFIER", 220, 238]]], ["Differently, we observed preference of Cys1808 labeling over the catalytic Cys1566 by K11-diUb-MA1 probe in the USP9X ZnF mutant (Fig. 4A).", [["Cys1566", "CHEMICAL", 75, 82], ["Cys1808", "CHEMICAL", 39, 46], ["Cys1566", "CHEMICAL", 75, 82], ["Cys1808", "GENE_OR_GENE_PRODUCT", 39, 46], ["K11", "GENE_OR_GENE_PRODUCT", 86, 89], ["USP9X ZnF", "GENE_OR_GENE_PRODUCT", 112, 121], ["catalytic Cys1566 by K11-diUb-MA1 probe", "DNA", 65, 104], ["USP9X ZnF mutant", "PROTEIN", 112, 128], ["Fig. 4A", "PROTEIN", 130, 137], ["the catalytic Cys", "TEST", 61, 78], ["K11", "TEST", 86, 89], ["diUb", "TEST", 90, 94]]], ["This observation suggests that the interaction between the USP9X ZnF and the Ub N-terminal region may influence the binding mode of the S1 Ub C-terminal tail and the attached proximal Ub.DiscussionAlthough DUBs are thought to possess endo- or exo-Ub chain cleavage specificity, few tools were available to interrogate the two cleavage modes.", [["N", "CHEMICAL", 80, 81], ["USP9X", "GENE_OR_GENE_PRODUCT", 59, 64], ["ZnF", "GENE_OR_GENE_PRODUCT", 65, 68], ["Ub", "GENE_OR_GENE_PRODUCT", 77, 79], ["DUB", "GENE_OR_GENE_PRODUCT", 206, 209], ["USP9X ZnF", "PROTEIN", 59, 68], ["Ub N-terminal region", "PROTEIN", 77, 97], ["S1 Ub C-terminal tail", "PROTEIN", 136, 157], ["DUB", "PROTEIN", 206, 209], ["Ub chain", "PROTEIN", 247, 255], ["This observation", "TEST", 0, 16], ["the USP9X ZnF", "TEST", 55, 68], ["DUBs", "PROBLEM", 206, 210], ["endo", "TEST", 234, 238], ["terminal", "ANATOMY_MODIFIER", 82, 90], ["binding mode", "OBSERVATION", 116, 128], ["S1", "ANATOMY_MODIFIER", 136, 138], ["Ub", "ANATOMY_MODIFIER", 139, 141], ["C-terminal tail", "ANATOMY", 142, 157], ["proximal", "ANATOMY_MODIFIER", 175, 183]]], ["To address this question, we designed and generated two types of triUb probes (Fig. 2B).", [["triUb probes", "DNA", 65, 77], ["triUb probes", "TREATMENT", 65, 77]]], ["We observed efficient endo-cleavage of the K11- and K63-, but not the K48-linked triUb-NC1-CL2 substrates (Fig. 5B).", [["K11", "GENE_OR_GENE_PRODUCT", 43, 46], ["K63", "GENE_OR_GENE_PRODUCT", 52, 55], ["triUb-NC1", "GENE_OR_GENE_PRODUCT", 81, 90], ["K11", "PROTEIN", 43, 46], ["K63", "PROTEIN", 52, 55], ["K48", "PROTEIN", 70, 73], ["triUb", "PROTEIN", 81, 86], ["NC1", "PROTEIN", 87, 90], ["CL2 substrates", "PROTEIN", 91, 105], ["Fig. 5B", "PROTEIN", 107, 114], ["the K11", "TEST", 39, 46], ["K63", "TEST", 52, 55], ["the K48", "TEST", 66, 73]]], ["When comparing the endo- and exo-modes of Ub chain processing using the triUb-MA1-CL2 probes, we found that an exo-cleavage is exclusively preferred for K48-polyUb chain.", [["Ub", "GENE_OR_GENE_PRODUCT", 42, 44], ["K48-polyUb chain", "GENE_OR_GENE_PRODUCT", 153, 169], ["endo", "PROTEIN", 19, 23], ["Ub chain", "PROTEIN", 42, 50], ["triUb-MA1-CL2 probes", "DNA", 72, 92], ["K48", "PROTEIN", 153, 156], ["polyUb chain", "PROTEIN", 157, 169], ["the endo", "TEST", 15, 23], ["an exo-cleavage", "PROBLEM", 108, 123]]], ["For K11-triUb chain, USP9X CD prefers endo- over exo-cleavage.", [["K11-triUb chain", "GENE_OR_GENE_PRODUCT", 4, 19], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 21, 29], ["K11", "PROTEIN", 4, 7], ["triUb chain", "PROTEIN", 8, 19], ["USP9X CD", "PROTEIN", 21, 29], ["endo- over exo-cleavage", "PROTEIN", 38, 61], ["K11", "TEST", 4, 7], ["endo", "TEST", 38, 42]]], ["These observations revealed linkage-dependent polyUb cleavage modes of the USP9X CD.", [["USP9X CD", "GENE_OR_GENE_PRODUCT", 75, 83], ["USP9X CD", "DNA", 75, 83], ["These observations", "TEST", 0, 18], ["linkage-dependent polyUb cleavage", "PROBLEM", 28, 61], ["dependent", "OBSERVATION_MODIFIER", 36, 45], ["polyUb cleavage", "OBSERVATION", 46, 61], ["USP9X CD", "OBSERVATION", 75, 83]]], ["Our results also suggest that the unique \u03b2-hairpin in box 6 facilitates the efficient endo-cleavage of K63-polyUb chain based on the reduced cleavage of K63-linked triUb-NC1-CL2 by the USP9X \u03b2-hairpin deletion mutant (Fig. 5E).DiscussionInterestingly, multiple E3 ligases are known to interact with USP9X, including HECT-type E3 ligases ITCH and SMURF1, and RING-type E3 ligases MARCH7, Mind bomb 1, and TRIM25 (16\u201318, 36, 37).", [["K63", "GENE_OR_GENE_PRODUCT", 103, 106], ["K63", "GENE_OR_GENE_PRODUCT", 153, 156], ["triUb-NC1-CL2", "GENE_OR_GENE_PRODUCT", 164, 177], ["USP9X", "GENE_OR_GENE_PRODUCT", 185, 190], ["E3", "GENE_OR_GENE_PRODUCT", 261, 263], ["USP9X", "GENE_OR_GENE_PRODUCT", 299, 304], ["HECT", "GENE_OR_GENE_PRODUCT", 316, 320], ["E3", "GENE_OR_GENE_PRODUCT", 326, 328], ["ITCH", "GENE_OR_GENE_PRODUCT", 337, 341], ["SMURF1", "GENE_OR_GENE_PRODUCT", 346, 352], ["RING-type E3", "GENE_OR_GENE_PRODUCT", 358, 370], ["MARCH7", "GENE_OR_GENE_PRODUCT", 379, 385], ["Mind bomb 1", "GENE_OR_GENE_PRODUCT", 387, 398], ["TRIM25", "GENE_OR_GENE_PRODUCT", 404, 410], ["\u03b2-hairpin", "PROTEIN", 41, 50], ["box 6", "PROTEIN", 54, 59], ["K63", "PROTEIN", 103, 106], ["polyUb chain", "PROTEIN", 107, 119], ["K63", "PROTEIN", 153, 156], ["triUb", "PROTEIN", 164, 169], ["NC1", "PROTEIN", 170, 173], ["CL2", "PROTEIN", 174, 177], ["USP9X \u03b2-hairpin deletion mutant", "PROTEIN", 185, 216], ["Fig. 5E", "PROTEIN", 218, 225], ["E3 ligases", "PROTEIN", 261, 271], ["USP9X", "PROTEIN", 299, 304], ["HECT", "PROTEIN", 316, 320], ["E3 ligases", "PROTEIN", 326, 336], ["ITCH", "PROTEIN", 337, 341], ["SMURF1", "PROTEIN", 346, 352], ["RING-type E3 ligases", "PROTEIN", 358, 378], ["MARCH7", "PROTEIN", 379, 385], ["Mind bomb 1", "PROTEIN", 387, 398], ["TRIM25", "PROTEIN", 404, 410], ["16\u201318, 36, 37", "PROTEIN", 412, 425], ["the unique \u03b2-hairpin in box", "TREATMENT", 30, 57], ["K63-polyUb chain", "TREATMENT", 103, 119], ["K63", "TEST", 153, 156], ["HECT", "TEST", 316, 320], ["SMURF1", "TEST", 346, 352]]], ["The formation of an E3 ligase and DUB complex is a recurring theme observed for many DUBs and probably plays a role in more precise control of substrate ubiquitination and the chain linkages through trimming and editing.", [["E3", "GENE_OR_GENE_PRODUCT", 20, 22], ["DUB", "GENE_OR_GENE_PRODUCT", 34, 37], ["DUBs", "GENE_OR_GENE_PRODUCT", 85, 89], ["E3 ligase", "PROTEIN", 20, 29], ["DUB complex", "PROTEIN", 34, 45], ["DUBs", "PROTEIN", 85, 89], ["an E3 ligase", "PROBLEM", 17, 29], ["DUB complex", "PROBLEM", 34, 45], ["many DUBs", "PROBLEM", 80, 89], ["E3 ligase", "OBSERVATION", 20, 29], ["DUB", "OBSERVATION_MODIFIER", 34, 37], ["complex", "OBSERVATION_MODIFIER", 38, 45]]], ["OTU-type DUB A20 contains both a ligase domain and a DUB domain and shows an exo-cleavage preference for K48-chain and endo-cleavage activity for the K63-chain, presumably allowing the assembly of an intact degradation signal (K48) while maintaining rapid control of signaling event through the K63-polyUb chain (38).", [["DUB A20", "GENE_OR_GENE_PRODUCT", 9, 16], ["DUB A20", "PROTEIN", 9, 16], ["ligase domain", "PROTEIN", 33, 46], ["DUB domain", "PROTEIN", 53, 63], ["K48", "PROTEIN", 105, 108], ["K63-chain", "PROTEIN", 150, 159], ["K48", "PROTEIN", 227, 230], ["K63", "PROTEIN", 295, 298], ["polyUb chain", "PROTEIN", 299, 311], ["a ligase domain", "TEST", 31, 46], ["a DUB domain", "TEST", 51, 63], ["K48-chain", "TREATMENT", 105, 114], ["endo-cleavage activity for the K63-chain", "TREATMENT", 119, 159], ["signaling event", "PROBLEM", 267, 282], ["type DUB", "OBSERVATION_MODIFIER", 4, 12], ["A20", "OBSERVATION", 13, 16], ["ligase domain", "OBSERVATION", 33, 46]]], ["USP9X plays multiple roles in cell cycle, endocytosis, and degradation.", [["cell", "ANATOMY", 30, 34], ["USP9X", "CHEMICAL", 0, 5], ["USP9X", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 30, 34], ["USP9X", "PROTEIN", 0, 5], ["endocytosis", "PROBLEM", 42, 53], ["multiple", "OBSERVATION_MODIFIER", 12, 20], ["cell cycle", "OBSERVATION", 30, 40]]], ["The endo-cleavage preference for K11- and exo-cleavage preference for K48-polyUb chains of USP9X may fit in its role in the different cellular processes, which needs to be further tested in a cellular system.DiscussionIn summary, while monoUb and diUbs provide a snapshot of substrate recognition by DUBs, our activity-based hybrid triUb probes allow deeper interrogation of the polyUb chain binding modes of USP9X and reveal interesting details.", [["cellular", "ANATOMY", 134, 142], ["cellular system", "ANATOMY", 192, 207], ["USP9X", "CHEMICAL", 91, 96], ["K11", "GENE_OR_GENE_PRODUCT", 33, 36], ["USP9X", "GENE_OR_GENE_PRODUCT", 91, 96], ["cellular", "CELL", 134, 142], ["cellular", "CELL", 192, 200], ["monoUb", "GENE_OR_GENE_PRODUCT", 236, 242], ["diUbs", "SIMPLE_CHEMICAL", 247, 252], ["DUBs", "GENE_OR_GENE_PRODUCT", 300, 304], ["USP9X", "GENE_OR_GENE_PRODUCT", 409, 414], ["K11", "PROTEIN", 33, 36], ["K48", "PROTEIN", 70, 73], ["polyUb chains", "PROTEIN", 74, 87], ["USP9X", "PROTEIN", 91, 96], ["monoUb", "PROTEIN", 236, 242], ["diUbs", "DNA", 247, 252], ["DUBs", "PROTEIN", 300, 304], ["hybrid triUb probes", "DNA", 325, 344], ["polyUb chain", "PROTEIN", 379, 391], ["USP9X", "PROTEIN", 409, 414], ["K11", "TEST", 33, 36], ["K48-polyUb chains", "TREATMENT", 70, 87], ["USP9X", "PROBLEM", 91, 96], ["hybrid triUb probes", "TREATMENT", 325, 344], ["deeper interrogation", "TEST", 351, 371], ["USP9X", "TEST", 409, 414]]], ["Linkage-dependent endo- and exo-Ub chain cleavage modes were clearly defined using the two types of hybrid triUb probes.", [["triUb", "GENE_OR_GENE_PRODUCT", 107, 112], ["hybrid triUb probes", "DNA", 100, 119], ["Linkage", "TEST", 0, 7], ["dependent endo", "TREATMENT", 8, 22], ["exo-Ub chain cleavage modes", "TREATMENT", 28, 55], ["hybrid triUb probes", "TREATMENT", 100, 119], ["dependent", "OBSERVATION_MODIFIER", 8, 17], ["endo", "OBSERVATION_MODIFIER", 18, 22], ["Ub", "ANATOMY_MODIFIER", 32, 34], ["chain cleavage", "OBSERVATION", 35, 49]]], ["We propose a model where the USP9X CD accommodates a chain of three Ubs, with the distal and proximal Ubs occupying the S2 and S1\u2032 sites close to the ZnF motif and \u03b2-hairpin insertion, respectively (Fig. 5A).", [["USP9X", "GENE_OR_GENE_PRODUCT", 29, 34], ["Ubs", "GENE_OR_GENE_PRODUCT", 68, 71], ["Ubs", "GENE_OR_GENE_PRODUCT", 102, 105], ["USP9X CD", "PROTEIN", 29, 37], ["Ubs", "PROTEIN", 68, 71], ["distal and proximal Ubs", "PROTEIN", 82, 105], ["S2 and S1\u2032 sites", "DNA", 120, 136], ["ZnF motif", "DNA", 150, 159], ["\u03b2-hairpin insertion", "DNA", 164, 183], ["the distal and proximal Ubs", "PROBLEM", 78, 105], ["the ZnF motif", "TREATMENT", 146, 159], ["\u03b2-hairpin insertion", "TREATMENT", 164, 183], ["chain", "OBSERVATION_MODIFIER", 53, 58], ["distal", "ANATOMY_MODIFIER", 82, 88], ["proximal", "ANATOMY_MODIFIER", 93, 101], ["S2", "ANATOMY", 120, 122], ["S1", "ANATOMY", 127, 129]]], ["A structure-based triUb recognition model has previously been proposed for the human OTU subfamily DUBs and SARS PLpro (39, 40).", [["human", "ORGANISM", 79, 84], ["triUb", "DNA", 18, 23], ["human OTU subfamily DUBs", "PROTEIN", 79, 103], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["SARS PLpro", "TEST", 108, 118]]], ["In our USP9X model, whereas the ZnF motif is rigid, the extended \u03b2-hairpin insertion is presumably flexible and may impart specificity for different chain topologies.", [["ZnF", "GENE_OR_GENE_PRODUCT", 32, 35], ["ZnF motif", "DNA", 32, 41], ["\u03b2-hairpin insertion", "DNA", 65, 84], ["rigid", "PROBLEM", 45, 50], ["the extended \u03b2-hairpin insertion", "TREATMENT", 52, 84], ["different chain topologies", "PROBLEM", 139, 165], ["rigid", "OBSERVATION_MODIFIER", 45, 50]]], ["PolyUb chains can bind USP9X in three distinct modes, which could dictate the endo- versus exo-cleavage specificity (Fig. 5A).", [["PolyUb chains", "GENE_OR_GENE_PRODUCT", 0, 13], ["USP9X", "GENE_OR_GENE_PRODUCT", 23, 28], ["PolyUb chains", "PROTEIN", 0, 13], ["USP9X", "PROTEIN", 23, 28], ["PolyUb chains", "TREATMENT", 0, 13], ["the endo", "TEST", 74, 82]]], ["A potential binding groove between BL1 and BL2, revealed by the specific labeling of the noncatalytic Cys1808, suggests an intriguing possibility that USP9X CD may recognize a branched polyUb chain, such as K11/K63 (41).", [["Cys1808", "CHEMICAL", 102, 109], ["Cys", "CHEMICAL", 102, 105], ["BL1", "GENE_OR_GENE_PRODUCT", 35, 38], ["BL2", "GENE_OR_GENE_PRODUCT", 43, 46], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 151, 159], ["BL1", "PROTEIN", 35, 38], ["BL2", "PROTEIN", 43, 46], ["noncatalytic Cys1808", "PROTEIN", 89, 109], ["USP9X CD", "PROTEIN", 151, 159], ["branched polyUb chain", "PROTEIN", 176, 197], ["K11", "PROTEIN", 207, 210], ["K63", "PROTEIN", 211, 214], ["A potential binding groove between BL1 and BL2", "TEST", 0, 46], ["the noncatalytic Cys", "TEST", 85, 105], ["USP9X CD", "PROBLEM", 151, 159], ["a branched polyUb chain", "PROBLEM", 174, 197], ["binding groove", "OBSERVATION", 12, 26], ["intriguing possibility", "UNCERTAINTY", 123, 145], ["branched", "OBSERVATION_MODIFIER", 176, 184]]], ["This remains to be tested in future studies.", [["future studies", "TEST", 29, 43]]], ["Overall, the USP9X CD provides a fascinating example of small, yet important structural features that may dictate the polyUb chain linkage specificity and influence the dynamics of polyUb binding and recognition by the USP catalytic core.Cloning and Protein Purification. ::: MethodsA human USP9X (amino acids 1,551\u20131,970) construct was cloned into the pET28-MHL vector (GenBank EF456735), which encodes a tobacco etch virus (TEV) protease cleavable N-terminal His6-tag.", [["polyUb", "CHEMICAL", 181, 187], ["USP9X", "CHEMICAL", 291, 296], ["amino acids 1,551\u20131,970", "CHEMICAL", 298, 321], ["amino acids", "CHEMICAL", 298, 309], ["N-", "CHEMICAL", 450, 452], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 13, 21], ["polyUb", "GENE_OR_GENE_PRODUCT", 181, 187], ["human", "ORGANISM", 285, 290], ["USP9X", "GENE_OR_GENE_PRODUCT", 291, 296], ["amino acids", "AMINO_ACID", 298, 309], ["1,551\u20131,970", "AMINO_ACID", 310, 321], ["pET28", "GENE_OR_GENE_PRODUCT", 353, 358], ["tobacco etch virus", "ORGANISM", 406, 424], ["USP9X CD", "PROTEIN", 13, 21], ["polyUb chain", "PROTEIN", 118, 130], ["USP catalytic core", "PROTEIN", 219, 237], ["human USP9X (amino acids 1,551\u20131,970) construct", "DNA", 285, 332], ["pET28", "DNA", 353, 358], ["MHL vector", "DNA", 359, 369], ["GenBank EF456735", "DNA", 371, 387], ["tobacco etch virus (TEV) protease cleavable N-terminal His6-tag", "PROTEIN", 406, 469], ["human", "SPECIES", 285, 290], ["human", "SPECIES", 285, 290], ["tobacco etch virus", "SPECIES", 406, 424], ["the USP9X CD", "TEST", 9, 21], ["polyUb binding", "PROBLEM", 181, 195], ["MethodsA human USP9X (amino acids", "TREATMENT", 276, 309], ["a tobacco etch virus", "TREATMENT", 404, 424], ["small", "OBSERVATION_MODIFIER", 56, 61]]], ["All USP9X proteins were overexpressed in Escherichia coli BL21-CodonPlus (DE3)-RIL strain grown in Terrific Broth using a LEX bioreactor (Epiphyte3) or in LB media using a shaker incubator.", [["USP9X", "GENE_OR_GENE_PRODUCT", 4, 9], ["Escherichia coli", "ORGANISM", 41, 57], ["BL21-CodonPlus", "ORGANISM", 58, 72], ["DE3", "GENE_OR_GENE_PRODUCT", 74, 77], ["Epiphyte3", "SIMPLE_CHEMICAL", 138, 147], ["USP9X proteins", "PROTEIN", 4, 18], ["Escherichia coli BL21", "SPECIES", 41, 62], ["Escherichia coli", "SPECIES", 41, 57], ["All USP9X proteins", "TEST", 0, 18], ["Escherichia coli BL21", "TEST", 41, 62], ["RIL strain", "PROBLEM", 79, 89], ["Terrific Broth", "TREATMENT", 99, 113], ["a LEX bioreactor (Epiphyte3)", "TREATMENT", 120, 148], ["a shaker incubator", "TREATMENT", 170, 188], ["Escherichia coli BL21", "OBSERVATION", 41, 62]]], ["Cells were grown at 37 \u00b0C until the OD600 reached 1.5 and protein expression was induced with 0.25 mM isopropyl-\u03b2-d-thiogalactopyranoside (IPTG) at 18 \u00b0C overnight using the LEX bioreactor.", [["Cells", "ANATOMY", 0, 5], ["isopropyl-\u03b2-d-thiogalactopyranoside", "CHEMICAL", 102, 137], ["IPTG", "CHEMICAL", 139, 143], ["isopropyl-\u03b2-d-thiogalactopyranoside", "CHEMICAL", 102, 137], ["IPTG", "CHEMICAL", 139, 143], ["Cells", "CELL", 0, 5], ["isopropyl-\u03b2-d-thiogalactopyranoside", "SIMPLE_CHEMICAL", 102, 137], ["IPTG", "SIMPLE_CHEMICAL", 139, 143], ["Cells", "TEST", 0, 5], ["protein expression", "TEST", 58, 76], ["d-thiogalactopyranoside (IPTG", "TREATMENT", 114, 143], ["the LEX bioreactor", "TREATMENT", 170, 188]]], ["Alternatively, shaker flask culture was grown at 37 \u00b0C until the OD600 reached 0.6 and protein expression was induced with 0.4 mM IPTG at 16 \u00b0C overnight.", [["IPTG", "CHEMICAL", 130, 134], ["IPTG", "CHEMICAL", 130, 134], ["shaker flask culture", "TEST", 15, 35], ["protein expression", "TEST", 87, 105]]], ["For USP9X purification, all buffers were adjusted to pH 8.0 at room temperature.", [["USP9X", "SIMPLE_CHEMICAL", 4, 9], ["USP9X", "PROTEIN", 4, 9], ["USP9X purification", "TREATMENT", 4, 22], ["all buffers", "TREATMENT", 24, 35], ["pH", "TEST", 53, 55]]], ["Harvested cells were resuspended in a lysis buffer (25 mM Tris, 500 mM NaCl, 5% glycerol) supplemented with 1 mM PMSF and benzamidine and lysed using sonication for 10 min with 5-/7-s on/off cycles (Sonicator 3000; Misonix).", [["cells", "ANATOMY", 10, 15], ["NaCl", "CHEMICAL", 71, 75], ["glycerol", "CHEMICAL", 80, 88], ["benzamidine", "CHEMICAL", 122, 133], ["Tris", "CHEMICAL", 58, 62], ["NaCl", "CHEMICAL", 71, 75], ["glycerol", "CHEMICAL", 80, 88], ["PMSF", "CHEMICAL", 113, 117], ["benzamidine", "CHEMICAL", 122, 133], ["cells", "CELL", 10, 15], ["glycerol", "SIMPLE_CHEMICAL", 80, 88], ["PMSF", "SIMPLE_CHEMICAL", 113, 117], ["benzamidine", "SIMPLE_CHEMICAL", 122, 133], ["Harvested cells", "TREATMENT", 0, 15], ["a lysis buffer", "TREATMENT", 36, 50], ["500 mM NaCl", "TREATMENT", 64, 75], ["5% glycerol)", "TREATMENT", 77, 89], ["1 mM PMSF", "TREATMENT", 108, 117], ["benzamidine", "TREATMENT", 122, 133], ["sonication", "TREATMENT", 150, 160], ["Sonicator", "TREATMENT", 199, 208], ["Misonix", "TREATMENT", 215, 222]]], ["The crude extract was then centrifuged at 36,000 \u00d7 g for 1 h at 4 \u00b0C. The protein was batch-absorbed using Ni-NTA resin (Qiagen), washed with 25 mM Tris (pH 8.0), 500 mM NaCl, 25 mM imidazole, and eluted with an elution buffer (25 mM Tris, 250 mM NaCl, 250 mM imidazole, 1 mM TCEP).", [["extract", "ANATOMY", 10, 17], ["Ni-NTA", "CHEMICAL", 107, 113], ["NaCl", "CHEMICAL", 170, 174], ["imidazole", "CHEMICAL", 182, 191], ["NaCl", "CHEMICAL", 247, 251], ["imidazole", "CHEMICAL", 260, 269], ["Ni-NTA", "CHEMICAL", 107, 113], ["Tris", "CHEMICAL", 148, 152], ["NaCl", "CHEMICAL", 170, 174], ["imidazole", "CHEMICAL", 182, 191], ["Tris", "CHEMICAL", 234, 238], ["NaCl", "CHEMICAL", 247, 251], ["imidazole", "CHEMICAL", 260, 269], ["TCEP", "CHEMICAL", 276, 280], ["Ni-NTA resin", "SIMPLE_CHEMICAL", 107, 119], ["imidazole", "SIMPLE_CHEMICAL", 182, 191], ["imidazole", "SIMPLE_CHEMICAL", 260, 269], ["The crude extract", "TREATMENT", 0, 17], ["Ni-NTA resin", "TREATMENT", 107, 119], ["pH", "TEST", 154, 156], ["500 mM NaCl", "TREATMENT", 163, 174], ["25 mM imidazole", "TREATMENT", 176, 191], ["an elution buffer", "TREATMENT", 209, 226], ["NaCl", "TREATMENT", 247, 251], ["imidazole", "TREATMENT", 260, 269], ["1 mM TCEP", "TREATMENT", 271, 280]]], ["The His6-tag was removed by overnight incubation with His6-tagged TEV protease during dialysis in 25 mM Tris, 200 mM NaCl, 5 mM \u03b2-mercaptoethanol.", [["NaCl", "CHEMICAL", 117, 121], ["\u03b2-mercaptoethanol", "CHEMICAL", 128, 145], ["Tris", "CHEMICAL", 104, 108], ["NaCl", "CHEMICAL", 117, 121], ["\u03b2-mercaptoethanol", "CHEMICAL", 128, 145], ["His6", "GENE_OR_GENE_PRODUCT", 4, 8], ["His6", "GENE_OR_GENE_PRODUCT", 54, 58], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 128, 145], ["His6", "PROTEIN", 4, 8], ["His6", "PROTEIN", 54, 58], ["TEV protease", "PROTEIN", 66, 78], ["His6", "TREATMENT", 54, 58], ["tagged TEV protease", "TREATMENT", 59, 78], ["dialysis", "TREATMENT", 86, 94], ["NaCl", "TREATMENT", 117, 121], ["5 mM \u03b2-mercaptoethanol", "TREATMENT", 123, 145]]], ["Uncleaved protein and the TEV protease were removed by passing through Ni-NTA resin, and the target protein was purified by anion exchange chromatography (HiTrap Q; GE Healthcare).", [["Ni-NTA", "CHEMICAL", 71, 77], ["Ni-NTA", "CHEMICAL", 71, 77], ["TEV", "GENE_OR_GENE_PRODUCT", 26, 29], ["Ni-NTA resin", "SIMPLE_CHEMICAL", 71, 83], ["anion", "SIMPLE_CHEMICAL", 124, 129], ["Uncleaved protein", "PROTEIN", 0, 17], ["TEV protease", "PROTEIN", 26, 38], ["Uncleaved protein", "PROBLEM", 0, 17], ["the TEV protease", "TREATMENT", 22, 38], ["Ni-NTA resin", "TREATMENT", 71, 83], ["the target protein", "TEST", 89, 107], ["anion exchange chromatography", "TREATMENT", 124, 153]]], ["The protein was further purified using a Superdex 200 column (GE Healthcare) preequilibrated in 25 mM Tris, 150 mM NaCl, 1 mM TCEP.", [["NaCl", "CHEMICAL", 115, 119], ["Tris", "CHEMICAL", 102, 106], ["NaCl", "CHEMICAL", 115, 119], ["TCEP", "CHEMICAL", 126, 130], ["TCEP", "SIMPLE_CHEMICAL", 126, 130], ["a Superdex 200 column (GE Healthcare", "TREATMENT", 39, 75], ["1 mM TCEP", "TREATMENT", 121, 130]]], ["Pooled fractions were concentrated using centrifugal concentrators (Amicon Ultra, molecular mass cut-off of 30 kDa) to 20 mg/mL, flash frozen, and stored at \u221280 \u00b0C. USP2 CD was used as a control, and its expression and purification were described previously (42).Cloning and Protein Purification. ::: MethodsUb-\u03b2-mercaptoethanesulfonic acid sodium derivative (Ub1\u201375-MESNA) was generated as previously described (32).", [["MethodsUb-\u03b2-mercaptoethanesulfonic acid sodium", "CHEMICAL", 301, 347], ["Ub1\u201375-MESNA", "CHEMICAL", 360, 372], ["MethodsUb-\u03b2-mercaptoethanesulfonic acid sodium", "CHEMICAL", 301, 347], ["Ub1\u201375-MESNA", "CHEMICAL", 360, 372], ["USP2", "GENE_OR_GENE_PRODUCT", 165, 169], ["MethodsUb-\u03b2-mercaptoethanesulfonic acid sodium derivative", "SIMPLE_CHEMICAL", 301, 358], ["Ub1\u201375-MESNA", "SIMPLE_CHEMICAL", 360, 372], ["USP2 CD", "DNA", 165, 172], ["Pooled fractions", "PROBLEM", 0, 16], ["centrifugal concentrators (Amicon Ultra, molecular mass cut", "TREATMENT", 41, 100], ["USP2 CD", "TREATMENT", 165, 172], ["MethodsUb", "TREATMENT", 301, 310], ["\u03b2-mercaptoethanesulfonic acid sodium derivative", "TREATMENT", 311, 358], ["MESNA", "TREATMENT", 367, 372], ["fractions", "OBSERVATION_MODIFIER", 7, 16], ["centrifugal concentrators", "OBSERVATION", 41, 66]]], ["Briefly, Ub1\u201375 was expressed as an intein fusion using a Ub1\u201375-pTYB1 plasmid transformed into BL21(DE3) strain.", [["Ub1\u201375", "CHEMICAL", 9, 15], ["Ub1\u201375", "GENE_OR_GENE_PRODUCT", 9, 15], ["Ub1", "GENE_OR_GENE_PRODUCT", 58, 61], ["pTYB1", "GENE_OR_GENE_PRODUCT", 65, 70], ["BL21", "GENE_OR_GENE_PRODUCT", 96, 100], ["DE3", "GENE_OR_GENE_PRODUCT", 101, 104], ["Ub1", "PROTEIN", 9, 12], ["Ub1\u201375-pTYB1 plasmid", "DNA", 58, 78], ["BL21", "SPECIES", 96, 100], ["an intein fusion", "TREATMENT", 33, 49], ["a Ub1", "TEST", 56, 61]]], ["Cells were cultured in LB media supplemented with 100 \u03bcg/mL ampicillin at 37 \u00b0C and the overexpression was induced with 0.4 mM IPTG at an OD600 of 0.6 for 16\u201318 h at 16 \u00b0C. Cells were harvested via centrifugation and resuspended in 20 mM Tris (pH 7.5), 200 mM NaCl, 1 mM EDTA, 5% glycerol.", [["Cells", "ANATOMY", 0, 5], ["Cells", "ANATOMY", 173, 178], ["ampicillin", "CHEMICAL", 60, 70], ["IPTG", "CHEMICAL", 127, 131], ["NaCl", "CHEMICAL", 260, 264], ["glycerol", "CHEMICAL", 280, 288], ["ampicillin", "CHEMICAL", 60, 70], ["IPTG", "CHEMICAL", 127, 131], ["Tris", "CHEMICAL", 238, 242], ["NaCl", "CHEMICAL", 260, 264], ["EDTA", "CHEMICAL", 271, 275], ["glycerol", "CHEMICAL", 280, 288], ["Cells", "CELL", 0, 5], ["ampicillin", "SIMPLE_CHEMICAL", 60, 70], ["Cells", "CELL", 173, 178], ["EDTA", "SIMPLE_CHEMICAL", 271, 275], ["glycerol", "SIMPLE_CHEMICAL", 280, 288], ["Cells", "TEST", 0, 5], ["ampicillin", "TREATMENT", 60, 70], ["0.4 mM IPTG", "TREATMENT", 120, 131], ["pH", "TEST", 244, 246], ["NaCl", "TEST", 260, 264], ["EDTA", "TEST", 271, 275], ["5% glycerol", "TREATMENT", 277, 288]]], ["Cells were lysed on the ice, and the lysate was cleared by centrifugation and incubated with chitin resin (New England Biolabs) at 4 \u00b0C for 2 h.", [["Cells", "ANATOMY", 0, 5], ["lysate", "ANATOMY", 37, 43], ["Cells", "CELL", 0, 5], ["chitin resin", "SIMPLE_CHEMICAL", 93, 105], ["the ice", "TREATMENT", 20, 27], ["the lysate", "TREATMENT", 33, 43], ["chitin resin", "TREATMENT", 93, 105], ["New England Biolabs)", "TREATMENT", 107, 127]]], ["Subsequently, the chitin resin was washed with 20 mM Tris (pH 7.5), 1 M NaCl, 1 mM EDTA, 5% glycerol, and equilibrated with 20 mM MES (pH 6.5), 100 mM NaCl.", [["chitin", "CHEMICAL", 18, 24], ["NaCl", "CHEMICAL", 72, 76], ["glycerol", "CHEMICAL", 92, 100], ["NaCl", "CHEMICAL", 151, 155], ["Tris", "CHEMICAL", 53, 57], ["NaCl", "CHEMICAL", 72, 76], ["EDTA", "CHEMICAL", 83, 87], ["glycerol", "CHEMICAL", 92, 100], ["NaCl", "CHEMICAL", 151, 155], ["chitin resin", "SIMPLE_CHEMICAL", 18, 30], ["EDTA", "SIMPLE_CHEMICAL", 83, 87], ["glycerol", "SIMPLE_CHEMICAL", 92, 100], ["the chitin resin", "TREATMENT", 14, 30], ["pH", "TEST", 59, 61], ["NaCl", "TEST", 72, 76], ["1 mM EDTA", "TREATMENT", 78, 87], ["5% glycerol", "TREATMENT", 89, 100], ["pH", "TEST", 135, 137]]], ["The resin was then incubated with 50-mL cleavage buffer containing 20 mM MES (pH 6.5), 100 mM NaCl, 75 mM \u03b2-MESNA salt for 12 h at room temperature to yield activated Ub1\u201375-MESNA.", [["NaCl", "CHEMICAL", 94, 98], ["\u03b2-MESNA salt", "CHEMICAL", 106, 118], ["Ub1\u201375-MESNA", "CHEMICAL", 167, 179], ["NaCl", "CHEMICAL", 94, 98], ["Ub1\u201375-MESNA", "CHEMICAL", 167, 179], ["Ub1", "GENE_OR_GENE_PRODUCT", 167, 170], ["Ub1", "PROTEIN", 167, 170], ["MESNA", "PROTEIN", 174, 179], ["The resin", "TREATMENT", 0, 9], ["50-mL cleavage buffer", "TREATMENT", 34, 55], ["pH", "TEST", 78, 80], ["MESNA salt", "TREATMENT", 108, 118], ["MESNA", "TREATMENT", 174, 179]]], ["Ub1\u201376 and its Lys-to-Cys mutants were expressed in BL21(DE3) cells using a Ub1\u201376-pET3a plasmid.", [["DE3) cells", "ANATOMY", 57, 67], ["Lys", "CHEMICAL", 15, 18], ["Cys", "CHEMICAL", 22, 25], ["Ub1\u201376", "GENE_OR_GENE_PRODUCT", 0, 6], ["BL21(DE3) cells", "CELL", 52, 67], ["Ub1", "GENE_OR_GENE_PRODUCT", 76, 79], ["pET3a", "GENE_OR_GENE_PRODUCT", 83, 88], ["Ub1", "PROTEIN", 0, 3], ["Lys-to-Cys mutants", "PROTEIN", 15, 33], ["BL21(DE3) cells", "CELL_LINE", 52, 67], ["Ub1\u201376-pET3a plasmid", "DNA", 76, 96], ["BL21", "SPECIES", 52, 56], ["Ub1", "TEST", 0, 3], ["its Lys", "TEST", 11, 18], ["Cys mutants", "PROBLEM", 22, 33], ["a Ub1", "TEST", 74, 79], ["pET3a plasmid", "TREATMENT", 83, 96]]], ["Cells were lysed in 50 mM ammonium acetate (pH 4.5), 50 mM NaCl and heat treated to precipitate E. coli proteins.", [["Cells", "ANATOMY", 0, 5], ["ammonium acetate", "CHEMICAL", 26, 42], ["NaCl", "CHEMICAL", 59, 63], ["ammonium acetate", "CHEMICAL", 26, 42], ["NaCl", "CHEMICAL", 59, 63], ["Cells", "CELL", 0, 5], ["ammonium acetate", "SIMPLE_CHEMICAL", 26, 42], ["E. coli", "ORGANISM", 96, 103], ["E. coli proteins", "PROTEIN", 96, 112], ["E. coli", "SPECIES", 96, 103], ["E. coli", "SPECIES", 96, 103], ["Cells", "TEST", 0, 5], ["50 mM ammonium acetate", "TREATMENT", 20, 42], ["pH", "TEST", 44, 46], ["50 mM NaCl", "TREATMENT", 53, 63], ["heat", "TREATMENT", 68, 72], ["E. coli proteins", "PROBLEM", 96, 112], ["coli proteins", "OBSERVATION", 99, 112]]], ["Subsequently, the supernatant was saturated with ammonium sulfate (80%) and centrifuged to isolate precipitate, which was redissolved in a buffer containing 20 mM MES (pH 6.5), 50 mM NaCl, and further purified on a HiLoad Superdex 200-pg column (GE Healthcare).", [["supernatant", "ANATOMY", 18, 29], ["ammonium sulfate", "CHEMICAL", 49, 65], ["NaCl", "CHEMICAL", 183, 187], ["ammonium sulfate", "CHEMICAL", 49, 65], ["NaCl", "CHEMICAL", 183, 187], ["ammonium sulfate", "SIMPLE_CHEMICAL", 49, 65], ["ammonium sulfate", "TREATMENT", 49, 65], ["pH", "TEST", 168, 170], ["50 mM NaCl", "TREATMENT", 177, 187], ["a HiLoad Superdex", "TREATMENT", 213, 230]]], ["Protein purity was assessed by SDS/PAGE, and the protein identity was confirmed using a Xevo Q-TOF mass spectrometer.Crystallization. ::: MethodsA surface entropy reduction (43) mutation (K1637E1638 to two alanines) was introduced to crystalize USP9X CD.", [["surface", "ANATOMY", 147, 154], ["alanines", "CHEMICAL", 206, 214], ["USP9X CD", "CHEMICAL", 245, 253], ["USP9X CD", "PROTEIN", 245, 253], ["Protein purity", "TEST", 0, 14], ["the protein identity", "TEST", 45, 65], ["a Xevo Q-TOF mass spectrometer", "TREATMENT", 86, 116], ["MethodsA surface entropy reduction", "TREATMENT", 138, 172], ["mutation (K1637E1638 to two alanines)", "TREATMENT", 178, 215]]], ["Crystal used for X-ray data collection was grown at room temperature using the sitting-drop vapor diffusion method by mixing 0.5-\u00b5L protein (20 mg/mL) with 0.5-\u00b5L reservoir solution containing 20% PEG3350 and 0.2 M diammonium tartrate.", [["PEG3350", "CHEMICAL", 197, 204], ["diammonium tartrate", "CHEMICAL", 215, 234], ["PEG3350", "CHEMICAL", 197, 204], ["diammonium tartrate", "CHEMICAL", 215, 234], ["PEG3350", "SIMPLE_CHEMICAL", 197, 204], ["0.2 M diammonium tartrate", "SIMPLE_CHEMICAL", 209, 234], ["Crystal", "TEST", 0, 7], ["X-ray data collection", "TEST", 17, 38], ["drop vapor diffusion method", "TREATMENT", 87, 114], ["\u00b5L protein", "TREATMENT", 129, 139], ["0.5-\u00b5L reservoir solution", "TREATMENT", 156, 181], ["diammonium tartrate", "TREATMENT", 215, 234]]], ["Crystal was cryoprotected by first immersion in the well solution supplemented with 10% ethylene glycol, then in Paratone-N (Hampton Research) before being flash frozen.Structure Determination and Refinement. ::: MethodsX-ray diffraction data for USP9X were collected at temperature 100 K at beamline 19ID of Advanced Photon Source (APS), Argonne National Laboratory.", [["ethylene glycol", "CHEMICAL", 88, 103], ["ethylene glycol", "CHEMICAL", 88, 103], ["ethylene glycol", "SIMPLE_CHEMICAL", 88, 103], ["Paratone-N", "SIMPLE_CHEMICAL", 113, 123], ["USP9X", "SIMPLE_CHEMICAL", 247, 252], ["USP9X", "PROTEIN", 247, 252], ["Crystal", "TEST", 0, 7], ["10% ethylene glycol", "TREATMENT", 84, 103], ["MethodsX", "TEST", 213, 221], ["ray diffraction data", "TEST", 222, 242], ["USP9X", "TEST", 247, 252], ["temperature", "TEST", 271, 282]]], ["The datasets were processed using the HKL-3000 suite (44) and indexed in the P21 space group.", [["P21 space", "OBSERVATION", 77, 86]]], ["Imposition of C2 symmetry incurred a significantly higher penalty than P2 and was not pursued.", [["P2", "DNA", 71, 73], ["C2 symmetry", "PROBLEM", 14, 25], ["a significantly higher penalty than P2", "PROBLEM", 35, 73], ["C2 symmetry", "OBSERVATION", 14, 25], ["significantly", "OBSERVATION_MODIFIER", 37, 50], ["higher", "OBSERVATION_MODIFIER", 51, 57]]], ["The USP9X structure was solved by molecular replacement using PDB ID code 1NBF as a search template with BALBES (45).", [["USP9X", "GENE_OR_GENE_PRODUCT", 4, 9], ["USP9X structure", "PROTEIN", 4, 19], ["The USP9X structure", "PROBLEM", 0, 19], ["molecular replacement", "TREATMENT", 34, 55]]], ["The graphics program COOT (46) was used for model building and visualization.", [["visualization", "TEST", 63, 76]]], ["Restrained refinement was performed using REFMAC v5.8 (47) incorporating NCS restraints.", [["Restrained refinement", "TREATMENT", 0, 21], ["REFMAC", "TEST", 42, 48], ["NCS restraints", "TREATMENT", 73, 87]]], ["The final structure was validated by MOLPROBITY (48) and deposited in the PDB under ID code 5WCH (49).", [["PDB", "ANATOMY", 74, 77]]], ["Raw diffraction images were deposited in the Integrated Resource for Reproducibility in Macromolecular Crystallography (50) under doi:10.18430/m35wch.", [["Raw diffraction images", "TEST", 0, 22], ["Macromolecular Crystallography", "TEST", 88, 118]]], ["X-ray data collection and refinement statistics are listed in Table 1.", [["X-ray data collection", "TEST", 0, 21]]], ["The two mutations K1637E1638AA are located on helix \u03b13 and did not impact structure analysis.Di- and PolyUb DUB Cleavage Assays. ::: MethodsDiUb cleavage assay was performed using 5 \u03bcM diUb and 0.5 \u03bcM USP9X CD in a 25 mM Tris buffer (pH 8.0) containing 50 mM NaCl and 5 mM DTT at 37 \u00b0C. Reactions were quenched at specified time points using NuPAGE LDS sample buffer (ThermoFisher) and the products resolved using SDS/PAGE.", [["USP9X", "CHEMICAL", 201, 206], ["NaCl", "CHEMICAL", 259, 263], ["DTT", "CHEMICAL", 273, 276], ["USP9X CD", "CHEMICAL", 201, 209], ["Tris", "CHEMICAL", 221, 225], ["NaCl", "CHEMICAL", 259, 263], ["DTT", "CHEMICAL", 273, 276], ["NuPAGE", "CHEMICAL", 342, 348], ["MethodsDiUb", "GENE_OR_GENE_PRODUCT", 133, 144], ["ThermoFisher", "SIMPLE_CHEMICAL", 368, 380], ["helix \u03b13", "PROTEIN", 46, 54], ["DUB", "PROTEIN", 108, 111], ["Di", "PROBLEM", 93, 95], ["MethodsDiUb cleavage assay", "TEST", 133, 159], ["a 25 mM Tris buffer", "TREATMENT", 213, 232], ["pH", "TEST", 234, 236], ["50 mM NaCl", "TREATMENT", 253, 263], ["5 mM DTT", "TREATMENT", 268, 276]]], ["TriUb and tetraUb assays were performed using 2.5 \u03bcM polyUb and 0.5 \u03bcM USP9X CD in 25 mM Tris buffer (pH 8.0) containing 50 mM NaCl and 2 mM DTT.", [["USP9X", "CHEMICAL", 71, 76], ["NaCl", "CHEMICAL", 127, 131], ["polyUb", "CHEMICAL", 53, 59], ["USP9X CD", "CHEMICAL", 71, 79], ["Tris", "CHEMICAL", 89, 93], ["NaCl", "CHEMICAL", 127, 131], ["DTT", "CHEMICAL", 141, 144], ["TriUb", "GENE_OR_GENE_PRODUCT", 0, 5], ["DTT", "SIMPLE_CHEMICAL", 141, 144], ["tetraUb assays", "TEST", 10, 24], ["25 mM Tris buffer", "TREATMENT", 83, 100], ["pH", "TEST", 102, 104], ["50 mM NaCl", "TREATMENT", 121, 131]]], ["All di-, tri-, and tetraUb substrates were purchased from UBPBio.", [["di-, tri-", "CHEMICAL", 4, 13], ["di-, tri-, and tetraUb", "CHEMICAL", 4, 26], ["di-, tri-", "SIMPLE_CHEMICAL", 4, 13], ["tetraUb substrates", "SIMPLE_CHEMICAL", 19, 37], ["All di-, tri-, and tetraUb substrates", "TREATMENT", 0, 37]]], ["For Western blotting, Ub was probed using P4D1 monoclonal antibody (BioLegend).", [["Ub", "GENE_OR_GENE_PRODUCT", 22, 24], ["P4D1", "GENE_OR_GENE_PRODUCT", 42, 46], ["BioLegend", "GENE_OR_GENE_PRODUCT", 68, 77], ["Ub", "PROTEIN", 22, 24], ["P4D1 monoclonal antibody", "PROTEIN", 42, 66], ["BioLegend", "PROTEIN", 68, 77], ["Western blotting", "TEST", 4, 20], ["Ub", "TEST", 22, 24], ["P4D1 monoclonal antibody", "TREATMENT", 42, 66]]], ["IRDye secondary antibodies (LI-COR) were used for indirect detection, and the results were visualized using an Odyssey CLx infrared imaging system.Generation of ABPs and Assays Using the ABPs. ::: MethodsThe monoUb-based probe was synthesized by reacting the Ub1\u201375-MESNA with PA or Gly-VME for 40 min followed by HiTrap SP HP cation exchange (GE Healthcare) column purification.", [["Ub1\u201375-MESNA", "CHEMICAL", 259, 271], ["Gly-VME", "CHEMICAL", 283, 290], ["IRDye", "CHEMICAL", 0, 5], ["Ub1\u201375-MESNA", "CHEMICAL", 259, 271], ["Gly-VME", "CHEMICAL", 283, 290], ["IRDye", "SIMPLE_CHEMICAL", 0, 5], ["ABPs", "GENE_OR_GENE_PRODUCT", 161, 165], ["monoUb", "SIMPLE_CHEMICAL", 208, 214], ["Ub1\u201375-MESNA", "SIMPLE_CHEMICAL", 259, 271], ["PA", "SIMPLE_CHEMICAL", 277, 279], ["Gly-VME", "SIMPLE_CHEMICAL", 283, 290], ["cation", "SIMPLE_CHEMICAL", 327, 333], ["IRDye secondary antibodies", "PROTEIN", 0, 26], ["LI", "PROTEIN", 28, 30], ["COR", "PROTEIN", 31, 34], ["CLx", "PROTEIN", 119, 122], ["ABPs", "PROTEIN", 161, 165], ["monoUb-based probe", "DNA", 208, 226], ["IRDye secondary antibodies", "TEST", 0, 26], ["indirect detection", "TEST", 50, 68], ["an Odyssey CLx infrared imaging system", "TEST", 108, 146], ["ABPs", "TEST", 161, 165], ["Assays", "TEST", 170, 176], ["the ABPs", "TEST", 183, 191], ["Methods", "TREATMENT", 197, 204], ["The monoUb-based probe", "TREATMENT", 204, 226], ["PA or Gly-VME", "TREATMENT", 277, 290], ["HiTrap SP HP cation exchange (GE Healthcare) column purification", "TREATMENT", 314, 378]]], ["To make diUb-NC1-PA2 probes, HA-tagged Ub1\u201375-MESNA was first reacted with an NC molecule followed by deprotection, as previously described to obtain HA- Ub1\u201375-NC (33).", [["Ub1\u201375-MESNA", "CHEMICAL", 39, 51], ["HA- Ub1\u201375-NC", "CHEMICAL", 150, 163], ["Ub1\u201375-NC", "CHEMICAL", 154, 163], ["diUb-NC1", "GENE_OR_GENE_PRODUCT", 8, 16], ["Ub1\u201375-MESNA", "SIMPLE_CHEMICAL", 39, 51], ["diUb-NC1-PA2 probes", "DNA", 8, 27], ["HA-tagged Ub1\u201375-MESNA", "DNA", 29, 51], ["diUb", "TEST", 8, 12], ["HA", "PROBLEM", 29, 31], ["an NC molecule", "TREATMENT", 75, 89], ["deprotection", "TREATMENT", 102, 114], ["HA", "TEST", 150, 152], ["Ub1", "TEST", 154, 157]]], ["In parallel, a mutant Ub1\u201375-MESNA with a Lys-to-Cys mutation at the selected lysine site was reacted with PA as described above to generate Cys-Ub-PA.", [["Lys-to-Cys", "CHEMICAL", 42, 52], ["lysine", "CHEMICAL", 78, 84], ["Lys", "CHEMICAL", 42, 45], ["Cys", "CHEMICAL", 49, 52], ["lysine", "CHEMICAL", 78, 84], ["Ub1", "GENE_OR_GENE_PRODUCT", 22, 25], ["lysine", "AMINO_ACID", 78, 84], ["PA", "GENE_OR_GENE_PRODUCT", 107, 109], ["Cys-Ub-PA", "GENE_OR_GENE_PRODUCT", 141, 150], ["mutant Ub1\u201375-MESNA", "DNA", 15, 34], ["Ub", "PROTEIN", 145, 147], ["a mutant Ub1", "TEST", 13, 25], ["MESNA", "TREATMENT", 29, 34], ["a Lys", "TEST", 40, 45], ["Cys mutation", "PROBLEM", 49, 61]]], ["After cation-exchange purification, equal molar amounts of HA-Ub-NC and Cys-Ub-PA were incubated at 0.5 mg/mL each in a 20 mM MES (pH 6.5) buffer containing 0.03 mM EDTA for 1 h at room temperature.", [["HA-Ub-NC", "CHEMICAL", 59, 67], ["Cys-Ub-PA", "CHEMICAL", 72, 81], ["EDTA", "CHEMICAL", 165, 169], ["Cys", "CHEMICAL", 72, 75], ["EDTA", "CHEMICAL", 165, 169], ["cation", "SIMPLE_CHEMICAL", 6, 12], ["HA-Ub-NC", "SIMPLE_CHEMICAL", 59, 67], ["Cys-Ub-PA", "SIMPLE_CHEMICAL", 72, 81], ["EDTA", "SIMPLE_CHEMICAL", 165, 169], ["Ub", "PROTEIN", 62, 64], ["Ub", "PROTEIN", 76, 78], ["cation-exchange purification", "TREATMENT", 6, 34], ["HA", "TEST", 59, 61], ["Ub", "TEST", 62, 64], ["NC", "TREATMENT", 65, 67], ["Cys", "TEST", 72, 75], ["a 20 mM MES (pH", "TREATMENT", 118, 133], ["NC", "ANATOMY", 65, 67]]], ["Subsequently, the reaction mixture was purified using an SP column followed by buffer exchange to a 20 mM MES (pH 6.5) buffer to yield the diUb-NC1-PA2 probes.Generation of ABPs and Assays Using the ABPs. ::: MethodsTo make diUb-MA1 probes, HA-Ub1\u201375-MESNA was first reacted with a MA linker molecule followed by deprotection as previously reported for generating HA-Ub1\u201375-MA (32).", [["HA-Ub1\u201375-MESNA", "CHEMICAL", 241, 256], ["HA-Ub1\u201375-MA", "CHEMICAL", 364, 376], ["ABPs", "GENE_OR_GENE_PRODUCT", 173, 177], ["diUb-MA1", "SIMPLE_CHEMICAL", 224, 232], ["diUb", "PROTEIN", 139, 143], ["NC1", "PROTEIN", 144, 147], ["PA2", "PROTEIN", 148, 151], ["ABPs", "PROTEIN", 173, 177], ["diUb-MA1 probes", "DNA", 224, 239], ["HA-Ub1\u201375-MESNA", "DNA", 241, 256], ["MA linker molecule", "PROTEIN", 282, 300], ["the reaction mixture", "TREATMENT", 14, 34], ["an SP column", "TREATMENT", 54, 66], ["buffer exchange", "TREATMENT", 79, 94], ["a 20 mM MES (pH", "TREATMENT", 98, 113], ["the diUb", "TEST", 135, 143], ["ABPs", "TEST", 173, 177], ["Assays", "TEST", 182, 188], ["the ABPs", "TEST", 195, 203], ["Methods", "TREATMENT", 209, 216], ["diUb", "TEST", 224, 228], ["HA", "TEST", 241, 243], ["MESNA", "TREATMENT", 251, 256], ["a MA linker molecule", "TREATMENT", 280, 300], ["deprotection", "TREATMENT", 313, 325], ["HA", "TEST", 364, 366]]], ["Concurrently, full-length Ub1\u201376 with a Lys-to-Cys mutation for the desired linkage was purified as described above.", [["Lys-to-Cys", "CHEMICAL", 40, 50], ["Lys", "CHEMICAL", 40, 43], ["Cys", "CHEMICAL", 47, 50], ["Ub1", "GENE_OR_GENE_PRODUCT", 26, 29], ["Ub1", "PROTEIN", 26, 29], ["a Lys", "TEST", 38, 43]]], ["HA-Ub1\u201375-MA was then incubated with Cys-Ub1\u201376 on ice at 0.5 mg/mL concentration each in a 20 mM MES (pH 6.5) buffer containing 0.03 mM EDTA.", [["HA-Ub1\u201375-MA", "CHEMICAL", 0, 12], ["Cys-Ub1\u201376", "CHEMICAL", 37, 47], ["Cys", "CHEMICAL", 37, 40], ["EDTA", "CHEMICAL", 137, 141], ["HA-Ub1\u201375-MA", "GENE_OR_GENE_PRODUCT", 0, 12], ["EDTA", "SIMPLE_CHEMICAL", 137, 141], ["HA", "TEST", 0, 2], ["Ub1", "TEST", 3, 6], ["Cys", "TEST", 37, 40], ["ice", "TREATMENT", 51, 54], ["a 20 mM MES (pH", "TREATMENT", 90, 105]]], ["The reaction mixture was then purified using an SP column followed by buffer exchange to a 20 mM MES (pH 6.5) solution to yield diUb-MA1 probes.Generation of ABPs and Assays Using the ABPs. ::: MethodsAssays of WT USP9X CD and mutants using monoUb and diUb-NC1-PA2 ABPs were performed in 20 mM Tris (pH 8.0), 50 mM NaCl and 1 mM DTT at room temperature for 2 h with 2-\u03bcM probes.", [["NaCl", "CHEMICAL", 315, 319], ["DTT", "CHEMICAL", 329, 332], ["Tris", "CHEMICAL", 294, 298], ["NaCl", "CHEMICAL", 315, 319], ["DTT", "CHEMICAL", 329, 332], ["diUb-MA1", "SIMPLE_CHEMICAL", 128, 136], ["ABPs", "GENE_OR_GENE_PRODUCT", 158, 162], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 214, 222], ["monoUb", "SIMPLE_CHEMICAL", 241, 247], ["diUb-NC1", "GENE_OR_GENE_PRODUCT", 252, 260], ["DTT", "SIMPLE_CHEMICAL", 329, 332], ["diUb", "PROTEIN", 128, 132], ["MA1", "PROTEIN", 133, 136], ["ABPs", "PROTEIN", 158, 162], ["monoUb and diUb-NC1-PA2 ABPs", "DNA", 241, 269], ["The reaction mixture", "TREATMENT", 0, 20], ["an SP column", "TREATMENT", 45, 57], ["buffer exchange", "TREATMENT", 70, 85], ["a 20 mM MES (pH", "TREATMENT", 89, 104], ["diUb", "TEST", 128, 132], ["ABPs", "TEST", 158, 162], ["Assays", "TEST", 167, 173], ["the ABPs", "TEST", 180, 188], ["monoUb", "TEST", 241, 247], ["diUb", "TEST", 252, 256], ["NC1", "TEST", 257, 260], ["PA2 ABPs", "TEST", 261, 269], ["Tris", "TEST", 294, 298], ["pH", "TEST", 300, 302], ["NaCl", "TEST", 315, 319]]], ["DiUb-MA1 labeling assays with USP9X CD and mutants were conducted in 20 mM Hepes (pH 7.0) buffer with no additional DTT present for 1 h at room temperature with 4-\u03bcM probes.", [["DTT", "CHEMICAL", 116, 119], ["DiUb-MA1", "GENE_OR_GENE_PRODUCT", 0, 8], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 30, 38], ["DTT", "SIMPLE_CHEMICAL", 116, 119], ["MA1", "PROTEIN", 5, 8], ["DiUb", "TEST", 0, 4], ["pH", "TEST", 82, 84], ["additional DTT", "TREATMENT", 105, 119]]], ["For comparison, labeling assays using K6-, K11-, K48-, and K63-linked diUb-MA1 and diUb-NC1-PA2 probes (\u223c4 \u03bcM) were performed alongside HA-Ub-VME and HA-Ub-PA against USP9X CD and USP9X \u0394(1924\u20131943) in 20 mM Hepes (pH 7) buffer with no additional DTT present for 1 h at room temperature.", [["DTT", "CHEMICAL", 247, 250], ["K6", "GENE_OR_GENE_PRODUCT", 38, 40], ["K11", "SIMPLE_CHEMICAL", 43, 46], ["K48", "SIMPLE_CHEMICAL", 49, 52], ["K63", "SIMPLE_CHEMICAL", 59, 62], ["diUb-MA1", "SIMPLE_CHEMICAL", 70, 78], ["diUb-NC1", "GENE_OR_GENE_PRODUCT", 83, 91], ["HA-Ub-VME", "SIMPLE_CHEMICAL", 136, 145], ["HA-Ub-PA", "SIMPLE_CHEMICAL", 150, 158], ["USP9X CD", "SIMPLE_CHEMICAL", 167, 175], ["DTT", "SIMPLE_CHEMICAL", 247, 250], ["K6-, K11-, K48-, and K63-linked diUb-MA1 and diUb-NC1-PA2 probes", "DNA", 38, 102], ["Ub", "PROTEIN", 139, 141], ["Ub", "PROTEIN", 153, 155], ["labeling assays", "TEST", 16, 31], ["K6", "TEST", 38, 40], ["K11", "TEST", 43, 46], ["K48", "TEST", 49, 52], ["K63", "TEST", 59, 62], ["diUb", "TEST", 70, 74], ["MA1", "TEST", 75, 78], ["diUb", "TEST", 83, 87], ["NC1", "TEST", 88, 91], ["PA2 probes", "TEST", 92, 102], ["HA", "TEST", 136, 138], ["Ub", "TEST", 139, 141], ["VME", "TEST", 142, 145], ["HA", "TEST", 150, 152], ["Ub", "TEST", 153, 155], ["USP9X CD", "TEST", 167, 175], ["USP9X", "TEST", 180, 185], ["Hepes", "TEST", 208, 213], ["pH", "TEST", 215, 217], ["additional DTT", "TEST", 236, 250], ["Ub", "ANATOMY", 153, 155]]], ["For all labeling assays, the WT and mutant USP9X CD concentrations were 1.4 \u03bcM.Generation of DiUb-AMC Fluorescent Substrates and Fluorescence-Based DUB Assays. ::: MethodsAMC-derived Ub, and Ub-like proteins (SUMO1, NEDD8, ISG15) (Boston Biochem) were used in fluorescence-based DUB assays to measure the activity of USP9X CD.", [["USP9X", "GENE_OR_GENE_PRODUCT", 43, 48], ["Ub", "GENE_OR_GENE_PRODUCT", 183, 185], ["Ub", "GENE_OR_GENE_PRODUCT", 191, 193], ["SUMO1", "GENE_OR_GENE_PRODUCT", 209, 214], ["NEDD8", "GENE_OR_GENE_PRODUCT", 216, 221], ["ISG15", "GENE_OR_GENE_PRODUCT", 223, 228], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 317, 325], ["DiUb", "PROTEIN", 93, 97], ["DUB", "PROTEIN", 148, 151], ["MethodsAMC", "PROTEIN", 164, 174], ["Ub", "PROTEIN", 183, 185], ["Ub", "PROTEIN", 191, 193], ["like proteins", "PROTEIN", 194, 207], ["SUMO1", "PROTEIN", 209, 214], ["NEDD8", "PROTEIN", 216, 221], ["ISG15", "PROTEIN", 223, 228], ["DUB", "PROTEIN", 279, 282], ["USP9X CD", "PROTEIN", 317, 325], ["all labeling assays", "TEST", 4, 23], ["the WT", "TEST", 25, 31], ["DiUb", "TEST", 93, 97], ["MethodsAMC", "TEST", 164, 174], ["Ub", "TEST", 191, 193], ["SUMO1", "TEST", 209, 214], ["NEDD8", "TEST", 216, 221], ["DUB assays", "TEST", 279, 289]]], ["Assays were carried out in 10-\u03bcL reaction volumes in 384-well black polypropylene PCR plates (PCR-384-BK; Axygen) and the fluorescence was measured on a Synergy plate reader (Biotek).", [["polypropylene", "CHEMICAL", 68, 81], ["Axygen", "SIMPLE_CHEMICAL", 106, 112], ["Assays", "TEST", 0, 6], ["volumes", "TEST", 42, 49], ["black polypropylene PCR plates", "TEST", 62, 92], ["PCR", "TEST", 94, 97], ["BK", "TEST", 102, 104], ["Axygen", "TEST", 106, 112], ["the fluorescence", "TEST", 118, 134], ["a Synergy plate", "TREATMENT", 151, 166]]], ["For AMC assays, 10 nM USP9X was mixed with 0.5 \u03bcM AMC substrate in 20 mM Tris (pH 8.0), 50 mM NaCl, 0.005% Triton X-100, and 2 mM DTT, and the excitation and emission wavelengths were set at 360 and 460 nm, respectively, with a 40-nm bandwidth filter.", [["USP9X", "CHEMICAL", 22, 27], ["NaCl", "CHEMICAL", 94, 98], ["Triton X-100", "CHEMICAL", 107, 119], ["USP9X", "CHEMICAL", 22, 27], ["Tris", "CHEMICAL", 73, 77], ["NaCl", "CHEMICAL", 94, 98], ["DTT", "CHEMICAL", 130, 133], ["USP9X", "SIMPLE_CHEMICAL", 22, 27], ["Triton X-100", "SIMPLE_CHEMICAL", 107, 119], ["DTT", "SIMPLE_CHEMICAL", 130, 133], ["AMC assays", "TEST", 4, 14], ["10 nM USP9X", "TEST", 16, 27], ["Tris", "TEST", 73, 77], ["pH", "TEST", 79, 81], ["50 mM NaCl", "TREATMENT", 88, 98], ["2 mM DTT", "TREATMENT", 125, 133], ["emission wavelengths", "TEST", 158, 178], ["a 40-nm bandwidth filter", "TREATMENT", 226, 250]]], ["All kinetic parameters were determined using Michaelis\u2013Menten regression analysis in Prism 6 software (GraphPad).Generation of DiUb-AMC Fluorescent Substrates and Fluorescence-Based DUB Assays. ::: MethodsContinuous diUb cleavage assays were performed using 50 nM USP9X CD and 500 nM K11- (Pos4, #UF-440; Boston Biochem) or 200 nM K63- (K63-2, #DU6302; LifeSensors) IQF-diUb substrates in an optimized USP9X buffer (20 mM Bicine, pH 8.0, 0.004% Triton X-100, 0.6 mM DTT), with excitation and emission wavelengths at 530 and 575 nm, respectively.", [["Bicine", "CHEMICAL", 422, 428], ["Triton X-100", "CHEMICAL", 445, 457], ["Bicine", "CHEMICAL", 422, 428], ["DTT", "CHEMICAL", 466, 469], ["diUb", "GENE_OR_GENE_PRODUCT", 216, 220], ["IQF-diUb", "SIMPLE_CHEMICAL", 366, 374], ["Bicine", "SIMPLE_CHEMICAL", 422, 428], ["Triton X-100", "SIMPLE_CHEMICAL", 445, 457], ["DTT", "SIMPLE_CHEMICAL", 466, 469], ["DiUb", "PROTEIN", 127, 131], ["DUB", "PROTEIN", 182, 185], ["All kinetic parameters", "TEST", 0, 22], ["DiUb", "TEST", 127, 131], ["MethodsContinuous diUb cleavage assays", "TEST", 198, 236], ["nM K11", "TEST", 281, 287], ["UF", "TEST", 297, 299], ["Boston Biochem", "TEST", 305, 319], ["nM K63", "TEST", 328, 334], ["K63", "TEST", 337, 340], ["an optimized USP9X buffer", "TREATMENT", 389, 414], ["pH", "TEST", 430, 432], ["excitation and emission wavelengths", "TREATMENT", 477, 512]]], ["Alternatively, for full kinetic analysis of K11 IQF-diUb and Ub-AMC substrate, 10\u201325 nM WT and mutant USP9X CD was used.", [["IQF-diUb", "GENE_OR_GENE_PRODUCT", 48, 56], ["Ub-AMC", "GENE_OR_GENE_PRODUCT", 61, 67], ["K11", "PROTEIN", 44, 47], ["IQF", "PROTEIN", 48, 51], ["diUb", "PROTEIN", 52, 56], ["Ub", "PROTEIN", 61, 63], ["mutant USP9X CD", "PROTEIN", 95, 110], ["full kinetic analysis", "TEST", 19, 40], ["K11", "TEST", 44, 47], ["IQF", "TEST", 48, 51], ["Ub", "TEST", 61, 63], ["nM WT", "TEST", 85, 90], ["mutant USP9X CD", "TREATMENT", 95, 110]]], ["Assays were performed in 50 mM Hepes (pH 7.8), 50 mM NaCl, 0.5 mM EDTA, 0.1 mg/mL BSA, and 1 mM DTT at 25 \u00b0C. Fluorescence was measured using a Fluoromax-4 fluorescence spectrometer (Horiba).", [["NaCl", "CHEMICAL", 53, 57], ["EDTA", "CHEMICAL", 66, 70], ["NaCl", "CHEMICAL", 53, 57], ["EDTA", "CHEMICAL", 66, 70], ["DTT", "CHEMICAL", 96, 99], ["EDTA", "SIMPLE_CHEMICAL", 66, 70], ["BSA", "SIMPLE_CHEMICAL", 82, 85], ["DTT", "SIMPLE_CHEMICAL", 96, 99], ["Assays", "TEST", 0, 6], ["Hepes", "TEST", 31, 36], ["pH", "TEST", 38, 40], ["50 mM NaCl", "TREATMENT", 47, 57], ["0.5 mM EDTA", "TREATMENT", 59, 70], ["1 mM DTT", "TREATMENT", 91, 99], ["Fluorescence", "TEST", 110, 122], ["a Fluoromax", "TREATMENT", 142, 153]]], ["For Ub-AMC, excitation and emission wavelengths at 355 and 440 nm were used, respectively.", [["Ub", "GENE_OR_GENE_PRODUCT", 4, 6], ["Ub", "PROTEIN", 4, 6], ["emission wavelengths", "TREATMENT", 27, 47]]], ["For IQF-diUb, excitation and emission wavelengths at 544 nm and 572 nm were used, respectively.Generation of DiUb-AMC Fluorescent Substrates and Fluorescence-Based DUB Assays. ::: MethodsK11-, K48-, and K63-linked diUb-NC1-AMC2 fluorescent substrates were generated by first reacting Ub1\u201375-MESNA containing a respective cysteine mutation at K11, K48, or K63 with 32 mM glycine-AMC in the presence of 0.5 M MESNA, 0.17 M collidine and 5 mg/mL N-hydroxysuccinimide for 40 h.", [["Ub1\u201375-MESNA", "CHEMICAL", 284, 296], ["glycine", "CHEMICAL", 370, 377], ["AMC", "CHEMICAL", 378, 381], ["MESNA", "CHEMICAL", 407, 412], ["collidine", "CHEMICAL", 421, 430], ["N-hydroxysuccinimide", "CHEMICAL", 443, 463], ["MethodsK11-, K48-, and K63", "CHEMICAL", 180, 206], ["Ub1\u201375-MESNA", "CHEMICAL", 284, 296], ["cysteine", "CHEMICAL", 321, 329], ["glycine", "CHEMICAL", 370, 377], ["MESNA", "CHEMICAL", 407, 412], ["collidine", "CHEMICAL", 421, 430], ["N-hydroxysuccinimide", "CHEMICAL", 443, 463], ["MethodsK11", "SIMPLE_CHEMICAL", 180, 190], ["K48", "SIMPLE_CHEMICAL", 193, 196], ["K63", "SIMPLE_CHEMICAL", 203, 206], ["diUb-NC1", "GENE_OR_GENE_PRODUCT", 214, 222], ["Ub1\u201375-MESNA", "SIMPLE_CHEMICAL", 284, 296], ["cysteine", "AMINO_ACID", 321, 329], ["glycine-AMC", "SIMPLE_CHEMICAL", 370, 381], ["MESNA", "SIMPLE_CHEMICAL", 407, 412], ["collidine", "SIMPLE_CHEMICAL", 421, 430], ["N-hydroxysuccinimide", "SIMPLE_CHEMICAL", 443, 463], ["IQF", "PROTEIN", 4, 7], ["diUb", "DNA", 8, 12], ["DiUb", "PROTEIN", 109, 113], ["DUB", "PROTEIN", 164, 167], ["diUb", "PROTEIN", 214, 218], ["NC1", "PROTEIN", 219, 222], ["AMC2", "PROTEIN", 223, 227], ["Ub1", "PROTEIN", 284, 287], ["MESNA", "PROTEIN", 291, 296], ["DiUb", "TEST", 109, 113], ["Fluorescence", "TEST", 145, 157], ["MethodsK11", "TEST", 180, 190], ["K48", "TEST", 193, 196], ["K63", "TEST", 203, 206], ["MESNA", "TREATMENT", 291, 296], ["a respective cysteine mutation", "TREATMENT", 308, 338], ["K48", "TEST", 347, 350], ["MESNA", "TREATMENT", 407, 412], ["collidine", "TREATMENT", 421, 430], ["hydroxysuccinimide", "TREATMENT", 445, 463]]], ["The resulting reaction mixture was treated with 10 mM DTT overnight, purified using an SP column with a salt gradient (50\u2013500 mM NaCl) and buffer exchanged into a 20 mM MES (pH 6.5) buffer.", [["NaCl", "CHEMICAL", 129, 133], ["DTT", "CHEMICAL", 54, 57], ["NaCl", "CHEMICAL", 129, 133], ["DTT", "SIMPLE_CHEMICAL", 54, 57], ["The resulting reaction mixture", "PROBLEM", 0, 30], ["10 mM DTT", "TREATMENT", 48, 57], ["an SP column", "TREATMENT", 84, 96], ["a salt gradient", "TREATMENT", 102, 117], ["a 20 mM MES (pH", "TREATMENT", 161, 176]]], ["Following purification, the cysteine-containing Ub-AMC was reacted with Ub-NC to generate diUb-NC1-AMC2 substrate (Fig. 2A) and further purified using an SP column with a salt gradient from 100 mM to 1 M NaCl.", [["cysteine", "CHEMICAL", 28, 36], ["Ub-AMC", "CHEMICAL", 48, 54], ["Ub-NC", "CHEMICAL", 72, 77], ["NaCl", "CHEMICAL", 204, 208], ["cysteine", "CHEMICAL", 28, 36], ["Ub-NC", "CHEMICAL", 72, 77], ["NaCl", "CHEMICAL", 204, 208], ["cysteine", "AMINO_ACID", 28, 36], ["Ub-AMC", "SIMPLE_CHEMICAL", 48, 54], ["Ub-NC", "SIMPLE_CHEMICAL", 72, 77], ["diUb-NC1", "GENE_OR_GENE_PRODUCT", 90, 98], ["Ub", "PROTEIN", 48, 50], ["AMC", "PROTEIN", 51, 54], ["Ub", "PROTEIN", 72, 74], ["diUb", "PROTEIN", 90, 94], ["NC1", "PROTEIN", 95, 98], ["AMC2 substrate", "PROTEIN", 99, 113], ["the cysteine", "TEST", 24, 36], ["Ub", "TEST", 72, 74], ["NC", "TREATMENT", 75, 77], ["diUb", "TEST", 90, 94], ["an SP column", "TREATMENT", 151, 163], ["a salt gradient", "TREATMENT", 169, 184]]], ["Fluorogenic assay was performed in a reaction buffer containing 50 mM Hepes (pH 7.8), 50 mM NaCl, 0.5 mM EDTA, 0.1 mg/mL BSA, and 1 mM DTT at 25 \u00b0C. Fluorescence was measured using a Fluoromax-4 fluorescence spectrometer (Horiba) with excitation and emission wavelength at 355 and 440 nm, respectively.Generation of Hybrid TriUb Probes. ::: MethodsK11-, K48-, and K63-linked triUb probes were generated chemoenzymatically in two steps as shown in Fig. 2B.", [["NaCl", "CHEMICAL", 92, 96], ["EDTA", "CHEMICAL", 105, 109], ["NaCl", "CHEMICAL", 92, 96], ["EDTA", "CHEMICAL", 105, 109], ["DTT", "CHEMICAL", 135, 138], ["MethodsK11-, K48-, and K63", "CHEMICAL", 341, 367], ["EDTA", "SIMPLE_CHEMICAL", 105, 109], ["BSA", "SIMPLE_CHEMICAL", 121, 124], ["DTT", "SIMPLE_CHEMICAL", 135, 138], ["MethodsK11", "GENE_OR_GENE_PRODUCT", 341, 351], ["K48", "SIMPLE_CHEMICAL", 354, 357], ["K63", "SIMPLE_CHEMICAL", 364, 367], ["2B", "GENE_OR_GENE_PRODUCT", 452, 454], ["MethodsK11-, K48-, and K63-linked triUb probes", "DNA", 341, 387], ["Fluorogenic assay", "TEST", 0, 17], ["a reaction buffer", "TREATMENT", 35, 52], ["pH", "TEST", 77, 79], ["50 mM NaCl", "TREATMENT", 86, 96], ["0.5 mM EDTA", "TREATMENT", 98, 109], ["1 mM DTT", "TREATMENT", 130, 138], ["Fluorescence", "TEST", 149, 161], ["a Fluoromax", "TREATMENT", 181, 192], ["MethodsK11", "TEST", 341, 351], ["K48", "TEST", 354, 357], ["K63", "TEST", 364, 367]]], ["First, diUbs containing a native isopeptide and appropriate Lys-to-Cys mutation were generated enzymatically.", [["Lys", "CHEMICAL", 60, 63], ["Lys", "CHEMICAL", 60, 63], ["Cys", "CHEMICAL", 67, 70], ["diUbs", "GENE_OR_GENE_PRODUCT", 7, 12], ["diUbs", "PROTEIN", 7, 12], ["a native isopeptide", "TREATMENT", 24, 43], ["Cys mutation", "TEST", 67, 79]]], ["Specifically, mouse E1 and E2-25K at 0.5 \u03bcM and 5 \u03bcM, respectively, were incubated with \u223c7 mg/mL of Ub K48C and Ub D77 in the presence of 2 mM ATP, and 0.5 mM DTT to generate K48-diUb.", [["E2-25K", "CHEMICAL", 27, 33], ["ATP", "CHEMICAL", 143, 146], ["ATP", "CHEMICAL", 143, 146], ["DTT", "CHEMICAL", 159, 162], ["mouse", "ORGANISM", 14, 19], ["E1", "CELL", 20, 22], ["Ub", "GENE_OR_GENE_PRODUCT", 100, 102], ["Ub D77", "GENE_OR_GENE_PRODUCT", 112, 118], ["ATP", "SIMPLE_CHEMICAL", 143, 146], ["DTT", "SIMPLE_CHEMICAL", 159, 162], ["K48-diUb", "GENE_OR_GENE_PRODUCT", 175, 183], ["Ub K48C", "PROTEIN", 100, 107], ["Ub D77", "PROTEIN", 112, 118], ["K48", "PROTEIN", 175, 178], ["diUb", "PROTEIN", 179, 183], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 14, 19], ["E2", "TEST", 27, 29], ["2 mM ATP", "TREATMENT", 138, 146], ["0.5 mM DTT", "TREATMENT", 152, 162]]], ["Similarly, mouse E1, E2 complex Ubc13/Mms2, Ub K63C and Ub D77 were used to generate K63C diUb.", [["mouse", "ORGANISM", 11, 16], ["E1", "GENE_OR_GENE_PRODUCT", 17, 19], ["E2", "GENE_OR_GENE_PRODUCT", 21, 23], ["Ubc13", "GENE_OR_GENE_PRODUCT", 32, 37], ["Mms2", "GENE_OR_GENE_PRODUCT", 38, 42], ["Ub", "GENE_OR_GENE_PRODUCT", 44, 46], ["Ub D77", "GENE_OR_GENE_PRODUCT", 56, 62], ["mouse E1", "PROTEIN", 11, 19], ["E2 complex", "PROTEIN", 21, 31], ["Ubc13", "PROTEIN", 32, 37], ["Mms2", "PROTEIN", 38, 42], ["Ub K63C", "PROTEIN", 44, 51], ["Ub D77", "PROTEIN", 56, 62], ["K63C diUb", "PROTEIN", 85, 94], ["mouse", "SPECIES", 11, 16], ["mouse", "SPECIES", 11, 16], ["mouse E1, E2 complex Ubc13", "TEST", 11, 37], ["Ub D77", "TREATMENT", 56, 62]]], ["Mouse E1, Ube2s-UBD, and AMSH at 0.5 \u03bcM, 5 \u03bcM, and 0.5 \u03bcM were incubated with Ub K11C and Ub D77 to generate K11-diUb adapted from the previously reported method (51).", [["AMSH", "CHEMICAL", 25, 29], ["Mouse", "ORGANISM", 0, 5], ["E1", "CELL", 6, 8], ["Ube2s-UBD", "CELL", 10, 19], ["Ub", "GENE_OR_GENE_PRODUCT", 78, 80], ["Ub", "GENE_OR_GENE_PRODUCT", 90, 92], ["K11-diUb", "GENE_OR_GENE_PRODUCT", 109, 117], ["Mouse E1, Ube2s-UBD, and AMSH", "DNA", 0, 29], ["Ub K11C", "PROTEIN", 78, 85], ["Ub D77", "PROTEIN", 90, 96], ["K11", "PROTEIN", 109, 112], ["diUb", "PROTEIN", 113, 117], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["AMSH", "TEST", 25, 29], ["K11", "TEST", 109, 112]]], ["All reactions were performed overnight in a reaction volume of 500 \u03bcL with buffer containing 50 mM Tris (pH 7.6), 5 mM MgCl2, 10 mM creatine, 0.6 unit inorganic phosphatase, and 0.6 unit creatine phosphokinase at 37 \u00b0C. The reaction mixture was buffer exchanged to a buffer containing 50 mM ammonium acetate (pH 4.5) and 50 mM NaCl, and purified using an SP column.Generation of Hybrid TriUb Probes. ::: MethodsTo generate hybrid triUb probes, the enzymatically synthesized diUb with a position-specific cysteine introduced in the distal Ub was incubated with an equal molar amount of HA-Ub1\u201375-NC or HA-Ub1\u201375-MA for 3 h at room temperature to generate triUb-NC1-CL2 and triUb-MA1-CL2 probes, respectively.", [["MgCl2", "CHEMICAL", 119, 124], ["creatine", "CHEMICAL", 132, 140], ["creatine", "CHEMICAL", 187, 195], ["ammonium acetate", "CHEMICAL", 291, 307], ["NaCl", "CHEMICAL", 327, 331], ["diUb", "CHEMICAL", 474, 478], ["cysteine", "CHEMICAL", 504, 512], ["HA-Ub1\u201375-NC", "CHEMICAL", 585, 597], ["HA-Ub1\u201375-MA", "CHEMICAL", 601, 613], ["Tris", "CHEMICAL", 99, 103], ["MgCl2", "CHEMICAL", 119, 124], ["creatine", "CHEMICAL", 132, 140], ["creatine", "CHEMICAL", 187, 195], ["ammonium acetate", "CHEMICAL", 291, 307], ["NaCl", "CHEMICAL", 327, 331], ["cysteine", "CHEMICAL", 504, 512], ["Ub1\u201375-NC", "CHEMICAL", 588, 597], ["MgCl2", "SIMPLE_CHEMICAL", 119, 124], ["creatine", "SIMPLE_CHEMICAL", 132, 140], ["creatine phosphokinase", "GENE_OR_GENE_PRODUCT", 187, 209], ["ammonium acetate", "SIMPLE_CHEMICAL", 291, 307], ["diUb", "GENE_OR_GENE_PRODUCT", 474, 478], ["cysteine", "AMINO_ACID", 504, 512], ["Ub", "GENE_OR_GENE_PRODUCT", 538, 540], ["Ub1\u201375-NC", "SIMPLE_CHEMICAL", 588, 597], ["HA-Ub1\u201375-MA", "SIMPLE_CHEMICAL", 601, 613], ["triUb-NC1", "GENE_OR_GENE_PRODUCT", 654, 663], ["hybrid triUb probes", "DNA", 423, 442], ["enzymatically synthesized diUb", "PROTEIN", 448, 478], ["distal Ub", "PROTEIN", 531, 540], ["triUb-NC1-CL2 and triUb-MA1-CL2 probes", "DNA", 654, 692], ["All reactions", "PROBLEM", 0, 13], ["a reaction volume", "TEST", 42, 59], ["pH", "TEST", 105, 107], ["MgCl2", "TEST", 119, 124], ["mM creatine", "TEST", 129, 140], ["inorganic phosphatase", "TEST", 151, 172], ["creatine phosphokinase", "TEST", 187, 209], ["The reaction mixture", "TREATMENT", 220, 240], ["a buffer containing 50 mM ammonium acetate", "TREATMENT", 265, 307], ["pH", "TEST", 309, 311], ["50 mM NaCl", "TREATMENT", 321, 331], ["an SP column", "TREATMENT", 352, 364], ["Hybrid TriUb Probes", "TREATMENT", 379, 398], ["Methods", "TREATMENT", 404, 411], ["hybrid triUb probes", "TREATMENT", 423, 442], ["a position-specific cysteine", "TREATMENT", 484, 512], ["HA", "TEST", 585, 587], ["Ub1", "TEST", 588, 591], ["NC", "TREATMENT", 595, 597], ["HA", "TEST", 601, 603], ["Ub1", "TEST", 604, 607], ["room temperature", "TEST", 625, 641], ["triUb", "TEST", 654, 659], ["triUb", "TEST", 672, 677], ["SP column", "ANATOMY", 355, 364], ["Hybrid TriUb", "OBSERVATION", 379, 391], ["distal", "ANATOMY_MODIFIER", 531, 537]]], ["The reaction mixture was then buffer exchanged into ammonium acetate (pH 4.5) and purified using an SP column.", [["ammonium acetate", "CHEMICAL", 52, 68], ["ammonium acetate", "CHEMICAL", 52, 68], ["ammonium acetate", "SIMPLE_CHEMICAL", 52, 68], ["The reaction mixture", "TREATMENT", 0, 20], ["ammonium acetate", "TREATMENT", 52, 68], ["pH", "TEST", 70, 72], ["an SP column", "TREATMENT", 97, 109], ["SP column", "ANATOMY", 100, 109]]], ["Alternatively, the reaction mixture was centrifuged at 16,000 \u00d7 g for 10 min and directly injected into a Superdex 75 pg size-exclusion column in 20 mM MES (pH 6.5), 100 mM NaCl, and 5 mM EDTA.", [["NaCl", "CHEMICAL", 173, 177], ["NaCl", "CHEMICAL", 173, 177], ["EDTA", "CHEMICAL", 188, 192], ["EDTA", "SIMPLE_CHEMICAL", 188, 192], ["the reaction mixture", "PROBLEM", 15, 35], ["pH", "TEST", 157, 159], ["NaCl", "TEST", 173, 177], ["size", "OBSERVATION_MODIFIER", 121, 125], ["column", "OBSERVATION_MODIFIER", 136, 142], ["20 mM", "OBSERVATION_MODIFIER", 146, 151], ["5 mM", "OBSERVATION_MODIFIER", 183, 187]]], ["The probes were characterized using SDS/PAGE and Xevo Q-TOF-MS.", [["SDS", "TEST", 36, 39], ["Xevo", "TEST", 49, 53]]], ["Protein concentration was determined using a combination of Bradford assay and SDS/PAGE based quantification.", [["Protein concentration", "TEST", 0, 21], ["Bradford assay", "TEST", 60, 74]]], ["Hybrid triUb probe assays were conducted in a 20 mM Hepes (pH 7.0) buffer containing 1 mM DTT for triUb-NC1-CL2 cleavage assay while no additional DTT was present for triUb-MA1-CL2 assay.", [["DTT", "CHEMICAL", 90, 93], ["DTT", "CHEMICAL", 147, 150], ["DTT", "SIMPLE_CHEMICAL", 90, 93], ["NC1", "GENE_OR_GENE_PRODUCT", 104, 107], ["DTT", "SIMPLE_CHEMICAL", 147, 150], ["triUb-MA1", "GENE_OR_GENE_PRODUCT", 167, 176], ["NC1", "PROTEIN", 104, 107], ["CL2", "PROTEIN", 108, 111], ["MA1", "PROTEIN", 173, 176], ["CL2", "PROTEIN", 177, 180], ["Hybrid triUb probe assays", "TEST", 0, 25], ["a 20 mM Hepes", "TREATMENT", 44, 57], ["pH", "TEST", 59, 61], ["1 mM DTT", "TREATMENT", 85, 93], ["triUb", "TEST", 98, 103], ["CL2 cleavage assay", "TEST", 108, 126], ["additional DTT", "TEST", 136, 150], ["triUb", "TEST", 167, 172], ["MA1", "TEST", 173, 176]]], ["All diUb-MA1 labeling assays were performed at room temperature for 1 h unless otherwise noted, and all triUb-MA1-CL2 labeling assays were performed at room temperature for up to 2 h.", [["diUb-MA1", "GENE_OR_GENE_PRODUCT", 4, 12], ["MA1", "PROTEIN", 9, 12], ["MA1", "PROTEIN", 110, 113], ["CL2", "PROTEIN", 114, 117], ["MA1 labeling assays", "TEST", 9, 28], ["all triUb", "TEST", 100, 109], ["MA1", "TEST", 110, 113]]], ["Assays with triUb-MA1-CL2 were performed with \u223c1.4 \u00b5M enzyme and 4-\u00b5M probe, while cleavage assays with triUb-NC1-CL2 were performed with 2.8-\u03bcM enzyme and 2-\u03bcM probe.In-Gel Digestion and High-Resolution MS/MS Analysis. ::: MethodsTo identify the cysteine residues responsible for labeling with the K11-diUb-MA1 probe, large-scale labeling of USP9X CD mutants was performed.", [["cysteine", "CHEMICAL", 247, 255], ["triUb-MA1-CL2", "GENE_OR_GENE_PRODUCT", 12, 25], ["triUb-NC1-CL2", "GENE_OR_GENE_PRODUCT", 104, 117], ["cysteine", "AMINO_ACID", 247, 255], ["K11", "GENE_OR_GENE_PRODUCT", 299, 302], ["USP9X CD", "GENE_OR_GENE_PRODUCT", 343, 351], ["triUb", "PROTEIN", 12, 17], ["MA1", "PROTEIN", 18, 21], ["CL2", "DNA", 22, 25], ["triUb", "PROTEIN", 104, 109], ["NC1", "PROTEIN", 110, 113], ["CL2", "PROTEIN", 114, 117], ["K11", "PROTEIN", 299, 302], ["diUb", "PROTEIN", 303, 307], ["MA1", "PROTEIN", 308, 311], ["USP9X CD mutants", "PROTEIN", 343, 359], ["Assays", "TEST", 0, 6], ["triUb", "TEST", 12, 17], ["MA1", "TEST", 18, 21], ["\u223c", "TEST", 46, 47], ["enzyme", "TEST", 54, 60], ["cleavage assays", "TEST", 83, 98], ["triUb", "TEST", 104, 109], ["enzyme", "TEST", 145, 151], ["Methods", "TREATMENT", 224, 231], ["the cysteine residues", "PROBLEM", 243, 264], ["the K11", "TEST", 295, 302], ["USP9X CD mutants", "PROBLEM", 343, 359], ["cysteine residues", "OBSERVATION", 247, 264], ["large", "OBSERVATION_MODIFIER", 319, 324]]], ["Labeling bands were excised and cut into 1-mm3 pieces and transferred to microcentrifuge tubes.", [["Labeling bands", "TREATMENT", 0, 14], ["microcentrifuge tubes", "TREATMENT", 73, 94], ["tubes", "OBSERVATION", 89, 94]]], ["Gel pieces were destained at 37 \u00b0C in a 50% acetonitrile solution containing 100 mM ammonium bicarbonate for 30 min and repeated until all stain was removed.", [["acetonitrile", "CHEMICAL", 44, 56], ["ammonium bicarbonate", "CHEMICAL", 84, 104], ["acetonitrile", "CHEMICAL", 44, 56], ["ammonium bicarbonate", "CHEMICAL", 84, 104], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 84, 104], ["Gel pieces", "TREATMENT", 0, 10], ["a 50% acetonitrile solution", "TREATMENT", 38, 65], ["100 mM ammonium bicarbonate", "TREATMENT", 77, 104], ["all stain", "TEST", 135, 144]]], ["The proteins in the gel pieces were reduced by incubation with 10 mM DTT at 60 \u00b0C for 10 min and alkylated with 100 mM iodoacetamide (IAA) in a 100 mM ammonium bicarbonate buffer.", [["DTT", "CHEMICAL", 69, 72], ["iodoacetamide", "CHEMICAL", 119, 132], ["IAA", "CHEMICAL", 134, 137], ["ammonium bicarbonate", "CHEMICAL", 151, 171], ["DTT", "CHEMICAL", 69, 72], ["iodoacetamide", "CHEMICAL", 119, 132], ["IAA", "CHEMICAL", 134, 137], ["ammonium bicarbonate", "CHEMICAL", 151, 171], ["DTT", "SIMPLE_CHEMICAL", 69, 72], ["iodoacetamide", "SIMPLE_CHEMICAL", 119, 132], ["IAA", "SIMPLE_CHEMICAL", 134, 137], ["The proteins in the gel pieces", "TREATMENT", 0, 30], ["10 mM DTT", "TREATMENT", 63, 72], ["100 mM iodoacetamide (IAA", "TREATMENT", 112, 137], ["a 100 mM ammonium bicarbonate buffer", "TREATMENT", 142, 178]]], ["After removal of the IAA solution, gel pieces were shrunk with acetonitrile, dried, and incubated in 50 \u03bcL of 0.01 mg/mL trypsin at 37 \u00b0C overnight.", [["IAA", "CHEMICAL", 21, 24], ["acetonitrile", "CHEMICAL", 63, 75], ["IAA", "CHEMICAL", 21, 24], ["acetonitrile", "CHEMICAL", 63, 75], ["IAA", "SIMPLE_CHEMICAL", 21, 24], ["acetonitrile", "SIMPLE_CHEMICAL", 63, 75], ["trypsin", "SIMPLE_CHEMICAL", 121, 128], ["trypsin", "PROTEIN", 121, 128], ["removal", "TREATMENT", 6, 13], ["the IAA solution", "TREATMENT", 17, 33], ["gel pieces", "TREATMENT", 35, 45], ["acetonitrile", "TREATMENT", 63, 75], ["trypsin", "TREATMENT", 121, 128]]], ["Following digestion and extraction, samples were lyophilized.", [["samples", "ANATOMY", 36, 43], ["extraction", "TREATMENT", 24, 34], ["samples", "TEST", 36, 43]]], ["Lyophilized samples were redissolved in 0.1% TFA solution and introduced into Q-Exactive Orbitrap via UPLC column.", [["samples", "ANATOMY", 12, 19], ["TFA", "CHEMICAL", 45, 48], ["TFA", "SIMPLE_CHEMICAL", 45, 48], ["Lyophilized samples", "TREATMENT", 0, 19], ["0.1% TFA solution", "TREATMENT", 40, 57]]], ["Subsequent proteomics analysis was performed with Proteome Discoverer v1.4 (ThermoFisher).", [["Subsequent proteomics analysis", "TEST", 0, 30]]]], "37d0bbc8c6e851a2039abc9a31dfb70b23db60a5": [["INTRODUCTIONThe use of electron microscopy (EM) has focussed attention on various viruses as possible enteric pathogens in young children.", [["children", "ORGANISM", 129, 137], ["children", "SPECIES", 129, 137], ["electron microscopy", "TEST", 23, 42], ["various viruses", "PROBLEM", 74, 89], ["enteric pathogens", "PROBLEM", 102, 119]]], ["Adenoviruses are secondary in frequency only to rotaviruses in faecal excretions [Brandt et al, 19791 .", [["faecal", "ANATOMY", 63, 69], ["rotaviruses", "ORGANISM", 48, 59], ["faecal", "ORGANISM_SUBSTANCE", 63, 69], ["Adenoviruses", "PROBLEM", 0, 12], ["rotaviruses", "PROBLEM", 48, 59], ["faecal excretions", "TEST", 63, 80]]], ["Most of the adenoviruses visualized by EM cannot be cultivated in cell cultures by conventional means; these will be referred to as \"enteric adenoviruses\" (EA) in this report.", [["cell cultures", "ANATOMY", 66, 79], ["adenoviruses", "ORGANISM", 12, 24], ["cell cultures", "CELL", 66, 79], ["adenoviruses", "ORGANISM", 141, 153], ["cell cultures", "CELL_LINE", 66, 79], ["the adenoviruses", "PROBLEM", 8, 24], ["cell cultures", "TEST", 66, 79]]], ["Johansson et a1 [1980] were able to recognize antigenically related adenoviruses by a type-specific ELISA in eight out of nine EM-positive faecal specimens.", [["faecal specimens", "ANATOMY", 139, 155], ["adenoviruses", "ORGANISM", 68, 80], ["a type-specific ELISA", "TEST", 84, 105]]], ["Kidd and Madeley [I9811 passaged some of the EA in Chang's conjunctival cells with CPE; again most of them appeared to be identical by neutralization (SN) with an antiserum prepared against an enteric adenovirus strain.", [["conjunctival cells", "ANATOMY", 59, 77], ["CPE", "CHEMICAL", 83, 86], ["conjunctival cells", "CELL", 59, 77], ["antiserum", "ORGANISM_SUBSTANCE", 163, 172], ["adenovirus", "ORGANISM", 201, 211], ["Chang's conjunctival cells", "CELL_LINE", 51, 77], ["CPE", "PROBLEM", 83, 86], ["an antiserum", "TREATMENT", 160, 172], ["an enteric adenovirus strain", "PROBLEM", 190, 218], ["conjunctival cells", "ANATOMY", 59, 77], ["neutralization", "OBSERVATION", 135, 149], ["enteric", "ANATOMY", 193, 200], ["adenovirus", "OBSERVATION", 201, 211]]], ["Hence, most of the EA appear to be related antigenically; they had been provisionally called adenovirus 38 (Ad38) candidate virus [De Jong et al, 19811 ; the number had to be changed later.", [["EA", "CANCER", 19, 21], ["adenovirus 38", "ORGANISM", 93, 106], ["Ad38", "ORGANISM", 108, 112], ["adenovirus", "PROBLEM", 93, 103]]], ["It turned out, however, that these fastidious adenovirus strains represent two clusters of strains which, although serologically closely related, exhibit great differences in their DNA structure [Wadell et al, 1980, in press] .", [["adenovirus strains", "ORGANISM", 46, 64], ["DNA", "CELLULAR_COMPONENT", 181, 184], ["these fastidious adenovirus strains", "PROBLEM", 29, 64], ["strains", "PROBLEM", 91, 98], ["great differences in their DNA structure", "PROBLEM", 154, 194], ["great", "OBSERVATION_MODIFIER", 154, 159]]], ["Since it is difficult to distinguish the two variants by serological methods, they are being referred to as Ad40/ 41, with the knowledge that this complex includes (at least) two viruses.", [["viruses", "OBSERVATION", 179, 186]]], ["Even so, if Ad40/41 can be identified in cell cultures, it is a step forward to indicate the etiological role of EA for gastroenteritis in children, which is as yet unproven.INTRODUCTIONThe possibility of growing at least some of the enteric adenoviruses in Chang's conjunctival cells prompted us to attempt a serological identification by SN directly from those faecal specimens, which contained adenovirus particles.", [["cell cultures", "ANATOMY", 41, 54], ["conjunctival cells", "ANATOMY", 266, 284], ["faecal specimens", "ANATOMY", 363, 379], ["Ad40/41", "CHEMICAL", 12, 19], ["EA", "CHEMICAL", 113, 115], ["gastroenteritis", "DISEASE", 120, 135], ["Ad40/41", "GENE_OR_GENE_PRODUCT", 12, 19], ["cell cultures", "CELL", 41, 54], ["EA", "SIMPLE_CHEMICAL", 113, 115], ["children", "ORGANISM", 139, 147], ["adenoviruses", "ORGANISM", 242, 254], ["Chang's conjunctival cells", "CELL", 258, 284], ["faecal specimens", "ORGANISM_SUBSTANCE", 363, 379], ["adenovirus", "ORGANISM", 397, 407], ["Ad40/41", "PROTEIN", 12, 19], ["cell cultures", "CELL_LINE", 41, 54], ["Chang's conjunctival cells", "CELL_LINE", 258, 284], ["children", "SPECIES", 139, 147], ["cell cultures", "TEST", 41, 54], ["gastroenteritis", "PROBLEM", 120, 135], ["the enteric adenoviruses", "PROBLEM", 230, 254], ["a serological identification", "TEST", 308, 336], ["those faecal specimens", "TEST", 357, 379], ["adenovirus particles", "PROBLEM", 397, 417], ["gastroenteritis", "OBSERVATION", 120, 135], ["possibility of", "UNCERTAINTY", 190, 204], ["growing", "OBSERVATION_MODIFIER", 205, 212], ["at least", "OBSERVATION_MODIFIER", 213, 221], ["enteric", "ANATOMY", 234, 241], ["adenoviruses", "OBSERVATION", 242, 254], ["adenovirus particles", "OBSERVATION", 397, 417]]], ["Indeed, identification was achieved in a considerable proportion of specimens, whereas no growth was obtained in 28%.", [["specimens", "ANATOMY", 68, 77], ["specimens", "CANCER", 68, 77]]], ["The reason for this failure might be quantitative or qualitative in nature.", [["this failure", "PROBLEM", 15, 27]]], ["We attempted to answer this question by demonstrating genus-specific adenovirus antigen either by immunofluorescence of inoculated cell cultures or by an ELISA.MATERIALS AND METHODS Cell CulturesChang's conjunctival cells (Chang cells), obtained from Flow Laboratories, were grown with Leibovitz medium + 5% foetal bovine serum; the maintenance medium contained 2% foetal bovine serum.", [["cell cultures", "ANATOMY", 131, 144], ["Cell", "ANATOMY", 182, 186], ["conjunctival cells", "ANATOMY", 203, 221], ["Chang cells", "ANATOMY", 223, 234], ["serum", "ANATOMY", 322, 327], ["serum", "ANATOMY", 379, 384], ["Leibovitz", "CHEMICAL", 286, 295], ["adenovirus", "ORGANISM", 69, 79], ["cell cultures", "CELL", 131, 144], ["Cell CulturesChang", "CELL", 182, 200], ["conjunctival cells", "CELL", 203, 221], ["Chang cells", "CELL", 223, 234], ["foetal", "ORGANISM", 308, 314], ["bovine", "ORGANISM", 315, 321], ["serum", "ORGANISM_SUBSTANCE", 322, 327], ["foetal", "ORGANISM", 365, 371], ["bovine", "ORGANISM", 372, 378], ["serum", "ORGANISM_SUBSTANCE", 379, 384], ["adenovirus antigen", "PROTEIN", 69, 87], ["inoculated cell cultures", "CELL_LINE", 120, 144], ["conjunctival cells", "CELL_TYPE", 203, 221], ["Chang cells", "CELL_LINE", 223, 234], ["bovine", "SPECIES", 315, 321], ["bovine", "SPECIES", 372, 378], ["bovine", "SPECIES", 315, 321], ["bovine", "SPECIES", 372, 378], ["genus-specific adenovirus antigen", "PROBLEM", 54, 87], ["inoculated cell cultures", "TEST", 120, 144], ["an ELISA", "TEST", 151, 159], ["METHODS Cell Cultures", "TEST", 174, 195], ["Flow Laboratories", "TEST", 251, 268], ["Leibovitz medium", "TEST", 286, 302], ["foetal bovine serum", "TEST", 308, 327], ["the maintenance medium", "TREATMENT", 329, 351], ["2% foetal bovine serum", "TREATMENT", 362, 384]]], ["After inoculation of the culture tubes, they were incubated at 33\u00b0C [Kidd and Madeley, 19811 .", [["culture tubes", "ANATOMY", 25, 38], ["the culture tubes", "TREATMENT", 21, 38]]], ["HeLa cell cultures, strain Saarbriicken, were incubated at 37\u00b0C with Eagle's MEN + 4% lactalbumin hydrolysate + 2% calf serum as maintenance medium.", [["HeLa cell cultures", "ANATOMY", 0, 18], ["serum", "ANATOMY", 120, 125], ["lactalbumin", "CHEMICAL", 86, 97], ["lactalbumin", "CHEMICAL", 86, 97], ["HeLa cell cultures", "CELL", 0, 18], ["lactalbumin", "SIMPLE_CHEMICAL", 86, 97], ["calf", "ORGANISM", 115, 119], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["HeLa cell cultures", "CELL_LINE", 0, 18], ["calf", "SPECIES", 115, 119], ["HeLa cell cultures", "TEST", 0, 18], ["lactalbumin hydrolysate", "TREATMENT", 86, 109]]], ["In both types of cultures, the medium was changed twice weekly.Faecal SamplesFaecal samples containing adenovirus particles by EM were obtained from 64 infants and small children with diarrhoea.Electron MicroscopyThe 10% stool suspensions in Eagle's MEM were prepared for electron microscopy either by ultracentrifugation with an airfuge (Beckman Instruments) with 50.000 rpm [Gelderblom et al, 19781 directly onto the grid or with the agar diffusion technique [Kelen et al, 1970, Baumeister et al, 19761 .Electron MicroscopyAfter staining with 6% phosphotungstic acid, the preparations were ready for electron microscopy (Siemens Elmiscop 101 or Zeiss EM 9S2; voltage 80 or 60 KV, respectively).", [["Faecal SamplesFaecal samples", "ANATOMY", 63, 91], ["diarrhoea", "DISEASE", 184, 193], ["phosphotungstic acid", "CHEMICAL", 548, 568], ["phosphotungstic acid", "CHEMICAL", 548, 568], ["Faecal SamplesFaecal samples", "ORGANISM_SUBSTANCE", 63, 91], ["adenovirus", "ORGANISM", 103, 113], ["infants", "ORGANISM", 152, 159], ["children", "ORGANISM", 170, 178], ["phosphotungstic acid", "SIMPLE_CHEMICAL", 548, 568], ["infants", "SPECIES", 152, 159], ["children", "SPECIES", 170, 178], ["adenovirus", "SPECIES", 103, 113], ["cultures", "TEST", 17, 25], ["Faecal SamplesFaecal samples containing adenovirus particles", "TREATMENT", 63, 123], ["diarrhoea", "PROBLEM", 184, 193], ["Electron Microscopy", "TEST", 194, 213], ["electron microscopy", "TEST", 272, 291], ["an airfuge (Beckman Instruments", "TREATMENT", 327, 358], ["Gelderblom et al", "TREATMENT", 377, 393], ["the agar diffusion technique", "TREATMENT", 432, 460], ["Electron MicroscopyAfter staining", "TEST", 506, 539], ["6% phosphotungstic acid", "TREATMENT", 545, 568], ["electron microscopy", "TEST", 602, 621], ["voltage", "TEST", 661, 668], ["cultures", "OBSERVATION", 17, 25], ["small", "OBSERVATION_MODIFIER", 164, 169], ["diarrhoea", "OBSERVATION", 184, 193]]], ["In addition to rotaviruses, coronaviruses, astroviruses, adenovirus particles could be visualized in the faecal samples and identified by their typical morphology; adenovirus-positive stool samples were sent from Muenster to Homburg by express mail.ldentif icationA rabbit antiserum (R.90), prepared by immunization with a filtered fecal extract containing EA particles of Ad40 type, was kindly provided by Dr. Alistair H. Kidd, London.", [["faecal samples", "ANATOMY", 105, 119], ["stool samples", "ANATOMY", 184, 197], ["extract", "ANATOMY", 338, 345], ["EA", "CHEMICAL", 357, 359], ["rotaviruses", "ORGANISM", 15, 26], ["coronaviruses", "ORGANISM", 28, 41], ["astroviruses", "GENE_OR_GENE_PRODUCT", 43, 55], ["adenovirus", "ORGANISM", 57, 67], ["faecal samples", "ORGANISM_SUBSTANCE", 105, 119], ["adenovirus", "ORGANISM", 164, 174], ["rabbit", "ORGANISM", 266, 272], ["antiserum", "ORGANISM_SUBSTANCE", 273, 282], ["rotaviruses", "SPECIES", 15, 26], ["rabbit", "SPECIES", 266, 272], ["adenovirus", "SPECIES", 57, 67], ["rabbit", "SPECIES", 266, 272], ["rotaviruses", "PROBLEM", 15, 26], ["coronaviruses", "PROBLEM", 28, 41], ["astroviruses", "PROBLEM", 43, 55], ["adenovirus particles", "PROBLEM", 57, 77], ["the faecal samples", "TEST", 101, 119], ["adenovirus", "TEST", 164, 174], ["positive stool samples", "PROBLEM", 175, 197], ["ldentif icationA rabbit antiserum", "TREATMENT", 249, 282], ["a filtered fecal extract", "TREATMENT", 321, 345], ["rotaviruses", "OBSERVATION", 15, 26], ["faecal", "ANATOMY", 105, 111], ["fecal", "ANATOMY", 332, 337]]], ["This serum had a homologous SN titer of 1:640.", [["serum", "ANATOMY", 5, 10], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["This serum", "TEST", 0, 10], ["a homologous SN titer", "TEST", 15, 36]]], ["It neutralized Ad41 strains with nearIy the same titer, but did not neutralize human adenoviruses I to 39 in a i : l O dilution, Either 0.1 in1 of R.90 diluted 1:20 or Hanks' BSS, respectively, was mixed with 0.3 ml of undiluted faecal suspension.", [["Ad41", "GENE_OR_GENE_PRODUCT", 15, 19], ["human", "ORGANISM", 79, 84], ["faecal", "ORGANISM_SUBSTANCE", 229, 235], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["undiluted faecal suspension", "TREATMENT", 219, 246]]], ["After incubation for 1 hr at 37\"C, 0.3 ml of both samples were inoculated into one Chang culture tube each.", [["samples", "ANATOMY", 50, 57], ["one Chang culture tube", "TREATMENT", 79, 101]]], ["The cultures were observed for CPE at least every other day until 12 days.", [["CPE", "CHEMICAL", 31, 34], ["The cultures", "TEST", 0, 12], ["CPE", "PROBLEM", 31, 34]]], ["Identification as Ad40/41 was considered positive, if the CPE in :he culture inoculated with virus-serum mixture remained negative or appeared 3 2 days after that in the virus control tube.", [["serum", "ANATOMY", 99, 104], ["Ad40/41", "GENE_OR_GENE_PRODUCT", 18, 25], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["tube", "TISSUE", 184, 188], ["Ad40/41", "DNA", 18, 25], ["positive", "PROBLEM", 41, 49], ["the CPE", "TEST", 54, 61], ["he culture", "TEST", 66, 76], ["virus", "PROBLEM", 93, 98], ["serum mixture", "TEST", 99, 112], ["the virus control tube", "TREATMENT", 166, 188], ["tube", "OBSERVATION", 184, 188]]], ["One HeLa culture tube was inoculated with each specimen and observed for 30 days.PassageCell cultures with maximal CPE were frozen and thawed twice.", [["HeLa culture tube", "ANATOMY", 4, 21], ["specimen", "ANATOMY", 47, 55], ["PassageCell cultures", "ANATOMY", 81, 101], ["HeLa", "CELL", 4, 8], ["tube", "TISSUE", 17, 21], ["PassageCell cultures", "CELL", 81, 101], ["PassageCell cultures", "CELL_LINE", 81, 101], ["One HeLa culture tube", "TREATMENT", 0, 21], ["PassageCell cultures", "TEST", 81, 101], ["maximal CPE", "PROBLEM", 107, 118], ["culture tube", "OBSERVATION", 9, 21]]], ["Then 0.1 ml was inoculated into two new culture tubes containing I ml of medium.", [["new culture tubes", "TREATMENT", 36, 53], ["tubes", "OBSERVATION", 48, 53]]], ["Cultures were observed for 10-12 days (Chang) or for at least 25 days (HeLa).", [["HeLa", "ANATOMY", 71, 75], ["HeLa", "CELL", 71, 75], ["Cultures", "TEST", 0, 8]]], ["Blind passages were not made.Passagelmmunofluorescence Indirect immunofluorescence to demonstrate infected cells containing the genusspecific (hexon) antigen was performed in Chang cells in Leighton tubes, which were harvested 3 days after inoculation and incubation at 37\u00b0C [Kron et al, 19741 .Enzyme-linked lmmunosorbent Assay (ELISA)A genus-specific ELISA was developed, similar to that described by H m o n et a! [ 19791.", [["cells", "ANATOMY", 107, 112], ["Chang cells", "ANATOMY", 175, 186], ["tubes", "ANATOMY", 199, 204], ["cells", "CELL", 107, 112], ["hexon) antigen", "GENE_OR_GENE_PRODUCT", 143, 157], ["Chang cells", "CELL", 175, 186], ["Leighton tubes", "TISSUE", 190, 204], ["infected cells", "CELL_TYPE", 98, 112], ["genusspecific (hexon) antigen", "PROTEIN", 128, 157], ["Chang cells", "CELL_LINE", 175, 186], ["Blind passages", "PROBLEM", 0, 14], ["Indirect immunofluorescence", "TEST", 55, 82], ["infected cells", "PROBLEM", 98, 112], ["the genusspecific (hexon) antigen", "PROBLEM", 124, 157], ["Chang cells in Leighton tubes", "TREATMENT", 175, 204], ["Enzyme", "TEST", 295, 301], ["lmmunosorbent Assay", "TEST", 309, 328], ["infected cells", "OBSERVATION", 98, 112], ["Leighton tubes", "OBSERVATION", 190, 204]]], ["The coating antibody was prepared from a rabbit antiserum after immunization with purified Ad5 hexon.", [["rabbit", "ORGANISM", 41, 47], ["antiserum", "ORGANISM_SUBSTANCE", 48, 57], ["Ad5", "ORGANISM", 91, 94], ["coating antibody", "PROTEIN", 4, 20], ["Ad5 hexon", "PROTEIN", 91, 100], ["rabbit", "SPECIES", 41, 47], ["rabbit", "SPECIES", 41, 47], ["Ad5", "SPECIES", 91, 94], ["The coating antibody", "TREATMENT", 0, 20], ["a rabbit antiserum", "TREATMENT", 39, 57], ["immunization", "TREATMENT", 64, 76], ["purified Ad5 hexon", "TREATMENT", 82, 100], ["coating antibody", "OBSERVATION", 4, 20]]], ["Hexon-specific antibodies were obtained by affinity chromatography on activated CH sepharose columns, coupled with Ad5 hexon.", [["CH", "CHEMICAL", 80, 82], ["Ad5", "ORGANISM", 115, 118], ["Hexon-specific antibodies", "PROTEIN", 0, 25], ["Ad5 hexon", "PROTEIN", 115, 124], ["Ad5", "SPECIES", 115, 118], ["Hexon-specific antibodies", "TEST", 0, 25], ["affinity chromatography", "TEST", 43, 66], ["activated CH sepharose columns", "TREATMENT", 70, 100], ["Ad5 hexon", "TREATMENT", 115, 124]]], ["The immunoglobulin obtained was diluted to contain 40 ng/ml protein in carbonate buffer of pH 9.5 and adsorbed to cobalt-sterilized \"immulon\" plates (Dynatech M 129 B) over night at 4\u00b0C. After washing the plates three times in PBS + 0.05% Tween 20, faecal specimens, clarified by low-speed centrifugation, diluted 1:2, 1:16, and 1: 128 in PBS-Tween, were inoculated into each of two cups and incubated for 1 hr at 37\u00b0C. After another washing, antihexon IgG from the same rabbit, labelled with peroxidase, diluted 1500, was inoculated and incubated for another 1 hr at 37\u00b0C. After final washing, a freshly prepared solution of 10 mg orthophenylene-diamine (Merck) in 10 ml phosphate buffer (pH 6.0, Sorensen), containing 10 p.1 perhydrol (Merck), was added.", [["faecal specimens", "ANATOMY", 249, 265], ["cobalt", "CHEMICAL", 114, 120], ["Dynatech M 129 B", "CHEMICAL", 150, 166], ["orthophenylene-diamine", "CHEMICAL", 632, 654], ["Merck", "CHEMICAL", 656, 661], ["phosphate", "CHEMICAL", 672, 681], ["p.1 perhydrol", "CHEMICAL", 723, 736], ["carbonate", "CHEMICAL", 71, 80], ["cobalt", "CHEMICAL", 114, 120], ["Tween 20", "CHEMICAL", 239, 247], ["Tween", "CHEMICAL", 343, 348], ["orthophenylene-diamine", "CHEMICAL", 632, 654], ["Merck", "CHEMICAL", 656, 661], ["phosphate", "CHEMICAL", 672, 681], ["perhydrol", "CHEMICAL", 727, 736], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 4, 18], ["carbonate", "SIMPLE_CHEMICAL", 71, 80], ["faecal specimens", "ORGANISM_SUBSTANCE", 249, 265], ["PBS-Tween", "SIMPLE_CHEMICAL", 339, 348], ["rabbit", "ORGANISM", 471, 477], ["peroxidase", "GENE_OR_GENE_PRODUCT", 493, 503], ["orthophenylene-diamine", "SIMPLE_CHEMICAL", 632, 654], ["Merck", "SIMPLE_CHEMICAL", 656, 661], ["10 p.1 perhydrol", "SIMPLE_CHEMICAL", 720, 736], ["Merck", "SIMPLE_CHEMICAL", 738, 743], ["immunoglobulin", "PROTEIN", 4, 18], ["antihexon IgG", "PROTEIN", 443, 456], ["peroxidase", "PROTEIN", 493, 503], ["rabbit", "SPECIES", 471, 477], ["rabbit", "SPECIES", 471, 477], ["The immunoglobulin", "TREATMENT", 0, 18], ["carbonate buffer", "TREATMENT", 71, 87], ["pH", "TEST", 91, 93], ["sterilized \"immulon\" plates", "TREATMENT", 121, 148], ["the plates", "TREATMENT", 201, 211], ["PBS", "TEST", 227, 230], ["faecal specimens", "TEST", 249, 265], ["another washing", "TREATMENT", 426, 441], ["antihexon IgG", "TREATMENT", 443, 456], ["peroxidase", "TREATMENT", 493, 503], ["a freshly prepared solution of 10 mg orthophenylene-diamine (Merck)", "TREATMENT", 595, 662], ["phosphate buffer (pH", "TREATMENT", 672, 692]]], ["The enzyme reaction was stopped after 30 min at room temperature by addition of 2 N H2S04; the extinctions were measured at 490 nm in a Micro ELISA Auto Reader MR 580 (Dynatech).", [["2 N H2S04", "CHEMICAL", 80, 89], ["2 N H2S04", "SIMPLE_CHEMICAL", 80, 89], ["The enzyme reaction", "PROBLEM", 0, 19], ["2 N H2S04", "TREATMENT", 80, 89], ["MR", "TEST", 160, 162]]], ["The volume of all reagents was 0.05 ml.", [["all reagents", "TREATMENT", 14, 26], ["volume", "OBSERVATION_MODIFIER", 4, 10]]], ["Samples with an extinction of at least 0.3 OD were considered positive, while negative samples had values of SO.", [["Samples", "ANATOMY", 0, 7], ["samples", "ANATOMY", 87, 94], ["Samples", "TEST", 0, 7]]], ["15.Virus IdentificationFrom the 64 faecal specimens positive by EM, 6 common adenovirus species were grown in both types of cell cultures (Table I) .", [["faecal specimens", "ANATOMY", 35, 51], ["cell cultures", "ANATOMY", 124, 137], ["Virus", "ORGANISM", 3, 8], ["adenovirus", "ORGANISM", 77, 87], ["cell cultures", "CELL", 124, 137], ["cell cultures", "CELL_LINE", 124, 137], ["Virus Identification", "TEST", 3, 23], ["the 64 faecal specimens", "TEST", 28, 51], ["common adenovirus species", "PROBLEM", 70, 95], ["cell cultures", "TEST", 124, 137]]], ["In 34 samples, Ad40/41 was identified by culture and SN in Chang cells.", [["samples", "ANATOMY", 6, 13], ["Chang cells", "ANATOMY", 59, 70], ["Ad40/41", "SIMPLE_CHEMICAL", 15, 22], ["Chang cells", "CELL", 59, 70], ["Ad40/41", "PROTEIN", 15, 22], ["Chang cells", "CELL_LINE", 59, 70], ["culture", "TEST", 41, 48], ["Chang cells", "OBSERVATION", 59, 70]]], ["The resulting CPE involved almost the whole cell sheet in about half of the samples, whereas 25 to 75% involvement was seen in the other half.", [["cell", "ANATOMY", 44, 48], ["samples", "ANATOMY", 76, 83], ["cell", "CELL", 44, 48], ["The resulting CPE", "PROBLEM", 0, 17], ["CPE", "OBSERVATION", 14, 17]]], ["In 29 of the 34 samples, identification by SN was definite in the first attempt.", [["samples", "ANATOMY", 16, 23], ["samples", "CANCER", 16, 23]]], ["In the other 5 samples, the delay of CPE by Ad40 antiserum appeared insufficient in the first passage.", [["samples", "ANATOMY", 15, 22], ["CPE", "CHEMICAL", 37, 40], ["Ad40", "CHEMICAL", 44, 48], ["Ad40 antiserum", "GENE_OR_GENE_PRODUCT", 44, 58], ["CPE", "TEST", 37, 40], ["Ad40 antiserum", "TEST", 44, 58]]], ["On repetition with a diminished virus concentration or with material from the first Chang passage, Ad40141 was also identified in these cases.", [["Ad40141", "CHEMICAL", 99, 106], ["Ad", "ORGANISM", 99, 101], ["a diminished virus concentration", "PROBLEM", 19, 51]]], ["Furthermore, the virus \"breaking through\" the SN was neutralized by R.90, which excluded the possibility of a mixture of two adenoviruses.", [["adenoviruses", "ORGANISM", 125, 137], ["the virus", "PROBLEM", 13, 22], ["two adenoviruses", "PROBLEM", 121, 137], ["virus", "OBSERVATION", 17, 22], ["adenoviruses", "OBSERVATION", 125, 137]]], ["Otber adenovirus antisera or normal rabbit serum did not inhibit the CPE produced by Ad4014 1-containing samples.", [["serum", "ANATOMY", 43, 48], ["samples", "ANATOMY", 105, 112], ["CPE", "CHEMICAL", 69, 72], ["Ad4014", "CHEMICAL", 85, 91], ["adenovirus", "ORGANISM", 6, 16], ["rabbit", "ORGANISM", 36, 42], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["Ad", "ORGANISM", 85, 87], ["samples", "TISSUE", 105, 112], ["rabbit", "SPECIES", 36, 42], ["rabbit", "SPECIES", 36, 42], ["Otber adenovirus antisera", "TEST", 0, 25], ["the CPE", "TEST", 65, 72]]], ["Eighteen specimens showed no CPE in either Chang of HeLa cell cultures.", [["specimens", "ANATOMY", 9, 18], ["HeLa cell cultures", "ANATOMY", 52, 70], ["HeLa cell cultures", "CELL", 52, 70], ["HeLa cell cultures", "CELL_LINE", 52, 70], ["Eighteen specimens", "TEST", 0, 18], ["CPE", "PROBLEM", 29, 32], ["HeLa cell cultures", "TEST", 52, 70], ["no", "UNCERTAINTY", 26, 28], ["CPE", "OBSERVATION", 29, 32], ["HeLa cell", "OBSERVATION", 52, 61]]], ["In 6 cases' the results were equivocal because of bacterial contamination or of overgrowth by enteroviruses.Time of CPEThe time until the CPE appeared in Chang cells inoculated with Ad40/4 1 -containing faecal specimens never exceeded 5 days after inoculation (Table 11) ; the CPE was often already evident after 1-2 days.", [["Chang cells", "ANATOMY", 154, 165], ["faecal specimens", "ANATOMY", 203, 219], ["enteroviruses", "DISEASE", 94, 107], ["Ad40/4 1 -", "CHEMICAL", 182, 192], ["Chang cells", "CELL", 154, 165], ["Ad40/4 1", "ORGANISM", 182, 190], ["faecal specimens", "ORGANISM_SUBSTANCE", 203, 219], ["Chang cells", "CELL_LINE", 154, 165], ["bacterial contamination", "PROBLEM", 50, 73], ["overgrowth", "PROBLEM", 80, 90], ["enteroviruses", "PROBLEM", 94, 107], ["the CPE", "TEST", 134, 141], ["Chang cells", "PROBLEM", 154, 165], ["faecal specimens", "TEST", 203, 219], ["the CPE", "PROBLEM", 273, 280], ["bacterial contamination", "OBSERVATION", 50, 73], ["overgrowth", "OBSERVATION", 80, 90], ["enteroviruses", "OBSERVATION", 94, 107]]], ["Since SN was read 2-3 days after the controls showed CPE, the whole isolation + identification procedure was mostly terminated within one week after inoculation.", [["CPE", "PROBLEM", 53, 56], ["the whole isolation", "TREATMENT", 58, 77], ["identification procedure", "TREATMENT", 80, 104]]], ["Five of the 6 samples with other adenoviruses produced a CPE in Chang and HeLa cell cultures between 2 and 9 days after inoculation; the last sample was slower.Virus Passage in Chang and HeLa Cell CulturesOf 32 Chang-positive materials 28 showed a CPE in the second passage in Chang cells.", [["samples", "ANATOMY", 14, 21], ["Chang", "ANATOMY", 64, 69], ["HeLa cell cultures", "ANATOMY", 74, 92], ["Chang", "ANATOMY", 177, 182], ["Cell", "ANATOMY", 192, 196], ["Chang cells", "ANATOMY", 277, 288], ["adenoviruses", "ORGANISM", 33, 45], ["Chang", "CELL", 64, 69], ["HeLa cell cultures", "CELL", 74, 92], ["Virus", "ORGANISM", 160, 165], ["Chang", "CELL", 177, 182], ["HeLa Cell", "CELL", 187, 196], ["Chang cells", "CELL", 277, 288], ["Chang and HeLa cell cultures", "CELL_LINE", 64, 92], ["Chang cells", "CELL_LINE", 277, 288], ["other adenoviruses", "TREATMENT", 27, 45], ["a CPE in Chang", "PROBLEM", 55, 69], ["HeLa cell cultures", "TEST", 74, 92], ["inoculation", "TEST", 120, 131], ["the last sample", "TEST", 133, 148], ["Virus Passage", "PROBLEM", 160, 173], ["HeLa Cell CulturesOf", "TEST", 187, 207], ["Chang-positive materials", "TEST", 211, 235], ["a CPE", "PROBLEM", 246, 251], ["HeLa cell", "OBSERVATION_MODIFIER", 74, 83], ["HeLa Cell", "OBSERVATION_MODIFIER", 187, 196], ["Chang cells", "OBSERVATION", 277, 288]]], ["It was often either weaker or slower to appear than after inoculation of the faecal material.", [["faecal material", "ANATOMY", 77, 92], ["faecal material", "MULTI-TISSUE_STRUCTURE", 77, 92], ["faecal", "ANATOMY", 77, 83]]], ["Further passage attempts in Chang cells were not always successful.", [["Chang cells", "ANATOMY", 28, 39], ["Chang cells", "CELL", 28, 39], ["Chang cells", "CELL_LINE", 28, 39], ["Chang cells", "TREATMENT", 28, 39]]], ["However, one strain was passaged more than 10 times in Chang cells with a constant CPE; the virus from the 10th passage was found serologically unchanged.Virus Passage in Chang and HeLa Cell CulturesIn HeLa cell cultures, 15 of the faecal specimens with Ad40141 (positive in Chang cells) produced an adenovirus-like CPE.", [["Chang cells", "ANATOMY", 55, 66], ["Chang", "ANATOMY", 171, 176], ["HeLa Cell CulturesIn HeLa cell cultures", "ANATOMY", 181, 220], ["faecal specimens", "ANATOMY", 232, 248], ["Chang cells", "ANATOMY", 275, 286], ["Ad40141", "CHEMICAL", 254, 261], ["Chang cells", "CELL", 55, 66], ["Virus", "ORGANISM", 154, 159], ["Chang", "CELL", 171, 176], ["HeLa Cell CulturesIn HeLa cell cultures", "CELL", 181, 220], ["faecal specimens", "ORGANISM_SUBSTANCE", 232, 248], ["Ad", "ORGANISM", 254, 256], ["Chang cells", "CELL", 275, 286], ["adenovirus", "ORGANISM", 300, 310], ["Chang cells", "CELL_LINE", 55, 66], ["Chang", "CELL_LINE", 171, 176], ["HeLa cell cultures", "CELL_LINE", 202, 220], ["one strain", "PROBLEM", 9, 19], ["a constant CPE", "PROBLEM", 72, 86], ["the virus", "PROBLEM", 88, 97], ["Virus Passage", "PROBLEM", 154, 167], ["HeLa Cell CulturesIn", "TEST", 181, 201], ["HeLa cell cultures", "TEST", 202, 220], ["the faecal specimens", "TEST", 228, 248], ["Ad", "TEST", 254, 256], ["Chang cells", "TEST", 275, 286], ["an adenovirus", "PROBLEM", 297, 310], ["CPE", "PROBLEM", 316, 319], ["constant", "OBSERVATION_MODIFIER", 74, 82], ["CPE", "OBSERVATION", 83, 86], ["serologically", "OBSERVATION_MODIFIER", 130, 143], ["unchanged", "OBSERVATION_MODIFIER", 144, 153], ["HeLa Cell", "OBSERVATION_MODIFIER", 181, 190], ["adenovirus", "OBSERVATION", 300, 310], ["CPE", "OBSERVATION", 316, 319]]], ["Only 4 samples, however, showed a CPE in the second passage, and in no case in the third passage.Comparison With lmmunofluorescenceAll available specimens negative by culture and eight positive specimens were tested by indirect immunofluorescence.", [["samples", "ANATOMY", 7, 14], ["specimens", "ANATOMY", 145, 154], ["specimens", "ANATOMY", 194, 203], ["a CPE", "PROBLEM", 32, 37], ["All available specimens", "TEST", 131, 154], ["culture", "TEST", 167, 174], ["eight positive specimens", "TEST", 179, 203], ["CPE", "OBSERVATION", 34, 37], ["no case", "UNCERTAINTY", 68, 75]]], ["As shown in Table 111 , all negative specimens were also negative by immunofluorescence, while most of the positives also showed fluorescent cells.Comparison With ELISATwenty-six of 28 samples containing Ad40/41 and 7 from 17 negative samples were positive in ELISA (Table IV ).", [["specimens", "ANATOMY", 37, 46], ["cells", "ANATOMY", 141, 146], ["samples", "ANATOMY", 185, 192], ["samples", "ANATOMY", 235, 242], ["specimens", "CANCER", 37, 46], ["cells", "CELL", 141, 146], ["Ad40/41", "CANCER", 204, 211], ["samples", "CANCER", 235, 242], ["fluorescent cells", "CELL_TYPE", 129, 146], ["immunofluorescence", "TEST", 69, 87], ["fluorescent cells", "PROBLEM", 129, 146], ["ELISATwenty", "TEST", 163, 174], ["Ad40/41", "TEST", 204, 211], ["fluorescent cells", "OBSERVATION", 129, 146]]], ["In addition, adenovirus antigen could be found in 4 of 5 specimens equivocal by culture.", [["specimens", "ANATOMY", 57, 66], ["adenovirus", "ORGANISM", 13, 23], ["adenovirus antigen", "PROTEIN", 13, 31], ["adenovirus", "SPECIES", 13, 23], ["adenovirus antigen", "PROBLEM", 13, 31], ["5 specimens", "TEST", 55, 66], ["culture", "TEST", 80, 87]]], ["A correlation of strong positive, weak positive, and negative specimens with the titer in our semiquantitative ELISA is evident from Table IV .", [["specimens", "ANATOMY", 62, 71], ["specimens", "CANCER", 62, 71], ["strong positive, weak positive", "PROBLEM", 17, 47], ["the titer", "TEST", 77, 86], ["our semiquantitative ELISA", "TEST", 90, 116]]], ["T P E present 1-2 days after inoculation ( + +), or later (+). bContamination or equivocal.", [["P E", "DNA", 2, 5], ["inoculation", "PROBLEM", 29, 40], ["bContamination", "TEST", 63, 77]]], ["\"Other adenoviruses.Age Distributionof different age (Table V) showed no significant differences between the groups.Age DistributionThe Occurrence of Ad40/41, other adenoviruses, and negative samples in childrenDISCUSSIONMore than half of the faecal specimens containing adenovirus particles by EM were found to yield positive cultures in Chang cells, identifiable as Ad40/41.", [["samples", "ANATOMY", 192, 199], ["faecal specimens", "ANATOMY", 243, 259], ["Chang cells", "ANATOMY", 339, 350], ["adenoviruses", "ORGANISM", 7, 19], ["adenoviruses", "ORGANISM", 165, 177], ["faecal specimens", "ORGANISM_SUBSTANCE", 243, 259], ["adenovirus", "ORGANISM", 271, 281], ["Chang cells", "CELL", 339, 350], ["Chang cells", "CELL_LINE", 339, 350], ["adenovirus", "SPECIES", 271, 281], ["Other adenoviruses", "PROBLEM", 1, 19], ["significant differences between the groups", "PROBLEM", 73, 115], ["Ad40/41", "TEST", 150, 157], ["other adenoviruses", "PROBLEM", 159, 177], ["the faecal specimens", "TEST", 239, 259], ["adenovirus particles", "PROBLEM", 271, 291], ["positive cultures in Chang cells", "PROBLEM", 318, 350], ["adenoviruses", "OBSERVATION", 7, 19], ["no", "UNCERTAINTY", 70, 72], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["differences", "OBSERVATION", 85, 96]]], ["Isolation and identification were mostly performed within a week, which is remarkably quick for adenoviruses to be grown and identified.", [["adenoviruses", "ORGANISM", 96, 108], ["Isolation", "TREATMENT", 0, 9], ["adenoviruses", "PROBLEM", 96, 108]]], ["The rate of positive Chang cultures equals that reported by Kidd and Madeley [1981] , who found 28 of 67 samples positive, including [Richmond et al, 19791 , and their epidemiology may now be studied more specifically.", [["Chang cultures", "ANATOMY", 21, 35], ["samples", "ANATOMY", 105, 112], ["positive Chang cultures", "CELL_LINE", 12, 35], ["positive Chang cultures", "TEST", 12, 35]]], ["An antiserum against Ad40, which broadly neutrali~e5 Ad40 and Ad41 strains in Chang cells [De Jong et al, 19821 , may be prepared against the Ad40 strain Dugan [De Jong et al, 19821, or alternatively by animal immunization with a filtered stool extract containing EA particles.DISCUSSIONSince the passage of Ad40/41 strains in Chang cells is often difficult or impossible, our method of direct isolation and identification from fecal specimens appears to be suitable for routine diagnostic from children with gastroenteritis, even without previous EM.", [["Chang cells", "ANATOMY", 78, 89], ["extract", "ANATOMY", 245, 252], ["Chang cells", "ANATOMY", 327, 338], ["fecal specimens", "ANATOMY", 428, 443], ["gastroenteritis", "DISEASE", 509, 524], ["antiserum", "ORGANISM_SUBSTANCE", 3, 12], ["Ad40", "GENE_OR_GENE_PRODUCT", 21, 25], ["Ad40", "GENE_OR_GENE_PRODUCT", 53, 57], ["Ad41", "GENE_OR_GENE_PRODUCT", 62, 66], ["Chang cells", "CELL", 78, 89], ["Ad40/41", "GENE_OR_GENE_PRODUCT", 308, 315], ["Chang cells", "CELL", 327, 338], ["fecal specimens", "ORGANISM_SUBSTANCE", 428, 443], ["children", "ORGANISM", 495, 503], ["Chang cells", "CELL_LINE", 78, 89], ["Ad40/41 strains", "CELL_LINE", 308, 323], ["Chang cells", "CELL_LINE", 327, 338], ["children", "SPECIES", 495, 503], ["An antiserum", "TEST", 0, 12], ["neutrali", "TEST", 41, 49], ["animal immunization", "TREATMENT", 203, 222], ["a filtered stool extract containing EA particles", "TREATMENT", 228, 276], ["direct isolation", "TREATMENT", 387, 403], ["fecal specimens", "TEST", 428, 443], ["gastroenteritis", "PROBLEM", 509, 524], ["gastroenteritis", "OBSERVATION", 509, 524]]], ["Chang cells are well suited for cultivating other human adenoviruses as well [Kidd et al, 19821 .", [["Chang cells", "ANATOMY", 0, 11], ["Chang cells", "CELL", 0, 11], ["human", "ORGANISM", 50, 55], ["adenoviruses", "ORGANISM", 56, 68], ["Chang cells", "CELL_LINE", 0, 11], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55]]], ["Chang's conjunctival cells allow some multiplication of at least some strains, as shown by passage, by immunofluorescent cell counting (data not shown), and by inhibition experiments with BUdR [Kidd and Madeley, 19811 .", [["conjunctival cells", "ANATOMY", 8, 26], ["cell", "ANATOMY", 121, 125], ["conjunctival cells", "CELL", 8, 26], ["cell", "CELL", 121, 125], ["conjunctival cells", "CELL_TYPE", 8, 26], ["Chang's conjunctival cells", "PROBLEM", 0, 26], ["some strains", "PROBLEM", 65, 77], ["immunofluorescent cell counting", "TEST", 103, 134], ["conjunctival cells", "OBSERVATION", 8, 26]]], ["Cell cultures of higher susceptibility are desirable.", [["Cell cultures", "ANATOMY", 0, 13], ["Cell cultures", "CELL", 0, 13], ["Cell cultures", "TEST", 0, 13], ["higher susceptibility", "PROBLEM", 17, 38], ["higher susceptibility", "OBSERVATION", 17, 38]]], ["Possibly a better growth may be obtained in Graham 293 cells [Takiff et al, 19811 or in tertiary cynomolgus kidney cells [De Jong et al, 1981, 19821 , but certainly not in human embryonic kidney cells which are superior for the isolation of most other human adenoviruses.", [["Graham 293 cells", "ANATOMY", 44, 60], ["kidney cells", "ANATOMY", 108, 120], ["embryonic kidney cells", "ANATOMY", 178, 200], ["Graham 293 cells", "CELL", 44, 60], ["cynomolgus", "ORGANISM", 97, 107], ["kidney cells", "CELL", 108, 120], ["human", "ORGANISM", 172, 177], ["embryonic kidney cells", "CELL", 178, 200], ["human", "ORGANISM", 252, 257], ["adenoviruses", "ORGANISM", 258, 270], ["Graham 293 cells", "CELL_LINE", 44, 60], ["tertiary cynomolgus kidney cells", "CELL_TYPE", 88, 120], ["human embryonic kidney cells", "CELL_TYPE", 172, 200], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 252, 257], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 252, 257], ["human embryonic kidney cells", "PROBLEM", 172, 200], ["kidney", "ANATOMY", 188, 194]]], ["Ad40141 appear to undergo an abortive replication cycle in HEK cells, since they may show a CPE in them, but cannot be passaged [Gary et al, 1979, Kidd and Madeley, 19811 .DISCUSSIONThe failure to grow virus in Chang cells from some of the samples may have different reasons:DISCUSSION1.", [["HEK cells", "ANATOMY", 59, 68], ["Chang cells", "ANATOMY", 211, 222], ["samples", "ANATOMY", 240, 247], ["Ad40141", "CHEMICAL", 0, 7], ["Ad40141", "ORGANISM", 0, 7], ["HEK cells", "CELL", 59, 68], ["Chang cells", "CELL", 211, 222], ["HEK cells", "CELL_LINE", 59, 68], ["Chang cells", "CELL_LINE", 211, 222], ["an abortive replication cycle in HEK cells", "TREATMENT", 26, 68], ["a CPE", "PROBLEM", 90, 95], ["The failure", "PROBLEM", 182, 193], ["virus", "PROBLEM", 202, 207], ["Chang cells", "PROBLEM", 211, 222], ["CPE", "OBSERVATION", 92, 95], ["failure", "OBSERVATION", 186, 193]]], ["Particles of a different adenovirus type, which cannot be cultivated and which 2.", [["adenovirus", "ORGANISM", 25, 35], ["a different adenovirus type", "PROBLEM", 13, 40], ["different", "OBSERVATION_MODIFIER", 15, 24], ["adenovirus type", "OBSERVATION", 25, 40]]], ["As above, abortive cycle in Chang cells with antigen-producing cells, but no 4.", [["Chang cells", "ANATOMY", 28, 39], ["cells", "ANATOMY", 63, 68], ["Chang cells", "CELL", 28, 39], ["antigen", "GENE_OR_GENE_PRODUCT", 45, 52], ["cells", "CELL", 63, 68], ["Chang cells", "CELL_LINE", 28, 39], ["antigen-producing cells", "CELL_TYPE", 45, 68], ["abortive cycle in Chang cells", "TEST", 10, 39], ["antigen", "TEST", 45, 52], ["no", "UNCERTAINTY", 74, 76]]], ["Ad40/41 present, but in small quantity; EM is more sensitive than culture in 5.", [["Ad40/41", "GENE_OR_GENE_PRODUCT", 0, 7], ["Ad40/41", "PROTEIN", 0, 7], ["culture", "TEST", 66, 73], ["small quantity", "OBSERVATION_MODIFIER", 24, 38]]], ["Particles not growing, due to coating with antibody.DISCUSSIONThe first possibility appears unIikely, as the genus-specific ELISA was positive in a number of samples negative by culture (Table IV) .", [["samples", "ANATOMY", 158, 165], ["coating with antibody", "PROBLEM", 30, 51], ["the genus", "TEST", 105, 114], ["specific ELISA", "TEST", 115, 129], ["culture", "TEST", 178, 185]]], ["Moreover, hexon antigen has been do not containing genus-specific (hexon) antigen. growth with CPE.", [["hexon antigen", "GENE_OR_GENE_PRODUCT", 10, 23], ["hexon) antigen", "GENE_OR_GENE_PRODUCT", 67, 81], ["hexon antigen", "PROTEIN", 10, 23], ["genus-specific (hexon) antigen", "PROTEIN", 51, 81], ["hexon antigen", "TREATMENT", 10, 23], ["CPE", "PROBLEM", 95, 98], ["CPE", "OBSERVATION", 95, 98]]], ["Chang cells.DISCUSSIONfound by counterimmunoelectrophoresis in nearly all faecal specimens containing adenovirus particles in EM [Gary et al, 1979, Mankikar et al, 19791.", [["Chang cells", "ANATOMY", 0, 11], ["faecal specimens", "ANATOMY", 74, 90], ["Chang cells", "CELL", 0, 11], ["faecal specimens", "ORGANISM_SUBSTANCE", 74, 90], ["adenovirus", "ORGANISM", 102, 112], ["Chang cells", "CELL_LINE", 0, 11], ["counterimmunoelectrophoresis", "TEST", 31, 59]]], ["Coating of virus particles with antibody (possibility 5 ) was not observed by Gary et a1 [1979] .", [["Coating of virus particles", "PROBLEM", 0, 26], ["virus particles", "OBSERVATION", 11, 26]]], ["The third possibility is ruled out by our finding that immunofluorescence was about equal in hensitivity as culture (Table 111) .DISCUSSIONAlthough the second possibility cannot be strictly excluded, it appears more likely that the negative specimens do contain Ad40141, but in amounts insufficient to be cultivated in Chang cells or to produce fluorescing cells (possibility 4).", [["specimens", "ANATOMY", 241, 250], ["Chang cells", "ANATOMY", 319, 330], ["cells", "ANATOMY", 357, 362], ["Ad40141", "CHEMICAL", 262, 269], ["Ad40141", "ORGANISM", 262, 269], ["Chang cells", "CELL", 319, 330], ["cells", "CELL", 357, 362], ["Chang cells", "CELL_LINE", 319, 330], ["fluorescing cells", "CELL_TYPE", 345, 362], ["immunofluorescence", "TEST", 55, 73], ["culture", "TEST", 108, 115], ["fluorescing cells", "PROBLEM", 345, 362], ["appears more likely", "UNCERTAINTY", 203, 222], ["fluorescing cells", "OBSERVATION", 345, 362]]], ["Hopefully, a more sensitive cell culture or else the application of a species-specific ELISA [Johansson et al, 19801 may help to answer this question.", [["cell culture", "ANATOMY", 28, 40], ["cell", "CELL", 28, 32], ["a more sensitive cell culture", "PROBLEM", 11, 40]]], ["The genus-specific ELISA applied in this study proved to be fairly sensitive (40 of 55 positive samples).", [["samples", "ANATOMY", 96, 103], ["samples", "CANCER", 96, 103], ["specific ELISA", "TEST", 10, 24], ["this study", "TEST", 36, 46], ["genus", "ANATOMY", 4, 9]]], ["Its specificity was proved by testing several faecal samples containing either rotavirus or no virus; all of them were negative.", [["faecal samples", "ANATOMY", 46, 60], ["faecal samples", "ORGANISM_SUBSTANCE", 46, 60], ["testing several faecal samples", "TEST", 30, 60], ["rotavirus", "PROBLEM", 79, 88], ["virus", "PROBLEM", 95, 100], ["negative", "OBSERVATION", 119, 127]]]], "PMC7223897": [["IntroductionThe survival of extremely low gestational age newborns (ELGANs) has dramatically improved; however, bronchopulmonary dysplasia (BPD) remains the most common morbidity of preterm birth.1 There are few effective and safe therapies to prevent BPD, which is associated with significant complications in the neonatal intensive care unit (NICU) and increased respiratory exacerbations, altered pulmonary function, and neurodevelopmental abnormalities after discharge.2\u20134 The pathogenesis for BPD is multifactorial, but an important component is inflammation that results from intrauterine events and postnatal hypoxia, hyperoxia, ventilator trauma and/or infection in susceptible infants with immature lungs.5\u20137 One of the most consistent clinical factors associated with the development of BPD is the need for mechanical ventilation, with BPD occurring in >70% of ELGANs who require ventilation at 7\u221214 days of age.8IntroductionSystemic postnatal corticosteroids (PCS) are potent anti-inflammatory agents and are one of the few therapies shown to decrease the severity of BPD.9,10 Unfortunately, the heterogeneous PCS treatment regimens that have been studied have not established the optimal type of corticosteroid, optimal dosage, or the optimal timing of initiation for the safe prevention of BPD.11 Early steroid treatment in conjunction with indomethacin treatment for the patent ductous arteriosus (PDA) has been associated with intestinal perforation.12,13 Systemic PCS, particularly dexamethasone, started at <8 days of life has been associated with increased cerebral palsy.14,15IntroductionThere is interest in the potential to deliver a postnatal steroid topically to the lungs to improve the benefit:risk ratio.", [["bronchopulmonary dysplasia", "ANATOMY", 112, 138], ["respiratory", "ANATOMY", 365, 376], ["pulmonary", "ANATOMY", 400, 409], ["intrauterine", "ANATOMY", 582, 594], ["lungs", "ANATOMY", 708, 713], ["patent ductous arteriosus", "ANATOMY", 1385, 1410], ["intestinal", "ANATOMY", 1442, 1452], ["cerebral", "ANATOMY", 1575, 1583], ["lungs", "ANATOMY", 1690, 1695], ["bronchopulmonary dysplasia", "DISEASE", 112, 138], ["BPD", "DISEASE", 140, 143], ["preterm birth", "DISEASE", 182, 195], ["BPD", "DISEASE", 252, 255], ["respiratory exacerbations", "DISEASE", 365, 390], ["neurodevelopmental abnormalities", "DISEASE", 424, 456], ["2\u20134", "CHEMICAL", 473, 476], ["BPD", "DISEASE", 498, 501], ["inflammation", "DISEASE", 551, 563], ["hypoxia", "DISEASE", 616, 623], ["hyperoxia", "DISEASE", 625, 634], ["ventilator trauma", "DISEASE", 636, 653], ["infection", "DISEASE", 661, 670], ["5\u20137", "CHEMICAL", 714, 717], ["BPD", "DISEASE", 797, 800], ["BPD", "DISEASE", 846, 849], ["ELGANs", "DISEASE", 871, 877], ["corticosteroids", "CHEMICAL", 954, 969], ["BPD", "DISEASE", 1079, 1082], ["BPD", "DISEASE", 1303, 1306], ["steroid", "CHEMICAL", 1316, 1323], ["indomethacin", "CHEMICAL", 1354, 1366], ["patent ductous arteriosus", "DISEASE", 1385, 1410], ["intestinal perforation", "DISEASE", 1442, 1464], ["dexamethasone", "CHEMICAL", 1498, 1511], ["cerebral palsy", "DISEASE", 1575, 1589], ["steroid", "CHEMICAL", 1665, 1672], ["corticosteroids", "CHEMICAL", 954, 969], ["steroid", "CHEMICAL", 1316, 1323], ["indomethacin", "CHEMICAL", 1354, 1366], ["dexamethasone", "CHEMICAL", 1498, 1511], ["steroid", "CHEMICAL", 1665, 1672], ["newborns", "ORGANISM", 58, 66], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 112, 138], ["pulmonary", "ORGAN", 400, 409], ["infants", "ORGANISM", 686, 693], ["lungs", "ORGAN", 708, 713], ["ELGANs", "CANCER", 871, 877], ["corticosteroid", "SIMPLE_CHEMICAL", 1208, 1222], ["steroid", "SIMPLE_CHEMICAL", 1316, 1323], ["indomethacin", "SIMPLE_CHEMICAL", 1354, 1366], ["ductous arteriosus", "MULTI-TISSUE_STRUCTURE", 1392, 1410], ["intestinal", "ORGAN", 1442, 1452], ["dexamethasone", "SIMPLE_CHEMICAL", 1498, 1511], ["cerebral", "ORGAN", 1575, 1583], ["lungs", "ORGAN", 1690, 1695], ["infants", "SPECIES", 686, 693], ["extremely low gestational age newborns", "PROBLEM", 28, 66], ["bronchopulmonary dysplasia", "PROBLEM", 112, 138], ["BPD", "PROBLEM", 140, 143], ["preterm birth", "PROBLEM", 182, 195], ["safe therapies", "TREATMENT", 226, 240], ["BPD", "PROBLEM", 252, 255], ["significant complications", "PROBLEM", 282, 307], ["increased respiratory exacerbations", "PROBLEM", 355, 390], ["altered pulmonary function", "PROBLEM", 392, 418], ["neurodevelopmental abnormalities", "PROBLEM", 424, 456], ["BPD", "PROBLEM", 498, 501], ["inflammation", "PROBLEM", 551, 563], ["intrauterine events", "PROBLEM", 582, 601], ["postnatal hypoxia", "PROBLEM", 606, 623], ["hyperoxia", "PROBLEM", 625, 634], ["ventilator trauma", "PROBLEM", 636, 653], ["infection", "PROBLEM", 661, 670], ["immature lungs", "PROBLEM", 699, 713], ["BPD", "PROBLEM", 797, 800], ["mechanical ventilation", "TREATMENT", 817, 839], ["BPD", "PROBLEM", 846, 849], ["ventilation", "TREATMENT", 890, 901], ["8IntroductionSystemic postnatal corticosteroids (PCS", "TREATMENT", 922, 974], ["potent anti-inflammatory agents", "TREATMENT", 980, 1011], ["the few therapies", "TREATMENT", 1027, 1044], ["BPD", "PROBLEM", 1079, 1082], ["the heterogeneous PCS treatment regimens", "TREATMENT", 1103, 1143], ["corticosteroid", "TREATMENT", 1208, 1222], ["BPD", "PROBLEM", 1303, 1306], ["Early steroid treatment", "TREATMENT", 1310, 1333], ["indomethacin treatment", "TREATMENT", 1354, 1376], ["the patent ductous arteriosus", "PROBLEM", 1381, 1410], ["intestinal perforation", "PROBLEM", 1442, 1464], ["Systemic PCS", "TREATMENT", 1471, 1483], ["dexamethasone", "TREATMENT", 1498, 1511], ["increased cerebral palsy", "PROBLEM", 1565, 1589], ["a postnatal steroid topically", "TREATMENT", 1653, 1682], ["dramatically", "OBSERVATION_MODIFIER", 80, 92], ["improved", "OBSERVATION_MODIFIER", 93, 101], ["bronchopulmonary", "ANATOMY", 112, 128], ["dysplasia", "OBSERVATION", 129, 138], ["preterm", "OBSERVATION", 182, 189], ["few", "OBSERVATION_MODIFIER", 208, 211], ["effective", "OBSERVATION_MODIFIER", 212, 221], ["associated with", "UNCERTAINTY", 266, 281], ["significant", "OBSERVATION_MODIFIER", 282, 293], ["complications", "OBSERVATION", 294, 307], ["increased", "OBSERVATION_MODIFIER", 355, 364], ["respiratory exacerbations", "OBSERVATION", 365, 390], ["pulmonary", "ANATOMY", 400, 409], ["inflammation", "OBSERVATION", 551, 563], ["hypoxia", "OBSERVATION", 616, 623], ["ventilator trauma", "OBSERVATION", 636, 653], ["infection", "OBSERVATION", 661, 670], ["immature", "OBSERVATION_MODIFIER", 699, 707], ["lungs", "ANATOMY", 708, 713], ["BPD", "OBSERVATION", 797, 800], ["mechanical ventilation", "OBSERVATION", 817, 839], ["BPD", "OBSERVATION", 1079, 1082], ["heterogeneous", "OBSERVATION_MODIFIER", 1107, 1120], ["BPD", "OBSERVATION", 1303, 1306], ["steroid treatment", "OBSERVATION", 1316, 1333], ["patent", "OBSERVATION", 1385, 1391], ["ductous arteriosus", "ANATOMY", 1392, 1410], ["intestinal", "ANATOMY", 1442, 1452], ["perforation", "OBSERVATION", 1453, 1464], ["increased", "OBSERVATION_MODIFIER", 1565, 1574], ["cerebral", "ANATOMY", 1575, 1583], ["palsy", "OBSERVATION", 1584, 1589], ["lungs", "ANATOMY", 1690, 1695]]], ["A trial of tapering inhaled budesonide started at <12 h of life in infants <28 weeks postmenstrual age (PMA) on any positive pressure support showed a significant decrease in BPD at 36 weeks PMA, but there was increased death in the treated group and no information on systemic levels of budesonide.16 Yeh et al. have conducted two unblinded pilot randomized trials of budesonide (0.25 mg/kg) mixed in surfactant (Survanta) versus surfactant alone administered soon after delivery to infants <1500 g with severe respiratory distress syndrome (RDS).", [["respiratory", "ANATOMY", 512, 523], ["budesonide", "CHEMICAL", 28, 38], ["BPD", "DISEASE", 175, 178], ["death", "DISEASE", 220, 225], ["budesonide", "CHEMICAL", 288, 298], ["budesonide", "CHEMICAL", 369, 379], ["Survanta", "CHEMICAL", 414, 422], ["surfactant", "CHEMICAL", 431, 441], ["respiratory distress syndrome", "DISEASE", 512, 541], ["RDS", "DISEASE", 543, 546], ["budesonide", "CHEMICAL", 28, 38], ["PMA", "CHEMICAL", 191, 194], ["budesonide", "CHEMICAL", 288, 298], ["budesonide", "CHEMICAL", 369, 379], ["budesonide", "SIMPLE_CHEMICAL", 28, 38], ["infants", "ORGANISM", 67, 74], ["PMA", "SIMPLE_CHEMICAL", 191, 194], ["budesonide", "SIMPLE_CHEMICAL", 288, 298], ["budesonide", "SIMPLE_CHEMICAL", 369, 379], ["surfactant", "SIMPLE_CHEMICAL", 402, 412], ["Survanta", "SIMPLE_CHEMICAL", 414, 422], ["surfactant", "SIMPLE_CHEMICAL", 431, 441], ["infants", "ORGANISM", 484, 491], ["infants", "SPECIES", 67, 74], ["infants", "SPECIES", 484, 491], ["tapering inhaled budesonide", "TREATMENT", 11, 38], ["any positive pressure support", "TREATMENT", 112, 141], ["a significant decrease in BPD", "PROBLEM", 149, 178], ["increased death", "PROBLEM", 210, 225], ["budesonide", "TREATMENT", 288, 298], ["budesonide", "TREATMENT", 369, 379], ["surfactant (Survanta)", "TREATMENT", 402, 423], ["surfactant", "TREATMENT", 431, 441], ["severe respiratory distress syndrome", "PROBLEM", 505, 541], ["RDS", "PROBLEM", 543, 546], ["significant", "OBSERVATION_MODIFIER", 151, 162], ["decrease", "OBSERVATION_MODIFIER", 163, 171], ["BPD", "OBSERVATION", 175, 178], ["increased", "OBSERVATION_MODIFIER", 210, 219], ["death", "OBSERVATION", 220, 225], ["severe", "OBSERVATION_MODIFIER", 505, 511], ["respiratory distress", "OBSERVATION", 512, 532]]], ["Both trials demonstrated a significant decrease in the primary outcome of death or BPD at 36 weeks PMA (p < 0.001) without adverse neurodevelopmental effects at 2 years of age.17\u201319 While these surfactant-based trials are encouraging, further investigation is required to assure efficacy and safety and to establish the lowest effective dose.", [["death", "DISEASE", 74, 79], ["BPD", "DISEASE", 83, 86], ["PMA", "CHEMICAL", 99, 102], ["a significant decrease", "PROBLEM", 25, 47], ["death", "PROBLEM", 74, 79], ["BPD", "PROBLEM", 83, 86], ["adverse neurodevelopmental effects", "PROBLEM", 123, 157], ["these surfactant", "TREATMENT", 188, 204], ["further investigation", "TEST", 235, 256], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["decrease", "OBSERVATION_MODIFIER", 39, 47]]], ["There are preclinical data supporting the use of a much lower dose of budesonide.", [["budesonide", "CHEMICAL", 70, 80], ["budesonide", "CHEMICAL", 70, 80], ["budesonide", "SIMPLE_CHEMICAL", 70, 80], ["a much lower dose of budesonide", "TREATMENT", 49, 80]]], ["For example, budesonide is five times more potent than dexamethasone for suppression of chemokines in fetal human lung explants;20 thus, treatment with 0.25 mg/kg budesonide in surfactant would expose the lung to much higher glucocorticoid levels than i.v.", [["fetal", "ANATOMY", 102, 107], ["lung explants", "ANATOMY", 114, 127], ["lung", "ANATOMY", 205, 209], ["budesonide", "CHEMICAL", 13, 23], ["dexamethasone", "CHEMICAL", 55, 68], ["budesonide", "CHEMICAL", 163, 173], ["budesonide", "CHEMICAL", 13, 23], ["dexamethasone", "CHEMICAL", 55, 68], ["budesonide", "CHEMICAL", 163, 173], ["budesonide", "SIMPLE_CHEMICAL", 13, 23], ["dexamethasone", "SIMPLE_CHEMICAL", 55, 68], ["human", "ORGANISM", 108, 113], ["lung explants", "MULTI-TISSUE_STRUCTURE", 114, 127], ["budesonide", "SIMPLE_CHEMICAL", 163, 173], ["surfactant", "SIMPLE_CHEMICAL", 177, 187], ["lung", "ORGAN", 205, 209], ["glucocorticoid", "SIMPLE_CHEMICAL", 225, 239], ["chemokines", "PROTEIN", 88, 98], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["budesonide", "TREATMENT", 13, 23], ["dexamethasone", "TREATMENT", 55, 68], ["chemokines in fetal human lung explants", "TREATMENT", 88, 127], ["treatment", "TREATMENT", 137, 146], ["budesonide", "TREATMENT", 163, 173], ["surfactant", "TREATMENT", 177, 187], ["budesonide", "OBSERVATION", 13, 23], ["lung", "ANATOMY", 114, 118], ["lung", "ANATOMY", 205, 209]]], ["0.25 mg/kg dexamethasone, an effective systemic dose for prevention of BPD.IntroductionThe objective of our study was to investigate the optimal dose of budesonide suspended in surfactant and given intratracheally to decrease the short-term respiratory support and pulmonary inflammatory response of intubated ELGANs at risk for BPD.", [["intratracheally", "ANATOMY", 198, 213], ["respiratory", "ANATOMY", 241, 252], ["pulmonary", "ANATOMY", 265, 274], ["dexamethasone", "CHEMICAL", 11, 24], ["BPD", "DISEASE", 71, 74], ["budesonide", "CHEMICAL", 153, 163], ["BPD", "DISEASE", 329, 332], ["dexamethasone", "CHEMICAL", 11, 24], ["budesonide", "CHEMICAL", 153, 163], ["dexamethasone", "SIMPLE_CHEMICAL", 11, 24], ["budesonide", "SIMPLE_CHEMICAL", 153, 163], ["surfactant", "SIMPLE_CHEMICAL", 177, 187], ["pulmonary", "ORGAN", 265, 274], ["dexamethasone", "TREATMENT", 11, 24], ["an effective systemic dose", "TREATMENT", 26, 52], ["BPD", "PROBLEM", 71, 74], ["our study", "TEST", 104, 113], ["budesonide", "TREATMENT", 153, 163], ["surfactant", "TREATMENT", 177, 187], ["the short-term respiratory support", "TREATMENT", 226, 260], ["pulmonary inflammatory response", "PROBLEM", 265, 296], ["BPD", "PROBLEM", 329, 332], ["BPD", "OBSERVATION", 71, 74], ["short-term", "OBSERVATION_MODIFIER", 230, 240], ["respiratory support", "OBSERVATION", 241, 260], ["pulmonary", "ANATOMY", 265, 274], ["inflammatory", "OBSERVATION", 275, 287]]], ["We hypothesized that a lower dose than the previously administered 0.25 mg/kg of budesonide would be equally effective in decreasing short-term respiratory support and the inflammatory response that contributes to BPD in intubated preterm infants.Study design and participants ::: MethodsThe Steroids And Surfactant In ELGANs study (SASSIE) was a phase I/II open label dose-escalation trial conducted at four US hospitals (Clinicaltrials.gov: NCT 02907593).", [["respiratory", "ANATOMY", 144, 155], ["budesonide", "CHEMICAL", 81, 91], ["BPD", "DISEASE", 214, 217], ["budesonide", "CHEMICAL", 81, 91], ["budesonide", "SIMPLE_CHEMICAL", 81, 91], ["infants", "ORGANISM", 239, 246], ["infants", "SPECIES", 239, 246], ["participants", "SPECIES", 264, 276], ["budesonide", "TREATMENT", 81, 91], ["decreasing short-term respiratory support", "TREATMENT", 122, 163], ["the inflammatory response", "PROBLEM", 168, 193], ["BPD in intubated preterm infants", "PROBLEM", 214, 246], ["Methods", "TREATMENT", 281, 288], ["The Steroids", "TREATMENT", 288, 300], ["Surfactant", "TREATMENT", 305, 315], ["a phase I/II open label dose-escalation trial", "TREATMENT", 345, 390], ["inflammatory", "OBSERVATION", 172, 184]]], ["We treated eight intubated ELGANs at risk for BPD with budesonide in surfactant at each of three dosing levels: 0.025, 0.05, 0.10 mg/kg.", [["ELGANs", "DISEASE", 27, 33], ["BPD", "DISEASE", 46, 49], ["budesonide", "CHEMICAL", 55, 65], ["budesonide", "CHEMICAL", 55, 65], ["budesonide", "SIMPLE_CHEMICAL", 55, 65], ["BPD", "PROBLEM", 46, 49], ["budesonide in surfactant", "TREATMENT", 55, 79]]], ["The first eight enrolled infants received the dose of 0.025 mg/kg, the second eight received 0.05 mg/kg, and the third group of eight received the dose of 0.10 mg/kg.", [["infants", "ORGANISM", 25, 32], ["infants", "SPECIES", 25, 32]]], ["Inclusion criteria were infants with a gestational age of 230/7 to 276/7 weeks who were mechanically ventilated between postnatal days 3\u221214.", [["infants", "ORGANISM", 24, 31], ["infants", "SPECIES", 24, 31], ["mechanically", "OBSERVATION_MODIFIER", 88, 100], ["ventilated", "OBSERVATION", 101, 111]]], ["Infants who had received systemic steroids, or indomethacin, ibuprofen, or acetominophen to treat a PDA \u226496 h before the enrollment window ended, or had congenital malformations or chromosomal anomalies were excluded.", [["chromosomal", "ANATOMY", 181, 192], ["steroids", "CHEMICAL", 34, 42], ["indomethacin", "CHEMICAL", 47, 59], ["ibuprofen", "CHEMICAL", 61, 70], ["acetominophen", "CHEMICAL", 75, 88], ["congenital malformations", "DISEASE", 153, 177], ["chromosomal anomalies", "DISEASE", 181, 202], ["steroids", "CHEMICAL", 34, 42], ["indomethacin", "CHEMICAL", 47, 59], ["ibuprofen", "CHEMICAL", 61, 70], ["acetominophen", "CHEMICAL", 75, 88], ["Infants", "ORGANISM", 0, 7], ["indomethacin", "SIMPLE_CHEMICAL", 47, 59], ["ibuprofen", "SIMPLE_CHEMICAL", 61, 70], ["acetominophen", "SIMPLE_CHEMICAL", 75, 88], ["chromosomal", "CELLULAR_COMPONENT", 181, 192], ["Infants", "SPECIES", 0, 7], ["systemic steroids", "TREATMENT", 25, 42], ["indomethacin", "TREATMENT", 47, 59], ["ibuprofen", "TREATMENT", 61, 70], ["acetominophen", "TREATMENT", 75, 88], ["congenital malformations", "PROBLEM", 153, 177], ["chromosomal anomalies", "PROBLEM", 181, 202], ["congenital", "OBSERVATION_MODIFIER", 153, 163], ["malformations", "OBSERVATION", 164, 177], ["chromosomal anomalies", "OBSERVATION", 181, 202]]], ["Case-matched infants who received calfactant in the Trial of Late SURFactant (TOLSURF) served as the control group.8 Controls were matched 2 to 1 for birth weight, gestational age, sex, race, and initial respiratory severity score (RSS = mean airway pressure \u00d7 fraction of inspired oxygen).Study design and participants ::: MethodsThe trial was conducted under the IND # 128102 for the combined use of budesonide with the standard dose of calfactant.", [["respiratory", "ANATOMY", 204, 215], ["airway", "ANATOMY", 243, 249], ["calfactant", "CHEMICAL", 34, 44], ["oxygen", "CHEMICAL", 282, 288], ["# 128102", "CHEMICAL", 369, 377], ["budesonide", "CHEMICAL", 402, 412], ["calfactant", "CHEMICAL", 439, 449], ["calfactant", "CHEMICAL", 34, 44], ["oxygen", "CHEMICAL", 282, 288], ["budesonide", "CHEMICAL", 402, 412], ["infants", "ORGANISM", 13, 20], ["airway", "MULTI-TISSUE_STRUCTURE", 243, 249], ["oxygen", "SIMPLE_CHEMICAL", 282, 288], ["budesonide", "SIMPLE_CHEMICAL", 402, 412], ["calfactant", "SIMPLE_CHEMICAL", 439, 449], ["infants", "SPECIES", 13, 20], ["participants", "SPECIES", 307, 319], ["calfactant", "TREATMENT", 34, 44], ["Late SURFactant (TOLSURF)", "TREATMENT", 61, 86], ["birth weight", "TEST", 150, 162], ["initial respiratory severity score", "PROBLEM", 196, 230], ["RSS", "TEST", 232, 235], ["mean airway pressure", "TEST", 238, 258], ["inspired oxygen", "TREATMENT", 273, 288], ["Methods", "TREATMENT", 324, 331], ["budesonide", "TREATMENT", 402, 412], ["calfactant", "TREATMENT", 439, 449]]], ["The research protocol was approved by the Institutional Review Boards of the participating institutions, and a parent of each infant provided written informed consent.", [["infant", "ORGANISM", 126, 132], ["infant", "SPECIES", 126, 132]]], ["An independent data safety monitoring board (DSMB) approved the protocol and met after each group of eight patients reached 28 days of age to review study progress and adverse events prior to approving progress to the next dosing level.Study design and participants ::: MethodsThe primary objective of the study was to determine the clinical and anti-inflammatory efficacy by monitoring clinical outcome up to 28 days of age, including RSS, and measuring tracheal aspirate cytokine levels.", [["tracheal aspirate", "ANATOMY", 455, 472], ["patients", "ORGANISM", 107, 115], ["cytokine", "PROTEIN", 473, 481], ["patients", "SPECIES", 107, 115], ["participants", "SPECIES", 253, 265], ["the protocol", "TREATMENT", 60, 72], ["adverse events", "PROBLEM", 168, 182], ["Methods", "TREATMENT", 270, 277], ["the study", "TEST", 302, 311], ["RSS", "TEST", 436, 439], ["measuring tracheal aspirate cytokine levels", "TEST", 445, 488], ["tracheal", "ANATOMY", 455, 463]]], ["By protocol, dose escalation was to be stopped if the DSMB had safety concerns or after two dose levels that met predefined efficacy criteria.", [["dose escalation", "TREATMENT", 13, 28], ["two dose levels", "TEST", 88, 103]]], ["Efficacy criteria included both clinical criteria (five of eight infants extubated within 72 h of the first study dose or after \u22643 daily treatments or one of several other predefined clinical respiratory outcomes at 28 days of age (see supplement) and evidence of anti-inflammation (\u226550% suppression of baseline tracheal aspirate interleukin-8 (IL-8) or monocyte chemoattractant protein 1 (MCP1) at 24\u221272 h after the initial dose of study medication).Study design and participants ::: MethodsWe chose to start the dose escalation at 0.025 mg/kg of budesonide mixed in the standard dose of calfactant because data from our fetal lung explant model20 had suggested this dose should effectively suppress lung chemokine levels.", [["respiratory", "ANATOMY", 192, 203], ["fetal lung", "ANATOMY", 622, 632], ["lung", "ANATOMY", 701, 705], ["budesonide", "CHEMICAL", 548, 558], ["budesonide", "CHEMICAL", 548, 558], ["infants", "ORGANISM", 65, 72], ["interleukin-8", "GENE_OR_GENE_PRODUCT", 330, 343], ["IL-8", "GENE_OR_GENE_PRODUCT", 345, 349], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 354, 388], ["MCP1", "GENE_OR_GENE_PRODUCT", 390, 394], ["budesonide", "SIMPLE_CHEMICAL", 548, 558], ["calfactant", "SIMPLE_CHEMICAL", 589, 599], ["fetal lung", "MULTI-TISSUE_STRUCTURE", 622, 632], ["lung", "ORGAN", 701, 705], ["tracheal aspirate interleukin-8 (IL-8", "PROTEIN", 312, 349], ["monocyte chemoattractant protein 1", "PROTEIN", 354, 388], ["MCP1", "PROTEIN", 390, 394], ["chemokine", "PROTEIN", 706, 715], ["infants", "SPECIES", 65, 72], ["participants", "SPECIES", 468, 480], ["\u22643 daily treatments", "TREATMENT", 128, 147], ["anti-inflammation", "PROBLEM", 264, 281], ["baseline tracheal aspirate interleukin", "TEST", 303, 341], ["IL", "TEST", 345, 347], ["monocyte chemoattractant protein", "TEST", 354, 386], ["study medication", "TREATMENT", 433, 449], ["the dose escalation", "TREATMENT", 510, 529], ["budesonide", "TREATMENT", 548, 558], ["calfactant", "TREATMENT", 589, 599], ["our fetal lung explant model20", "TREATMENT", 618, 648], ["lung chemokine levels", "TEST", 701, 722], ["anti-inflammation", "OBSERVATION", 264, 281], ["tracheal", "ANATOMY", 312, 320], ["lung", "ANATOMY", 628, 632]]], ["The subsequent dosing levels of budesonide were 0.05 mg/kg and 0.10 mg/kg.", [["budesonide", "CHEMICAL", 32, 42], ["budesonide", "CHEMICAL", 32, 42], ["budesonide", "SIMPLE_CHEMICAL", 32, 42], ["The subsequent dosing levels of budesonide", "TREATMENT", 0, 42]]], ["The research pharmacy at each institution prepared the study medication as described in Methods Supplement.", [["the study medication", "TREATMENT", 51, 71]]], ["Infants were dosed every 24 h if still requiring ventilation and could receive up to five doses.", [["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["ventilation", "TREATMENT", 49, 60]]], ["Clinical guidelines for management of ventilation and other patient care practices were developed and approved by investigators.8Materials and procedures ::: MethodsTracheal aspirate (TA) samples were collected for markers of inflammation.", [["samples", "ANATOMY", 188, 195], ["inflammation", "DISEASE", 226, 238], ["patient", "ORGANISM", 60, 67], ["MethodsTracheal aspirate", "MULTI-TISSUE_STRUCTURE", 158, 182], ["patient", "SPECIES", 60, 67], ["management of ventilation", "TREATMENT", 24, 49], ["MethodsTracheal aspirate (TA) samples", "TEST", 158, 195], ["inflammation", "PROBLEM", 226, 238], ["inflammation", "OBSERVATION", 226, 238]]], ["Dried blood spot (DBS) samples were collected for the measurement of budesonide and untargeted metabolomics to assess time- and dose-dependent changes in cortisol and other biochemicals.", [["blood", "ANATOMY", 6, 11], ["samples", "ANATOMY", 23, 30], ["budesonide", "CHEMICAL", 69, 79], ["cortisol", "CHEMICAL", 154, 162], ["budesonide", "CHEMICAL", 69, 79], ["cortisol", "CHEMICAL", 154, 162], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["budesonide", "SIMPLE_CHEMICAL", 69, 79], ["cortisol", "SIMPLE_CHEMICAL", 154, 162], ["Dried blood spot (DBS) samples", "TEST", 0, 30], ["budesonide", "TREATMENT", 69, 79], ["untargeted metabolomics", "TEST", 84, 107], ["dependent changes in cortisol and other biochemicals", "PROBLEM", 133, 185]]], ["TA were collected from the infant\u2019s endotracheal tube prior to and 12 h after the first study dose, just before each of the subsequent doses, and 48 h after the fifth dose if the infant remained intubated.8 DBS samples were collected at 15 min and at 1, 4, and 24 h after the initial dose if the infant had a central line, or 1, 4, and 24 h after the first dose if obtained by heel stick, and at 24 h after subsequent doses.21,22Materials and procedures ::: MethodsHuman chemokines CXCL-8/IL-8 and MCP-1/CCL2 were quantified in TA samples by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) that have intraassay variability of 5.8% each and interassay variability of 7.7% and 5.7%, respectively.", [["endotracheal tube", "ANATOMY", 36, 53], ["DBS samples", "ANATOMY", 207, 218], ["TA samples", "ANATOMY", 528, 538], ["TA", "GENE_OR_GENE_PRODUCT", 0, 2], ["infant", "ORGANISM", 27, 33], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 36, 53], ["infant", "ORGANISM", 179, 185], ["DBS samples", "CANCER", 207, 218], ["heel", "ORGANISM_SUBDIVISION", 377, 381], ["CXCL-8", "GENE_OR_GENE_PRODUCT", 482, 488], ["IL-8", "GENE_OR_GENE_PRODUCT", 489, 493], ["MCP-1", "GENE_OR_GENE_PRODUCT", 498, 503], ["CCL2", "GENE_OR_GENE_PRODUCT", 504, 508], ["TA samples", "TISSUE", 528, 538], ["MethodsHuman chemokines", "PROTEIN", 458, 481], ["CXCL-8", "PROTEIN", 482, 488], ["IL-8", "PROTEIN", 489, 493], ["MCP-1", "PROTEIN", 498, 503], ["CCL2", "PROTEIN", 504, 508], ["infant", "SPECIES", 27, 33], ["TA", "TEST", 0, 2], ["endotracheal tube", "TREATMENT", 36, 53], ["intubated", "TREATMENT", 195, 204], ["DBS samples", "TEST", 207, 218], ["a central line", "TREATMENT", 307, 321], ["heel stick", "TEST", 377, 387], ["MethodsHuman chemokines", "TEST", 458, 481], ["CXCL", "TEST", 482, 486], ["IL", "TEST", 489, 491], ["MCP", "TEST", 498, 501], ["TA samples", "TEST", 528, 538], ["enzyme", "TEST", 542, 548], ["immunosorbent assay", "TEST", 556, 575], ["intraassay variability", "TEST", 625, 647], ["interassay variability", "TEST", 665, 687], ["endotracheal tube", "OBSERVATION", 36, 53], ["central line", "OBSERVATION", 309, 321]]], ["Both assays have a sensitivity range of 31\u22122000 pg/ml.", [["Both assays", "TEST", 0, 11]]], ["Secretory human IgA (sIgA) was used to normalize cytokine/chemokine data and was measured by ELISA (Lifespan Biosciences, Inc., Seattle, WA); intraassay variability of 5.8% and interassay variability of 6.0%, with a sensitivity range of 0.3\u221220 ng/\u00b5l).", [["human", "ORGANISM", 10, 15], ["IgA", "GENE_OR_GENE_PRODUCT", 16, 19], ["IgA", "GENE_OR_GENE_PRODUCT", 22, 25], ["Secretory human IgA", "PROTEIN", 0, 19], ["IgA", "PROTEIN", 22, 25], ["cytokine", "PROTEIN", 49, 57], ["chemokine", "PROTEIN", 58, 67], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["Secretory human IgA", "TEST", 0, 19], ["cytokine/chemokine data", "TEST", 49, 72], ["intraassay variability", "TEST", 142, 164], ["interassay variability", "TEST", 177, 199], ["a sensitivity range", "TEST", 214, 233]]], ["All samples were assayed in duplicate as twofold dilutions.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["We used the Victor3 multichannel plate reader (Perkin Elmer, Waltham, MA) for absorbance measurements.Materials and procedures ::: MethodsNine additional inflammatory mediators (IL-10, IL-12p70, IL-13, IL-1\u03b2, IL-2, IL-4, TNF-\u03b1, INF-\u03b3) were measured from TA samples collected during the 0.1 mg/kg dose of budesonide; analysis was by a multiplex assay as previously described.23,24Materials and procedures ::: MethodsBudesonide concentrations were measured in DBS using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) as previously described.22 The assay was linear between 1 and 50 ng/ml.", [["TA samples", "ANATOMY", 254, 264], ["budesonide", "CHEMICAL", 304, 314], ["MethodsBudesonide", "CHEMICAL", 408, 425], ["budesonide", "CHEMICAL", 304, 314], ["MethodsBudesonide", "CHEMICAL", 408, 425], ["IL-10", "GENE_OR_GENE_PRODUCT", 178, 183], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 185, 193], ["IL-13", "GENE_OR_GENE_PRODUCT", 195, 200], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 202, 207], ["IL-2", "GENE_OR_GENE_PRODUCT", 209, 213], ["IL-4", "GENE_OR_GENE_PRODUCT", 215, 219], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 221, 226], ["INF-\u03b3", "GENE_OR_GENE_PRODUCT", 228, 233], ["TA samples", "TISSUE", 254, 264], ["budesonide", "SIMPLE_CHEMICAL", 304, 314], ["MethodsBudesonide", "SIMPLE_CHEMICAL", 408, 425], ["inflammatory mediators", "PROTEIN", 154, 176], ["TNF", "PROTEIN", 221, 224], ["INF-\u03b3", "PROTEIN", 228, 233], ["the Victor3 multichannel plate", "TREATMENT", 8, 38], ["absorbance measurements", "TEST", 78, 101], ["Methods", "TREATMENT", 131, 138], ["Nine additional inflammatory mediators", "TEST", 138, 176], ["IL", "TEST", 178, 180], ["IL", "TEST", 185, 187], ["IL", "TEST", 195, 197], ["IL", "TEST", 202, 204], ["IL", "TEST", 209, 211], ["IL", "TEST", 215, 217], ["TNF", "TEST", 221, 224], ["TA samples", "TEST", 254, 264], ["budesonide", "TREATMENT", 304, 314], ["analysis", "TEST", 316, 324], ["a multiplex assay", "TEST", 332, 349], ["MethodsBudesonide concentrations", "TREATMENT", 408, 440], ["a validated liquid chromatography", "TEST", 468, 501], ["tandem mass spectrometry", "TEST", 502, 526], ["MS", "PROBLEM", 534, 536], ["The assay", "TEST", 565, 574], ["inflammatory", "OBSERVATION_MODIFIER", 154, 166]]], ["Pharmacokinetic (PK) analysis of blood budesonide was conducted using the noncompartmental analysis module in Phoenix WinNonLin v6.4 (Certara, Princeton, NJ).", [["blood", "ANATOMY", 33, 38], ["budesonide", "CHEMICAL", 39, 49], ["budesonide", "CHEMICAL", 39, 49], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["budesonide", "SIMPLE_CHEMICAL", 39, 49], ["Pharmacokinetic (PK) analysis", "TEST", 0, 29], ["blood budesonide", "TREATMENT", 33, 49], ["the noncompartmental analysis", "TEST", 70, 99]]], ["An extravascular dosing model was used to represent budesonide administration via intratracheal instillation.", [["extravascular", "ANATOMY", 3, 16], ["budesonide", "CHEMICAL", 52, 62], ["budesonide", "CHEMICAL", 52, 62], ["extravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 3, 16], ["budesonide", "SIMPLE_CHEMICAL", 52, 62], ["An extravascular dosing model", "TREATMENT", 0, 29], ["budesonide administration", "TREATMENT", 52, 77], ["intratracheal instillation", "TREATMENT", 82, 108], ["extravascular", "OBSERVATION", 3, 16], ["budesonide", "OBSERVATION", 52, 62], ["intratracheal instillation", "OBSERVATION", 82, 108]]], ["The elimination slope was fit to the 1 and 4 h samples, and the linear up-log down calculation method was used.", [["the linear up-log down calculation method", "TREATMENT", 60, 101]]], ["Data below the limit of quantitation for the LC-MS/MS assay (i.e. <1 ng/ml) were set as missing values.Materials and procedures ::: MethodsGlobal metabolomic analysis using DBS was performed by Metabolon Inc. using ultrahigh performance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS).", [["quantitation", "TEST", 24, 36], ["the LC", "TEST", 41, 47], ["MS/MS assay", "TEST", 48, 59], ["MethodsGlobal metabolomic analysis", "TEST", 132, 166], ["DBS", "TEST", 173, 176], ["ultrahigh performance liquid chromatography", "TEST", 215, 258], ["tandem mass spectroscopy", "TEST", 259, 283], ["UPLC", "TEST", 285, 289]]], ["The processing, assay and analysis procedures have been described in detail.25Statistical analysis ::: MethodsData are presented as mean \u00b1 SD unless otherwise indicated.", [["assay", "TEST", 16, 21], ["analysis procedures", "TEST", 26, 45]]], ["Cytokine and chemokine data were analyzed using Mann\u2212Whitney test and analysis of variance (ANOVA) as appropriate.", [["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["Cytokine", "PROTEIN", 0, 8], ["chemokine", "PROTEIN", 13, 22], ["Cytokine and chemokine data", "TEST", 0, 27], ["Whitney test", "TEST", 53, 65]]], ["Dose-dependent differences in systemic budesonide exposure were assessed using ANOVA with Tukey post-hoc tests in GraphPad Prism v8.1 (GraphPad Software, San Diego, CA).", [["budesonide", "CHEMICAL", 39, 49], ["budesonide", "CHEMICAL", 39, 49], ["budesonide", "SIMPLE_CHEMICAL", 39, 49], ["dependent differences", "PROBLEM", 5, 26], ["systemic budesonide exposure", "TREATMENT", 30, 58], ["hoc tests", "TEST", 101, 110], ["GraphPad Prism", "TEST", 114, 128], ["dependent", "OBSERVATION_MODIFIER", 5, 14], ["systemic budesonide", "OBSERVATION", 30, 49]]], ["ANOVA contrasts and Welch\u2019s two-sample t test were used to identify biochemicals that differed significantly between the dosing levels of budesonide.", [["budesonide", "CHEMICAL", 138, 148], ["budesonide", "CHEMICAL", 138, 148], ["budesonide", "SIMPLE_CHEMICAL", 138, 148], ["ANOVA contrasts", "TEST", 0, 15], ["sample t test", "TEST", 32, 45], ["budesonide", "TREATMENT", 138, 148]]], ["Analysis by two-way ANOVA identified biochemicals exhibiting significant interaction and main effects for experimental parameters of dose and time point.ResultsPatients were enrolled between 3/11/2017 and 3/29/2018.", [["Analysis", "TEST", 0, 8], ["significant interaction", "PROBLEM", 61, 84], ["experimental parameters of dose", "TREATMENT", 106, 137], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["interaction", "OBSERVATION", 73, 84]]], ["A total of 280 ELGANs were screened with 63 eligible and 25 consented into the study (Fig. 1).", [["ELGANs", "CANCER", 15, 21], ["the study", "TEST", 75, 84]]], ["One infant in the 0.1 mg/kg group had consent withdrawn prior to treatment.", [["infant", "ORGANISM", 4, 10], ["infant", "SPECIES", 4, 10], ["treatment", "TREATMENT", 65, 74]]], ["An additional infant was enrolled at that dosing level to provide eight infants per dosing level.", [["infant", "ORGANISM", 14, 20], ["infants", "ORGANISM", 72, 79], ["infant", "SPECIES", 14, 20], ["infants", "SPECIES", 72, 79]]], ["Three dosing levels of budesonide in calfactant were administered.", [["budesonide", "CHEMICAL", 23, 33], ["calfactant", "CHEMICAL", 37, 47], ["budesonide", "CHEMICAL", 23, 33], ["budesonide", "SIMPLE_CHEMICAL", 23, 33], ["calfactant", "SIMPLE_CHEMICAL", 37, 47], ["budesonide in calfactant", "TREATMENT", 23, 47]]], ["Enrollment into the study was stopped after completion of the 0.1 mg/kg dosing as no patient at any of the three dosing levels had fulfilled the predefined efficacy criteria.ResultsThe mean gestational age, birth weight, and age at study dosing of enrolled infants at the respective dosing levels are presented in Table 1 along with the demographics of the 48 matched TOLSURF infants.", [["patient", "ORGANISM", 85, 92], ["infants", "ORGANISM", 257, 264], ["infants", "ORGANISM", 376, 383], ["patient", "SPECIES", 85, 92], ["infants", "SPECIES", 257, 264], ["infants", "SPECIES", 376, 383], ["the study", "TEST", 16, 25], ["birth weight", "TEST", 207, 219]]], ["All of the infants at the first two dosing levels and six of eight at the third dosing level had received surfactant within the first 24 h as per standard of care.", [["infants", "ORGANISM", 11, 18], ["infants", "SPECIES", 11, 18], ["surfactant", "TREATMENT", 106, 116]]], ["All SASSIE infants remained intubated after the first dose of study drug and received two to five doses.ResultsNo infant at any of the three dosing levels achieved the primary outcome of meeting both the predefined clinical respiratory criteria and a >50% suppression of IL-8 or CCL2.", [["infants", "ORGANISM", 11, 18], ["IL-8", "GENE_OR_GENE_PRODUCT", 271, 275], ["CCL2", "GENE_OR_GENE_PRODUCT", 279, 283], ["IL-8", "PROTEIN", 271, 275], ["CCL2", "PROTEIN", 279, 283], ["infants", "SPECIES", 11, 18], ["intubated", "TREATMENT", 28, 37], ["study drug", "TREATMENT", 62, 72], ["IL", "TEST", 271, 273], ["CCL2", "PROBLEM", 279, 283]]], ["There was a significant decrease in RSS at 24 h after initial dosing for the 0.025 mg/kg group and for the entire cohort (Table 1).ResultsTable 2 shows the respiratory outcomes of SASSIE and TOLSURF infants at 28 days and 36 and 40 weeks of PMA.", [["respiratory", "ANATOMY", 156, 167], ["PMA", "CHEMICAL", 241, 244], ["infants", "ORGANISM", 199, 206], ["PMA", "SIMPLE_CHEMICAL", 241, 244], ["infants", "SPECIES", 199, 206], ["a significant decrease in RSS", "PROBLEM", 10, 39], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["decrease", "OBSERVATION_MODIFIER", 24, 32]]], ["All infants required respiratory support at 28 days.", [["respiratory", "ANATOMY", 21, 32], ["infants", "ORGANISM", 4, 11], ["infants", "SPECIES", 4, 11], ["respiratory support", "TREATMENT", 21, 40], ["respiratory support", "OBSERVATION", 21, 40]]], ["Survival without BPD at 36 and 40 weeks was higher in the 0.025 mg/kg dosing group than the 0.05 or 0.10 mg/kg groups; however, the mean birth weight of the 0.025 mg/kg group was 885 g compared to 704 and 651 g in the other two groups.", [["BPD", "DISEASE", 17, 20], ["BPD", "PROBLEM", 17, 20], ["the mean birth weight", "TEST", 128, 149]]], ["Overall, 3 of 24 (12.5%) in SASSIE vs. 2 of 48 (4.2%) TOLSURF infants died and fewer infants in SASSIE survived without BPD at 36 and 40 weeks (17% vs. 31 and 29% vs. 60%).", [["BPD", "DISEASE", 120, 123], ["infants", "ORGANISM", 62, 69], ["infants", "ORGANISM", 85, 92], ["infants", "SPECIES", 62, 69], ["infants", "SPECIES", 85, 92], ["SASSIE", "TEST", 28, 34], ["BPD", "PROBLEM", 120, 123]]], ["No death or serious adverse events were considered to be related to treatment.ResultsBudesonide was detected in the circulation of all 24 subjects; however, two (one in the 0.025 mg/kg and one in the 0.05 mg/kg dose cohorts) had insufficient data to calculate an elimination slope based on 1 and 4 h data.", [["death", "DISEASE", 3, 8], ["ResultsBudesonide", "CHEMICAL", 78, 95], ["ResultsBudesonide", "SIMPLE_CHEMICAL", 78, 95], ["death", "PROBLEM", 3, 8], ["serious adverse events", "PROBLEM", 12, 34], ["treatment", "TREATMENT", 68, 77], ["an elimination slope", "TEST", 260, 280], ["death", "OBSERVATION", 3, 8], ["serious", "OBSERVATION_MODIFIER", 12, 19], ["circulation", "ANATOMY_MODIFIER", 116, 127]]], ["All but two of the samples collected at 24 h after the prior dose were below the limit of quantitation (n = 71 of 73 collected samples).", [["samples", "ANATOMY", 19, 26], ["samples", "ANATOMY", 127, 134], ["samples", "CANCER", 127, 134], ["the samples", "TEST", 15, 26]]], ["Figure 2a shows the observed concentrations of budesonide in DBS at 0.25, 1, and 4 h following the first dose for all three dosing cohorts.ResultsThe half-life of blood budesonide was short (3.4 h) and similar between all dosing cohorts with mean peak concentrations for the 0.025, 0.05, and 0.10 mg/kg dose cohorts of 7.7, 8.6, and 18.7 ng/ml, respectively.", [["blood", "ANATOMY", 163, 168], ["budesonide", "CHEMICAL", 47, 57], ["budesonide", "CHEMICAL", 169, 179], ["budesonide", "CHEMICAL", 47, 57], ["budesonide", "CHEMICAL", 169, 179], ["budesonide", "SIMPLE_CHEMICAL", 47, 57], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["budesonide", "SIMPLE_CHEMICAL", 169, 179], ["budesonide in DBS", "TREATMENT", 47, 64], ["all three dosing cohorts", "TREATMENT", 114, 138], ["blood budesonide", "TREATMENT", 163, 179], ["mean peak concentrations", "TREATMENT", 242, 266]]], ["Combined, these data suggest that while systemic budesonide is eliminated at the same rate independent of dose, the systemic absorption from the intratracheal dose was not dose-linear in this cohort.ResultsWe assessed anti-inflammatory effects of budesonide in infant lungs by the assay of TA levels of two chemokines.20 There was adequate recovery of lung fluid for assay of IL-8, MCP1 and sIgA in TA of 22 of the 24 enrolled infants.", [["intratracheal", "ANATOMY", 145, 158], ["lungs", "ANATOMY", 268, 273], ["lung fluid", "ANATOMY", 352, 362], ["budesonide", "CHEMICAL", 49, 59], ["budesonide", "CHEMICAL", 247, 257], ["budesonide", "CHEMICAL", 49, 59], ["budesonide", "CHEMICAL", 247, 257], ["budesonide", "SIMPLE_CHEMICAL", 49, 59], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 145, 158], ["budesonide", "SIMPLE_CHEMICAL", 247, 257], ["lungs", "ORGAN", 268, 273], ["TA", "GENE_OR_GENE_PRODUCT", 290, 292], ["lung", "ORGAN", 352, 356], ["fluid", "ORGANISM_SUBSTANCE", 357, 362], ["IL-8", "GENE_OR_GENE_PRODUCT", 376, 380], ["MCP1", "GENE_OR_GENE_PRODUCT", 382, 386], ["sIgA", "GENE_OR_GENE_PRODUCT", 391, 395], ["infants", "ORGANISM", 427, 434], ["chemokines", "PROTEIN", 307, 317], ["IL-8", "PROTEIN", 376, 380], ["MCP1", "PROTEIN", 382, 386], ["sIgA", "PROTEIN", 391, 395], ["infant", "SPECIES", 261, 267], ["infants", "SPECIES", 427, 434], ["systemic budesonide", "TREATMENT", 40, 59], ["the systemic absorption", "PROBLEM", 112, 135], ["the intratracheal dose", "TREATMENT", 141, 163], ["budesonide in infant lungs", "TREATMENT", 247, 273], ["two chemokines", "TREATMENT", 303, 317], ["IL", "TEST", 376, 378], ["MCP1", "TEST", 382, 386], ["sIgA in TA", "TEST", 391, 401], ["lungs", "ANATOMY", 268, 273], ["adequate", "OBSERVATION_MODIFIER", 331, 339], ["recovery", "OBSERVATION_MODIFIER", 340, 348], ["lung", "ANATOMY", 352, 356], ["fluid", "OBSERVATION", 357, 362]]], ["The ratio of the mean chemokine value during treatment (from 12 h after the first dose to 24 h after the last dose) was determined, and infants designated as apparent responders if there was >20% decrease compared to predosing.", [["infants", "ORGANISM", 136, 143], ["chemokine", "PROTEIN", 22, 31], ["infants", "SPECIES", 136, 143], ["the mean chemokine value", "TEST", 13, 37], ["treatment", "TREATMENT", 45, 54]]], ["The time course for IL-8 in two infants is shown in Fig. 3a; infant 1 had a sustained decrease in IL-8 beginning 12 h after the first dose with an increase at 48 h after the last dose, whereas infant 2 had no consistent change in IL-8 levels until after 6 days of therapy.", [["IL-8", "GENE_OR_GENE_PRODUCT", 20, 24], ["infants", "ORGANISM", 32, 39], ["IL-8", "GENE_OR_GENE_PRODUCT", 98, 102], ["IL-8", "GENE_OR_GENE_PRODUCT", 230, 234], ["IL-8", "PROTEIN", 20, 24], ["IL-8", "PROTEIN", 98, 102], ["IL", "PROTEIN", 230, 232], ["infants", "SPECIES", 32, 39], ["infant", "SPECIES", 61, 67], ["IL-8", "TREATMENT", 20, 24], ["a sustained decrease in IL", "TREATMENT", 74, 100], ["therapy", "TREATMENT", 264, 271], ["decrease", "OBSERVATION_MODIFIER", 86, 94], ["change", "OBSERVATION_MODIFIER", 220, 226]]], ["Infant 1 in this figure represented a responder, while infant 2 was a nonresponder (Fig. 3a).", [["infant", "SPECIES", 55, 61]]], ["Overall for the 22 infants, there were 11 apparent responders for IL-8 and 8 for MCP-1 (Fig. 3b), with a similar mean level of suppression noted for IL-8 (69 \u00b1 13%) vs. MCP1 (60 \u00b1 21%, NS).ResultsWe explored possible factors related to the chemokine response to budesonide.", [["budesonide", "CHEMICAL", 262, 272], ["budesonide", "CHEMICAL", 262, 272], ["infants", "ORGANISM", 19, 26], ["IL-8", "GENE_OR_GENE_PRODUCT", 66, 70], ["MCP-1", "GENE_OR_GENE_PRODUCT", 81, 86], ["IL-8", "GENE_OR_GENE_PRODUCT", 149, 153], ["MCP1", "GENE_OR_GENE_PRODUCT", 169, 173], ["budesonide", "SIMPLE_CHEMICAL", 262, 272], ["IL", "PROTEIN", 66, 68], ["MCP", "PROTEIN", 81, 84], ["IL-8", "PROTEIN", 149, 153], ["MCP1", "PROTEIN", 169, 173], ["chemokine", "PROTEIN", 240, 249], ["infants", "SPECIES", 19, 26], ["IL", "TEST", 66, 68], ["MCP", "TEST", 81, 84], ["IL", "TEST", 149, 151], ["MCP1", "TEST", 169, 173], ["NS", "TEST", 185, 187], ["budesonide", "TREATMENT", 262, 272]]], ["Of interest, the predose levels of IL-8 and MCP1 varied widely (1096-fold and 3323-fold, respectively) and the levels of the two chemokines were strongly correlated (r = 0.98, p = 8\u221216).", [["IL-8", "GENE_OR_GENE_PRODUCT", 35, 39], ["MCP1", "GENE_OR_GENE_PRODUCT", 44, 48], ["IL-8", "PROTEIN", 35, 39], ["MCP1", "PROTEIN", 44, 48], ["chemokines", "PROTEIN", 129, 139], ["the predose levels", "TEST", 13, 31], ["IL", "TEST", 35, 37], ["MCP1", "TEST", 44, 48], ["p", "TEST", 176, 177]]], ["There was a strong association between predose levels and the decrease during treatment, with higher baseline levels for both IL-8 and MCP (~22-fold, p < 0.01) for responders compared to nonresponders (Fig. 3c).", [["IL-8", "GENE_OR_GENE_PRODUCT", 126, 130], ["MCP", "GENE_OR_GENE_PRODUCT", 135, 138], ["IL-8", "PROTEIN", 126, 130], ["MCP", "PROTEIN", 135, 138], ["predose levels", "TEST", 39, 53], ["treatment", "TREATMENT", 78, 87], ["IL", "TEST", 126, 128], ["MCP", "TEST", 135, 138], ["responders", "PROBLEM", 164, 174], ["strong", "OBSERVATION_MODIFIER", 12, 18], ["decrease", "OBSERVATION_MODIFIER", 62, 70]]], ["There was a weak correlation between blood budesonide level (at 4 h) and the change in TA IL-8 at 24 h (r = 0.46, p = 0.04, n = 20, Fig. 4), indicating that responsiveness was not strongly related to systemic budesonide levels.", [["blood", "ANATOMY", 37, 42], ["budesonide", "CHEMICAL", 43, 53], ["budesonide", "CHEMICAL", 209, 219], ["budesonide", "CHEMICAL", 43, 53], ["budesonide", "CHEMICAL", 209, 219], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["budesonide", "SIMPLE_CHEMICAL", 43, 53], ["IL-8", "GENE_OR_GENE_PRODUCT", 90, 94], ["budesonide", "SIMPLE_CHEMICAL", 209, 219], ["IL", "PROTEIN", 90, 92], ["blood budesonide level", "TEST", 37, 59], ["TA IL", "TEST", 87, 92], ["p", "TEST", 114, 115], ["systemic budesonide levels", "TEST", 200, 226], ["weak", "OBSERVATION_MODIFIER", 12, 16]]], ["No significant differences were observed in clinical parameters comparing infants with suppression of IL-8 vs. those without suppression, although more of the responders (8/11) than nonresponders (4/11, p = 0.08) had a decrease in RSS with budesonide treatment (Table 4).ResultsNeither the number of responders, nor the level of suppression of IL-8 among responders, showed apparent dose-dependency: 5 of 8 with 56 \u00b1 13% suppression at 0.025 mg/kg, 2 of 7 and 84 \u00b1 13% suppression at 0.05 mg/kg, and 4 of 7 and 79 \u00b1 12% suppression at 0.1 mg/kg.", [["budesonide", "CHEMICAL", 240, 250], ["budesonide", "CHEMICAL", 240, 250], ["infants", "ORGANISM", 74, 81], ["IL-8", "GENE_OR_GENE_PRODUCT", 102, 106], ["budesonide", "SIMPLE_CHEMICAL", 240, 250], ["IL-8", "GENE_OR_GENE_PRODUCT", 344, 348], ["IL", "PROTEIN", 102, 104], ["IL", "PROTEIN", 344, 346], ["infants", "SPECIES", 74, 81], ["significant differences", "PROBLEM", 3, 26], ["clinical parameters", "TEST", 44, 63], ["suppression of IL", "TREATMENT", 87, 104], ["nonresponders", "TEST", 182, 195], ["a decrease in RSS", "PROBLEM", 217, 234], ["budesonide treatment", "TREATMENT", 240, 260], ["IL", "TEST", 344, 346], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION", 15, 26], ["decrease", "OBSERVATION_MODIFIER", 219, 227]]], ["Corresponding numbers for MCP1 were 3/8, 2/7, and 3/7 with suppression of 46 \u00b1 21%, 73 \u00b1 13%, and 54 \u00b1 35%, respectively.", [["MCP1", "GENE_OR_GENE_PRODUCT", 26, 30], ["MCP1", "PROTEIN", 26, 30], ["MCP1", "TEST", 26, 30], ["suppression", "TEST", 59, 70]]], ["We used a multiplex approach to assay an additional nine inflammatory mediators in TA from infants receiving the 0.1 mg/kg dose (Table 5).23 Consistent decreases during budesonide treatment were observed for all mediators (mean % suppression values ranging from 51 to 79%) in three of the four infants with suppression of IL-8.", [["budesonide", "CHEMICAL", 169, 179], ["budesonide", "CHEMICAL", 169, 179], ["infants", "ORGANISM", 91, 98], ["budesonide", "SIMPLE_CHEMICAL", 169, 179], ["infants", "ORGANISM", 294, 301], ["IL-8", "GENE_OR_GENE_PRODUCT", 322, 326], ["inflammatory mediators", "PROTEIN", 57, 79], ["IL-8", "PROTEIN", 322, 326], ["infants", "SPECIES", 91, 98], ["infants", "SPECIES", 294, 301], ["a multiplex approach", "TREATMENT", 8, 28], ["an additional nine inflammatory mediators", "TREATMENT", 38, 79], ["budesonide treatment", "TREATMENT", 169, 189], ["mean % suppression values", "TEST", 223, 248], ["suppression of IL", "TREATMENT", 307, 324], ["decreases", "OBSERVATION_MODIFIER", 152, 161]]], ["Baseline levels were higher for responders than nonresponding infants for each mediator (range 1.8- to 5.0-fold) as observed for IL-8 and MCP1 (5.8- and 5.7-fold) at this budesonide dose.", [["budesonide", "CHEMICAL", 171, 181], ["budesonide", "CHEMICAL", 171, 181], ["infants", "ORGANISM", 62, 69], ["IL-8", "GENE_OR_GENE_PRODUCT", 129, 133], ["MCP1", "GENE_OR_GENE_PRODUCT", 138, 142], ["budesonide", "SIMPLE_CHEMICAL", 171, 181], ["IL-8", "PROTEIN", 129, 133], ["MCP1", "PROTEIN", 138, 142], ["infants", "SPECIES", 62, 69], ["Baseline levels", "TEST", 0, 15], ["IL", "TEST", 129, 131], ["MCP1", "TEST", 138, 142], ["this budesonide dose", "TREATMENT", 166, 186]]], ["Overall, our results provide evidence for a strong anti-inflammatory response in the lung for some, but not all, infants that is independent of the budesonide dose between 0.025 and 0.1 mg/kg and is related to elevated inflammatory status in the lung at baseline.ResultsWe identified eight infants in the TOLSURF cohort who received late surfactant, but not systemic PCS, and who had five TA samples collected over a 9 \u00b1 2-day period.", [["lung", "ANATOMY", 85, 89], ["lung", "ANATOMY", 246, 250], ["samples", "ANATOMY", 392, 399], ["budesonide", "CHEMICAL", 148, 158], ["budesonide", "CHEMICAL", 148, 158], ["lung", "ORGAN", 85, 89], ["infants", "ORGANISM", 113, 120], ["budesonide", "SIMPLE_CHEMICAL", 148, 158], ["lung", "ORGAN", 246, 250], ["infants", "ORGANISM", 290, 297], ["infants", "SPECIES", 113, 120], ["infants", "SPECIES", 290, 297], ["a strong anti-inflammatory response in the lung", "PROBLEM", 42, 89], ["the budesonide dose", "TREATMENT", 144, 163], ["elevated inflammatory status", "PROBLEM", 210, 238], ["late surfactant", "TREATMENT", 333, 348], ["systemic PCS", "PROBLEM", 358, 370], ["strong", "OBSERVATION_MODIFIER", 44, 50], ["anti-inflammatory response", "OBSERVATION", 51, 77], ["lung", "ANATOMY", 85, 89], ["elevated", "OBSERVATION_MODIFIER", 210, 218], ["inflammatory", "OBSERVATION", 219, 231], ["lung", "ANATOMY", 246, 250]]], ["In this group, comparing mean levels for samples 2\u22125 with sample 1, there was a consistent suppression of IL-8 and MCP1 in 3 and 1 infants, respectively, with suppression ranging between 54 and 69%.", [["IL-8", "GENE_OR_GENE_PRODUCT", 106, 110], ["MCP1", "GENE_OR_GENE_PRODUCT", 115, 119], ["infants", "ORGANISM", 131, 138], ["IL-8", "PROTEIN", 106, 110], ["MCP1", "PROTEIN", 115, 119], ["infants", "SPECIES", 131, 138], ["mean levels", "TEST", 25, 36], ["samples", "TEST", 41, 48], ["sample", "TEST", 58, 64], ["IL", "TEST", 106, 108], ["MCP1", "TEST", 115, 119]]], ["To examine systemic responses to budesonide, we performed untargeted metabolomics on SASSIE DBS.25 A total of 829 named biochemicals were detected in 121 dried blood spots from 23 infants over 7 time points (15 min\u221296 h post 3 infants with declining chemokine levels over time, baseline values (sample 1) were near the median treatment initiation).", [["blood", "ANATOMY", 160, 165], ["budesonide", "CHEMICAL", 33, 43], ["budesonide", "CHEMICAL", 33, 43], ["budesonide", "SIMPLE_CHEMICAL", 33, 43], ["biochemicals", "CANCER", 120, 132], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["infants", "ORGANISM", 180, 187], ["infants", "ORGANISM", 227, 234], ["chemokine", "PROTEIN", 250, 259], ["infants", "SPECIES", 180, 187], ["infants", "SPECIES", 227, 234], ["budesonide", "TREATMENT", 33, 43], ["SASSIE DBS", "TREATMENT", 85, 95], ["blood spots", "TEST", 160, 171], ["declining chemokine levels", "TEST", 240, 266], ["the median treatment initiation", "TREATMENT", 315, 346]]], ["There was a statistically significant, time-dependent decrease in cortisol for infants receiving 0.05 and 0.1 mg/kg budesonide, with decreased levels occurring at 4 h and mean suppression of 52% and 75%, respectively, at 24 h (Fig. 5a).", [["cortisol", "CHEMICAL", 66, 74], ["budesonide", "CHEMICAL", 116, 126], ["cortisol", "CHEMICAL", 66, 74], ["budesonide", "CHEMICAL", 116, 126], ["cortisol", "SIMPLE_CHEMICAL", 66, 74], ["infants", "ORGANISM", 79, 86], ["budesonide", "SIMPLE_CHEMICAL", 116, 126], ["infants", "SPECIES", 79, 86], ["cortisol", "TREATMENT", 66, 74], ["budesonide", "TREATMENT", 116, 126], ["decreased levels", "PROBLEM", 133, 149], ["mean suppression", "TEST", 171, 187], ["statistically", "OBSERVATION_MODIFIER", 12, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["decrease", "OBSERVATION_MODIFIER", 54, 62]]], ["By contrast, blood cortisol did not change significantly for the group of infants treated with 0.025 mg/kg budesonide.ResultsTo evaluate global systemic metabolic responses, the number of significant (p < 0.05) changes (decreased or increased) were determined for each time point compared to the 15-min value (Fig. 5b).", [["blood", "ANATOMY", 13, 18], ["cortisol", "CHEMICAL", 19, 27], ["budesonide", "CHEMICAL", 107, 117], ["cortisol", "CHEMICAL", 19, 27], ["budesonide", "CHEMICAL", 107, 117], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["cortisol", "SIMPLE_CHEMICAL", 19, 27], ["infants", "ORGANISM", 74, 81], ["budesonide", "SIMPLE_CHEMICAL", 107, 117], ["infants", "SPECIES", 74, 81], ["blood cortisol", "TEST", 13, 27], ["budesonide", "TREATMENT", 107, 117], ["systemic", "OBSERVATION_MODIFIER", 144, 152], ["metabolic responses", "OBSERVATION", 153, 172], ["significant", "OBSERVATION_MODIFIER", 188, 199], ["decreased", "OBSERVATION_MODIFIER", 220, 229], ["increased", "OBSERVATION_MODIFIER", 233, 242]]], ["There was a time-dependent increase in number of changes at all three doses, with a similar relatively low level of changes (<40) in the first 24 h, and a dose-dependent response at later time points; at 96 h, the number of metabolite changes were 48, 127, and 260 at 0.025, 0.05, and 0.1 mg/kg, respectively, representing 5.8%, 15.3%, and 31.4% of the known biochemicals detected.", [["the known biochemicals", "PROBLEM", 349, 371], ["dependent", "OBSERVATION_MODIFIER", 17, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["number", "OBSERVATION_MODIFIER", 39, 45], ["biochemicals", "OBSERVATION", 359, 371]]], ["These results indicate that intratracheal budesonide:surfactant treatment, at the doses and frequency used, has an approximately linear dose\u2212response impact on blood biochemicals, consistent with extra-pulmonary effects of circulating steroid.DiscussionWe performed a dose-escalation study of budesonide in calfactant given intratracheally to ELGANs still requiring mechanical ventilation at 3\u221214 days of age starting at one-tenth the dose used in previous studies.18,19 Although most infants had a decrease in RSS following treatment, there were no differences between dosing groups in clinical respiratory outcomes at 28th day.", [["blood", "ANATOMY", 160, 165], ["intratracheally", "ANATOMY", 324, 339], ["respiratory", "ANATOMY", 596, 607], ["budesonide", "CHEMICAL", 42, 52], ["surfactant", "CHEMICAL", 53, 63], ["steroid", "CHEMICAL", 235, 242], ["budesonide", "CHEMICAL", 293, 303], ["calfactant", "CHEMICAL", 307, 317], ["budesonide", "CHEMICAL", 42, 52], ["steroid", "CHEMICAL", 235, 242], ["budesonide", "CHEMICAL", 293, 303], ["budesonide", "SIMPLE_CHEMICAL", 42, 52], ["surfactant", "SIMPLE_CHEMICAL", 53, 63], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["steroid", "SIMPLE_CHEMICAL", 235, 242], ["budesonide", "SIMPLE_CHEMICAL", 293, 303], ["calfactant", "SIMPLE_CHEMICAL", 307, 317], ["infants", "ORGANISM", 485, 492], ["infants", "SPECIES", 485, 492], ["intratracheal budesonide", "TREATMENT", 28, 52], ["surfactant treatment", "TREATMENT", 53, 73], ["blood biochemicals", "TEST", 160, 178], ["extra-pulmonary effects", "PROBLEM", 196, 219], ["circulating steroid", "TREATMENT", 223, 242], ["a dose-escalation study", "TREATMENT", 266, 289], ["budesonide", "TREATMENT", 293, 303], ["calfactant", "TREATMENT", 307, 317], ["mechanical ventilation", "TREATMENT", 366, 388], ["previous studies", "TEST", 448, 464], ["a decrease in RSS", "PROBLEM", 497, 514], ["treatment", "TREATMENT", 525, 534], ["dosing groups", "TREATMENT", 570, 583], ["intratracheal budesonide", "OBSERVATION", 28, 52], ["surfactant treatment", "OBSERVATION", 53, 73], ["consistent with", "UNCERTAINTY", 180, 195], ["extra-pulmonary effects", "OBSERVATION", 196, 219], ["circulating steroid", "OBSERVATION", 223, 242], ["decrease", "OBSERVATION_MODIFIER", 499, 507]]], ["BPD at 36 or 40 weeks PMA was less common in infants in the 0.025 mg/kg group; however, these infants had a higher mean birth weight than the other two groups.", [["BPD", "DISEASE", 0, 3], ["PMA", "CHEMICAL", 22, 25], ["PMA", "CHEMICAL", 22, 25], ["PMA", "SIMPLE_CHEMICAL", 22, 25], ["infants", "ORGANISM", 45, 52], ["infants", "ORGANISM", 94, 101], ["infants", "SPECIES", 45, 52], ["infants", "SPECIES", 94, 101], ["BPD", "PROBLEM", 0, 3]]], ["Only half of the infants had evidence of increased inflammatory markers in TA at initiation of the study, and these infants had a similar decrease in levels of the two cytokines with treatment at all three dosing levels.", [["infants", "ORGANISM", 17, 24], ["infants", "ORGANISM", 116, 123], ["inflammatory markers", "PROTEIN", 51, 71], ["cytokines", "PROTEIN", 168, 177], ["infants", "SPECIES", 17, 24], ["infants", "SPECIES", 116, 123], ["increased inflammatory markers", "PROBLEM", 41, 71], ["the study", "TEST", 95, 104], ["the two cytokines", "TREATMENT", 160, 177], ["treatment", "TREATMENT", 183, 192], ["evidence of", "UNCERTAINTY", 29, 40], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["inflammatory", "OBSERVATION", 51, 63], ["decrease", "OBSERVATION_MODIFIER", 138, 146]]], ["There was a dose-dependent increase in both suppression of blood cortisol and in the number of alterations in levels of other blood metabolites indicating systemic absorption and effects of the corticosteroid.", [["blood", "ANATOMY", 59, 64], ["blood", "ANATOMY", 126, 131], ["cortisol", "CHEMICAL", 65, 73], ["cortisol", "CHEMICAL", 65, 73], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["cortisol", "SIMPLE_CHEMICAL", 65, 73], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["corticosteroid", "SIMPLE_CHEMICAL", 194, 208], ["dependent increase", "PROBLEM", 17, 35], ["blood cortisol", "TEST", 59, 73], ["other blood metabolites", "PROBLEM", 120, 143], ["systemic absorption", "PROBLEM", 155, 174], ["the corticosteroid", "TREATMENT", 190, 208], ["dependent", "OBSERVATION_MODIFIER", 17, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["both suppression", "OBSERVATION", 39, 55], ["systemic absorption", "OBSERVATION", 155, 174], ["corticosteroid", "OBSERVATION", 194, 208]]], ["These results suggest that intratracheal budesonide reduces lung inflammation only in infants who have elevated inflammatory status, and that this effect occurs at the lowest dose tested (0.025 mg/kg), which has minimal systemic metabolic effects and can be safely repeated if the infant remains intubated.DiscussionSurvival without BPD for SASSIE infants was lower than for the historical matched TOLSURF cohort, which may reflect in part benefit from inhaled nitric oxide in nonwhite infants.26 The apparent lack of clinical benefit is also in contrast to the two pilot RCTs of Yeh et al., in which significantly fewer infants in the treated group (single dose of 0.25 mg/kg budesonide in Survanta) had BPD at 36 weeks PMA.18,19 There are several possible explanations for this difference.", [["intratracheal", "ANATOMY", 27, 40], ["lung", "ANATOMY", 60, 64], ["budesonide", "CHEMICAL", 41, 51], ["lung inflammation", "DISEASE", 60, 77], ["BPD", "DISEASE", 333, 336], ["nitric oxide", "CHEMICAL", 461, 473], ["budesonide", "CHEMICAL", 677, 687], ["BPD", "DISEASE", 705, 708], ["PMA", "CHEMICAL", 721, 724], ["budesonide", "CHEMICAL", 41, 51], ["nitric oxide", "CHEMICAL", 461, 473], ["budesonide", "CHEMICAL", 677, 687], ["PMA", "CHEMICAL", 721, 724], ["budesonide", "SIMPLE_CHEMICAL", 41, 51], ["lung", "ORGAN", 60, 64], ["infants", "ORGANISM", 86, 93], ["infant", "ORGANISM", 281, 287], ["infants", "ORGANISM", 348, 355], ["inhaled nitric oxide", "SIMPLE_CHEMICAL", 453, 473], ["infants", "ORGANISM", 486, 493], ["infants", "ORGANISM", 621, 628], ["PMA", "SIMPLE_CHEMICAL", 721, 724], ["infants", "SPECIES", 86, 93], ["infants", "SPECIES", 348, 355], ["infants", "SPECIES", 486, 493], ["infants", "SPECIES", 621, 628], ["intratracheal budesonide", "TREATMENT", 27, 51], ["lung inflammation", "PROBLEM", 60, 77], ["elevated inflammatory status", "PROBLEM", 103, 131], ["intubated", "TREATMENT", 296, 305], ["BPD", "PROBLEM", 333, 336], ["inhaled nitric oxide", "TREATMENT", 453, 473], ["budesonide", "TREATMENT", 677, 687], ["Survanta", "TREATMENT", 691, 699], ["BPD", "PROBLEM", 705, 708], ["this difference", "PROBLEM", 775, 790], ["intratracheal budesonide", "OBSERVATION", 27, 51], ["lung", "ANATOMY", 60, 64], ["inflammation", "OBSERVATION", 65, 77], ["elevated", "OBSERVATION_MODIFIER", 103, 111], ["inflammatory", "OBSERVATION", 112, 124], ["minimal", "OBSERVATION_MODIFIER", 212, 219], ["systemic", "OBSERVATION_MODIFIER", 220, 228], ["metabolic effects", "OBSERVATION", 229, 246], ["possible explanations for", "UNCERTAINTY", 749, 774]]], ["Our study did not have concurrent controls nor was it powered to detect significant differences in clinical outcomes.", [["Our study", "TEST", 0, 9], ["significant differences in clinical outcomes", "PROBLEM", 72, 116]]], ["Importantly, in the Yeh studies,18,19 infants were enrolled within the first 24 h of receiving FiO2 > 0.6 and were mechanically ventilated whereas infants in SASSIE were only enrolled if they required mechanical ventilation between postnatal days 3 and 14 and were therefore in the highest risk group (>70%) for BPD.8 The lack of apparent clinical response may also reflect differences in the patient populations.", [["BPD", "DISEASE", 312, 315], ["infants", "ORGANISM", 38, 45], ["infants", "ORGANISM", 147, 154], ["patient", "ORGANISM", 393, 400], ["infants", "SPECIES", 38, 45], ["infants", "SPECIES", 147, 154], ["patient", "SPECIES", 393, 400], ["FiO2", "TREATMENT", 95, 99], ["mechanical ventilation", "TREATMENT", 201, 223], ["BPD", "PROBLEM", 312, 315], ["may also reflect", "UNCERTAINTY", 357, 373], ["differences", "OBSERVATION_MODIFIER", 374, 385]]], ["The infants in Yeh\u2019s studies were more mature and larger than the infants in SASSIE.", [["infants", "ORGANISM", 4, 11], ["infants", "ORGANISM", 66, 73], ["infants", "SPECIES", 4, 11], ["infants", "SPECIES", 66, 73], ["larger", "OBSERVATION_MODIFIER", 50, 56]]], ["In SASSIE, infants treated within 96 h of dosing for a PDA were excluded to minimize any potential interactions with study medication and this may have biased results.DiscussionYeh et al. previously described the pharmacokinetics of budesonide in ten preterm neonates (<1500 g at birth) following intratracheal instillation of 0.25 mg/kg budesonide.18 The observed elimination half-life (3.4 h) in our study was similar to the Yeh study (4.1 h).", [["intratracheal", "ANATOMY", 297, 310], ["budesonide", "CHEMICAL", 233, 243], ["budesonide", "CHEMICAL", 338, 348], ["budesonide", "CHEMICAL", 233, 243], ["budesonide", "CHEMICAL", 338, 348], ["infants", "ORGANISM", 11, 18], ["budesonide", "SIMPLE_CHEMICAL", 233, 243], ["neonates", "ORGANISM", 259, 267], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 297, 310], ["budesonide", "SIMPLE_CHEMICAL", 338, 348], ["infants", "SPECIES", 11, 18], ["a PDA", "PROBLEM", 53, 58], ["study medication", "TREATMENT", 117, 133], ["budesonide", "TREATMENT", 233, 243], ["ten preterm neonates", "PROBLEM", 247, 267], ["intratracheal instillation", "TREATMENT", 297, 323], ["budesonide", "TREATMENT", 338, 348], ["our study", "TEST", 398, 407], ["the Yeh study", "TEST", 423, 436]]], ["The AUC reported in Yeh\u2019s study (AUC0\u22128 = 115.7 ng \u00d7 h/ml) extrapolates to an AUC24 of approximately 200 ng \u00d7 h/ml.", [["The AUC", "TEST", 0, 7], ["AUC0\u22128", "TEST", 33, 39], ["an AUC24", "TEST", 75, 83]]], ["When normalized for dose, this value is similar to the AUC24 observed for the 0.10 mg/kg cohort in our study.", [["our study", "TEST", 99, 108]]], ["These kinetics support daily treatment to sustain elevated blood budesonide.", [["blood", "ANATOMY", 59, 64], ["budesonide", "CHEMICAL", 65, 75], ["budesonide", "CHEMICAL", 65, 75], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["budesonide", "SIMPLE_CHEMICAL", 65, 75], ["daily treatment", "TREATMENT", 23, 38], ["elevated blood budesonide", "TREATMENT", 50, 75]]], ["Concentrations of budesonide in human lung are not known, but in lambs levels in lung tissue decrease to 0.4% of the initial dose at 24 h.27DiscussionThe Yeh study observed a peak concentration of approximately 20 ng/ml at 30 min after dose.", [["lung", "ANATOMY", 38, 42], ["lung tissue", "ANATOMY", 81, 92], ["budesonide", "CHEMICAL", 18, 28], ["budesonide", "CHEMICAL", 18, 28], ["budesonide", "SIMPLE_CHEMICAL", 18, 28], ["human", "ORGANISM", 32, 37], ["lung", "ORGAN", 38, 42], ["lambs", "ORGANISM", 65, 70], ["lung tissue", "TISSUE", 81, 92], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["budesonide in human lung", "TREATMENT", 18, 42], ["lambs levels", "TEST", 65, 77], ["The Yeh study", "TEST", 150, 163], ["budesonide", "OBSERVATION", 18, 28], ["human", "ANATOMY_MODIFIER", 32, 37], ["lung", "ANATOMY", 38, 42], ["lung", "ANATOMY", 81, 85], ["tissue", "OBSERVATION_MODIFIER", 86, 92], ["decrease", "OBSERVATION_MODIFIER", 93, 101]]], ["This peak concentration is similar to the Cmax of 18.7 ng/ml at 15 min post dose from a lower dose (0.10 mg/kg) in our study, suggesting a ~2.5-fold difference in observed Cmax between the studies.18 From the data collected, it is unclear whether the difference in Cmax is due to a difference in absorption secondary to the surfactant used (Survanta in Yeh\u2019s trial, Calfactant in our study), the gestational weight and/or age differences between study populations, the difference between samples collected at 15 and 30 min post dose, and/or methodologic differences.DiscussionThe plasma concentrations of budesonide in infants can be compared to those achieved with antenatal betamethasone for enhancing fetal maturity and postnatal dexamethasone given for prevention of BPD.", [["samples", "ANATOMY", 488, 495], ["plasma", "ANATOMY", 580, 586], ["fetal", "ANATOMY", 704, 709], ["Cmax", "CHEMICAL", 42, 46], ["Cmax", "CHEMICAL", 172, 176], ["Cmax", "CHEMICAL", 265, 269], ["budesonide", "CHEMICAL", 605, 615], ["betamethasone", "CHEMICAL", 676, 689], ["dexamethasone", "CHEMICAL", 733, 746], ["BPD", "DISEASE", 771, 774], ["budesonide", "CHEMICAL", 605, 615], ["betamethasone", "CHEMICAL", 676, 689], ["dexamethasone", "CHEMICAL", 733, 746], ["Cmax", "SIMPLE_CHEMICAL", 172, 176], ["Cmax", "SIMPLE_CHEMICAL", 265, 269], ["plasma", "ORGANISM_SUBSTANCE", 580, 586], ["budesonide", "SIMPLE_CHEMICAL", 605, 615], ["infants", "ORGANISM", 619, 626], ["betamethasone", "SIMPLE_CHEMICAL", 676, 689], ["fetal", "ANATOMICAL_SYSTEM", 704, 709], ["dexamethasone", "SIMPLE_CHEMICAL", 733, 746], ["infants", "SPECIES", 619, 626], ["This peak concentration", "TEST", 0, 23], ["our study", "TEST", 115, 124], ["a ~2.5-fold difference", "PROBLEM", 137, 159], ["the studies", "TEST", 185, 196], ["a difference in absorption", "PROBLEM", 280, 306], ["the surfactant", "TREATMENT", 320, 334], ["Survanta", "TREATMENT", 341, 349], ["Calfactant", "TREATMENT", 366, 376], ["our study", "TEST", 380, 389], ["the gestational weight", "TEST", 392, 414], ["study populations", "TEST", 446, 463], ["samples", "TEST", 488, 495], ["The plasma concentrations of budesonide", "TREATMENT", 576, 615], ["antenatal betamethasone", "TREATMENT", 666, 689], ["enhancing fetal maturity", "PROBLEM", 694, 718], ["postnatal dexamethasone", "TREATMENT", 723, 746], ["BPD", "PROBLEM", 771, 774], ["BPD", "OBSERVATION", 771, 774]]], ["In this calculation, we convert corticosteroid levels to cortisol equivalents using factors of 7-fold for betamethasone and dexamethasone and 50-fold for budesonide based on receptor affinity and dose\u2212response data from cultured human fetal lung.20,28 Mean peak concentrations as cortisol equivalents are: 4 \u00b5g/dl for normal 25-week human fetus, 15 \u00b5g/dl in cord blood after intramuscular antenatal betamethasone, 140 \u00b5g/dl with 0.25 mg/kg postnatal dexamethasone, and 72 \u00b5g/dl after 0.1 mg/kg intratracheal budesonide.29\u201331 Thus, both postnatal dexamethasone and budesonide at current doses transiently expose the infant to plasma concentrations considerably greater than those occurring with physiologic stress in the newborn (e.g., RDS ~15 \u00b5g/dl).", [["fetal lung", "ANATOMY", 235, 245], ["fetus", "ANATOMY", 339, 344], ["cord blood", "ANATOMY", 358, 368], ["intramuscular", "ANATOMY", 375, 388], ["plasma", "ANATOMY", 625, 631], ["cortisol", "CHEMICAL", 57, 65], ["betamethasone", "CHEMICAL", 106, 119], ["dexamethasone", "CHEMICAL", 124, 137], ["budesonide", "CHEMICAL", 154, 164], ["cortisol", "CHEMICAL", 280, 288], ["betamethasone", "CHEMICAL", 399, 412], ["dexamethasone", "CHEMICAL", 450, 463], ["budesonide", "CHEMICAL", 508, 518], ["dexamethasone", "CHEMICAL", 546, 559], ["budesonide", "CHEMICAL", 564, 574], ["RDS", "DISEASE", 735, 738], ["cortisol", "CHEMICAL", 57, 65], ["betamethasone", "CHEMICAL", 106, 119], ["dexamethasone", "CHEMICAL", 124, 137], ["budesonide", "CHEMICAL", 154, 164], ["cortisol", "CHEMICAL", 280, 288], ["betamethasone", "CHEMICAL", 399, 412], ["dexamethasone", "CHEMICAL", 450, 463], ["budesonide", "CHEMICAL", 508, 518], ["dexamethasone", "CHEMICAL", 546, 559], ["budesonide", "CHEMICAL", 564, 574], ["corticosteroid", "SIMPLE_CHEMICAL", 32, 46], ["cortisol", "SIMPLE_CHEMICAL", 57, 65], ["betamethasone", "SIMPLE_CHEMICAL", 106, 119], ["dexamethasone", "SIMPLE_CHEMICAL", 124, 137], ["budesonide", "SIMPLE_CHEMICAL", 154, 164], ["human", "ORGANISM", 229, 234], ["fetal", "MULTI-TISSUE_STRUCTURE", 235, 240], ["lung", "ORGAN", 241, 245], ["cortisol", "SIMPLE_CHEMICAL", 280, 288], ["human", "ORGANISM", 333, 338], ["fetus", "DEVELOPING_ANATOMICAL_STRUCTURE", 339, 344], ["cord blood", "ORGANISM_SUBSTANCE", 358, 368], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 375, 388], ["betamethasone", "SIMPLE_CHEMICAL", 399, 412], ["dexamethasone", "SIMPLE_CHEMICAL", 450, 463], ["budesonide", "SIMPLE_CHEMICAL", 508, 518], ["dexamethasone", "SIMPLE_CHEMICAL", 546, 559], ["budesonide", "SIMPLE_CHEMICAL", 564, 574], ["infant", "ORGANISM", 615, 621], ["plasma", "ORGANISM_SUBSTANCE", 625, 631], ["human", "SPECIES", 229, 234], ["human", "SPECIES", 333, 338], ["human", "SPECIES", 229, 234], ["human", "SPECIES", 333, 338], ["this calculation", "TEST", 3, 19], ["corticosteroid levels", "TREATMENT", 32, 53], ["cortisol equivalents", "TEST", 57, 77], ["betamethasone", "TREATMENT", 106, 119], ["dexamethasone", "TREATMENT", 124, 137], ["budesonide", "TREATMENT", 154, 164], ["receptor affinity", "TREATMENT", 174, 191], ["dose\u2212response data", "TEST", 196, 214], ["Mean peak concentrations", "TEST", 252, 276], ["cortisol equivalents", "TEST", 280, 300], ["human fetus", "TEST", 333, 344], ["cord blood", "TEST", 358, 368], ["intramuscular antenatal betamethasone", "TREATMENT", 375, 412], ["postnatal dexamethasone", "TREATMENT", 440, 463], ["intratracheal budesonide", "TREATMENT", 494, 518], ["both postnatal dexamethasone", "TREATMENT", 531, 559], ["budesonide", "TREATMENT", 564, 574], ["plasma concentrations", "TEST", 625, 646], ["physiologic stress in the newborn", "PROBLEM", 694, 727], ["RDS", "TEST", 735, 738], ["fetal", "ANATOMY_MODIFIER", 235, 240], ["lung", "ANATOMY", 241, 245], ["cord", "ANATOMY", 358, 362], ["physiologic stress", "OBSERVATION", 694, 712]]], ["Risks for the infant associated with these higher exposures may depend on both the concentration of corticosteroid and duration of exposure.DiscussionTreatment with budesonide in surfactant primarily targets lung inflammation, although it is possible that local effects are modulated by systemic exposure to budesonide.", [["lung", "ANATOMY", 208, 212], ["budesonide", "CHEMICAL", 165, 175], ["lung inflammation", "DISEASE", 208, 225], ["budesonide", "CHEMICAL", 308, 318], ["budesonide", "CHEMICAL", 165, 175], ["budesonide", "CHEMICAL", 308, 318], ["infant", "ORGANISM", 14, 20], ["corticosteroid", "SIMPLE_CHEMICAL", 100, 114], ["budesonide", "SIMPLE_CHEMICAL", 165, 175], ["lung", "ORGAN", 208, 212], ["budesonide", "SIMPLE_CHEMICAL", 308, 318], ["infant", "SPECIES", 14, 20], ["these higher exposures", "PROBLEM", 37, 59], ["corticosteroid", "TREATMENT", 100, 114], ["budesonide in surfactant", "TREATMENT", 165, 189], ["lung inflammation", "PROBLEM", 208, 225], ["budesonide", "TREATMENT", 308, 318], ["lung", "ANATOMY", 208, 212], ["inflammation", "OBSERVATION", 213, 225]]], ["To assess local effects of budesonide, we measured two chemokines in lung fluid that are chemoattractants for neutrophils (IL-8) and lymphocytes (MCP1).", [["lung fluid", "ANATOMY", 69, 79], ["neutrophils", "ANATOMY", 110, 121], ["lymphocytes", "ANATOMY", 133, 144], ["budesonide", "CHEMICAL", 27, 37], ["budesonide", "CHEMICAL", 27, 37], ["budesonide", "SIMPLE_CHEMICAL", 27, 37], ["lung", "ORGAN", 69, 73], ["fluid", "ORGANISM_SUBSTANCE", 74, 79], ["neutrophils", "CELL", 110, 121], ["IL-8", "GENE_OR_GENE_PRODUCT", 123, 127], ["lymphocytes", "CELL", 133, 144], ["MCP1", "GENE_OR_GENE_PRODUCT", 146, 150], ["chemokines", "PROTEIN", 55, 65], ["chemoattractants", "PROTEIN", 89, 105], ["neutrophils", "CELL_TYPE", 110, 121], ["IL-8", "PROTEIN", 123, 127], ["lymphocytes", "CELL_TYPE", 133, 144], ["MCP1", "PROTEIN", 146, 150], ["budesonide", "TREATMENT", 27, 37], ["two chemokines in lung fluid", "TREATMENT", 51, 79], ["neutrophils", "TEST", 110, 121], ["IL", "TEST", 123, 125], ["lymphocytes", "TEST", 133, 144], ["MCP1", "TEST", 146, 150], ["lung", "ANATOMY", 69, 73], ["fluid", "OBSERVATION", 74, 79], ["lymphocytes", "ANATOMY", 133, 144]]], ["Both mediators are produced in human fetal lung and are suppressed by glucocorticoids in explant culture.20 Levels of the two chemokines were strongly correlated at both baseline and after treatment, which is consistent with a previous observation for multiple cyto/chemokine levels in TA32 and indicate that our findings likely reflect the overall inflammatory status in the lung.", [["fetal lung", "ANATOMY", 37, 47], ["lung", "ANATOMY", 376, 380], ["glucocorticoids", "CHEMICAL", 70, 85], ["human", "ORGANISM", 31, 36], ["fetal", "ORGAN", 37, 42], ["lung", "ORGAN", 43, 47], ["glucocorticoids", "SIMPLE_CHEMICAL", 70, 85], ["TA32", "GENE_OR_GENE_PRODUCT", 286, 290], ["lung", "ORGAN", 376, 380], ["chemokines", "PROTEIN", 126, 136], ["chemokine", "PROTEIN", 266, 275], ["TA32", "CELL_LINE", 286, 290], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["explant culture", "TEST", 89, 104], ["the two chemokines", "TEST", 118, 136], ["treatment", "TREATMENT", 189, 198], ["multiple cyto/chemokine levels", "TEST", 252, 282], ["TA32", "TEST", 286, 290], ["the overall inflammatory status in the lung", "PROBLEM", 337, 380], ["fetal", "ANATOMY_MODIFIER", 37, 42], ["lung", "ANATOMY", 43, 47], ["two", "OBSERVATION_MODIFIER", 122, 125], ["chemokines", "OBSERVATION", 126, 136], ["consistent with", "UNCERTAINTY", 209, 224], ["likely reflect", "UNCERTAINTY", 322, 336], ["overall", "OBSERVATION_MODIFIER", 341, 348], ["inflammatory", "OBSERVATION", 349, 361], ["lung", "ANATOMY", 376, 380]]], ["Apparent suppression of IL-8 and MCP1 was observed in half of the SASSIE infants and was strongly associated with higher baseline levels, suggesting that inflammation is not a universal feature of lung injury in the first week and that benefit from budesonide (or any glucocorticoid) will only occur in selected infants with elevated inflammatory status.DiscussionThe global blood metabolomic data demonstrated a clear dose\u2212response association with budesonide.", [["lung", "ANATOMY", 197, 201], ["blood", "ANATOMY", 375, 380], ["inflammation", "DISEASE", 154, 166], ["lung injury", "DISEASE", 197, 208], ["budesonide", "CHEMICAL", 249, 259], ["budesonide", "CHEMICAL", 450, 460], ["budesonide", "CHEMICAL", 249, 259], ["budesonide", "CHEMICAL", 450, 460], ["IL-8", "GENE_OR_GENE_PRODUCT", 24, 28], ["MCP1", "GENE_OR_GENE_PRODUCT", 33, 37], ["SASSIE", "CANCER", 66, 72], ["infants", "ORGANISM", 73, 80], ["lung", "ORGAN", 197, 201], ["budesonide", "SIMPLE_CHEMICAL", 249, 259], ["infants", "ORGANISM", 312, 319], ["blood", "ORGANISM_SUBSTANCE", 375, 380], ["budesonide", "SIMPLE_CHEMICAL", 450, 460], ["IL-8", "PROTEIN", 24, 28], ["MCP1", "PROTEIN", 33, 37], ["infants", "SPECIES", 73, 80], ["infants", "SPECIES", 312, 319], ["MCP1", "TREATMENT", 33, 37], ["inflammation", "PROBLEM", 154, 166], ["lung injury", "PROBLEM", 197, 208], ["budesonide", "TREATMENT", 249, 259], ["elevated inflammatory status", "PROBLEM", 325, 353], ["The global blood metabolomic data", "TEST", 364, 397], ["budesonide", "TREATMENT", 450, 460], ["suppression", "OBSERVATION_MODIFIER", 9, 20], ["IL", "OBSERVATION_MODIFIER", 24, 26], ["inflammation", "OBSERVATION", 154, 166], ["lung", "ANATOMY", 197, 201], ["injury", "OBSERVATION", 202, 208], ["elevated", "OBSERVATION_MODIFIER", 325, 333], ["inflammatory", "OBSERVATION", 334, 346]]], ["At 0.025 mg/kg budesonide, there was a small suppression of cortisol, and limited changes in other biochemicals, and both responses increased progressively with higher doses.", [["budesonide", "CHEMICAL", 15, 25], ["cortisol", "CHEMICAL", 60, 68], ["budesonide", "CHEMICAL", 15, 25], ["cortisol", "CHEMICAL", 60, 68], ["budesonide", "SIMPLE_CHEMICAL", 15, 25], ["cortisol", "SIMPLE_CHEMICAL", 60, 68], ["budesonide", "TREATMENT", 15, 25], ["a small suppression of cortisol", "PROBLEM", 37, 68], ["limited changes in other biochemicals", "PROBLEM", 74, 111], ["small", "OBSERVATION_MODIFIER", 39, 44], ["increased", "OBSERVATION_MODIFIER", 132, 141]]], ["This pattern contrasts with suppression of TA chemokines where no differences were apparent between doses, and is consistent with elevated levels of budesonide within the lung, compared to systemic levels, with intratracheal delivery.", [["lung", "ANATOMY", 171, 175], ["budesonide", "CHEMICAL", 149, 159], ["budesonide", "CHEMICAL", 149, 159], ["TA chemokines", "GENE_OR_GENE_PRODUCT", 43, 56], ["budesonide", "SIMPLE_CHEMICAL", 149, 159], ["lung", "ORGAN", 171, 175], ["TA chemokines", "PROTEIN", 43, 56], ["suppression of TA chemokines", "TREATMENT", 28, 56], ["elevated levels of budesonide within the lung", "PROBLEM", 130, 175], ["systemic levels", "TEST", 189, 204], ["intratracheal delivery", "TREATMENT", 211, 233], ["consistent with", "UNCERTAINTY", 114, 129], ["elevated", "OBSERVATION", 130, 138], ["budesonide", "OBSERVATION", 149, 159], ["lung", "ANATOMY", 171, 175], ["intratracheal delivery", "OBSERVATION", 211, 233]]], ["Thus, our results suggest that the best benefit:risk ratio of budesonide:surfactant therapy occurs at doses of 0.025/0.05 mg/kg, which are five- to tenfold lower than used currently in clinical studies.DiscussionStrengths of our study include the study population of intubated ELGANs who are at high risk for BPD, the dose-escalation study design, and measurement of multiple biomarkers for both lung anti-inflammatory and systemic effects of budesonide.", [["lung", "ANATOMY", 396, 400], ["budesonide", "CHEMICAL", 62, 72], ["surfactant", "CHEMICAL", 73, 83], ["BPD", "DISEASE", 309, 312], ["budesonide", "CHEMICAL", 443, 453], ["budesonide", "CHEMICAL", 62, 72], ["budesonide", "CHEMICAL", 443, 453], ["budesonide", "SIMPLE_CHEMICAL", 62, 72], ["surfactant", "SIMPLE_CHEMICAL", 73, 83], ["lung", "ORGAN", 396, 400], ["budesonide", "SIMPLE_CHEMICAL", 443, 453], ["budesonide", "TREATMENT", 62, 72], ["surfactant therapy", "TREATMENT", 73, 91], ["clinical studies", "TEST", 185, 201], ["our study", "TEST", 225, 234], ["the study", "TEST", 243, 252], ["BPD", "PROBLEM", 309, 312], ["the dose-escalation study", "TEST", 314, 339], ["multiple biomarkers", "TEST", 367, 386], ["both lung anti-inflammatory", "TREATMENT", 391, 418], ["budesonide", "TREATMENT", 443, 453], ["lung", "ANATOMY", 396, 400], ["anti-inflammatory", "OBSERVATION", 401, 418]]], ["Previous studies33,34 using surfactant-antibiotic mixtures had demonstrated interactions between these agents; however, we recently reported no apparent adverse effect of budesonide on calfactant activity in vitro nor an effect of calfactant on budesonide action.20 An important limitation of our chemokine data is the possibility that, in some infants, the lower chemokine levels during budesonide treatment reflected decreasing inflammation independent of glucocorticoid exposure as observed in some of the TOLSURF infants.", [["budesonide", "CHEMICAL", 171, 181], ["calfactant", "CHEMICAL", 231, 241], ["budesonide", "CHEMICAL", 245, 255], ["budesonide", "CHEMICAL", 388, 398], ["inflammation", "DISEASE", 430, 442], ["budesonide", "CHEMICAL", 171, 181], ["budesonide", "CHEMICAL", 245, 255], ["budesonide", "CHEMICAL", 388, 398], ["budesonide", "SIMPLE_CHEMICAL", 171, 181], ["calfactant", "SIMPLE_CHEMICAL", 185, 195], ["calfactant", "SIMPLE_CHEMICAL", 231, 241], ["budesonide", "SIMPLE_CHEMICAL", 245, 255], ["infants", "ORGANISM", 345, 352], ["budesonide", "SIMPLE_CHEMICAL", 388, 398], ["glucocorticoid", "SIMPLE_CHEMICAL", 458, 472], ["infants", "ORGANISM", 517, 524], ["chemokine", "PROTEIN", 297, 306], ["chemokine", "PROTEIN", 364, 373], ["infants", "SPECIES", 517, 524], ["Previous studies", "TEST", 0, 16], ["surfactant-antibiotic mixtures", "TREATMENT", 28, 58], ["these agents", "TREATMENT", 97, 109], ["budesonide", "TREATMENT", 171, 181], ["calfactant activity", "TREATMENT", 185, 204], ["calfactant", "TREATMENT", 231, 241], ["budesonide action", "TREATMENT", 245, 262], ["our chemokine data", "TEST", 293, 311], ["the lower chemokine levels", "TREATMENT", 354, 380], ["budesonide treatment", "TREATMENT", 388, 408], ["decreasing inflammation", "PROBLEM", 419, 442], ["glucocorticoid exposure", "TREATMENT", 458, 481], ["no apparent", "UNCERTAINTY", 141, 152], ["decreasing", "OBSERVATION_MODIFIER", 419, 429], ["inflammation", "OBSERVATION", 430, 442], ["glucocorticoid exposure", "OBSERVATION", 458, 481]]], ["However, the pattern of suppression observed with budesonide, beginning in most infants 12 h after the first dose and sustained during the treatment period, is consistent with suppression in response to budesonide.", [["budesonide", "CHEMICAL", 50, 60], ["budesonide", "CHEMICAL", 203, 213], ["budesonide", "CHEMICAL", 50, 60], ["budesonide", "CHEMICAL", 203, 213], ["budesonide", "SIMPLE_CHEMICAL", 50, 60], ["budesonide", "SIMPLE_CHEMICAL", 203, 213], ["infants", "SPECIES", 80, 87], ["budesonide", "TREATMENT", 50, 60], ["budesonide", "TREATMENT", 203, 213], ["suppression", "OBSERVATION", 24, 35], ["consistent with", "UNCERTAINTY", 160, 175], ["suppression", "OBSERVATION", 176, 187]]], ["Also, we used sIgA to normalize chemokine levels to volume of lung fluid in the TA sample; it is possible that sIgA production in vivo varied during the collection period, which would introduce variability in the chemokine data.", [["lung fluid", "ANATOMY", 62, 72], ["TA sample", "ANATOMY", 80, 89], ["sIgA", "GENE_OR_GENE_PRODUCT", 14, 18], ["lung", "ORGAN", 62, 66], ["fluid", "ORGANISM_SUBSTANCE", 67, 72], ["sIgA", "GENE_OR_GENE_PRODUCT", 111, 115], ["sIgA", "PROTEIN", 14, 18], ["chemokine", "PROTEIN", 32, 41], ["sIgA", "PROTEIN", 111, 115], ["chemokine", "PROTEIN", 213, 222], ["sIgA", "TREATMENT", 14, 18], ["chemokine levels", "TEST", 32, 48], ["lung fluid in the TA sample", "TEST", 62, 89], ["sIgA production", "PROBLEM", 111, 126], ["the chemokine data", "TEST", 209, 227], ["lung", "ANATOMY", 62, 66], ["fluid", "OBSERVATION", 67, 72], ["sIgA production", "OBSERVATION", 111, 126]]], ["A limitation of our pharmacokinetic analysis is the absence of data after the 4 h time point; however, our half-life value was similar to that reported by Yeh et al., supporting the accuracy of our PK results.18DiscussionThe dose-escalation study design limited the number of infants studied at each dosing level.", [["PK", "GENE_OR_GENE_PRODUCT", 198, 200], ["infants", "ORGANISM", 276, 283], ["infants", "SPECIES", 276, 283], ["our pharmacokinetic analysis", "TEST", 16, 44], ["The dose-escalation study", "TEST", 221, 246]]], ["Also, concurrent controls were not included in the study design, for ethical reasons, and the matched historical controls received inhaled NO and were not evaluated for other potential confounding factors such as chorioamnionitis.", [["NO", "CHEMICAL", 139, 141], ["chorioamnionitis", "DISEASE", 213, 229], ["NO", "CHEMICAL", 139, 141], ["NO", "SIMPLE_CHEMICAL", 139, 141], ["the study", "TEST", 47, 56], ["potential confounding factors", "PROBLEM", 175, 204], ["chorioamnionitis", "PROBLEM", 213, 229], ["chorioamnionitis", "OBSERVATION", 213, 229]]], ["Earlier dosing, longer dosing, or the use of noninvasive approaches to surfactant delivery may result in different clinical outcomes.", [["surfactant", "SIMPLE_CHEMICAL", 71, 81], ["noninvasive approaches", "TREATMENT", 45, 67], ["surfactant delivery", "TREATMENT", 71, 90]]], ["The original study design included a fourth dosing level (which would have been either 0.20 mg/kg or 0.25 mg/kg contingent on the response to dosing level 3), which may have provided more detail regarding clinical and anti-inflammatory response to the combination of the study medications.", [["The original study", "TEST", 0, 18], ["the study medications", "TREATMENT", 267, 288]]], ["However, we decided not to continue enrolling the infants in this study after the first three dosage levels failed to show clinical benefit.", [["infants", "ORGANISM", 50, 57], ["infants", "SPECIES", 50, 57], ["this study", "TEST", 61, 71]]], ["Given that aggressive use of noninvasive mechanical ventilation has not reduced the incidence of BPD, that BPD may develop in ELGAN babies with little clinical initial evidence of lung disease, and that inflammation associated with BPD worsens over the first weeks after birth, the question of whether serial instillation of budesonide suspended in surfactant reduces BPD remains an unanswered question.", [["lung", "ANATOMY", 180, 184], ["BPD", "DISEASE", 97, 100], ["BPD", "DISEASE", 107, 110], ["lung disease", "DISEASE", 180, 192], ["inflammation", "DISEASE", 203, 215], ["BPD", "DISEASE", 232, 235], ["budesonide", "CHEMICAL", 325, 335], ["surfactant", "CHEMICAL", 349, 359], ["BPD", "DISEASE", 368, 371], ["budesonide", "CHEMICAL", 325, 335], ["lung", "ORGAN", 180, 184], ["budesonide", "SIMPLE_CHEMICAL", 325, 335], ["noninvasive mechanical ventilation", "TREATMENT", 29, 63], ["BPD", "PROBLEM", 97, 100], ["BPD", "PROBLEM", 107, 110], ["lung disease", "PROBLEM", 180, 192], ["inflammation", "PROBLEM", 203, 215], ["BPD", "PROBLEM", 232, 235], ["serial instillation of budesonide", "TREATMENT", 302, 335], ["surfactant", "TREATMENT", 349, 359], ["BPD", "PROBLEM", 368, 371], ["lung", "ANATOMY", 180, 184], ["disease", "OBSERVATION", 185, 192], ["inflammation", "OBSERVATION", 203, 215]]], ["Future randomized trials in ELGANs at high risk for BPD should require treatment over the biological period of risk to assess efficacy and safety in a fair way.DiscussionOur results do not support the \u201clate\u201d treatment of intubated ELGANs with a regimen of budesonide in surfactant at the three dosages we tested, but do provide important insights into blood budesonide concentrations, lung anti-inflammatory effects and potentially global metabolomics effects that are critical to the consideration of treatment with this combination of medications.DiscussionWe were not powered to investigate association of inflammation with near-term pulmonary outcome, but we suggest that measurement of TA inflammatory mediators would be informative in future trials of PCS therapy.DiscussionIn conclusion, assuming that the respiratory benefits of PCS therapy primarily relate to anti-inflammatory effects in the lung, our results suggest that one-tenth the budesonide dose in surfactant used in previous studies is sufficient to reduce inflammation with minimal systemic effects even with repeated treatment.", [["blood", "ANATOMY", 352, 357], ["lung", "ANATOMY", 385, 389], ["pulmonary", "ANATOMY", 637, 646], ["lung", "ANATOMY", 902, 906], ["BPD", "DISEASE", 52, 55], ["ELGANs", "DISEASE", 231, 237], ["budesonide", "CHEMICAL", 256, 266], ["budesonide", "CHEMICAL", 358, 368], ["inflammation", "DISEASE", 609, 621], ["budesonide", "CHEMICAL", 947, 957], ["surfactant", "CHEMICAL", 966, 976], ["inflammation", "DISEASE", 1026, 1038], ["budesonide", "CHEMICAL", 256, 266], ["budesonide", "CHEMICAL", 358, 368], ["budesonide", "CHEMICAL", 947, 957], ["ELGANs", "SIMPLE_CHEMICAL", 231, 237], ["budesonide", "SIMPLE_CHEMICAL", 256, 266], ["surfactant", "SIMPLE_CHEMICAL", 270, 280], ["blood", "ORGANISM_SUBSTANCE", 352, 357], ["budesonide", "SIMPLE_CHEMICAL", 358, 368], ["lung", "ORGAN", 385, 389], ["pulmonary", "ORGAN", 637, 646], ["TA", "GENE_OR_GENE_PRODUCT", 691, 693], ["lung", "ORGAN", 902, 906], ["budesonide", "SIMPLE_CHEMICAL", 947, 957], ["surfactant", "SIMPLE_CHEMICAL", 966, 976], ["Future randomized trials", "TREATMENT", 0, 24], ["BPD", "PROBLEM", 52, 55], ["treatment", "TREATMENT", 71, 80], ["intubated ELGANs", "TREATMENT", 221, 237], ["budesonide in surfactant", "TREATMENT", 256, 280], ["blood budesonide concentrations", "TREATMENT", 352, 383], ["lung anti-inflammatory effects", "TREATMENT", 385, 415], ["treatment", "TREATMENT", 502, 511], ["this combination of medications", "TREATMENT", 517, 548], ["inflammation", "PROBLEM", 609, 621], ["TA inflammatory mediators", "PROBLEM", 691, 716], ["PCS therapy", "TREATMENT", 758, 769], ["PCS therapy", "TREATMENT", 837, 848], ["anti-inflammatory effects in the lung", "PROBLEM", 869, 906], ["the budesonide dose in surfactant", "TREATMENT", 943, 976], ["previous studies", "TEST", 985, 1001], ["inflammation", "PROBLEM", 1026, 1038], ["minimal systemic effects", "PROBLEM", 1044, 1068], ["repeated treatment", "TREATMENT", 1079, 1097], ["lung", "ANATOMY", 385, 389], ["anti-inflammatory effects", "OBSERVATION", 390, 415], ["inflammation", "OBSERVATION", 609, 621], ["pulmonary", "ANATOMY", 637, 646], ["anti-inflammatory", "OBSERVATION_MODIFIER", 869, 886], ["lung", "ANATOMY", 902, 906], ["inflammation", "OBSERVATION", 1026, 1038], ["minimal", "OBSERVATION_MODIFIER", 1044, 1051], ["systemic", "OBSERVATION", 1052, 1060]]], ["Additional trials of this promising lung-targeted approach to preventing BPD are needed using lower doses of budesonide with further study of efficacy, safety, inflammatory markers and endocrine and metabolic responses.", [["lung", "ANATOMY", 36, 40], ["endocrine", "ANATOMY", 185, 194], ["BPD", "DISEASE", 73, 76], ["budesonide", "CHEMICAL", 109, 119], ["budesonide", "CHEMICAL", 109, 119], ["lung", "ORGAN", 36, 40], ["budesonide", "SIMPLE_CHEMICAL", 109, 119], ["targeted approach", "TREATMENT", 41, 58], ["BPD", "PROBLEM", 73, 76], ["budesonide", "TREATMENT", 109, 119], ["further study", "TEST", 125, 138], ["inflammatory markers", "TEST", 160, 180], ["lung", "ANATOMY", 36, 40]]]], "PMC7278246": [["IntroductionDespite India\u2019s consistent ascendancy as one of the fastest growing developing economies in the world for quite a long period of time (for almost one and half decades except the present recessionary milieu since 2019\u20132020 which is characterised by sluggish pace of domestic demand and recession in major economies in the world and again outbreak of Covid-19 exposing the world economy into serious economic perils),1 it is believed that the quality of governance and provisioning of public goods and services in India continue to be the modest.", [["recession", "PROBLEM", 297, 306], ["Covid", "TEST", 361, 366], ["economies", "OBSERVATION", 91, 100], ["sluggish", "OBSERVATION_MODIFIER", 260, 268]]], ["There exists a greater complementarity relation between the two.", [["greater", "OBSERVATION_MODIFIER", 15, 22], ["complementarity", "OBSERVATION", 23, 38]]], ["Effective governance can go a long way to ensure the efficiency in the delivery of public services and similarly, optimal availability of public infrastructure especially in terms of the wide-accessibility of modern technologies (such as ICT or digital facilities) can also to a large extent ensure the efficiency in delivery of public services through greater accountability and transparency in information between the service providers, government agencies and the intended beneficiaries of those public services.2IntroductionMost of the studies while examining the factors influencing the tax compliances by the tax payers for greater tax revenues although admit to face practical difficulties in measuring the compliance gap (tax evasion) and obtaining the statistical information relating to the factors influencing the compliances for all the economies in general, but they observe lesser degree of compliances or higher levels of tax evasion in developing economies (Andreoni et al. 1998).", [["tax", "PROTEIN", 592, 595], ["tax", "PROTEIN", 615, 618], ["tax", "PROTEIN", 638, 641], ["tax", "PROTEIN", 937, 940], ["public services", "TREATMENT", 83, 98], ["public infrastructure", "TREATMENT", 138, 159], ["the studies", "TEST", 536, 547], ["face practical difficulties", "PROBLEM", 669, 696], ["efficiency", "OBSERVATION_MODIFIER", 303, 313]]], ["This along with the economic structure (lower income base/low level of economic development), fragmented politics, weak institutional structure and low transparency drive for a low proportion of tax revenue to GDP environment for the developing economies comparing the rich economies (Besley and Persson 2014).3 Studies consider effective enforcement by tax authorities (tax administration) and availability of information about the potential tax payers, as critical factors in influencing the compliance behaviour of tax payers.", [["GDP", "CHEMICAL", 210, 213], ["GDP", "SIMPLE_CHEMICAL", 210, 213], ["tax", "PROTEIN", 195, 198], ["tax", "PROTEIN", 371, 374], ["the economic structure", "PROBLEM", 16, 38], ["fragmented politics", "PROBLEM", 94, 113], ["weak institutional structure", "PROBLEM", 115, 143], ["low level", "OBSERVATION_MODIFIER", 58, 67], ["fragmented", "OBSERVATION_MODIFIER", 94, 104], ["politics", "OBSERVATION_MODIFIER", 105, 113], ["weak", "OBSERVATION_MODIFIER", 115, 119], ["low transparency", "OBSERVATION_MODIFIER", 148, 164]]], ["In view of the absence information about the extent of improvement in effectiveness in tax administration (or efficiency in tax collection by tax authorities) and degree of tax compliances by the tax payers for a developing economy like India, this study focuses on examining the quality of governance and access to modern ICT facilities as proximate measures of the extent of efficiency in tax administration and degree of tax compliances and their role, to what extent they are responsible for improvement in the realisation of tax revenues for India.IntroductionAlthough over the last two\u2013three decades there has been an acceleration in the availability and use of physical infrastructures and modern information services by all economies including India, however, India has been still facing economy-wide physical infrastructure constraints in many spheres of economic activities including the ICT infrastructure facilities.", [["tax", "PROTEIN", 87, 90], ["tax", "PROTEIN", 124, 127], ["tax", "PROTEIN", 173, 176], ["tax", "PROTEIN", 391, 394], ["tax", "PROTEIN", 424, 427], ["tax", "PROTEIN", 530, 533], ["tax administration", "TREATMENT", 87, 105], ["this study", "TEST", 244, 254], ["modern ICT facilities", "TREATMENT", 316, 337], ["tax administration", "TREATMENT", 391, 409], ["improvement", "OBSERVATION_MODIFIER", 55, 66], ["tax compliances", "OBSERVATION", 173, 188], ["efficiency", "OBSERVATION", 377, 387], ["tax compliances", "OBSERVATION", 424, 439], ["acceleration", "OBSERVATION_MODIFIER", 624, 636]]], ["This restrains in the realisation of full benefits of digitalisation not only for the government but also for the public.", [["This restrains", "TREATMENT", 0, 14], ["digitalisation", "TREATMENT", 54, 68]]], ["These constraints can clearly be visible when it involves the synergy between the delivery of services by various public agencies and private sector\u2019s access to those services through the modern technologies.", [["the modern technologies", "TREATMENT", 184, 207]]], ["The deficiencies can be observed in accomplishing the relevant works being ultimately and successfully done by the public.IntroductionSimilarly, when it comes to measuring the quality of governance for developing economies including India, there is either modest improvement or no improvement over the years.", [["The deficiencies", "PROBLEM", 0, 16], ["modest", "OBSERVATION_MODIFIER", 256, 262], ["improvement", "OBSERVATION", 263, 274], ["no", "UNCERTAINTY", 278, 280], ["improvement", "OBSERVATION_MODIFIER", 281, 292]]], ["In the global corruption perception index ranking by the Transparency International, India, was ranked 79th position in 2016 among 176 countries.", [["global", "OBSERVATION_MODIFIER", 7, 13], ["corruption", "OBSERVATION", 14, 24], ["index", "OBSERVATION_MODIFIER", 36, 41], ["Transparency", "OBSERVATION_MODIFIER", 57, 69]]], ["With its rank being slipped to 81st in 2017 in the list of 180 countries, the Transparency International (2019) on the basis of perception of public sector corruption put it among the worst offenders in graft and press freedom in Asia Pacific Region.4 In 2018, although it could improve its position marginally to 78th most corrupt country in the world along with Burkina Faso, Ghana, Kuwait, Lesotho, Trinidad and Tobago, and Turkey, all scoring the same on the corruption metre, however, in 2019, it again slipped to 80th among 180 nations.5It is claimed that on account of absence of clear mechanism to establish accountability, the corrupt officials in the name of public welfare improvement, channel public funds to wasteful projects which generate bribes, depleting public funds that could otherwise have been spent productively on heads such as health, education and other services.", [["graft", "TISSUE", 203, 208], ["public sector corruption", "TREATMENT", 142, 166], ["graft", "TREATMENT", 203, 208], ["graft", "OBSERVATION", 203, 208]]], ["This could have potentially benefitted the poor in most significant ways.6 Poor quality of governance and lack of progressive modern infrastructure and digitalisation facilities are likely to have important bearings on the fiscal performance of national governments of developing economies.", [["progressive modern infrastructure", "PROBLEM", 114, 147], ["progressive", "OBSERVATION_MODIFIER", 114, 125], ["economies", "OBSERVATION", 280, 289]]], ["Weakness in both the factors not only leads to low levels of revenue realisation but also increases their fiscal deficits.", [["Weakness", "DISEASE", 0, 8], ["Weakness", "PROBLEM", 0, 8], ["their fiscal deficits", "PROBLEM", 100, 121], ["fiscal deficits", "OBSERVATION", 106, 121]]], ["The developing economies\u2019 governments fail to control their fiscal deficits more especially when they fail to achieve efficiency in government expenditure allocations and not being able to restrain total expenditures in response to increasing population and cost of provisioning of public goods and services on account of escalation in inflation.IntroductionSince a developing economy like India with vast geographical size has been experiencing a rapid population boom (although the population is growing at a lesser rate in the recent decades comparing prior years of 1990s), it requires provision of various basic public services and facilities by various concerned governments over which they retain their authority in terms of their jurisdictional setting.", [["their fiscal deficits", "PROBLEM", 54, 75], ["increasing population", "PROBLEM", 232, 253], ["escalation in inflation", "TREATMENT", 322, 345], ["a rapid population boom", "PROBLEM", 446, 469], ["economies", "OBSERVATION_MODIFIER", 15, 24], ["inflation", "OBSERVATION", 336, 345], ["size", "OBSERVATION_MODIFIER", 419, 423], ["rapid", "OBSERVATION_MODIFIER", 448, 453], ["population", "OBSERVATION", 454, 464]]], ["7 Facilitating the public with provisioning of access to modern information and communication technologies (ICT) assumes critical importance in enabling the public to comply with various governmental laws as per various official/departmental bureaucratic rules along with provisioning of most convenient public transportation facilities with proper carrier/container capacity for smooth movement of goods and people across locations and equipping the nation with necessary roads and infrastructures.", [["people", "SPECIES", 409, 415]]], ["This can be assessed considering the per capita availability of various infrastructure indices made available with the World Bank and other national statistical official agencies suggesting congestion in accession to most of the public services.", [["congestion", "PROBLEM", 190, 200], ["congestion", "OBSERVATION", 190, 200]]], ["As a case in point, this problem is being more severely pronounced when the tax payers while trying to comply with implementation of new taxation policies at the initiation of every round of new major indirect taxation reforms carried by the government in India like introduction of VAT and GST, the tax payers have to struggle very hard besides overcoming other constraints in meeting the desired compliances.", [["VAT", "TISSUE", 283, 286], ["GST", "GENE_OR_GENE_PRODUCT", 291, 294], ["GST", "PROTEIN", 291, 294], ["new taxation policies", "TREATMENT", 133, 154]]], ["In recent times, on several occasions, it is reported that even after several months of implementation of GST in India, the situation has remained so precarious that the tax payers are not able to have proper access to the government\u2019s e-filing tax network system either to e-file their taxes or even timely claim the input tax credits on their input purchases while filing the taxes on the sale of their final goods.", [["GST", "GENE_OR_GENE_PRODUCT", 106, 109], ["GST", "PROTEIN", 106, 109], ["tax", "PROTEIN", 324, 327]]], ["This clearly reflects the capacity constraints facing the government and tax administration authorities in equipping with adoption of suitable ICT infrastructure facilities to the public on the one hand, and more particularly, when the authorities are trying very hard to enforce new tax policy changes to be complied by the tax payers (manufacturers and sellers) on the other.", [["tax", "PROTEIN", 284, 287], ["the capacity constraints", "PROBLEM", 22, 46], ["tax administration", "TREATMENT", 73, 91]]], ["Given the prevailing uneasy and disruptive environment, this could reflect severe financial resource constraint and skilled personnel crunch facing the governments to meet and improve the physical and administrative capacity necessary for a growing and populous economy.", [["severe financial resource constraint", "PROBLEM", 75, 111], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["populous economy", "OBSERVATION", 253, 269]]], ["This in effect is failing to pass the test of economic efficiency, when the government radically aims at amending the economy\u2019s tax policies before the system is ready to accommodate the change.", [["economic efficiency", "PROBLEM", 46, 65]]], ["Moreover, this has also resulted in less realisation of revenues than its potential levels for both the central and state governments what the authorities had expected prior to the implementation of indirect tax policy changes, i.e. GST.IntroductionThe financial resource constraint being faced by the governments over the years including the recent period gets reflected from the higher level of fiscal deficits and increasing debt of the central government relative to the states and the Union Territories (UTs).", [["GST", "GENE_OR_GENE_PRODUCT", 233, 236], ["tax", "PROTEIN", 208, 211], ["GST", "PROTEIN", 233, 236], ["fiscal deficits", "PROBLEM", 397, 412], ["less", "OBSERVATION_MODIFIER", 36, 40], ["central", "ANATOMY_MODIFIER", 440, 447]]], ["This weak fiscal situation has arisen despite the continuous efforts by both the governments to maintain fiscal discipline by putting ceilings on their respective fiscal deficits and debt levels and increasing efforts for greater tax revenue collections as per their changing fiscal rules from time to time.", [["tax", "PROTEIN", 230, 233], ["This weak fiscal situation", "PROBLEM", 0, 26], ["debt levels", "TEST", 183, 194], ["greater tax revenue collections", "TREATMENT", 222, 253]]], ["The mobilisation of financial resources among other things hinges on methods and mechanism of collecting tax revenues with proper deployment of quantity and quality of modern physical infrastructures, efficient tax collectors, transparency and accountability in the system (transparency in methods of collecting tax revenues by public officials and honesty and morality of the tax payers in complying with the changed tax laws), tracking of information on portion of income generated in the private sector but legally falling outside the purview of untaxed sector (which again hinges on changing structural features of the economy), simplification of the tax laws, knowledge and awareness of the citizens to comply with tax laws and financial and real punishments associated with defaults in tax payments among others.IntroductionWith revolution of ICT infrastructure which seems to be the sine qua non for the global economy, this study looks at whether the use of modern ICT infrastructures has resulted in greater collection of tax revenues in view of potential contributory power of ICT infrastructures to confer towards transparency and accountability in the taxation system.", [["tax", "PROTEIN", 105, 108], ["tax", "PROTEIN", 792, 795], ["tax", "PROTEIN", 1031, 1034], ["financial resources", "TREATMENT", 20, 39], ["ICT infrastructure", "PROBLEM", 849, 867], ["this study", "TEST", 927, 937], ["modern ICT infrastructures", "TREATMENT", 966, 992], ["ICT infrastructures", "TREATMENT", 1087, 1106], ["mobilisation", "OBSERVATION_MODIFIER", 4, 16], ["greater", "OBSERVATION_MODIFIER", 1009, 1016]]], ["The use of ICT infrastructure (digitalisation) is not only gaining importance in realisation of revenues for the governments, but also for improvement of governance quality, and services delivery by the public agencies.", [["ICT infrastructure", "TREATMENT", 11, 29]]], ["The ICTs are not only accounting for the rapid improvement in general service delivery, but within the context of public sector performance, they are increasingly seen as panacea to many problems that the governments are facing while trying to serve the citizens in most efficient ways in their respective jurisprudence.", [["general service delivery", "TREATMENT", 62, 86], ["not only accounting for", "UNCERTAINTY", 13, 36], ["rapid", "OBSERVATION_MODIFIER", 41, 46], ["improvement", "OBSERVATION_MODIFIER", 47, 58], ["respective jurisprudence", "OBSERVATION", 295, 319]]], ["E-governance has been publicised as a means to cut costs, while at the same time it improves the quality, timeliness and access to service delivery by public agencies.8IntroductionOn the other side, it is also possible for one to argue that when governments can realise greater revenues that itself could enable the government to enhance its capacity to deploy more quality physical infrastructures including modern ICT infrastructures and thereby enhancing the levels of general welfare in the economy.", [["its capacity", "PROBLEM", 338, 350], ["modern ICT infrastructures", "TREATMENT", 409, 435], ["enhancing", "OBSERVATION_MODIFIER", 448, 457]]], ["Apart from efficient deployment and use of ICT infrastructures, unless tax administration is efficiently complemented with the quality of governance machinery and proper institutional structure, ICT infrastructure alone may not be of adequate help to realise desired revenue productivity gains for the governments.", [["tax", "PROTEIN", 71, 74], ["ICT infrastructures", "TREATMENT", 43, 62], ["governance machinery", "TREATMENT", 138, 158], ["ICT infrastructure", "TREATMENT", 195, 213], ["efficient", "OBSERVATION_MODIFIER", 11, 20], ["deployment", "OBSERVATION", 21, 31]]], ["Therefore, it is important to examine role of ICT infrastructure along with governance quality (or institutional mechanism) in realisation of greater tax revenue productivity or revenue augmentation for a developing economy like India.", [["tax", "PROTEIN", 150, 153], ["ICT infrastructure", "TREATMENT", 46, 64], ["governance quality", "TREATMENT", 76, 94], ["revenue augmentation", "TREATMENT", 178, 198]]], ["Placing the emphasis on quality of governance is quite significant for realisation of potential revenues, without which there will be greater leakages/wastages of public resources and tax evasion, ultimately compromising with the aggregate welfare through its distortionary consequences.IntroductionA study conducted by IMF (2016) on \u201cCorruption: Costs and Mitigating Strategies\u201d points out corruption imposes a greater social cost on nations as it weakens state\u2019s capacity to perform its core functions.", [["greater leakages", "PROBLEM", 134, 150], ["public resources", "TREATMENT", 163, 179], ["tax evasion", "TREATMENT", 184, 195], ["IntroductionA study", "TEST", 287, 306], ["Mitigating Strategies", "TREATMENT", 357, 378]]], ["It affects macro-financial stability, public and private investment, human capital formation, curbs on economic growth and thereby undermining the potential drivers of inclusive growth.", [["human", "ORGANISM", 69, 74], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 69, 74], ["human capital formation", "TREATMENT", 69, 92], ["economic growth", "PROBLEM", 103, 118], ["inclusive growth", "PROBLEM", 168, 184], ["stability", "OBSERVATION_MODIFIER", 27, 36]]], ["Countries with higher corruption tend to have poor access and low quality infrastructure for a given level of public capital stock, thereby undermining the efforts to improve over the infrastructure gap and productivity of existing capital.", [["poor access", "PROBLEM", 46, 57], ["low quality infrastructure", "PROBLEM", 62, 88], ["public capital stock", "TREATMENT", 110, 130], ["capital stock", "OBSERVATION", 117, 130]]], ["The worldwide, bribery alone which constitutes around 1% of total corruption is estimated to cost around $2 trillion a year, equivalent to the size of the GDP of many smaller wealthy countries like Italy and many times of $\\end{document}TaxRevenu2GDP=\u03b11GovernanceQuality+\u03b12ICT+\u03b13\u03b13LRGDPPerCapita+\u03b14TradeOpenness+\u03b15RGDPgr+\u03b16Dependencyratio+\u03b17AgriShare+u2whereas, governance quality may affect the tax revenues positively or negatively, ICT and per capita income are supposed to have positive influence on revenue collection, trade openness is supposed to have negatively affect the tax revenues due to competition among nations to reduce both export and import duties, growth rate is supposed to have positive influence on tax revenues, and dependency ratio and agricultural share are likely to adversely affect the tax revenue realisations.Data sources and descriptions of variables usedThe coverage of the analysis spans from the period from 1990\u20131991 to 2017\u20132018, where there are lot of reform measures undertaken in areas of fiscal policy specifically in respect of taxation and external sector, and monetary policy measures.", [["tax", "PROTEIN", 396, 399], ["tax", "PROTEIN", 581, 584], ["tax", "PROTEIN", 722, 725], ["tax", "PROTEIN", 815, 818], ["TaxRevenu2GDP=\u03b11GovernanceQuality+\u03b12ICT+\u03b13\u03b13LRGDPPerCapita+\u03b14TradeOpenness+\u03b15RGDPgr+\u03b16Dependencyratio+\u03b17AgriShare", "TREATMENT", 237, 350], ["growth rate", "TEST", 668, 679], ["reform measures", "TREATMENT", 990, 1005], ["fiscal policy", "TREATMENT", 1029, 1042], ["external sector", "TREATMENT", 1083, 1098], ["monetary policy measures", "TREATMENT", 1104, 1128], ["size", "OBSERVATION_MODIFIER", 143, 147], ["smaller", "OBSERVATION_MODIFIER", 167, 174]]], ["With recommendation of Tax Reform Committee (TRC 1991), a number of systematic and comprehensive tax reform measures were initiated at the central level from December 1991 along with initiation of other market-based economic reforms.", [["Tax", "PROTEIN", 23, 26]]], ["Since then, there are significant tax reform measures being initiated over different periods.", [["tax", "PROTEIN", 34, 37], ["significant tax reform measures", "TREATMENT", 22, 53], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["tax reform", "OBSERVATION", 34, 44]]], ["With an aim to relate the use of ICT infrastructure and governance quality with tax revenue mobilisation, the key reason of starting the period of the analysis from 1990 to 1991 is that the statistics on many of the modern infrastructure indicators were not available prior to 1990\u20131991, which may be due to their recent introduction and thin intensity in their use in the Indian economy prior to this period.", [["tax", "PROTEIN", 80, 83], ["ICT infrastructure", "TREATMENT", 33, 51], ["tax revenue mobilisation", "TREATMENT", 80, 104]]], ["The data on tax revenues of centre and states, GDP, are collected from the Handbook of Statistics on the Indian Economy of Reserve Bank of India (RBI).", [["GDP", "SIMPLE_CHEMICAL", 47, 50], ["India (RBI", "TREATMENT", 139, 149]]], ["The statistics on population to convert GDP and revenue variables into their per capita terms along with the data on 6 other types of ICT-related infrastructure variables such as internet users per million, mobile cellular phones per million, fixed telephone subscriptions per million, fixed broadband subscriptions per million, access to electricity consumption per million are collected from the World Bank Development Indicators of the World Bank to form a composite of an ICT infrastructure variable through the use of principal component analysis (PCA).", [["cellular", "ANATOMY", 214, 222], ["GDP", "CHEMICAL", 40, 43], ["GDP", "SIMPLE_CHEMICAL", 40, 43], ["cellular", "CELL", 214, 222], ["an ICT infrastructure", "TREATMENT", 473, 494]]], ["The statistics to capture the quality of governance, political, social and judicial system (overall average measure of institutional quality based on 5 major parameters and by replacing it with an aggregative overall 12 indicators) are drawn from Political Risk Services International Country Risk Guide (PRS) published by the PRS Group.25 An overall average high score on sum of all these parameters would imply lower risk or a favourable institutional, socioeconomic conditions and governance settings for an economy; while on the contrary, a lower score implies greater political risk.", [["governance settings", "TREATMENT", 484, 503], ["a lower score", "PROBLEM", 543, 556], ["lower risk", "OBSERVATION_MODIFIER", 413, 423], ["greater", "OBSERVATION_MODIFIER", 565, 572], ["political risk", "OBSERVATION", 573, 587]]], ["As an alternative to this, we had also substituted with the rule of law variables drawn from the World Bank Development Indicators.", [["law variables", "PROBLEM", 68, 81]]], ["The study also consistently used VAT adoption dummy at the state level from the period 2005 for state indirect tax revenue and combined total tax revenue equations.Econometric resultsThe two revenue models specified in the above Eqs.", [["VAT", "TISSUE", 33, 36], ["tax", "PROTEIN", 111, 114], ["tax", "PROTEIN", 142, 145], ["The study", "TEST", 0, 9], ["VAT adoption dummy", "TREATMENT", 33, 51], ["Econometric results", "TEST", 164, 183]]], ["In the latter, tax revenue is normalised w.r.t.", [["tax", "PROTEIN", 15, 18]]], ["GDP and is directly estimated in ratio form without converting the variables in logarithmic form.", [["GDP", "CHEMICAL", 0, 3], ["GDP", "CHEMICAL", 0, 3], ["GDP", "SIMPLE_CHEMICAL", 0, 3], ["GDP", "PROBLEM", 0, 3]]], ["This is done as a standard practice in many other studies, with the intent that it does not pose any interpretational problem.Econometric resultsSince the data used are time series in nature, before we decide to implement any relevant time series methods for the estimation of our tax revenue models, we investigated the unit root property of variables used in our models.", [["root", "ANATOMY", 326, 330], ["tax", "PROTEIN", 281, 284], ["many other studies", "TEST", 39, 57], ["Econometric results", "TEST", 126, 145]]], ["It applies the traditional procedures such as Augmented Dickey\u2013Fuller (ADF) and Phillips\u2013Perron (PP) tests, the results for which are producedin Table 1.", [["the traditional procedures", "TREATMENT", 11, 37]]], ["Both the procedures confirmed that except two variables such as average of composite of political risk and growth rate of GDP, which are level stationary, all other variables are difference stationary, i.e. I(1) as they are found to be first difference stationary, after taking one time difference of values from their respective previous values in the series.", [["GDP", "CHEMICAL", 122, 125], ["GDP", "CHEMICAL", 122, 125], ["GDP", "SIMPLE_CHEMICAL", 122, 125], ["the procedures", "TEST", 5, 19], ["political risk", "OBSERVATION", 88, 102]]], ["Since this suggests that there exists mixed order of integrated variables in our models simultaneously along with the issue of short sample period of analysis, thus, we tried to apply the ARDL approach to cointegration.", [["the ARDL approach", "TREATMENT", 184, 201]]], ["We have also conducted sequential Bai\u2013Perron test to trace if there exists any structural breaks in variables used in our per capita specification.", [["sequential Bai\u2013Perron test", "TEST", 23, 49], ["any structural breaks in variables", "PROBLEM", 75, 109], ["structural breaks", "OBSERVATION", 79, 96]]], ["These results are produced in Table 5 in the appendix.Econometric resultsTable 2 produces unit root test results of variables used in our revenue effort model without considering their logarithmic values.", [["appendix", "ANATOMY", 45, 53], ["appendix", "ORGAN", 45, 53], ["Econometric results", "TEST", 54, 73], ["root test", "TEST", 95, 104], ["appendix", "ANATOMY", 45, 53]]], ["It shows that except growth rate variable, all the variables are found to be integrated of order one, i.e. I(1).", [["growth rate", "TEST", 21, 32], ["growth", "OBSERVATION_MODIFIER", 21, 27]]], ["The corresponding variables\u2019 sequential Bai\u2013Perron multiple structural break test results are also presented in \u201cAppendix\u201d Table 6.", [["sequential Bai\u2013Perron", "TREATMENT", 29, 50], ["multiple structural break test", "TEST", 51, 81], ["Appendix", "ANATOMY", 113, 121]]], ["Considering the resultant break dates as exogenous, we generated the dummies since those break period, so as to capture their effects in our model for removing any estimational biasness or the misspecification error.26Econometric resultsAt first we conducted the test of cointegration using the ARDL technique on our revenue per capita model.", [["any estimational biasness", "TREATMENT", 160, 185], ["the misspecification error", "PROBLEM", 189, 215], ["cointegration", "TREATMENT", 271, 284], ["the ARDL technique", "TREATMENT", 291, 309], ["resultant", "OBSERVATION_MODIFIER", 16, 25], ["break", "OBSERVATION_MODIFIER", 26, 31]]], ["This is carried out with respect to when the dependent variable is substituted with combined direct tax revenues (column 2), combined indirect tax revenue (column 3), state indirect tax revenues (column 4) and then combined total revenues (column 5) for two higher most tiers of governments and are reported in Table 3.", [["tax", "PROTEIN", 143, 146], ["tax", "PROTEIN", 182, 185], ["the dependent variable", "PROBLEM", 41, 63], ["combined total revenues (column", "TREATMENT", 215, 246]]], ["In order to take care of the structural features of the economy; we have incorporated the incomes or outputs generated in agricultural sector as percentage to total GDP as this largely falls outside the purview of direct and indirect taxation.", [["GDP", "CHEMICAL", 165, 168], ["GDP", "CHEMICAL", 165, 168], ["GDP", "SIMPLE_CHEMICAL", 165, 168], ["total GDP", "TEST", 159, 168], ["direct and indirect taxation", "TREATMENT", 214, 242]]], ["The cointegration test result in the form of F-statistic confirms the presence of cointegration in all the per capita revenue models with different types of taxes considered corresponding to both levels of governments.", [["The cointegration test", "TEST", 0, 22], ["cointegration", "PROBLEM", 82, 95]]], ["It shows the computed F-statistics exceed the tabulated F-statistics provided in Pesaran et al. (2001).Econometric resultsAt first, estimating the long-run parameters of the combined direct tax revenue per capita model, it shows that ICT infrastructure instead of helping the government to realise greater revenues from direct income sources, it has rather adversely affected the direct tax revenue realisation.", [["tax", "PROTEIN", 190, 193], ["tax", "PROTEIN", 387, 390], ["Econometric results", "TEST", 103, 122], ["ICT infrastructure", "PROBLEM", 234, 252]]], ["This means introduction of ICT infrastructure instead of serving as an enabling measure in making it easy to file the income taxes from various sources of incomes, it has not helped the government to realise greater revenues collections from direct tax revenue sources.", [["ICT infrastructure", "TREATMENT", 27, 45]]], ["The composite governance quality measuring the overall institutional quality did not show significant effect on the revenue mobilisation.", [["the revenue mobilisation", "TREATMENT", 112, 136], ["composite", "OBSERVATION_MODIFIER", 4, 13], ["governance quality", "OBSERVATION", 14, 32], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["effect", "OBSERVATION", 102, 108], ["revenue mobilisation", "OBSERVATION", 116, 136]]], ["It is the per capita income and surprisingly the dependency ratio which exert positive and significant influence for greater direct revenue collections.", [["the dependency ratio", "PROBLEM", 45, 65], ["greater direct revenue collections", "PROBLEM", 117, 151], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["collections", "OBSERVATION", 140, 151]]], ["The growth rate and openness exert positive impacts on direct tax revenue collections.", [["tax", "PROTEIN", 62, 65], ["The growth rate", "TEST", 0, 15], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["positive", "OBSERVATION_MODIFIER", 35, 43], ["impacts", "OBSERVATION_MODIFIER", 44, 51]]], ["It also shows that an increase in agricultural share has a negative impact on the combined direct tax revenues.Econometric resultsIn contrast, the estimation of combined indirect tax revenues per capita shows that the composite indicator of ICT infrastructure has a significant and adverse impact similar to its impact on direct tax revenues.", [["tax", "PROTEIN", 98, 101], ["tax", "PROTEIN", 179, 182], ["tax", "PROTEIN", 329, 332], ["Econometric results", "TEST", 111, 130], ["ICT infrastructure", "PROBLEM", 241, 259], ["a significant and adverse impact", "PROBLEM", 264, 296], ["direct tax revenues", "TREATMENT", 322, 341], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["agricultural", "OBSERVATION_MODIFIER", 34, 46], ["negative impact", "OBSERVATION_MODIFIER", 59, 74], ["significant", "OBSERVATION_MODIFIER", 266, 277]]], ["And composite of governance quality has no influence on combined indirect tax revenue per capita similar to its no impact on combined direct tax revenues.", [["tax", "PROTEIN", 74, 77], ["tax", "PROTEIN", 141, 144]]], ["Further, It is both the levels of RGDP per capita and its growth rate which play significant positive influence on indirect tax revenue collection and surprisingly the trade openness is found to have no impact along with agricultural share and dependency ratio.", [["tax", "PROTEIN", 124, 127], ["its growth rate", "TEST", 54, 69], ["significant positive influence", "PROBLEM", 81, 111], ["dependency ratio", "PROBLEM", 244, 260], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["positive", "OBSERVATION", 93, 101]]], ["This implies Indian economy in the process of taking part in the process of globalisation, by undertaking liberalisation measures in terms of cutting down its tariffs; this might have resulted in drastic reductions in realisation of indirect tax revenue collections for the combined governments.", [["undertaking liberalisation measures", "TREATMENT", 94, 129], ["drastic reductions", "PROBLEM", 196, 214], ["indirect tax revenue collections", "TREATMENT", 233, 265], ["drastic", "OBSERVATION_MODIFIER", 196, 203], ["reductions", "OBSERVATION_MODIFIER", 204, 214]]], ["As a result, it has no significant contribution to indirect tax revenues comparing its positive impact on direct taxes.Econometric resultsWhen we estimate a similar model with respect to state indirect tax revenues per capita, it shows that governance quality index is significantly and negatively associated with indirect tax revenue realisation at the state level.", [["tax", "PROTEIN", 60, 63], ["tax", "PROTEIN", 202, 205], ["tax", "PROTEIN", 323, 326], ["indirect tax revenues", "TREATMENT", 51, 72], ["direct taxes", "TREATMENT", 106, 118], ["Econometric results", "TEST", 119, 138], ["governance quality index", "TEST", 241, 265], ["no significant", "UNCERTAINTY", 20, 34]]], ["This could reflect weak governance quality across the Indian states, which might have led to their falling indirect tax revenue realisation or a drastic deteriorating effect on revenue realisation.", [["tax", "PROTEIN", 116, 119], ["weak governance quality", "PROBLEM", 19, 42], ["a drastic deteriorating effect", "PROBLEM", 143, 173], ["weak", "OBSERVATION_MODIFIER", 19, 23], ["governance", "OBSERVATION", 24, 34], ["drastic", "OBSERVATION_MODIFIER", 145, 152], ["deteriorating", "OBSERVATION_MODIFIER", 153, 166]]], ["However, contrasting with respect to both combined direct and indirect tax revenue per capita, the ICT infrastructure shows no significant impact in generation of indirect tax revenues at the state levels.", [["tax", "PROTEIN", 71, 74], ["tax", "PROTEIN", 172, 175], ["the ICT infrastructure", "TEST", 95, 117], ["no", "UNCERTAINTY", 124, 126], ["significant", "OBSERVATION_MODIFIER", 127, 138], ["impact", "OBSERVATION_MODIFIER", 139, 145]]], ["It is the increase in RGDP per capita income which significantly has helped the state governments to realise greater collection of revenues.", [["increase", "OBSERVATION_MODIFIER", 10, 18]]], ["More surprising is the result, about the effects of GDP growth rate which is not helping the states to generate greater revenues along with no significant contribution from increasing share of agricultural incomes.", [["GDP", "CHEMICAL", 52, 55], ["GDP", "CHEMICAL", 52, 55], ["GDP", "SIMPLE_CHEMICAL", 52, 55], ["GDP growth rate", "TEST", 52, 67]]], ["It also shows that the trade openness is not playing any significant role in realisation of indirect tax revenues at the state level along with the dependency ratio.", [["tax", "PROTEIN", 101, 104], ["the dependency ratio", "PROBLEM", 144, 164], ["trade openness", "OBSERVATION", 23, 37]]], ["The trade openness showing no significant impact on indirect tax revenues is quite surprising as the state governments mobilise greater revenues from the sale of imported crude oil and natural gas which constitute a major import basket of India.Econometric resultsWe have also tried to estimate similar model with respect to the combined total tax revenues which comprises both the direct and indirect tax revenues for which the result is reported in the last column of Table 3.", [["oil", "ANATOMY", 177, 180], ["oil", "ORGANISM_SUBSTANCE", 177, 180], ["tax", "PROTEIN", 61, 64], ["tax", "PROTEIN", 344, 347], ["tax", "PROTEIN", 402, 405], ["Econometric results", "TEST", 245, 264], ["trade openness", "OBSERVATION", 4, 18], ["no", "UNCERTAINTY", 27, 29], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["impact", "OBSERVATION_MODIFIER", 42, 48]]], ["When the total revenue is considered in per capita terms, it shows that it is the total real GDP per capita which significantly and positively influences the per capita total revenues of both the combined governments.", [["GDP", "CHEMICAL", 93, 96], ["GDP", "SIMPLE_CHEMICAL", 93, 96]]], ["The institutional quality to capture the effects of governance quality does not play any role in total revenue collection for the combined government.", [["governance quality", "TREATMENT", 52, 70]]], ["And the composite ICT infrastructure consistently plays a negative and significant role in the mobilisation of combined total revenues for both the governments including UTs.", [["the composite ICT infrastructure", "PROBLEM", 4, 36], ["combined total revenues", "TREATMENT", 111, 134]]], ["While growth rate of GDP in overall does not play any important role for greater revenue mobilisation of combined government, the share of agriculture plays as a crucial adversary role for greater mobilisation of total revenues for the combined government.27 Trade openness does not influence the combined total revenues per capita of both the tiers of governments but surprisingly the dependency ratio turned out to exert a positive influence on the combined total tax revenues of both the governments.Econometric resultsThe sign and significances of the ECM term point out that there is causality in the model running from independent variables to direct and indirect tax revenues of the combined government and the state governments.", [["GDP", "CHEMICAL", 21, 24], ["GDP", "CHEMICAL", 21, 24], ["GDP", "SIMPLE_CHEMICAL", 21, 24], ["ECM", "CELLULAR_COMPONENT", 556, 559], ["tax", "PROTEIN", 466, 469], ["total revenues", "TREATMENT", 213, 227], ["the dependency ratio", "PROBLEM", 382, 402], ["a positive influence", "PROBLEM", 423, 443], ["Econometric results", "TEST", 503, 522], ["positive", "OBSERVATION", 425, 433]]], ["The ECM coefficients vary from 61 per cent to 82 per cent implying that if there are any short-run deviations from the trend path of dependent variables from their long-run equilibrium values, it takes more than a year to restore to their long-run equilibrium values.", [["ECM", "ANATOMY", 4, 7], ["ECM", "CELLULAR_COMPONENT", 4, 7], ["The ECM coefficients", "TEST", 0, 20], ["any short-run deviations", "PROBLEM", 85, 109], ["dependent variables", "PROBLEM", 133, 152]]], ["The short-run parameter estimates also show that there is some kind of consistency in parameter estimates in line with parameter estimates obtained in long-run in terms of their signs and significances.", [["parameter estimates", "TEST", 119, 138], ["consistency", "OBSERVATION", 71, 82]]], ["In particular, ICT infrastructures, GDP per capita and to some extent the trade openness, dependency ratio and share of agricultural output variables have the same signs and significances, except governance factor which plays a positive significant crucial role in realisation of total combined revenues in the short run.Econometric resultsIn Table 4, we have considered the role of same set of factors including the structural change measured in terms of output share of agriculture sector, how they influence the tax efforts of the combined government of centre, states and UTs.", [["GDP", "CHEMICAL", 36, 39], ["GDP", "SIMPLE_CHEMICAL", 36, 39], ["dependency ratio", "PROBLEM", 90, 106], ["agricultural output variables", "TEST", 120, 149], ["the structural change", "PROBLEM", 413, 434], ["trade openness", "OBSERVATION", 74, 88], ["agricultural output", "OBSERVATION", 120, 139]]], ["Similar to the above exercise, we considered combined direct tax revenue as a percentage to GDP(column 2), combined indirect tax revenues as percentage to GDP(column 3) and combined total tax revenue as a percentage to GDP (Column 5) as alternative dependent variables.", [["GDP", "CHEMICAL", 92, 95], ["GDP", "CHEMICAL", 219, 222], ["GDP", "SIMPLE_CHEMICAL", 92, 95], ["GDP", "SIMPLE_CHEMICAL", 155, 158], ["GDP", "SIMPLE_CHEMICAL", 219, 222], ["tax", "PROTEIN", 125, 128], ["tax", "PROTEIN", 188, 191], ["combined total tax revenue", "TREATMENT", 173, 199], ["a percentage to GDP (Column 5", "TREATMENT", 203, 232], ["alternative dependent variables", "PROBLEM", 237, 268]]], ["However, we are not able to produce the results on basis of Model 2 for the indirect tax revenue efforts of only states and UT governments as the model estimation did not find evidence of cointegration as observed from Column 4 with a low value of F-statistic, while there existed cointegration for other models.Econometric resultsEstimating the model for combined direct tax revenue as a ratio to GDP (Column 2), it shows that the composite governance quality measuring the overall institutional quality plays no significant role in realisation of greater direct revenue collection.", [["GDP", "SIMPLE_CHEMICAL", 398, 401], ["tax", "PROTEIN", 372, 375], ["the model estimation", "TEST", 142, 162], ["cointegration", "PROBLEM", 188, 201], ["Econometric results", "TEST", 312, 331], ["the composite governance quality", "PROBLEM", 428, 460], ["greater direct revenue collection", "PROBLEM", 549, 582], ["no", "UNCERTAINTY", 511, 513], ["significant", "OBSERVATION_MODIFIER", 514, 525], ["greater", "OBSERVATION_MODIFIER", 549, 556]]], ["This again reflects poor quality administration of direct tax collection by the central government leading to no effect on the combined direct tax collection.", [["tax", "PROTEIN", 58, 61], ["tax", "PROTEIN", 143, 146], ["direct tax collection", "TREATMENT", 51, 72], ["the combined direct tax collection", "PROBLEM", 123, 157], ["poor quality", "OBSERVATION_MODIFIER", 20, 32], ["central", "ANATOMY_MODIFIER", 80, 87]]], ["It also shows that the ICT infrastructure instead of helping to realise greater revenues from direct income sources, it has rather adversely affected direct tax revenue collection.", [["tax", "PROTEIN", 157, 160], ["the ICT infrastructure", "PROBLEM", 19, 41]]], ["This means introduction of ICT infrastructure instead of serving as an enabling measure for greater reporting or filing of taxes on earnings from various sources, this has not helped the central government to realise greater revenues from direct tax sources.", [["tax", "PROTEIN", 246, 249], ["ICT infrastructure", "TREATMENT", 27, 45]]], ["This might be due to the fact that tax payers might be concealing their income and carrying the transactions outside the purview of using the ICT infrastructures, so as to escape reporting or hide their true earnings.", [["the ICT infrastructures", "TREATMENT", 138, 161]]], ["It is the per capita income and surprisingly the dependency ratio which exert positive and significant influences for greater direct revenue collections.28 The growth rate of income and openness exert positive impact on direct tax revenue collections.", [["tax", "PROTEIN", 227, 230], ["the dependency ratio", "PROBLEM", 45, 65], ["significant influences", "PROBLEM", 91, 113], ["greater direct revenue collections", "PROBLEM", 118, 152], ["collections", "OBSERVATION", 141, 152], ["growth", "OBSERVATION_MODIFIER", 160, 166], ["positive", "OBSERVATION_MODIFIER", 201, 209]]], ["The trade openness leading to a rise of direct tax revenues efforts similar to the above could indirectly indicate that although effective corporate tax revenue has been falling over time in correspondence with global trend for most of the countries, however, as the countries compete for receiving greater foreign business and investment, and further when low corporate tax rate is combined with low tariff rates on imports of raw materials, those could prove as potential factors to attract business from outside.", [["tax", "PROTEIN", 149, 152], ["tax", "PROTEIN", 371, 374], ["low tariff rates", "PROBLEM", 397, 413], ["trade openness", "OBSERVATION", 4, 18]]], ["It is also shown that an increase in agricultural share has a negative impact on the combined direct tax revenues.Econometric resultsIn contrast, the estimation of the combined indirect tax revenue effort (column 3) shows that neither governance/institutional quality nor the ICT infrastructure positively contributes to combined government indirect tax revenues.", [["tax", "PROTEIN", 101, 104], ["tax", "PROTEIN", 186, 189], ["tax", "PROTEIN", 350, 353], ["Econometric results", "TEST", 114, 133], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["agricultural", "OBSERVATION_MODIFIER", 37, 49]]], ["The composite index of ICT infrastructure plays no significant role unlike its negative impact on direct tax revenues, while the composite governance quality has a negative influence on the combined indirect tax revenue effort unlike its no impact on combined direct tax revenue effort.", [["tax", "PROTEIN", 105, 108], ["tax", "PROTEIN", 208, 211], ["tax", "PROTEIN", 267, 270], ["The composite index", "TEST", 0, 19], ["no", "UNCERTAINTY", 48, 50], ["significant", "OBSERVATION_MODIFIER", 51, 62]]], ["It is the GDP per capita along with dependency ratio which plays a positive and significant role in raising indirect tax revenue efforts.", [["GDP", "CHEMICAL", 10, 13], ["GDP", "CHEMICAL", 10, 13], ["GDP", "SIMPLE_CHEMICAL", 10, 13], ["tax", "PROTEIN", 117, 120], ["dependency ratio", "TEST", 36, 52]]], ["Surprisingly, the growth rate of GDP is found to be insignificant along with trade openness.", [["GDP", "CHEMICAL", 33, 36], ["GDP", "CHEMICAL", 33, 36], ["GDP", "SIMPLE_CHEMICAL", 33, 36], ["the growth rate of GDP", "PROBLEM", 14, 36], ["insignificant", "OBSERVATION", 52, 65], ["trade openness", "OBSERVATION", 77, 91]]], ["This indicates that as India makes effort to gradually liberalise to remove the trade barriers by reducing the tariffs and other duties, the trade openness is not directly contributing to indirect tax revenues.", [["tax", "PROTEIN", 197, 200], ["the trade barriers", "TREATMENT", 76, 94]]], ["This also gets reflected in our observed trends of indirect tax revenues as a proportion of GDP over the years.", [["GDP", "CHEMICAL", 92, 95], ["GDP", "CHEMICAL", 92, 95], ["GDP", "SIMPLE_CHEMICAL", 92, 95], ["tax", "PROTEIN", 60, 63]]], ["The share of agriculture sector has an adverse impact on indirect tax revenue effort.Econometric resultsWhen we estimate the total combined revenue of centre and states and UTs from both direct and indirect sources (Column 5), it shows that both the institutional setting (governance quality) and the ICT infrastructure significantly and negatively contribute to the combined total tax revenue collection efforts of the combined government.", [["tax", "PROTEIN", 382, 385], ["Econometric results", "TEST", 85, 104], ["the ICT infrastructure", "TEST", 297, 319], ["adverse", "OBSERVATION_MODIFIER", 39, 46]]], ["It is the per capita income and dependency pressure encourage the governments to put more tax revenue efforts, while a greater share of agriculture output neutralises the tax efforts.", [["tax", "PROTEIN", 90, 93], ["tax", "PROTEIN", 171, 174], ["dependency pressure", "TREATMENT", 32, 51]]], ["In overall, on account of liberalisation tendencies of the economy, the trade openness leads to making greater revenue efforts.", [["liberalisation tendencies", "PROBLEM", 26, 51], ["overall", "OBSERVATION_MODIFIER", 3, 10], ["economy", "OBSERVATION_MODIFIER", 59, 66], ["greater", "OBSERVATION_MODIFIER", 103, 110]]], ["The dependency is consistently putting pressure on tax effort of the combined government, which may be on account of its expanding size of the dependency population.", [["the dependency population", "PROBLEM", 139, 164], ["dependency", "OBSERVATION_MODIFIER", 4, 14], ["consistently", "OBSERVATION_MODIFIER", 18, 30], ["pressure", "OBSERVATION_MODIFIER", 39, 47], ["combined", "OBSERVATION_MODIFIER", 69, 77], ["government", "OBSERVATION", 78, 88], ["may be", "UNCERTAINTY", 96, 102], ["expanding", "OBSERVATION_MODIFIER", 121, 130], ["size", "OBSERVATION_MODIFIER", 131, 135], ["dependency", "OBSERVATION_MODIFIER", 143, 153], ["population", "OBSERVATION_MODIFIER", 154, 164]]], ["The combined government greatly have to spend on higher education of the adults and address social security and healthcare needs of the elderly population.Econometric resultsIn all the models were estimated, the ECM coefficients have relevant signs and significances reflecting there is causation running from one or more variables to the combined indirect and direct tax revenues to GDP proportions.", [["ECM", "ANATOMY", 212, 215], ["GDP", "CHEMICAL", 384, 387], ["GDP", "CHEMICAL", 384, 387], ["ECM", "CELLULAR_COMPONENT", 212, 215], ["GDP", "SIMPLE_CHEMICAL", 384, 387], ["tax", "PROTEIN", 368, 371], ["Econometric results", "TEST", 155, 174], ["relevant signs", "PROBLEM", 234, 248]]], ["This implies that it takes about half a year for the full adjustment to take place in case there is any short-run departure of the revenue efforts from their long-run equilibrium trends.Econometric resultsWhen we consider all the dependent revenue variables as a ratio to GDP, we observe governance and infrastructural quality instead of aiding to mobilise greater aggregate revenues for both the levels of governments, contrary to theoretical prediction, it results in either reduction of tax revenues or neutrality in revenue generations.", [["GDP", "SIMPLE_CHEMICAL", 272, 275], ["tax", "PROTEIN", 490, 493], ["Econometric results", "TEST", 186, 205], ["tax revenues", "TREATMENT", 490, 502]]], ["This shows that the tax system of the country instead of harnessing the benefits from modern ICT infrastructural facilities for greater revenue productivity, it might be getting misutilised in the opposite direction either for manipulation or all the transactions are not feed into the ICT system to escape from taxation levies.", [["modern ICT infrastructural facilities", "TREATMENT", 86, 123]]], ["In presence of a weak tax administration, tax payers might not be reporting their true incomes and sometimes they might be attempting to receive their incomes outside the ICT infrastructures.", [["tax", "PROTEIN", 22, 25], ["a weak tax administration", "TREATMENT", 15, 40], ["weak tax", "OBSERVATION", 17, 25]]], ["This calls for greater attention of the policy to redesign the governance in taxation system of the country towards making it more efficient and transparent which would go a long way to mobilise greater revenues and thereby contributing to the overall growth of the economy.", [["growth", "OBSERVATION_MODIFIER", 252, 258]]], ["The increase in agricultural income in total output results in less total tax revenue mobilisation.", [["tax", "PROTEIN", 74, 77], ["total output", "TEST", 39, 51], ["less total tax revenue mobilisation", "TREATMENT", 63, 98], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["agricultural", "OBSERVATION_MODIFIER", 16, 28], ["income", "OBSERVATION_MODIFIER", 29, 35], ["revenue mobilisation", "OBSERVATION", 78, 98]]], ["This is quite obvious as agricultural sector largely remains outside the purview of both the direct tax revenues and indirect tax revenues, and moreover, people with agricultural incomes; their pattern of consumption is such that they might not be consuming high value added products which otherwise might attract higher tax rates.", [["tax", "PROTEIN", 100, 103], ["tax", "PROTEIN", 126, 129], ["tax", "PROTEIN", 321, 324], ["people", "SPECIES", 154, 160]]], ["The openness in trade is resulting in significant gains in direct tax revenues but is not leading to generation of indirect tax revenues and on net it shows a positive association with combined total tax revenues which could be due to its base effects.Econometric resultsAlternatively, when we adopted a general to specific approach in estimating both the Model A and Model B, we did not find much deviation from our above reported results.", [["tax", "PROTEIN", 66, 69], ["tax", "PROTEIN", 124, 127], ["tax", "PROTEIN", 200, 203], ["combined total tax revenues", "TREATMENT", 185, 212], ["its base effects", "PROBLEM", 235, 251], ["Econometric results", "TEST", 252, 271], ["openness", "OBSERVATION", 4, 12], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["could be due to", "UNCERTAINTY", 219, 234]]], ["However, surprisingly with a minor deviation, the effects of institutional quality are found to exert a positive impact only for the combined direct tax revenue per capita as reported in \u201cAppendix\u201d Table 7 and the openness of trade which did not have an effect on the overall combined (direct and indirect) tax revenues per capita and state indirect tax revenue per capita.", [["tax", "PROTEIN", 149, 152], ["tax", "PROTEIN", 307, 310], ["tax", "PROTEIN", 350, 353], ["a minor deviation", "PROBLEM", 27, 44], ["minor", "OBSERVATION_MODIFIER", 29, 34], ["deviation", "OBSERVATION", 35, 44], ["Appendix", "ANATOMY", 188, 196]]], ["Similarly, when we tried to adopt specific model by retaining only governance and ICT infrastructures in our per capita revenue model, the results remain largely unaltered.", [["ICT infrastructures", "TREATMENT", 82, 101], ["largely", "OBSERVATION_MODIFIER", 154, 161], ["unaltered", "OBSERVATION", 162, 171]]], ["And when we also tried similar models for ratio equation, most of our results seem to be consistent and the results for which are not reported for sake of brevity.Conclusion and policy suggestionsIn light of various reform measures undertaken in areas of direct and indirect taxes over the years more especially after the initiation of new economic reform measures encompassing broad changes in taxation policies such as implementation of VAT at the state level in 2005 and recently Goods and Services Tax (GST) in India from 1st July 2017 on the one hand and evolution in the use of ICT infrastructures on the other, current study attempts to assess whether governance and ICT infrastructures have played any significant roles in ways of mobilising greater revenues for the combined government of centre and states and UTs or those reform measures themselves are posing any major serious challenges for the tax administration of the country by dampening revenue collection potential.Conclusion and policy suggestionsIt looked at both direct and indirect tax collection trends and tried to link up revenue mobilisation of combined and separate governments with ICT infrastructures by constructing a composite index of various infrastructures, by collating the data from World Bank Development Indicators along with an aggregative measure of governance (institutional quality) indicator of PRS Group from their International Country Political Risk Guide.", [["VAT", "TISSUE", 439, 442], ["Tax", "PROTEIN", 502, 505], ["GST", "PROTEIN", 507, 510], ["tax", "PROTEIN", 908, 911], ["ratio equation", "TEST", 42, 56], ["various reform measures", "TREATMENT", 208, 231], ["new economic reform measures", "TREATMENT", 336, 364], ["broad changes in taxation policies", "TREATMENT", 378, 412], ["VAT", "TREATMENT", 439, 442], ["ICT infrastructures", "TREATMENT", 584, 603], ["current study", "TEST", 618, 631], ["ICT infrastructures", "TREATMENT", 1161, 1180]]], ["It hypothesised that ICT infrastructure and governance might have aided the governments in achieving greater tax compliances, helping both the centre and states and UTs governments to realise greater tax revenues in India over the years.", [["tax", "PROTEIN", 109, 112], ["tax", "PROTEIN", 200, 203]]], ["On the basis of empirical findings, finally it tried to offer some insights for the future tax policies.Conclusion and policy suggestionsThe study tried to largely focus on post new economic policy reform phases, where lot of reform efforts are made with respect to both direct and indirect taxation.", [["the future tax policies", "TREATMENT", 80, 103], ["The study", "TEST", 137, 146]]], ["Thereby, it tried to cover sales tax, VAT and GST regimes by introducing dummy only for the State VAT regime since the year 2005.", [["VAT", "TISSUE", 38, 41], ["GST", "GENE_OR_GENE_PRODUCT", 46, 49], ["tax", "PROTEIN", 33, 36], ["VAT and GST regimes", "TREATMENT", 38, 57], ["the State VAT regime", "TREATMENT", 88, 108]]], ["It assumed that introduction of new methods of collection of indirect taxes under GST regime is not completely different from previous VAT regime.", [["GST", "GENE_OR_GENE_PRODUCT", 82, 85], ["VAT", "TISSUE", 135, 138], ["GST", "PROTEIN", 82, 85], ["new methods of collection of indirect taxes under GST regime", "TREATMENT", 32, 92], ["previous VAT regime", "TREATMENT", 126, 145], ["new", "OBSERVATION_MODIFIER", 32, 35]]], ["Thereby, the current study makes an attempt to understand the role of ICT infrastructures and institutional/governance quality in understanding their contributions towards efficient revenue mobilisation.", [["the current study", "TEST", 9, 26], ["ICT infrastructures", "TREATMENT", 70, 89], ["institutional/governance quality", "TREATMENT", 94, 126]]], ["It comes out with the surprising (rather tantalising) evidence that there are greater weaknesses in areas of both governance and use of ICT infrastructures which have led to failings in realisation of greater tax revenues and tax efforts of the combined governments in India.", [["tax", "PROTEIN", 209, 212], ["ICT infrastructures", "TREATMENT", 136, 155], ["greater", "OBSERVATION_MODIFIER", 78, 85], ["weaknesses", "OBSERVATION", 86, 96]]], ["Hence, it suggests the need for strengthening in both areas which can potentially contribute to greater tax revenue productivity.", [["tax", "PROTEIN", 104, 107], ["greater", "OBSERVATION_MODIFIER", 96, 103], ["tax", "OBSERVATION_MODIFIER", 104, 107], ["revenue productivity", "OBSERVATION", 108, 128]]], ["Greater penetration of ICT may not enable to generate greater amounts of revenues in a developing country like India unless people are compelled to do most of the transactions (above certain minimum ceilings) through banks and with the help of medium of ICT.", [["people", "ORGANISM", 124, 130], ["people", "SPECIES", 124, 130], ["Greater penetration of ICT", "PROBLEM", 0, 26]]], ["In a developing country like India, where major portion of gross national income is generated in the informal sector, this may contribute to squeezing up the tax base.29 However, it is rather the increase in per capita GDP and dependency ratio which majorly have played key role in enhancing the tax revenues for the combined governments.", [["GDP", "CHEMICAL", 219, 222], ["GDP", "SIMPLE_CHEMICAL", 219, 222], ["tax", "PROTEIN", 296, 299], ["dependency ratio", "PROBLEM", 227, 243], ["base", "ANATOMY_MODIFIER", 162, 166], ["increase", "OBSERVATION_MODIFIER", 196, 204]]], ["And the increase in share of agricultural output has led to reduced tax revenues in India.", [["tax", "PROTEIN", 68, 71], ["agricultural output", "PROBLEM", 29, 48], ["increase", "OBSERVATION_MODIFIER", 8, 16], ["agricultural output", "OBSERVATION", 29, 48], ["reduced", "OBSERVATION_MODIFIER", 60, 67], ["tax revenues", "OBSERVATION", 68, 80]]], ["Given that agriculture in recent years is giving rise to business at the higher end of value chain with emergence of processing industries and demand for the processed food, the government needs to think up these emerging areas for taxation.Conclusion and policy suggestionsGiven the findings, it also tends to suggest that the ICT infrastructure alone may not lead to mobilisation of greater tax revenues, unless it is greatly supplemented with the governance quality and efficient administrative machinery to plug the loopholes and properly govern the taxation system of the country.", [["tax", "PROTEIN", 393, 396], ["the ICT infrastructure", "PROBLEM", 324, 346], ["plug the loopholes", "TREATMENT", 511, 529]]], ["It would be difficult to realise the potential revenue capacity unless corrective measures are put in place with respect to tax governance in particular and overall governance of the economy in general.", [["corrective measures", "TREATMENT", 71, 90]]], ["While remedying the situation, it is the political, institutional and human capacity constraints may hinder the government to make innovation and go for any advanced solutions in the field of taxation.", [["human", "ORGANISM", 70, 75], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["institutional and human capacity constraints", "TREATMENT", 52, 96], ["any advanced solutions", "TREATMENT", 153, 175]]], ["For instance, an existence of corrupt bureaucratic system can open up avenues for the dishonest taxpayers to bypass the digital systems to evade the taxes.", [["corrupt bureaucratic system", "PROBLEM", 30, 57], ["the dishonest taxpayers", "TREATMENT", 82, 105]]], ["However, it is also true that while harnessing the modern ICT mediums, it may help the low income developing countries to leverage revenue generation comparable with advanced countries\u2019 potential capacity, thereby supporting their socioeconomic development.", [["potential capacity", "PROBLEM", 186, 204]]], ["Further, the potential can be limited if large segments of the population lack access to digital advancement, which is happening elsewhere around the globe.", [["digital advancement", "TREATMENT", 89, 108], ["globe", "ANATOMY", 150, 155]]], ["Given that there exists a greater digital divide within the economy to access those modern facilities, therefore, the government should put necessary efforts in direction of ensuring universal accession to modern technology for the public which will not only help the private business to grow but also help the government in realisation of greater revenue potentials, and thereby ICT system acquiring the characteristics of public goods in a similar way that the WiFi connection is being provided in major cities covered under smart city mission program in India.Conclusion and policy suggestionsIn sum, the study finds that the ICT infrastructure and governance taken separately do not majorly help in greater revenue mobilisation as expected.", [["the study", "TEST", 604, 613], ["greater", "OBSERVATION_MODIFIER", 26, 33], ["greater", "OBSERVATION_MODIFIER", 703, 710], ["revenue mobilisation", "OBSERVATION", 711, 731]]], ["Introducing the reform into taxation system without correcting the loopholes in administration would have limited impact on revenue realisation.", [["the loopholes in administration", "TREATMENT", 63, 94], ["revenue realisation", "TREATMENT", 124, 143]]], ["Modern technologies of tax collection would have limited role, unless tax administration assumes its effective role in ensuring efficiency in tax governance.", [["tax", "PROTEIN", 23, 26], ["tax", "PROTEIN", 70, 73], ["tax", "PROTEIN", 142, 145], ["tax collection", "PROBLEM", 23, 37], ["tax administration", "TREATMENT", 70, 88], ["tax collection", "OBSERVATION", 23, 37]]], ["Thus, tax reform implying better governance/administration should be at the fore.", [["tax", "PROTEIN", 6, 9]]], ["To quote Casanegra de Jantscher (1990), he pointed out that \u201cthe developing countries\u2019 tax administration is their tax policy\u201d which highlights the critical role of tax administration in ensuring effectiveness of tax policy.", [["tax", "PROTEIN", 165, 168], ["tax", "PROTEIN", 213, 216], ["tax administration", "TREATMENT", 165, 183]]], ["However, the main limitation with this analysis is that it is aggregative at least for indirect tax revenues for the states and UTs.", [["tax", "PROTEIN", 96, 99], ["this analysis", "TEST", 34, 47], ["main", "OBSERVATION_MODIFIER", 13, 17]]], ["When it comes to collection of state tax revenues, the states primarily collect more indirect tax revenues than their direct revenues.", [["tax", "PROTEIN", 94, 97]]], ["As a result, their aggregate indirect revenue share in combined total indirect tax revenue is little less than the centre\u2019s share in the combined total indirect tax revenue collections.", [["tax", "PROTEIN", 79, 82], ["little less", "OBSERVATION_MODIFIER", 94, 105], ["revenue collections", "OBSERVATION", 165, 184]]], ["Given that the penetration of ICT infrastructure is likely to vary across the states, therefore, while examining the role of ICT infrastructure and governance in states\u2019 indirect tax revenue collection, one may analyse for a panel of individual states to take into account of state specific characteristics in tax revenue model.", [["tax", "PROTEIN", 179, 182], ["tax", "PROTEIN", 310, 313], ["the penetration of ICT infrastructure", "PROBLEM", 11, 48], ["a panel", "TEST", 223, 230]]], ["This may give more insights about whether the ICT infrastructure and governance factors have enabled the states in realisation of greater accrual of indirect tax revenues.", [["tax", "PROTEIN", 158, 161], ["the ICT infrastructure and governance factors", "PROBLEM", 42, 87]]]]}